An evaluation of the use of supercritical fluid extraction techniques to recover drugs from biological matrices by Scott, Karen S.
Glasgow Theses Service 
http://theses.gla.ac.uk/ 
theses@gla.ac.uk 
 
 
 
 
 
Scott, Karen S. (1998) An evaluation of the use of supercritical fluid 
extraction techniques to recover drugs from biological matrices.  
 
PhD thesis 
 
 
 
 
http://theses.gla.ac.uk/3460/ 
 
 
 
Copyright and moral rights for this thesis are retained by the author 
 
A copy can be downloaded for personal non-commercial research or 
study, without prior permission or charge 
 
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the Author 
 
When referring to this work, full bibliographic details including the 
author, title, awarding institution and date of the thesis must be given 
 AN  EVALUATION  OF  THE  USE  OF 
SUPERCRITICAL  FLUID  EXTRACTION 
TECHNIQUES  TO  RECOVER  DRUGS 
FROM  BIOLOGICAL  MATRICES 
T!!  ES!  s  SuaitnTED  !  1V  ACCORDANCE  WIT!!  T!!!: 
REQUIREMIENTSOFTIlE  UNiVE  SITYOFGIASGowI' 
FOR  THE  DEGREE  OF  DOCTOR  OF  PHILOSOPHY 
by 
￿4a  vl2 
'3.  cScoif 
r(.  fw  ,  "is  a 
Department  of  Forcusic  Mcdieinc  and  Scicincc 
June  1998 Acknowledgements 
I  would  like  to  express  my  gratitude  to  my  supervisor,  Dr  John  S.  Oliver,  for  his  guidance 
and  faith  throughout  this  project  and  also  to  Dr  Robert  A.  Anderson,  Professor  Hamilton 
Smith  and  Dr  William  J.  Kerr  (Department  of  Pure  and  Applied  Chemistry,  University  of 
Strathclyde)  for  invaluable  advice.  I  would  also  like  to  thank  the  Department  of  Forensic 
Medicine  and  Science  for  financial  support. 
Grateful  thanks  are  extended  to  all  Research  Students  and  Assistants  (past  and  present)  for 
bearing  with  me  through  panics  great  and  small  and  being  a  great  bunch  of  friends.  Thanks 
also  go  to  the  technical  staff  at  the  Department  of  Forensic  Medicine  and  Science  for  all 
their  assistance  with  instrumentation  and  the  patter  in  the  lab.  Many  thanks  to  Jeff 
Cockburn  and  Graeme  McCombe  for  their  patience  and  PC  training.  The  secretarial  and 
other  staff  at  the  Department  are  also  gratefully  acknowledged  for  their  help  and 
entertaining  stories. 
To  all  my  friends,  in  particular  Nicola  (Buchanan)  Watt,  Claire  MacDonald  and  Christine 
Breakell  (and  Spoons  and  Huggles  my  substitute  best  buddies)  thanks  for  believing  in  me 
and  for  always  being  there. 
For  their  unfailing  confidence  in  me  (and  financial  support  over  the  past  28  years!  )  endless 
thanks  go  to  my  family.  Finally  I  would  like  to  acknowledge  Dr  James  (R)  Scott,  not  least 
for  getting  me  through  this  in  one  piece  (I  think  I  still  have  my  sanity!!  ).  Thanks  for  being 
you  (and  having  me). 
%'e,  Jar V-P 
TO  MY  PARS 
Xý  m- Table  Of  Contents  i 
LIST  OF  ABBREVIATIONS 
..............................................................................................  xv 
SUMMARY 
........................................................................................................................  XVI 
1.  SUPERCRITICAL  FLUIDS 
.............................................................................................. 
1 
1.1  INTRODUCTION 
.................................................................................................................. 
1 
1.1.1  Properties  of  Supercritical  Fluids 
............................................................................  .2 
1.1.1.1  Solubility 
...........................................................................................................  .3 
1.1.1.2  Solubility  Parameter 
..........................................................................................  .4 
1.1.2  Phase  Behaviour  for  Supercritical  Fluid-Solute  Mixtures 
........................................ 
5 
........................................ 
9 
..  . 
1  2  SUPERCRITICAL  FLUID  EXTRAC  ION  .  .  .  ..................................... 
1.2.1  Method  Development  in  SFE  ................................................................................... 
10 
1.2.2  Analytes 
................................................................................................................... 
12 
1.2.3  Matrices 
................................................................................................................... 
12 
1.2.4  Choice  of  Extracting  Fluid 
...................................................................................... 
13 
1.2.5  Selectivity  in  Extraction 
........................................................................................... 
13 
1.2.6  Particle  size  ............................................................................................................. 
17 
1.2.7  Extraction  Methodology  ..........................................................................................  17 
1.2.8  Off-Line  SFE  versus  On-Line  SFE 
..........................................................................  17 
1.2.8.1  Off-Line  SFE  ....................................................................................................  18 
1.2.8.2  On-Line  SFE 
.....................................................................................................  18 
1.2.9  SFE-Coupled  Techniques  ........................................................................................  18 
1.2.9.1  Trapping  Techniques  for  SFE-Coupled  Techniques 
........................................  18 
1.2.9.2  SFE-TLC 
..........................................................................................................  19 
1.2.9.3  SFE-HPLC 
........................................................................................................  19 
1.2.9.4  SFE-GC 
............................................................................................................  20 
1.2.9.5  SFE-SFC 
...........................................................................................................  20 
1.2.10  Trapping  Techniques  in  SFE 
.................................................................................  21 
1.2.10.1  Liquid  Collection 
............................................................................................  22 
1.2.10.2  Dry  Deposition 
...............................................................................................  23 
1.2.10.3  Solid  Phase  Sorption 
.......................................................................................  23 
1.2.11  Applications  of  SFE 
...............................................................................................  23 
1.2.11.1  SFE  Of  Drugs 
.................................................................................................  24 Table  Of  Contents 
11 
1.3  INSTRUMENTATION  IN  SFE 
.............................................................................................. 
25 
1.3.1  Introduction  ............................................................................................................. 
25 
1.3.2  SFE  Pumps  .............................................................................................................. 
26 
1.3.3  Carbon  Dioxide  ....................................................................................................... 
27 
1.3.4  Modifiers  .................................................................................................................. 
27 
1.3.5  Extraction  Vessel  ..................................................................................................... 
27 
1.3.6  The  Back  Pressure  Regulator  .................................................................................. 
28 
1.3.7  Detection  in  SFE 
...................................................................................................... 
29 
1.3.8  Flow  Through  the  System 
........................................................................................ 
30 
1.4  SETTING  UP  OF  INSTRUMENTATION 
.................................................................................. 
31 
2.  BENZODIAZEPINES 
...................................................................................................... 
34 
34  2.1  INTRODUCTION  ...................................................................  ............................................. 
34 
..............................................................  2  PRESCRIPTION  2  .............................................  .......  . 
34  2.3  CHEMICAL  STRUCTURE  .................................................................................................... 
36  4  PHARMACOLOGY 
............................................................... 
2  ..............................................  . 
37  2.5  METABOLISM 
.....................................................................  .............................................. 
..........................................  2  6  PHARMAcoxugFncs  .............................................. 
38 
................  . 
2.7  PHARMACODYNAMICS  .......................................................  .............................................. 
39 
2.8  LEGAL  STATUS 
...  ............................................................................................................. 
39 
2.9  ANALYSIS  OF  BENZODIAZEPINES 
..................................................................................... 
39 
2.10  SUPERCRITICAL  FLUID  ANALYSIS  OF  BENZODIAZEPINES 
............................................... 
40 
2.11  CURRENT  METHODOLOGY 
............................................................................................. 
40 
2.11.1  SPE  of  Benzodiazepines  ........................................................................................ 
41 
2.12  HPLC  OF  BENZODIAZEPINES  ......................................................................................... 
41 
2.12.1  Set-up  of  HPLC 
...................................................................................................... 
41 
2.12.1.1  Experimental  ................................................................................................... 
41 
2.12.1.2  Results  and  Discussion  ................................................................................... 
42 
2.12.2  Determination  of  Retention  Time  of  Chlordiazepoxide,  Nitrazepam  and 
Lorazepam  .......................................................................................................................  . 
43 
2.12.2.1  Experimental,  results  and  discussion 
.............................................................  . 
43 
2.12.3  Chlordiazepoxide  Stability 
...................................................................................  . 
44 
2.12.3.1  Experimental 
...................................................................................................  44 Table  Of  Contents 
111 
2.12.3.2  Results  and  Discussion  ................................................................................... 
45 
2.12.4  Identity  of  Chlordiazepoxide  Impurity  Peak 
.......................................................... 
47 
2.12.4.1  Experimental 
................................................................................................... 
47 
2.12.5  Retention  Time  Reproducibility  ............................................................................. 
49 
2.12.5.1  Experimental  ................................................................................................... 
49 
2.12.5.2  Results  and  Discussion  ................................................................................... 
49 
2.13  SETUP  of  SFE  SYSTEM  ................................................................................................. 
49 
50  2.13.1  Initial  Set-up  ...................................................................  ....................................... 
51 
.............................................  .  erimental  1  Ex  1  2  13  .......................................  ..  ............  p  .  .  . 
51 
................................  2  Results  and  Discussion  1  2  13  ........................................  ...........  .  .  . 
53  2.14  METHOD  DEVELOPMENT:  SFE  OF  BENZODIAZEPINES 
...........  ........................................ 
53  2.14.1  SFE  of  Triazolam  ...........................................................  ........................................ 
..  ntal  1E  i  14  1  2  ........................................ 
53 
.........................................................  me  xper  .  .  . 
i  i  53 
.  .  on  .................................................................................  scuss  2.14.1.2  Results  and  D 
........................................ 
54 
..  am  e  a  fT  2  SFE  14  2  .....................................................  p  em  o  z  .  .  . 
2.14.2.1  Experimental  ..........................................................  ......................................... 
54 
2.14.2.2  Results  and  Discussion  ..........................................  ......................................... 
55 
2.14.3  SFE  of  the  Standard  Mix  +  Internal  Standard 
...................................................... 
55 
2.14.3.1  Experimental 
................................................................................................... 
55 
2.14.3.2  Results  and  Discussion  ................................................................................... 
55 
2.14.4  Temperature  Effects 
............................................................................................... 
56 
2.14.4.1  Experimental  ................................................................................................... 
56 
2.14.4.2  Results  and  Discussion  ................................................................................... 
57 
2.14.5  Critical  Temperature  of  CO2  and  MeOH  Mixtures  ............................................... 
57 
2.14.6  Continuation  of  Temazepam  Method  Development 
............................................... 
58 
2.14.6.1  Experimental  ................................................................................................... 
58 
2.14.7  Optimisation  of  Temazepam  Extraction 
................................................................ 
59 
2.14.8  Effect  of  Altering  the  %  Modifier 
........................................................................... 
60 
2.14.8.1  Experimental 
................................................................................................... 
60 
2.14.8.2  Results  and  Discussion 
................................................................................... 
60 
2.14.9  Reproducibility  of  Extraction  with  MeOH  (40%)  as  the  Modifier 
........................ 
60 
2.14.9.1  Experimental 
...................................................................................................  60 Table  Of  Contents  iv 
2.14.9.2  Results  and  Discussion  ................................................................................... 
61 
2.14.10  HPLC  System  Reproducibility  ............................................................................. 
61 
2.14.10.1  Experimental 
................................................................................................. 
61 
2.14.10.2  Results  and  Discussion  ................................................................................. 
61 
2.14.11  Temazepam  Extraction  from  Whole  Blood  .......................................................... 
62 
2.14.11.1  Experimental 
................................................................................................. 
62 
2.14.11.2  Results  and  Discussion  ................................................................................. 
62 
2.14.12  Effect  of  Altering  the  Type  of  Modifier  ................................................................ 
63 
2.14.12.1  Experimental 
................................................................................................. 
64 
2.14.12.2  Results  and  Discussion  for  70  °C 
................................................................. 
64 
2.14.12.3  Results  and  Discussion  for  50  °C 
................................................................. 
64 
2.14.13  Effect  of  Temperature  with  EtAc  (15%)  as  the  Modifier  ..................................... 
64 
2.14.13.1  Experimental  ................................................................................................. 
64 
2.14.13.2  Results  and  Discussion  ................................................................................. 
65 
2.14.14  Alteration  of  Extraction  Cell  Length 
................................................................... 
67 
2.14.15  Confirmation  of  EtAc  (5%)  as  the  Modifier  of  Choice 
........................................ 
67 
2.14.15.1  Experimental  ................................................................................................. 
67 
2.14.15.2  Results  and  Discussion  ................................................................................. 
67 
2.14.16  Addition  of  other  Benzodiazepines  to  the  System 
................................................ 
67 
2.14.16.1  Experimental 
................................................................................................  . 
67 
2.14.16.2  Results  and  Discussion  ................................................................................  . 
67 
2.14.17  Effect  of  Pressure  ...............................................................................................  . 
68 
2.14.17.1  Experimental  ................................................................................................  . 
68 
2.14.17.2  Results  and  Discussion  ................................................................................  . 
68 
2.14.18  Variation  of  Pressure  Within  the  SFE  System 
....................................................  .  70 
2.14.18.1  Experimental 
.................................................................................................  70 
2.14.18.2  Results  and  Discussion 
.................................................................................  70 
2.14.19  Repeat  of  Extraction  at  3000  psi  .........................................................................  71 
2.14.19.1  Experimental 
..............................................................................  ................. 
71  .. 
2.14.19.2  Results  and  Discussion 
...............................................................................  .. 
71 
2.14.20  Effect  of  Temperature 
........................................................................................  .. 
72 
2.14.20.1  Experimental 
...............................................................................................  ..  72 Table  Of  Contents  V 
2.14.20.2  Results  and  Discussion 
................................................................................. 
72 
2.14.21  Effect  of  Collection  Solvent  and  Continuation  of  Temperature  Study 
................ 
73 
2.14.21.1  Experimental  ................................................................................................. 
73 
2.14.21.2  Results  and  Discussion  ................................................................................. 
73 
2.14.22  Extraction  of  Temazepam  and  Prazepam  from  Blood  ......................................... 
75 
2.14.22.1  Experimental  ................................................................................................. 
75 
2.14.22.2  Results  and  Discussion  ................................................................................. 
75 
2.14.23  Alternative  Method  of  Preventing  Restrictor  Plugging  ....................................... 
76 
2.14.23.1  Experimental 
................................................................................................. 
76 
2.14.23.2  Results  and  Discussion  ................................................................................. 
76 
2.14.24  Preparation  of  Standard  Temazepam  and  Prazepam  ......................................... 
77 
2.14.24.1  Experimental  ................................................................................................. 
77 
2.14.25  Comparison  of  SFE  and  SPEfor  Temazepam  and  Prazepam  ............................ 
77 
2.14.25.1  Experimental  ................................................................................................. 
77 
2.14.25.2  Results  and  Discussion 
................................................................................. 
77 
2.14.26  Procedure  for  Drying  of  Blood  Samples 
............................................................. 
77 
2.14.27  Effect  of  Altering  the  Support  Medium 
................................................................ 
79 
2.14.27.1  Experimental  ................................................................................................. 
79 
2.14.27.2  Results  and  Discussion  ................................................................................. 
79 
2.14.28  Conclusions  from  Method  Development 
.............................................................. 
79 
2.15  METHOD  VALIDATION  FOR  TEMAZEPAM 
....................................................................... 
80 
2.15.1  High  Concentration  Calibration  Curves 
............................................................... 
80 
2.15.1.1  Experimental 
................................................................................................... 
80 
2.15.1.2  Results  and  Discussion 
...................................................................................  81 
2.15.2  Extractions  with  Internal  Standard 
........................................................................ 
82 
2.15.2.1  Experimental 
...................................................................................................  82 
2.15.2.2  Results  and  Discussion  ...................................................................................  82 
2.15.3  Linearity  of  Extraction  Above  the  Terapeutic  Concentration 
............................... 
83 
2.15.3.1  Experimental 
...................................................................................................  83 
2.15.3.2  Results  and  Discussion 
...................................................................................  83 
2.15.4  Continuation  of  Calibration  with  System  Controller 
............................................  85 
2.15.4.1  Experimental 
...................................................................................................  85 Table  Of  Contents  vi 
2.15.4.2  Results  and  Discussion 
................................................................................... 
85 
2.15.5  Intra-  and  Inter-Day  Reproducibility 
.................................................................... 
87 
2.15.5.1  Experimental  ...................................................................................................  87 
2.15.5.2  Results  and  Discussion 
................................................................................... 
87 
2.15.6  Alteration  of  Outlet  Restriction  ............................................................................. 
88 
2.15.6.1  Experimental 
................................................................................................... 
88 
2.15.6.2  Results  and  Discussion  ................................................................................... 
88 
2.15.7  Vitreous  Humor 
..................................................................................................... 
89 
2.15.7.1  Definition  ........................................................................................................ 
89 
2.15.8  Analysis  .................................................................................................................. 
90 
2.15.8.1  Vitreous  Humor  Analysis  for  Benzodiazepines  ............................................. 
90 
2.15.9  Extractions  with  EtAc  (10%)  as  the  Modifier  ........................................................ 
91 
2.15.9.1  Experimental 
................................................................................................... 
91 
2.15.9.2  Results  and  Discussion  ................................................................................... 
91 
2.16  METHOD  VALIDATION  FOR  ALL  FIVE  STANDARDS 
......................................................... 
93 
2.16.1,  Linearity  of  Diazepam,  Desmethyldiazepam,  Chlordiazepoxide  and  Triazolam 
Methanol  Standards 
.......................................................................................................... 
93 
2.16.1.1  Experimental 
................................................................................................... 
93 
2.16.1.2  Results  and  Discussion 
...................................................................................  93 
2.16.2  Linearity  of  Diazepam  and  Desmethyldiazepam  Blood  Standards 
....................... 
94 
2.16.2.1  Experimental 
...................................................................................................  94 
2.16.2.2  Results  and  Discussion 
...................................................................................  94 
2.16.3  Preparation  of  Fresh  Standards  and  Calculation  of  Limits  of  Detection 
............. 
95 
2.16.3.1  Experimental 
...................................................................................................  95 
2.16.3.2  Results  and  Discussion 
...................................................................................  95 
2.17  CONCLUSIONS 
................................................................................................................  97 
3.  OPIATES 
.........................................................................................................................  98 
3.1  INTRODUCnOrr 
................................................................................................................  98 
3.2  PRESCRIPTION 
..................................................................................................................  99 
3.3  CHEMICAL  STRUCTURE 
....................................................................................................  99 
3.4  PHARMACOLOGY 
...........................................................................................................  100 
3.5  METABOLISM 
.................................................................................................................  101 Table  Of  Contents  vii 
3.6  PHARMACOxiNETics  ...................................................................................................... 
102 
3.7  LEGAL  STATUS 
.............................................................................................................. 
103 
3.8  ANALYSIS  OF  MORPHINE 
............................................................................................... 
103 
3.9  SFB  ANALYSIS  OF  MORPHINE 
....................................................................................... 
104 
3.10  STATUS  OF  CASES 
........................................................................................................ 
105 
3.11  CURRENT  METHODOLOGY 
........................................................................................... 
105 
3.12  GC/MS  METHODOLOGY 
............................................................................................. 
106 
3.13  ExPERIMENTAL  ............................................................................................................ 
107 
3.13.1  Sub-Critical  Fluid  Extraction  of  Morphine 
......................................................... 
108 
3.13.1.1  Experimental  ................................................................................................. 
108 
3.13.1.2  Results  and  Discussion  ................................................................................. 
108 
3.13.2  Extraction  at  Various  Volumes  of  Morphine/d3-Morphine  ................................. 
110 
3.13.2.1  Experimental  ................................................................................................. 
110 
3.13.2.2  Results  and  Discussion  ................................................................................. 
110 
3.13.3  Lineariy  of  Morphine  Extraction  ......................................................................... 
111 
3.13.3.1  Experimental  ................................................................................................. 
111 
3.13.3.2  Results  and  Discussion  ................................................................................. 
111 
3.13.4  Supercritical  Fluid  Extraction  Method  ............................................................... 
112 
3.13.4.1  Experimental 
................................................................................................. 
112 
3.13.4.2  Results  and  Discussion  ................................................................................. 
113 
3.13.5  Linearity  of  Morphine  Extraction 
........................................................................ 
115 
3.13.5.1  Experimental 
................................................................................................. 
115 
3.13.5.2  Results  and  Discussion  .................................................................................  115 
3.13.6  Comparison  of  SFE  and  SPE 
..............................................................................  116 
3.13.6.1  Experimental  .................................................................................................  116 
3.13.6.2  Results  and  Discussion  .................................................................................  116 
3.13.7  Effect  of  Derivatisation  Time 
...............................................................................  117 
3.13.7.1  Experimental 
.................................................................  ......  ........  ......  ..... 
117 
..  .  ...  . 
3.13.7.2  Results  and  Discussion 
..............  .....  117 
....  .......................................................... 
3.13.8  Conclusions  on  Method  To  Use 
...........................................................................  118 
3.14  INTRODUCrIoN  OF  6MAM  mrrro  M  SFE 
....................................................................  118 
3.14.1  Determination  of  m/z  340/400  Ratio  for  Verification  Purposes 
.......................... 
119 Table  Of  Contents  VI" 
3.14.1.1  Experimental 
.................................................................................................  119 
3.14.1.2  Results  and  Discussion  .................................................................................  119 
3.14.2  Stability  of  6MAM  in  the  SFE  System  and  its  Effect  on  Morphine 
......................  120 
3.14.2.1  Experimental 
.................................................................................................  120 
3.14.2.2  Results  and  Discussion  .................................................................................  120 
3.14.3  Investigation  of  Morphine  Glucuronide 
.............................................................. 
121 
3.14.3.1  Experimental 
................................................................................................. 
121 
3.14.3.2  Results  and  Discussion 
................................................................................. 
122 
3.14.4  Extraction  With  Fresh  Morphine  Glucuronide  ................................................... 
122 
3.14.4.1  Experimental 
................................................................................................. 
122 
3.14.5  Check  of  SFE  Conditions  for  the  Determination  of  Morphine  and  6MAM 
......... 
122 
3.14.5.1  Experimental  ................................................................................................. 
122 
3.14.5.2  Results  and  Discussion  ................................................................................. 
123 
3.14.6  Investigation  of  m/z  399  peak  for  Verification  Purposes 
...................................  . 
125 
3.14.6.1  Experimental  ................................................................................................  . 
125 
3.14.6.2  Results  and  Discussion  ................................................................................  .  125 
3.14.7  Linearity  and  LOD  for  6MAM 
............................................................................  .  126 
3.14.7.1  Experimental 
................................................................................................  . 
126 
3.14.7.2  Results  and  Discussion 
................................................................................  . 
126 
3.15  CONCLUSIONS 
.............................................................................................................. 
127 
4.  METHADONE 
..............................................................................................................  128 
4.1  INTRODUC  I`IOrr  ..............................................................................................................  128 
4.2  PRESCRIPTION 
................................................................................................................  129 
4.3  CHEMICAL  STRUCTURE 
..................................................................................................  129 
4.4  PHARMACOLOGY 
...........................................................................................................  130 
4.5  METABOLISM 
.................................................................................................................  130 
4.6  PHARMACOKINETICS 
......................................................................................................  131 
4.7  LEGAL  STATUS 
..............................................................................................................  132 
4.8  ANALYSIS  OF  METHADONE 
............................................................................................  132 
4.9  SFE  ANALYSIS  OF  METHADONE 
....................................................................................  132 
4.10  STATUS  OF  CASES 
........................................................................................................  133 
4.11  CURRENT  METHODOLOGY 
...........................................................................................  133 Table  Of  Contents  ix 
4.12  EXPERIMENTA 
. ............................................................................................................. 
134 
4.12.1  Analysis  Instrumentation  ..................................................................................... 
134 
4.12.2  GC  Injection  Reproducibility  .............................................................................. 
135 
4.12.2.1  Experimental  ................................................................................................. 
135 
4.12.2.2  Results  and  Discussion  ................................................................................. 
135 
4.12.3  Extraction  of  Methadone  Using  EtAc  as  a  Modifier  ........................................... 
135 
4.12.3.1  Experimental  ................................................................................................. 
135 
4.12.3.2  Results  and  Discussion  ................................................................................. 
136 
4.12.4  Extraction  of  Methadone  by  SFE  using  MeOH  as  a  Modifier  ............................ 
136 
4.12.4.1  Experimental 
................................................................................................. 
13  6 
4.12.4.2  Results  and  Discussion  ................................................................................. 
136 
4.12.5  Extractions  from  C8  ............................................................................................. 
137 
4.12.5.1  Experimental  ................................................................................................. 
137 
4.12.5.2  Results  and  Discussion  ................................................................................. 
137 
4.12.6  Determination  of  Interfering  System  Peaks 
......................................................... 
138 
4.12.6.1  Experimental 
................................................................................................. 
13  8 
4.12.6.2  Results  and  Discussion 
................................................................................. 
138 
4.12.7  Extraction  of  Methadone  using  the  Benzodiazepine  SFE  Conditions  ................. 
139 
4.12.7.1  Experimental 
................................................................................................. 
139 
4.12.7.2  Results  and  Discussion  ................................................................................. 
139 
4.12.8  Extractions  Using  EtAc  and  C8 
........................................................................... 
139 
4.12.8.1  Experimental  .................................................................................................  139 
4.12.9  Extractions  with  EtAc  and  C8  Continued 
............................................................  140 
4.12.9.1  Experimental 
.................................................................................................  140 
4.12.10  Extractions  Using  Alternative  Supports 
............................................................  140 
4.12.10.1  Experimental 
................................................................................  .  ......... 
140 
.  .... 
4.12.11  Check  of  SFE  System  .....................................................  141  .................................... 
4.12.11.1  Experimental 
...........................................  .  .  .  ...  141 
...  ..  .  ..  ...................................... 
4.12.11.2  Results  and  Discussion 
...  141  ............................................................................ 
4.12.12  System  Flush 
......................................................................................................  141 
4.12.13  New  Retention  Times  for  Methadone  and  Cyclizine 
.......................................... 
142 
4.12.13.1  Experimental 
...............................................................................................  142 Table  Of  Contents  X 
4.12.13.2  Results  and  Discussion 
...............................................................................  142 
4.12.14  Repeat  of  Extractions  with  New  Pressure  Regulator 
........................................ 
143 
4.12.14.1  Experimental 
...............................................................................................  143 
4.12.14.2  Results  and  Discussion  ...............................................................................  143 
4.12.1  5  Extractions  at  Various  Pressures  ...................................................................... 
143 
4.12.15.1  Experimental 
............................................................................................... 
143 
4.12.15.2  Results  and  Discussion  ............................................................................... 
143 
4.12.16  Investigation  of  pKa  .......................................................................................... 
144 
4.12.17  Extraction  using  Morphine  Conditions 
............................................................. 
144 
4.12.17.1  Experimental 
............................................................................................... 
144 
4.12.17.2  Results  and  Discussion  ............................................................................... 
145 
4.12.18  Morphine  Modifier  Methadone  Extraction 
........................................................ 
146 
4.12.18.1  Experimental 
............................................................................................... 
146 
4.12.18.2  Results  and  Discussion  ............................................................................... 
146 
4.12.19  Linearity  of  Methadone  with  Cyclizine  as  the  Internal  Standard 
.....................  . 
147 
4.12.19.1  Experimental  ..............................................................................................  . 
147 
4.12.19.2  Results  and  Discussion  ..............................................................................  .  147 
4.12.20  GC/MS  analysis  of  Methadone 
.........................................................................  . 
150 
4.12.20.1  Experimental 
..............................................................................................  . 
150 
20  4  12  2  Results  and  Discussion  150  .  .  .  ..............................................................................  . 
4.13  CONCLUSIONS 
.............................................................................................................. 
152 
5.  HAIR  ANALYSIS 
.........................................................................................................  153 
5.1  INTRODUCTION 
..............................................................................................................  153 
5.2  STRUCTURE  OF  HAIR 
.....................................................................................................  154 
5.2.1  Introduction 
...........................................................................................................  154 
5.2.2  Anatomy  of  Hair  ....................................................................................................  154 
5.2.3  Chemical  Composition  of  Hair 
..............................................................................  155 
5.2.4  The  Hair  Follicle 
...................................................................................................  155 
5.2.5  Secretory  Glands 
...................................................................................................  156 
5.2.5.1  Sebaceous  Glands 
...........................................................................................  157 
5.2.5.2  Apocrine  Glands 
.............................................................................................  158 
5.2.5.3  Sweat  Glands  (Eccrine  or  Merocrine) 
............................................................  158 Table  Of  Contents  xi 
5.2.6  The  Dermal  Papilla  and  Blood  Supply  to  the  Follicle 
.......................................... 
158 
5.2.7  Structure  of  the  Hair  Shaft 
....................................................................................  159 
5.2.7.1  Outer  Cuticle 
.................................................................................................. 
159 
5.2.7.2  Central  Cortex  ................................................................................................ 
159 
5.2.7.3  Central  Medulla  .............................................................................................. 
160 
5.2.8  The  Melanin  Granule  ............................................................................................ 
161 
5.2.9  The  Growth  Cycle  .................................................................................................. 
162 
5.2.9.1  Anagen  Phase  ................................................................................................. 
162 
5.2.9.2  Catagen  Phase  ................................................................................................. 
163 
5.2.9.3  Telogen  Phase  ................................................................................................. 
163 
5.2.9.4  Summary 
......................................................................................................... 
163 
5.2.10  Rate  of  Growth 
.................................................................................................... 
163 
5.2.11  Scalp  Hair  v  Beard  Hair  v  Pubic  Hair  as  a  Specimen  ........................................ 
164 
5.2.11.1  Scalp  Hair  ..................................................................................................... 
164 
5.2.11.2  Beard  Hair  ..................................................................................................... 
164 
5.2.11.3  Pubic  Hair  ..................................................................................................... 
165 
5.2.12  Summary 
.............................................................................................................. 
165 
5.3  TRANSFER  OF  DRUGS  INTO  HAIR 
...................................................................................  165 
5.3.1  Simple  Passive  Transfer  Model  .............................................................................  166 
5.3.2  Problems  with  the  Simple  Passive  Transfer  Model 
............................................... 
166 
5.3.2.1  Correlation  ...................................:...........  167  ....................................................... 
5.3.2.2  Drug  Metabolite  Ratios  ....................................................  . 
167 
.....  ........................ 
5.3.2.3  Time  Course  of  Drug  Incorporation 
...............................................................  167 
5.3.3  Multicompartment  Model 
..................................  .  .  :  :  168  .  ...  ..........  ...................  ............... 
5.3.4  Proposed  Model  .............................................  168  ....................................................... 
5.3.4.1  Transfer  via  Sweat,  Sebaceous  and  Apocrine  Glands 
....................................  168 
5.3.4.2  Transfer  from  the  External  Environment 
........................................................  169 
5.3.4.3  Transfer  from  Deep  Compartments  in  the  Skin 
..............................................  169 
5.4  ANALYSIS 
...........................................  170 
5.4.1  Quantitative  Aspects  of  Hair  Analysis 
.............................  170  ...................................... 
5.4.2  Wash  Procedures  172  ................................................................................................... 
5.4.3  Digestion  /  Extraction  Procedures  173  .......................................................................  . Table  Of  Contents  X11 
5.4.3.1  Benzodiazepine  Hair  Analysis 
........................................................................ 
174 
5.4.3.2  Opiates  Hair  Analysis  ..................................................................................... 
174 
5.4.3.3  Methadone  Hair  Analysis  ............................................................................... 
175 
5.4.3.4  SFE  Hair  Analysis  .......................................................................................... 
175 
5.4.4  Avoiding  False  Positives  ....................................................................................... 
176 
5.4.4.1  Contamination  ................................................................................................ 
176 
5.4.4.2  Measurement  of  metabolites  ........................................................................... 
176 
5.5  METHOD  DEVELOPMENT  FOR  HAIR  ANALYSIS 
.............................................................. 
177 
5.5.1  Preparation  of  Hair  standards  .............................................................................. 
178 
5.5.1.1  Wash  Procedure  .............................................................................................. 
178 
5.5.1.2  Grinding  Procedure 
......................................................................................... 
178 
S_5.2  Hair  Svikine  Procedure  ......................................................................................... 
179 
5.6  EXTRACTION  METHODOLOGY 
........................................................................................ 
179 
5.7  METHOD  DEVELOPMENT  FOR  THE  EXTRACTION  OF  BENZODIAZEPINES  FROM  HAIR 
....... 
180 
5.7.1  Preliminary  Extractions  ........................................................................................ 
180 
5.7.1.1  Experimental  ................................................................................................... 
180 
5.7.1.2  Results  and  Discussion  ................................................................................... 
180 
5.7.2  Extraction  of  Temazepam,  Desmethyldiazepam  and  Diazepam  ............................ 
181 
5.7.2.1  Experimental  ................................................................................................... 
181 
5.7.2.2  Results  and  Discussion  ................................................................................... 
181 
5.7.3  Effect  of  Temperature  on  the  Extraction  of  Temazepam  from  Hair 
...................... 
182 
5.7.3.1  Experimental  ................................................................................................... 
182 
5.7.3.2  Results  and  Discussion  ................................................................................... 
182 
5.7.4  Effect  of  Temperature  on  the  Extraction  of  Benzodiazepines  from  Hair  with  EtAc 
as  a  Modifier  ................................................................................................................... 
183 
5.7.4.1  Experimental  ...................................................................................................  183 
5.7.4.2  Results  and  Discussion  ...................................................................................  183 
5.7.5  Effect  of  Temperature  on  the  Extraction  of  Benzodiazepines  from  Hair  with 
McOH:  Et3N.  "H20  as  a  Modifier 
.....................................................................................  183 
5.7.5.1  Experimental 
...................................................................................................  183 
5.7.5.2  Results  and  Discussion 
...................................................................................  184 
5.7.6  Extraction  of  an  Authentic  Hair  Sample 
...............................................................  184 Table  Of  Contents  xiii 
5.7.6.1  Experimental 
...................................................................................................  184 
5.7.7  Linearityfor  the  Extraction  of  Benzodiazepines  from  Hair 
..................................  185 
5.7.7.1  Experimental 
...................................................................................................  185 
5.7.7.2  Results  and  Discussion 
...................................................................................  185 
5.8  METHOD  DEVELOPMENT  FOR  THE  EXTRACTION  OF  MORPHINE  FROM  HAIR 
................... 
186 
5.8.1  Preliminary  Check  of  Methodology 
....................................................................... 
186 
5.8.2  Effect  of  Temperature  on  the  Extraction  of  Morphine  from  Hair  (Internal  Standard 
Added  Pre-Extraction) 
.................................................................................................... 
187 
5.8.2.1  Experimental  ...................................................................................................  187 
5.8.2.2  Results  and  Discussion 
................................................................................... 
187 
5.8.3  Effect  of  Temperature  on  the  Extraction  of  Morphine  from  Hair  (Internal  Standard 
Added  Post-Extraction) 
.................................................................................................. 
188 
5.8.3.1  Experimental 
...................................................................................................  188 
5.8.3.2  Results  and  Discussion 
...................................................................................  188 
5.8.4  Direct  Comparison  of  Pre  and  Post  Adding  of  Internal  Standard 
........................ 
189 
5.8.4.1  Experimental 
..................................................  189 
................................................. 
5.8.4.2  Results  and  Discussion 
.  189  .................................................................................. 
5.8.5  Introduction  of  6MAM  to  Hair  Extractions 
...........................................................  190 
5.8.5.1  Experimental 
..........................................................  .  190  .  ....................................... 
5.8.5.2  Results  and  Discussion 
.................................  190  .................................................. 
5.8.6  Linearity  of  Morphine  and  6MAM 
........................................................................  191 
5.8.6.1  Experimental 
............................................  191  ....................................................... 
5.8.6.2  Results  and  Discussion 
...............................  191  .................................................... 
5.9  METHOD  DEVELOPMENT  FOR  THE  EXTRACTION  OF  METHADONE  FROM  HAIR 
............... 
192 
5.10  CONCLUSIONS 
..............................................................................................................  194 
6.  CASE  STUDIES 
............................................................................................................  196 
6.1  INTRODUCTION 
..............................................................................................................  196 
6.2  CASE  INFORMATION 
.......................................................................................................  196 
6.3  CIRCUMSTANCES  SURROUNDING  DEATH  AND  OTHER  RELEVANT  INFORMATION 
.......... 
200 
6.4  RESULTS  AND  DISCUSSION 
............................................................................................  214 
6.4.1  Blood  and  Vitreous  Humor 
....................................................................................  214 
6.4.1.1  Benzodiazepines 
.............................................................................................  214 Table  Of  Contents  xiv 
6.4.1.1.1  Analysis  of  PM  and  RTD  Blood  Samples 
.................................................... 
214 
6.4.1.1.2  Blood  and  Vitreous  Humor  Case  Samples  by  EIA  and  RIA  ........................... 
216 
6.4.1.2  Morphine  and  6MAM  in  Blood  and  Vitreous  Humor 
.................................... 
224 
6.4.1.3  Methadone  in  Blood  and  Vitreous  humor 
...................................................... 
226 
6.4.2  Hair  Analysis 
.........................................................................................................  229 
6.5  COMPARISON  OF  SFE  RESULTS  wrrn  CASE  HISTORIES 
.................................................. 
233 
6.5.1  Comparison  of  Case  History_  with  Blood  and  Vitreous  Humor  Result 
.................. 
233 
6.5.2  Comparison  of  Case  Histories  with  Hair  Results 
................................................. 
235 
6.6  CONCLUSIONS 
................................................................................................................ 
238 
7.  CONCLUSIONS  FROM  THESIS 
................................................................................. 
240 
8.  REFERENCES 
APPENDIX  ONE:  CALCULATION  METHODS  USED 
242 
261 
APPENDIX  Two:  CALCULATION  OF  STANDARD  DEVIATION  262 
APPENDIX  THREE:  DISTRIBUTION  OF  AGE/SEX  OF  CASES  263 
APPENDIX  FOUR:  PAPERS  IN  SUPPORT  OF  THIS  THESIS  264 List  of  Abbreviations  xv 
Drugs  and  Materials 
Tem/Temaz:  Temazepam 
Diaz:  Diazepam 
DMD:  Desmethyldiazepam 
CDP:  Chlordiazepoxide 
Triaz:  Triazolam 
Praz:  Prazepam 
Morph:  Morphine 
6MAM:  6-monoacetylmorphine 
DHC:  Dihydrocodeine 
Meth:  Methadone 
Cycl:  Cyclizine 
d3:  tri-deuterated 
MeOH:  Methanol 
DCM:  Dichloromethane 
EtAc:  Ethyl  acetate 
Analytical  Methods 
HPLC:  High  performance  liquid  chromatography 
GC:  Gas  chromatography 
MS:  Mass  spectrometry 
FID:  Flame  ionisation  detector 
EIA:  Enzyme-immumoassay 
RIA:  Radio-immunoassay 
Other 
psi:  Pounds  per  square  inch 
NPM:  Needle  puncture  mark 
IVDA:  Intravenous  Drug  Abuser 
PM:  Post-mortem 
RTD:  Road  traffic  drug Summary  xvi 
SUMMARY 
The  use  of  supercritical  fluid  extraction  (SFE)  was  evaluated  for  the  determination  of  drugs 
of  Forensic  interest.  Three  matrices  were  investigated.  The  first  two  (blood  and  vitreous 
humor)  were  compared  to  SPE  and  LLE  methodology  currently  in  use  at  the  Department  of 
Forensic  Science  and  Medicine.  The  third  matrix,  hair,  was  assessed  to  determine  its 
usefulness  as  a  marker  of  past  drug  use. 
Three  types  of  drugs  were  investigated  by  SFE  namely,  benzodiazepines,  morphine  and 
methadone.  These  drugs  were  chosen  due  to  their  high  frequency  of  occurrence  in  post- 
mortem  cases  in  the  West  of  Scotland.  Successful  methodology  was  developed  for  all 
three  matrices  and  all  three  drug  types,  providing  an  efficient,  reproducible  alternative 
method  to  SPE  and  LLE,  which  reduced  the  environmental  risks  from  organic  solvents. 
The  developed  methods  were  applied  to  the  analysis  of  authentic  forensic  samples.  In 
addition  to  comparing  well  with  the  results  obtained  with  the  conventional  techniques, 
good  correlation  was  obtained  between  blood  and  vitreous  humor  results  for  temazepam, 
diazepam,  methadone  and  morphine.  Thus,  in  cases  where  a  body  is badly  decomposed  or 
burned,  vitreous  humor  can  be  used  as  an  alternative  post-mortem  sample. 
In  addition  to  the  determination  of  morphine,  6-monoacetyl  morphine  (6MAM)  was  used 
as  a  marker  of  heroin  abuse.  6MAM  was  detected  in  all  three  samples  matrices,  thus 
confirming  the  use  of  heroin  prior  to  death. 
Hair  analysis  for  all  three  types  of  drugs  was  carried  out  using  a  single  extraction  method. 
A  wide  range  of  concentrations  was  found  for  all  drug  types.  As  with  blood  and  vitreous 
humor,  6MAM  was  detected  and  used  as  a  marker  of  heroin  abuse.  From  this,  61%  of 
known  heroin  users  were  confirmed. 
On  the  whole,  the  developed  extraction  methodologies  provided  an  efficient  alternative 
approach  to  drug  analysis  in  Forensic  Toxicology. from  'Little  QcIcnd:  T  S.  C-IIiot Chapter  One:  Introduction  to  Supercritical  Fluids  Pagel 
1.  SUPERCRITICAL  FLUIDS 
1.1  INTRODUCTION 
One  hundred  and  seventy  five  years  ago  Baron  Charles  Cagniard  de  la  Tour  discovered  that 
above  certain  temperatures  and  pressures,  some  substances  can  no  longer  be  classified  as 
either  liquids  or  gases  but  share  the  properties  of  both.  '  The  ability  to  manipulate  these 
properties  for  a  variety  of  applications,  by  regulating  pressure  and  temperature,  is  now 
being  exploited  by  the  analytical  chemist.  The  most  commonly  used  analytical  tools  which 
have  resulted  from  the  discovery  of  supercritical  fluids  are,  supercritical  fluid  extraction 
(SFE)  and  supercritical  fluid  chromatography  (SFC). 
It  is  possible  to  describe  a  supercritical  fluid  (SF)  by  reference  to  Figure  1.1.2  The  areas  of 
solid,  liquid  and  gas  are  well  defined  by  boundaries.  Moving  along  the  gas  liquid 
boundary,  both  temperature  and  pressure  increase.  The  liquid  becomes  less  dense  due  to 
thermal  expansion  and  as  a  result  of  increasing  pressure,  the  gas  becomes  more  dense.  3  At 
the  critical  point  (C.  P.  )  the  densities  of  the  two  phases  are  identical  and  there  is  no 
distinction  between  the  gas  and  liquid  phases.  The  substance  can  now  only  be  described  as 
a  fluid. 
The  critical  point  has  co-ordinates  of  temperature  and  pressure  as  seen  in  Figure  1.1.  These 
points  are  specific  to  a  substance  and  are  referred  to  as  the  critical  temperature  (Tc)  and 
critical  pressure  (pc).  Other  important  critical  parameters  are  the  critical  density  (pc)  and 
the  critical  volume  (Vc)  for  one  mole  of  substance.  The  term  supercritical  fluid  is  used  to 
describe  substances  above  their  critical  temperature  and  pressure.  Critical  parameters  of 
some  of  the  substances  used  as  supercritical  fluids  are  shown  in  Table  I.  I.  Of  these 
substances,  the  most  commonly  used  supercritical  fluid  in  analysis  is  carbon  dioxide 
(CO2)  4  This  is  due  to  its  convenient  supercritical  temperature  and  pressure,  its  cheapness, 
its  non-explosive  nature  and  its  non-toxicity. Chapter  One:  Introduction  to  Supercritical  Fluids  Page2 
Supercritical 
Fluid 
p  72.9  r-  ,  C.  P. 
c  P 
(Atm) 
Liquid 
Solid 
Gas 
Triple  point 
T(OC) 
Tc31.3 
Figure  1.1:  Phase  Diagram  for  Carbon  Dioxide 
Table  1.1:  Physical  Properties  of  Selected  Supercritical  Fluids 
Substance  T  (°C)  pc  (atm)  (g  cm-3) 
CO  31.3  79.2  0.47 
N,  20  36.5  72.5  0.45 
SF6  45.5  37.1  0.74 
NH  132.5  112.5  0.24 
H-20  374  227  0.34 
n-C  H  152  37.5  0.23 
n-C  H  197  33.3  0.23 
Xe  16.6  58.4  1.10 
CC17  7F  112  40.7  0.56 
CHF  25.9  46.9  0.52 
1.1.1  PROPERTIES  OF  SUPERCRITICAL  FLUIDS 
From  a  historical  viewpoint,  the  solvating  power  of  a  supercritical  fluid  (SF)  was  first 
discovered  more  than  a  century  ago  by  Hannay  and  Horgarth.  However,  it  is  only  in  the  s 
past  thirty  years  that  their  use  as  an  analytical  tool  has  been  developed. 
Supercritical  fluids  have  several  analytically  desirable  properties.  Table  1.2  gives  a 
comparison  between  gas,  liquid  and  supercritical  fluid  phases  for  density,  diffusivity  and Chapter  One:  Introduction  to  Supercritical  Fluids  Page3 
dynamic  viscosity  4  It  can  be  seen  that  SF's  have  densities  comparable  to  liquids,  dynamic 
viscosities  comparable  to  gases  and  diffusivities  between  liquids  and  gases. 
Table  1.2:  Comparison  of  Properties  of  Gases,  Liquids  and  SCFs4 
Phase  Density 
p  (g  m1'1) 
Diffusivity 
D  (cm2  s') 
Dynamic  viscosity 
71  (g  cm'ls'1) 
Gas  =10-3  0.01-1.0  0.5-3.5(x10-4) 
SCF  0.2-0.9  3.3-0.1(x10-4)  0.2-1.0(x10-3) 
Liquid  0.8-1.0  0.5-2.0(x10-5)  0.3-2.4(x10-2) 
The  combined  gas-like  mass  transfer  and  liquid-like  solvating  characteristics  of 
supercritical  fluids,  first  led  analytical  chemists  to  use  them  as  chromatographic  mobile 
phases  (supercritical  fluid  chromatography  (SFC))6  and  later  as  fluids  capable  of  removing 
species  from  solid  samples  (supercritical  fluid  extraction  (SFE)).  In  both  these  techniques, 
probably  the  most  important  factor  for  consideration  is  the  ability  of  the  mobile  phase  (in 
SFC)  or  extractant  (in  SFE)  to  solubilise  the  analytes  of  interest.  The  solvent  strength  of  a 
liquid  is  essentially  constant  regardless  of  the  extraction  conditions.  However,  the  solvent 
strength  of  a  supercritical  fluid  is  dependant  on  the  temperature  and  pressure  used  for  the 
extraction.  7 
1.1.1.1  SOLUBILITY 
By  using  supercritical  fluid  technology  it  is  possible  to  exploit  the  unusual  variations  in 
solubility  with  pressure  and  temperature,  which  occur  immediately  above  the  critical  point 
of  a  volatile  solvent.  8  As  stated  previously,  the  solvent  strength  of  a  SF  depends  on  the 
pressure  and  temperature  used  for  the  extraction.  At  constant  temperature,  extraction  at 
lower  pressures  will  favour  less  polar  analytes  and  extraction  at  higher  pressure  will  favour 
more  polar  and  higher  molecular  weight  analytes.  This  variation  in  solvent  strength  is 
highlighted  in  Figure  1.2  which  shows  the  dependence  of  the  Hildebrand  solubility 
parameter  on  temperature  and  pressure  for  supercritical  carbon  dioxide  (SF-CO2). Chapter  One:  Introduction  to  Supercritical  Fluids  Page4 
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Figure  1.2:  Effect  of  Temperature  and  Pressure  on  the  Hildebrand  Solubility  Parameter 
for  SF-CO  78 
It  is  essential  that  the  analyte  of  interest  dissolves  in  the  supercritical  fluid  and  thus  without 
any  knowledge  of  analyte  solubility,  the  optimisation  of  analysis  conditions  can  only  be 
carried  out  on  a  trial  and  error  basis.  However,  there  are  many  models  available  which 
describe  the  solubility  of  analytes  in  SF's.  The  simplest  of  these  is  the  solubility  parameter. 
1.1.1.2  SOLUBILITY  PARAMETER 
The  dissolution  of  a  solute  in  a  supercritical  fluid  is  a  complicated  phenomenon  thus,  the 
theoretical  prediction  of  equilibrium  solubility  is  often  difficult.  The  maximum  solubility 
which  a  solute  can  attain  in  a  SF  can  be  approximated  by  relating  the  solubility  parameter 
(8)  of  the  gas  to  its  critical  and  reduced  state  properties  using  Giddings  equation:  9 Chapter  One:  Introduction  to  Supercritical  Fluids  Pages 
S  =1.25p,  1/2  Pr8 
P  rl 
where:  pc  =  critical  pressure 
p,  g  =  reduced  density  of  gas 
p,  ý  =  reduced  density  of  liquid 
For  maximum  solubility,  the  solubility  parameters  of  the  fluid  and  the  solute  should  be 
identical.  Therefore,  by  using  the  above  expression  we  can  estimate  which  supercritical 
fluid  could  be  used,  and  at  what  density  for  a  given  solute. 
Other  methods  which  have  been  used  to  predict  solubility  data  include  equations  of  state,  10 
Hildebrand  solubility  parameters"  and  the  virial  coefficient.  12  These  approaches  require 
some  experimental  data  to  compute  unknown  parameters  and  often  utilise  complicated 
equations.  '  A  simple  empirical  method  was  developed  by  Mitra  and  Wilson13  which 
predicts  solubility  as  a  function  of  the  prevailing  temperature,  pressure  and  density  based 
on  the  fact  that  solubility  is  determined  by  a  combination  of  temperature  and  density. 
However,  other  properties  such  as  viscosity,  diffusivity  and  polarity  also  change  with 
temperature  and  pressure  and  these  may  affect  the  equilibrium  solubility.  Mitra  and 
Wilsons'  theory  is  based  on  a  negative  gradient  linear  relationship  existing  between 
temperature  and  density,  i.  e.  if  the  density  is  raised,  the  temperature  has  to  be  lowered  to 
keep  the  pressure  constant. 
1.1.2  PHASE  BEHAVIOUR  FOR  SUPERCRTTICAL  FLUID-SOLUTE  MIXTURES 
Interpreting  and  extrapolating  high  pressure  phase  behaviour  data  can  be  a  relentless  task. 
This  is  a  result  of  the  complexity  of  high  pressure  phase  behaviour  of  substances  at  or  near 
their  critical  points,  even  in  simple  binary  mixtures,  where  the  components  are  chemically 
similar.  14  For  a  given  practical  application  of  SF  technology,  it  is  likely  that  not  only  will 
the  mixture  components  be  different  in  molecular  size,  but  they  will  also  differ  in  shape, 
structure  and  polarity.  When  the  mixture  components  are  so  diverse,  or  when  the  mixture 
has  numerous  components,  the  resultant  phase  behaviour  can  be  very  complex. Chapter  One:  Introduction  to  Supercritical  Fluids  Page6 
The  addition  of  polar  modifiers  to  CO2  is  well  documented.  15  The  modifier  acts  in  two 
ways,  firstly  by  interacting  with  the  analyte/matrix  complex  to  facilitate  rapid  desorption 
into  the  supercritical  fluid  and  secondly  by  enhancing  the  solubility  properties  of  SF-C02. 
The  phase  behaviour  of  binary  systems  is  highly  varied  and  much  more  complex  than 
single  component  systems.  Even  simple  binary  compositions  can  undergo  complicated 
phase  transitions  near  the  critical  region.  Gas-liquid  or  gas-gas  immiscibility  can  occur  at 
conditions  exceeding  the  Tc  or  pc  of  either  pure  component.  As  a  result,  inhomogeneous 
phases  can  occur.  For  mixed  phases,  the  critical  constants  of  temperature  and  pressure  for 
the  mixture  can  be  approximated  as  the  arithmetic  mean  of  the  critical  temperatures  and 
pressure  i.  e.: 
Tc  =  XaTa  +  XbTb 
Pc  =  XaPa  +  XbPb 
where  xa  and  Xb  are  the  mole  fractions,  TA  and  Tb  are  the  critical  temperature  of  a  and  b  and 
pa  and  Pb  the  critical  pressures  of  components  a  and  b  respectively.  More  elaborate 
methods  are  based  on  the  method  of  Cheuh  and  Prausnitz16  for  the  critical  temperature  and 
Kreglewski  and  Kay17  for  the  critical  pressure. 
A  comprehensive  treatment  of  phase  diagrams  as  well  as  phase  behaviour  in  binary  and 
ternary  systems  has  been  published  by  McHugh  and  Krukonis.  18  Of  the  systems  described, 
the  simplest  is  concerned  with  a  binary  mixture  of  a  single  SF  solvent  and  a  single  solute.  19 
In  1970,  Scott  and  van  Konynenburg2°  demonstrated  that  virtually  all  experimentally 
observed  binary  phase  diagrams  can  be  qualitatively  described  using  the  van  der  Waals 
equation  of  state.  From  this,  five  classes  of  possible  binary  phase  diagrams  were  derived  as 
indicated  in  Figure  1.3.  Points  C1  and  C2  represent  the  critical  points  of  components  1  and 
2  respectively.  The  dashed  line  depicts  the  critical  mixture  curve  for  the  binary  mixture, 
and  the  open  triangles,  represent  the  critical  end  points.  Figure  1.3a  is  the  simplest  binary 
phase  diagram.  The  critical-mixture  curve  runs  continuously  from  the  critical  point  of  the 
heavier  component  to  the  critical  point  of  the  lighter  component. Chapter  One:  Introduction  to  Supercritical  Fluids  Pagel 
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Figure  1.3:  Five  Classes  of  Possible  Binary  Phase  Diagrams18 
The  use  of  these  phase  diagrams  provides  the  basis  for  an  understanding  of  the  phase- 
equilibrium  principles  that  are  operative  during  SF  solvent  extraction  of  mixtures,  and  for 
simplicity  they  are  drawn  as  two-dimensional  p-T  plots.  By  looking  at  the  general  three- 
dimensional  p-T-x  plot  where  x  denotes  the  composition  of  the  heavier  component  for  type 
I  binary  mixtures  (Figure  1.4),  it  can  be  seen  how  these  p-T  plots  are  formed.  The  p-T-x 
diagram  is  constructed  by  compiling  a  number  of  isothermal  p-x  plots  as  shown  in  figures 
1.4c  and  1.4d.  Figure  1.4c  is  a  plot  at  a  temperature  which  is  below  the  critical  temperature 
of  the  two  components.  A  vapour-liquid  envelope  is  observed  which  intersects  the 
pressure  axis  at  two  points:  the  vapour  pressure  of  pure  component  1  and  the  vapour 
pressure  of  pure  component  2.  At  a  fixed  overall  composition  (denoted  by  x*)  a  single Chapter  One:  Introduction  to  Supercritical  Fluids  PPage8 
vapour  phase  exists  at  low  pressures.  As  the  pressure  is  isothermally  increased,  the  two- 
phase  vapour-liquid  envelope  is  intersected  and  a  liquid  phase  now  appears.  The  locus  of 
points  which  separates  the  two-phase  vapour-liquid  region  from  the  one  phase  vapour 
region  is  called  the  "dew-point  curve".  The  concentration  of  the  equilibrium  vapour  and 
liquid  phases  within  the  two-phase  boundary  of  the  vapour-liquid  envelope  is  determined 
by  a  horizontal  tieline. 
As  the  pressure  is  increased  further,  the  amount  of  liquid  phase  in  the  mixture  increases 
and  the  amount  of  vapour  decreases  until  only  a  small  bubble  of  vapour  exists.  As  the 
pressure  is  increased  still  further,  the  bubble  of  vapour  disappears  and  only  a  liquid 
remains.  The  locus  of  points  which  separates  the  two-phase  vapour-liquid  region  from  the 
one  phase  liquid  region  is  called  the  "bubble-point  curve".  This  vapour-liquid  envelope  is 
shown  at  the  front  of  the  three-dimensional  p-T-x  plot  (1.4a). 
If  the  temperature  is  now  increased  to  a  temperature  above  the  critical  temperature  of  the 
component  1  (Tc1),  the  behaviour  shown  in  figure  1.4d  is  observed.  The  vapour-liquid 
envelope  is  similar  to  that  in  figure  1.4c,  however  the  envelope  intersects  the  pressure  axis 
only  at  the  vapour  pressure  of  component  2.  As  the  temperature  is  greater  than  Tcl,  the 
vapour-liquid  equilibrium  line  for  component  1  is  never  crossed.  If  an  experiment  is 
performed  at  an  overall  composition  of  x**,  the  vapour-liquid  envelope  is  first  intersected 
along  the  dew-point  curve  at  low  pressures  and  then  at  its  highest  pressure.  The  second 
intersection  corresponds  to  the  critical  mixture  point  for  this  temperature  and  composition. 
If  the  overall  composition  is  to  the  right  of  x**  and  the  pressure  is  decreased,  a  bubble 
point  is  observed  and  if  the  overall  composition  is  to  the  left  of  this  point  a  dew  point  is 
observed.  Again  the  three-dimensional  plot  at  this  temperatre  (T2)  is  shown  in  figure  1.4a. 
In  order  to  create  the  full  critical  curve,  p-x  diagrams  are  produced  at  higher  and  higher 
temperatures  to  determine  the  critical  mixture  points.  These  p-x  diagrams  are  then 
assembled  to  form  the  three-dimensional  p-T-x  representation  and  the  critical  mixture 
curve  plotted  by  joining  the  critical  mixture  points.  Figure  1.3a  is  created  from  this  by 
projecting  the  three-dimensional  p-T-x  diagram  onto  a  two-dimensional  p-T  diagram. Chapter  One:  Introduction  to  Supercritical  Fluids  Page9 
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Figure  1.4:  P-T-x  p-T  and  y-x  Diagrams  for  a  Type  I  Binary  Mixture 
The  same  principles  apply  when  creating  the  other  four  binary  phase  diagrams.  An  in 
depth  description  of  all  five  classes  of  binary  mixture  behaviour  is  provided  by  McHugh 
and  Krukonis.  '8 
1.2  SUPERCRITICAL  FLUID  EXTRACTION 
The  first  step  in  biological  sample  analysis  involves  separating  the  compounds  of  interest 
from  the  matrix  (e.  g.  blood,  tissue,  urine).  At  present,  this  is  done  mainly  by  liquid 
extraction  techniques  such  as  solid-phase  extraction  (SPE)  and  liquid-liquid  extraction 
(LLE).  These  can  prove  to  be  time  consuming  and  costly  as  they  require.  high 
.  purity 
organic  solvents.  2'  The  use  of  high  purity  solvents  also  means  that  there  is  a  significant 
amount  of  toxic  waste  produced.  Supercritical  fluid  extraction  (SFE)  which  is  a  quicker, 
more  convenient  alternative  method  to  liquid  extraction  techniques  offers  the  following 
advantages.  22 
"  Improved  efficiency 
"  Non-toxicity  and  cost  effectiveness  of  extraction  fluid Chapter  One:  Introduction  to  Supercritical  Fluids  Page  10 
"  Extraction  of  thermally  labile  compounds 
"  Easy  control  of  conditions 
"  Ease  of  separation  of  analytes  from  the  supercritical  fluid 
"  Possibility  of  direct  analysis  of  complex  matrices  and  thus  reduced  risk  of  sample 
contamination 
"  Potential  of  fractionation 
"  Compatibility  with  on-line  methods 
"  Possibility  of  class  sensitive  extraction  by  choosing  fluid  polarity  and  density  and/or  the 
use  of  a  modifier 
1.2.1  METHOD  DEVELOPMENT  IN  SFE 
Before  developing  a  method  for  SFE,  it  is  essential  that  the  analyst  has  an  understanding  of 
the  composition  of  the  matrix  and  the  properties  of  the  analytes.  23  Solubility  data  and 
correlations  as  discussed  earlier,  provide  useful  information  for  choosing  initial  SFE 
conditions.  However,  the  determination  of  the  optimum  extraction  conditions  has  been 
largely  experimental  for  two  reasons.  8  Firstly,  analytical  SFE  often  involves  the  recovery 
of  a  complex  mixture  of  analytes  rather  than  a  single  analyte.  In  such  cases,  the  extraction 
must  be  optimised  for  several  groups  of  compounds  which  complicates  the  prediction  of 
conditions.  Secondly,  consideration  of  solubility  only  addresses  part  of  the  extraction 
problem.  As  the  extraction  of  an  analyte  depends  on  its  distribution  between  the  SF  and 
the  sorptive  sites  on  the  sample  matrix,  the  ability  of  the  SF  to  compete  with  the  analyte  for 
the  sorptive  sites  may  be  more  significant  than  solubility  considerations  in  determining  the 
optimum  extraction  conditions. 
Most  SFE  methods  concentrate  on  the  use  of  CO2  due  to  its  reasonable  critical  properties, 
its  low  toxicity  and  its  chemical  inertness.  It  is  an  excellent  choice  for  non-polar  organic 
compounds.  However,  it  has  a  severe  limitation  in  that  its  polarity  is  often  too  low  to 
obtain  efficient  extractions,  either  because  the  analytes  lack  sufficient  solubility  or  the 
extractant  has  poor  ability  to  displace  the  analytes  from  the  active  matrix  sites.  As  most  of 
the  work  on  SFE  has  used  analytes  spiked  on  inert  supports,  it  has  been  assumed  that  CO2 
is  the  ideal  leacher.  However,  in  authentic  samples,  the  matrix-analyte  interactions Chapter  One:  Introduction  to  Supercritical  Fluids  Page  11 
dramatically  reduce  the  extraction  efficiency  which  further  reduces  as  the  polarity  of  the 
analytes  increases.  There  are  however  ways  of  getting  round  this  problem  as  summarised 
24  in  Figure  1.5 
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Figure  1.5:  Strategies  for  Facilitating  SFE  of  Polar  and  Ionic  Compounds 
The  simplest  of  these  strategies  to  apply,  when  SF-CO2  at  its  most  polar  is  ineffectual, 
would  be  to  use  an  alternative  supercritical  fluid.  However,  in  practice,  many  difficulties 
are  encountered  when  using  polar  fluids  (e.  g.  ammonia  tends  to  dissolve  pump  seals  and 
water  has  impractical  critical  parameters  (Tc  =  374  °C,  pe  =  227  atm)).  As  a  result  of  this, 
the  extraction  of  polar  analytes  is  usually  carried  out  with  the  addition  of  polarity 
modifiers. 
The  combination  of  modifier  and  high  temperature  has  been  shown  by  Yang  et  a125  to  be 
highly  effective  in  the  extraction  of  polar  analytes.  The  modifier  can  either  be  added 
directly  to  the  sample  in  the  extraction  cell  or  mixed  with  the  CO2.  In  general,  the  latter  is 
more  effective  since  the  modifier  is  continuously  passed  through  the  sample.  However,  as 
will  be  seen  later,  the  addition  of  the  modifier  directly  to  the  sample  also  has  its 
advantages. 
Although  methanol  is  the  most  widely  used  modifier  in  SFE,  a  variety  of  organic 
compounds  have  been  used  including  alcohols,  propylene  carbonate,  2-methoxyethanol  and Chapter  One:  Introduction  to  Supercritical  Fluids  Page  12 
methylene  chloride.  26  The  selection  of  modifiers  and  their  concentration  has  been  largely 
empirical  as  very  little  analyte  solubility  data  exists  for  modified  SFs.  In  addition,  the 
competitive  interactions  between  the  modified  SF  and  the  target  analytes  with  the  sorptive 
sites  on  the  matrix  are  poorly  understood.  Janssen  et  a127  have  evaluated  methods  of 
estimating  critical  properties  and  densities  of  mixed  fluids. 
The  use  of  modifiers  in  SFE  was  first  reported  by  Zhuze28  Probably  the  best  known 
extraction  using  SFE  is  that  of  caffeine  from  coffee  and  tea.  9  Although  caffeine  is 
extremely  soluble  in  COZ,  it  cannot  be  extracted  from  coffee  and  tea  leaves  using  CO2 
alone.  The  addition  of  a  small  amount  of  water  to  the  CO2  allows  almost  complete 
extraction  thus,  emphasising  the  importance  of  the  use  of  modifiers. 
1.2.2  ANALYTES 
The  choice  of  analyte  is  not  a  free  variable,  but  is  predetermined  by  the  sample.  Analysts 
are  interested  in  qualitative  presence  and  quantitative  amounts  of  a  small  number  of  the 
compounds  present  in  the  sample.  By  adjusting  the  solubilizing  power  of  CO2  in  SFE,  we 
can  selectively  reduce  the  number  of  compounds  extracted  30  This  is  done  by  adjusting  the 
temperature  and/or  pressure  or  by  the  addition  of  a  modifier. 
For  samples  in  e.  g.  blood,  serum  and  plasma,  the  non-polar  nature  of  SF-CO2  allows  easy 
extraction  of  non-polar  drugs  e.  g.  nitroglycerine  from  water,  salts,  proteins,  carbohydrates, 
peptides,  amino  acids  and  other  interfering  compounds  in  a  biological  matrix.  In  general, 
drugs  of  abuse  are  polar  in  nature  and  thus,  the  addition  of  a  polar  modifier  to  SF-CO2  is 
essential  to  the  extraction  process.  31 
1.2.3  MATRICES 
SFE  exhibits  its  best  advantage  when  extracting  analytes  from  solids  or  semi-solids  as 
opposed  to  liquids,  fluids  and  gases.  0  The  primary  limitation  in  extracting  from  a  liquid  or 
fluid  sample  matrix  is  the  design  of  the  extraction  cell.  The  matrix  is  held  within  the 
extraction  cell  by  porous  frits,  similar  to  those  used  for  the  end  frits  in  HPLC  columns. 
These  frits  hold  small  particles  inside  the  column  and  allow  fluids  to  pass  through,  thus Chapter  One:  Introduction  to  Supercritical  Fluids  Page13 
attempts  to  pass  SF-CO2  through  a  liquid  will  result  in  the  liquid  matrix  passing  through 
the  frits.  Successful  SFE  of  liquids  requires  the  liquid  being  mixed  with  a  solid  material 
e.  g.  diatomaceous  earth  so  that  the  sample  is  no  longer  free  flowing. 
1.2.4  CHOICE  OF  EXTRACTING  FLUID 
A  good  solvent  for  extraction  should:  21 
"  Be  selective:  as  the  objective  is  to  separate  the  analyte  from  a  matrix,  the  solvent  should 
be  able  to  dissolve  the  desired  analyte  better  than  the  other  constituents  of  the  matrix 
"  Have  a  high  capacity  for  the  analyte:  this  helps  minimise  the  volume  and  time  required 
to  extract  quantities  suitable  for  analysis 
"  Be  stable  and  unreactive  to  the  solute  and  matrix  under  the  conditions  of  the  extraction 
"  Not  be  corrosive  to  the  equipment 
"  Be  relatively  inexpensive 
"  Be  non-toxic 
From  an  extraction  point  of  view,  the  important  properties  of  supercritical  fluids  include 
the  diffusion  coefficient,  the  density  and  the  viscosity.  Faster  diffusion  leads  to  more 
efficient  separations  than  liquids  facilitate.  The  viscosity  of  a  supercritical  fluid  falls 
between  that  of  a  gas  and  a  liquid,  which  facilitates  pumping  and  fluid  flow.  Enhanced 
passage  of  the  solvent  into  the  interstices  of  the  matrix  occurs  as  a  result  of  low  viscosity 
and  the  absence  of  surface  tension. 
1.2.5  SELECTIVITY  IN  EXTRACTIONS 
The  extraction  of  analytes  from  adsorbing  matrices  involves  three  basic  steps:  32 
1.  Removal  of  compounds  from  the  matrix  surface. 
2.  Solvation  of  analytes  in  the  fluid. 
3.  Mass  transport  of  solubilized  molecules  to  the  bulk  of  the  fluid  to  allow  removal  from 
the  extraction  vessel. Chapter  One:  Introduction  to  Supercritical  Fluids  Page14 
To  optimise  analytical  SFE,  it  is  necessary  to  define  a  rate  determining  step  (RDS).  Due  to 
the  chemical  differences  of  each  molecule  and  matrix,  the  analyte-matrix  interactions  are 
unique  for  each  sample.  Conditions  have  to  be  selected  to  emphasise  the  differences 
between  any  interferences  present  and  the  target  analyte  in  order  to  achieve  effective 
extraction. 
Step  three  is  least  likely  to  introduce  selectivity.  The  primary  driving  force  here  is 
molecular  diffusion  within  the  solid  matrix  and  the  rate  is  defined  by  the  diffusion 
coefficient.  33  This  is  inversely  proportional  to  the  square  root  of  the  molecular  weight  of 
the  solute  at  constant  density  of  the  fluid,  therefore  if  this  was  the  RDS,  separation  would 
only  occur  between  species  of  substantially  different  weights.  34  These  differences  can  be 
emphasised  by  adjusting  the  porosity  of  the  extraction  matrix.  35  However,  in  most  cases 
the  interferents  do  not  differ  substantially  from  the  analytes  in  weight. 
Step  two  has  been  extensively  investigated.  36.37  To  ensure  dissolution  of  the  analyte  in  the 
fluid,  the  cohesive  energy  (i.  e.  the  energy  which  holds  the  structure  of  a  substance  together) 
must  be  overcome  by  the  interaction  of  the  molecules  with  the  fluid.  When  this  is  the  case 
the  solubility  properties  of  the  solutes  are  defined  by  the  solubility  parameter  (8).  38 
lo.  s  [D(Hv 
-  RT)  0.5 
M 
where:  AE￿  =  energy  of  vaporisation  V=  molar  volume 
D=  density  OH￿  =  heat  of  vaporisation 
R=  Gas  constant  (8.314  J  K''  mol"1)  T=  temperature 
M=  molecular  weight  of  solute  or  fluid 
This  same  value  of  S  can  however  be  calculated  for  a  SF  more  conveniently  by  using 
Giddings  equation  as  described  in  section  1.1.1.2. 
As  the  solubility  of  analytes  in  a  fluid  is  related  to  the  difference  between  their  solubility 
parameters,  the  more  similar  the  solubility  parameters  are,  the  greater  the  solubility.  It  is Chapter  One:  Introduction  to  Supercritical  Fluids  Page  15 
therefore  feasible  to  design  experiments  where  the  analyte  is  soluble  in  the  fluid,  but  the 
interferents  are  not.  This  is  only  possible  if  the  analyte  and  the  interferents  have  different 
solubility  parameters. 
The  most  promising  separations  are  achieved  by  the  presence  of  an  additional  phase  in  the 
system.  A  distribution  constant  K,  can  be  defined,  which  is  related  to  the  differences  in  the 
solubility  properties  of  the  two  phases.  39  There  must  be  a  substantial  difference  between 
the  distribution  constants  and  the  solubility  parameters  corresponding  to  the  analyte  and 
interferences  to  ensure  complete  separation  based  on  a  low  efficiency  system  such  as  a 
loosely  packed  extraction  column. 
In  addition  to  determining  a  single  type  of  analyte,  the  selectivity  of  SFE  can  be  exploited 
by  controlling  the  temperature  and  pressure,  to  perform  a  sequential  extraction  of  various 
classes  of  analytes,  providing  they  are  of  suitably  different  polarities.  At  a  constant 
temperature,  the  extraction  of  non-polar  analytes  is  favoured  at  low  pressures,  while  the 
extraction  of  polar  analytes  requires  increased  pressure.  Most  extractions  use  a  low 
temperature  of  the  order  of  50  °C  and  increasing  pressure  is  used  to  extract  increasingly 
more  polar  target  analytes  to  obviate  the  risks  to  thermolabile  compounds.  However, 
Langenfeld  et  a14°  demonstrated  that  the  influence  of  temperature  is  paramount  to  the 
efficiency  of  the  extraction  of  polar  compounds  in  environmental  matrices. 
Step  one  makes  use  of  solid  surface  adsorbants.  Separation  occurs  due  to  partitioning 
differences  caused  by  different  interactions  between  the  target  analyte  and  interactions  with 
the  surface.  Interactions  between  the  surface  and  the  analyte  can  be  in  the  form  of  weak 
adsorption  through  dispersive  interactions,  but  can  also  involve  sharing  of  electrons 
between  the  adsorbent  and  the  analyte  (chemisorption)  41  Interactions  with  a  surface,  are 
much  more  specific  than  with  a  liquid.  Small  differences  in  geometry,  basicity  or  acidity  of 
the  molecules  can  differentiate  between  individual  molecules.  This  means  that  molecules 
with  similar  solubility  properties  which  differ  in  chemical  or  steric  properties  can  be 
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The  other  advantage  is  that  the  elution  process  can  be  designed  to  be  selective  since  it 
proceeds  through  the  formation  of  the  activation  complex.  Figure  1.6  shows  the  energy 
requirements  for  the  desorption  process  of  an  analyte  from  a  solid  surface.  If  partitioning  is 
involved,  with  a  liquid  as  the  stationary  phase,  equilibrium  is  established  immediately 
according  to  the  partition  coefficient  (neglecting  adsorption/desorption  kinetics  at  the 
interface).  If  the  process  involved  is  desorption  from  a  solid  surface  it  is  kinetically  limited 
due  to  the  energy  barrier  of  desorption. 
Free 
Energy  Analyte 
on  surface 
Partition  (K) 
Activation 
Energy  (Ea) 
of  Desorption 
Analyte  in  fluid 
Reaction  coordinate 
Figure  1.6:  Free  Energy  v  Reaction  Coordinate  Indicating  Enerey  Requirements  for 
Desorption  of  Chemisorbed  Species31 
The  thermal  energy  easily  overcomes  the  low  energy  barriers  associated  with  weakly 
adsorbed  species.  However,  strongly  adsorbed  species  require  that  the  activation  energy 
(Ea)  be  reduced  by  selective  interaction  of  solvent  molecules  with  the  matrix-solute 
complex  in  order  to  break  the  bonds.  Instead  of  the  solubility  parameter  of  the  eluting 
solvent  being  the  most  important  parameter,  its  chemical/structural  properties  have  more  of 
an  effect.  It  should  be  noted  that  it  may  be  easier  to  remove  the  interferents  first,  leaving 
the  analyte  of  interest  on  the  extraction  surface  until  harsher  conditions  are  applied. Chapter  One:  Introduction  to  Supercritical  Fluids  Page  17 
1.2.6  PARTICLE  SIZE 
Another  factor  effecting  extraction  recoveries  is  the  particle  size  of  the  extracting  media. 
Diffusion  from  the  sample  matrix  is  very  important.  It  has  been  shown  that  the  percentage 
recovery  increases  from  78%  to  99%  by  halving  the  particle  size.  21  An  alternative  way  to 
increase  the  recovery  would  be  to  increase  the  extraction  time  by  a  factor  of  four.  As  one 
of  the  main  advantages  of  SFE  is  its  reduced  time,  this  is  extremely  impractical. 
1.2.7  EXTRACTION  METHODOLOGY 
SFE  can  be  carried  out  in  either  a  dynamic  or  a  static  mode.  8  However,  most  SFE  methods 
are  in  the  dynamic  mode  where  the  SF  is  passed  continuously  through  the  extraction  cell. 
Pressure  is  controlled  via  a  flow  restrictor  which  maintains  supercritical  conditions  inside 
the  extraction  vessel,  but  allows  depressurisation  into  a  collection  device.  Static  SFE  is 
carried  out  by  pressurising  the  extraction  vessel  and  extracting  the  sample  without  an 
outflow  of  the  SF.  After  a  pre-defined  time,  a  valve  is  opened  which  allows  the  extracted 
analytes  to  be  swept  out  into  the  collection  device.  It  is  here  that  the  advantage  of  adding 
the  modifier  directly  to  the  extraction  vessel  is  important.  A  fixed  amount  of  modifier  can 
be  added  to  the  matrix  and  then  the  extraction  vessel  pressurised  using  only  CO2. 
An  advantage  of  dynamic  SFE  is  that  fresh  SF  is  constantly  passed  over  the  surface  of  the 
matrix  containing  the  analytes.  However,  this  method  uses  more  fluid  than  static  SFE 
which  is  particularly  important  when  the  sample  volumes  are  large. 
1.2.8  OFF-LINE  SFE  VERSUS  ON-LINE  SFE 
Off-line  SFE  is  inherently  simpler  than  on-line  SFE,  as  only  the  extraction  step  needs  to  be 
optimised  and  the  extract  can  be  analysed  by  any  appropriate  method.  8  On-line  SFE 
requires  optimisation  of  both  the  SFE  and  the  chromatographic  conditions  and  unlike  with 
off-line  SFE,  the  sample  extract  is  not  available  for  subsequent  analyses.  The  principle 
advantages  of  on-line  SFE  are,  the  elimination  of  sample  handling  between  the  extraction 
and  chromatographic  analysis  and  the  potential  to  achieve  maximum  sensitivity  by 
quantitatively  transferring  the  extracted  analytes  into  the  chromatographic  system. Chapter  One:  Introduction  to  Supercritical  Fluids  Page  18 
1.2.8.1  OFF-LINE  SFE 
Off-line  SFE  has  been  extensively  studied  as  a  sample  preparation  technique  for 
chromatographic  analysis.  8  The  analytes  are  most  often  collected  in  a  few  millilitres  of  a 
liquid  solvent  and  analysis  is  carried  out  as  it  would  be  in  a  conventional  liquid  solvent 
extraction.  It  is  adaptable  to  sample  sizes  ranging  from  milligrams  to  several  grams  and  is 
equally  applicable  to  the  recovery  of  trace  analytes  or  complex  mixtures.  2  One  important 
concern  with  off-line  SFE  is  the  efficacy  of  the  analyte  trapping/collection  method  as 
discussed  in  section  1.2.9. 
1.2.8.2  ON-LINE  SFE 
The  combination  of  SFE  with  a  chromatographic  technique  is  a  logical  extension  of  the 
process.  8  The  variable  solvating  power  of  a  SF  provides  the  mechanism  for  the  selective 
extraction  of  the  components  of  interest  from  the  sample  matrix.  It  also  provides  the  basis 
for  an  automated  method  where  the  sample  preparation  and  final  analysis  can  be 
instrumentally  linked.  On-line  SFE  is  particularly  attractive  for  small  sample  sizes  and/or 
trace  analysis. 
1.2.9  SFE-COUPLED  TECHNIQUES 
A  variety  of  techniques  have  been  used  for  both  on  and  off  line  analysis  with  SFE.  22,43  The 
most  common  of  these  is  GC8  with  both  packed  and  capillary  columns.  Other  methods 
which  have  been  used  include  TLC44,  HPLC45,  SFC  46  Selection  of  the  best  technique  for 
coupling  is  based  on  the  nature  of  the  analytes  e.  g.  if  the  analytes  have  sufficient  vapour 
pressure,  GC  is  a  good  choice  due  to  high  resolution  per  unit  time  and  the  possibility  for 
the  use  of  many  types  of  detector. 
1.2.9.1  TRAPPING  TECHNIQUES  FOR  SFE-  COUPLED  TECHNIQUES 
For  good  results  with  chromatographic  coupling,  it  is  essential  to  trap  and  focus  the 
analytes  before  chromatography  commences.  If  this  step  was  omitted,  the  resulting 
chromatogram  would  be  a  collection  of  flat  broad  peaks.  The  trapping  methods  used  must 
be  capable  of  quantitatively  collecting  all  the  analytes  at  relatively  high  flow  rates. Chapter  One:  Introduction  to  Supercritical  Fluids  Page  19 
Trapping  can  be  external  or  on-column.  External  trapping  can  be  done  using  either  a  cold 
trap  or  a  sorbent  resin.  The  extract  is  depressurised  onto  the  trap  and  once  the  SFE  has 
finished,  the  trap  is  heated  and  the  analytes  swept  onto  the  chromatographic  column.  This 
method  is  preferable  to  on-column  trapping  as  the  fluid  does  not  have  to  be  vented  and 
hence,  there  is  no  risk  of  contaminating  the  column  or  detector.  However,  if  the  primary 
objective  is  quantitation,  on-column  trapping  is  far  superior.  The  use  of  an  external 
cryogenic  trap  is  particularly  useful  with  SFE-GC  where  a  FID  is  used.  Modifiers  e.  g. 
MeOH,  cause  detector  problems  and  since  the  trapping  can  be  made  selective,  the  MeOH 
can  be  removed  prior  to  injection  onto  the  column. 
1.2.9.2  SFE-TLC 
SFE-TLC  provides  a  rapid  and  simple  insight  into  the  performance  of  an  extraction.  The 
strength  in  this  technique  is  that  the  extract  is  deposited  directly  onto  the  TLC  plate  and 
therefore,  detection  is  a  static  process.  47  Both  one  and  two  dimensional  chromatography 
can  be  carried  out. 
There  are  several  limitations  with  this  technique  including  difficult  quantitation  and  low 
resolution  compared  to  SFE  coupled  with  HPLC,  GC  or  SFC.  There  is  also  the  possibility 
that  the  high  pressures  involved  in  the  SFE  can  cause  problems  with  the  TLC  support 
material. 
1.2.9.3  SFE-HPLC 
Various  off-line  applications  of  SFE-HPLC  have  been  reported  e.  g.  investigating  the 
effects  of  different  extraction  parameters  on  the  amount  of  caffeine  extracted  from  roast 
coffee  beans.  48  Off-line  SFE-HPLC  can  be  carried  out  using  a  closed  loop  system  with 
recycling  and  a  trap  column.  The  analytes  are  washed  from  the  trap  column,  collected  and 
injected  into  the  HPLC  system. 
On-line  SFE-HPLC  was  first  reported  by  Unger  and  Roumeliots  in  1983  49  Their  system 
consisted  of  two  high  pressure  sample  injection  valves  connected  in  series.  The  first  of 
these  valves  acted  as  a  switch  valve  to  the  loop  and  controlled  the  pressure  over  the Chapter  One:  Introduction  to  Supercritical  Fluids  Page2O 
column.  Two  short  microbore  columns  were  placed  between  the  valves  to  absorb  the 
analytes  and  act  as  a  sample  loop  for  the  second  valve  which  served  as  an  injector  for  the 
HPLC  column. 
1.2.9.4  SFE-GC 
Most  of  the  work  on  coupled  SFE  techniques  concentrates  on  SFE-GC,  although  SFE-SFC 
is  becoming  more  widespread.  Examples  of  off-line  SFE-GC  include  the  analysis  of 
polyaromatic  hydrocarbons  (PAH's)  and  polychlorinated  biphenols  (PCB's)  which  are  well 
documented  in  the  literature.  2  As  samples  for  GC  analysis  tend  to  be  volatile,  the  method 
by  which  the  analytes  are  trapped  is  very  important.  Various  trapping  methods  have  been 
tried  including  solvent  traps  and  sorbent  traps  (e.  g.  XAD-2,  polyurethane  foam  and 
Tenax),  so 
On-line  SFE-GC  was  first  carried  out  by  Hawthorne  and  Miller51  when  they  successfully 
analysed  automobile-exhaust  organics.  Since  then,  the  number  of  applications  reported  on 
this  technique  has  increased  dramatically. 
There  are  several  possible  modes  of  action  for  SFE-GC,  such  as  quantitative  extraction  of 
analytes  from  a  matrix,  quantitative  extraction  and  concentration  of  trace  analytes  and 
selective  extraction  at  various  solvating  powers.  The  supercritical  extract  can  either  be 
directly  pressurised  inside  a  conventional  split/splitless  injection  port  or  on  the  column 
itself.  The  best  sensitivity  is  achieved  where  the  sample  is  small  since  all  the  extracted 
analytes  go  directly  onto  the  column.  If  the  sample  is  large,  the  split  mode  can  be  used. 
1.2.9.5  SFE-SFC 
An  obvious  advantage  of  SFE  is  that  it  is  an  ideal  way  to  introduce  a  sample  into  an  SFC 
system.  The  injection  solvent  is  the  same  as  the  mobile  phase  and  therefore,  the  criteria  for 
successful  coupling  of  different  techniques  are  fulfilled.  An  additional  advantage  that  the 
technique  has  over  SFE-HPLC/GC  is  that  it  is  highly  unlikely  that  sample  components 
which  are  insoluble  in  the  mobile  phase  will  be  introduced  into  the  column. Chapter  One:  Introduction  to  Supercritical  Fluids  Page2l 
There  are  many  ways  of  combining  SFE  with  SFC.  Conventional  packed  columns, 
capillary  columns  and  packed  capillary  columns  have  all  been  successfully  used.  2 
Directly  coupled  SFE-SFC  with  packed  columns  was  introduced  in  1985  by  Sugiyama  et 
a152  for  the  analysis  of  powdered  coffee  beans.  No  sample  pretreatment  was  required.  The 
system  was  set  up  with  an  injector  valve  containing  an  extract  trap  loop  after  the  extraction 
column  and  another  valve  prior  to  the  SFC  column,  which  remained  closed  during  the 
extraction  step.  Once  extraction  was  complete,  the  valve  prior  to  the  column  was  opened 
and  the  contents  of  the  extract  trap  loop  flushed  onto  the  column.  The  use  of  valve 
switching  is  very  common  in  SFE-SFC  and  is  well  documented  53 
SFE  with  capillary  SFC  has  also  been  widely  investigated.  Gmur  et  al54  investigated  the 
optimisation  of  important  instrumental  parameters  for  the  analysis  of  natural  products.  On- 
line  SFE-capillary  SFC  had  also  been  coupled  with  off-line  FTIR  for  the  separation  and 
identification  of  PAH's  in  coal  pitch.  In  this  case  the  samples  were  collected  on  a  bromide 
ss  disc  after  the  SFC. 
The  use  of  packed  capillary  columns  is  advantageous  as  it  provides  higher  loading 
capabilities  and  shorter  analysis  times  than  capillary  columns.  However,  capillary  columns 
give  lower  pressure  drops,  lower  flow  rates  and  higher  efficiencies  than  packed  column 
SFC. 
1.2.10  TRAPPING  TECHNIQUES  IN  SFE 
Three  different  trapping  techniques  are  commonly  used  in  off-line  SFE  for  the  collection  of 
analytes. 
"  Liquid  collection 
"  Dry  deposition  onto  a  solid  surface 
"  Solid  phase  sorption 
All  three  systems  have  their  advantages  and  disadvantages  with  respect  to  choice  of 
restrictor  type,  maximum  flow  rate  and  compatibility  with  various  types  of  SF's,  modifiers 
and  analytes.  56 Chapter  One:  Introduction  to  Supercritical  Fluids  Page22 
One  of  the  main  problems  in  SFE,  is  the  limitation  in  the  decompression  speed  after  the 
extraction  due  to  difficulties  in  collecting  the  extracted  analytes  with  good  efficiency.  In 
most  systems,  the  maximum  flow  through  the  restrictor  is  in  the  range  of  0.5-2.0  mLmin-' 
which  is  equivalent  to  a  flow  after  the  restrictor  of  500-1000  mLmiri'  of  gas.  Since  it  is 
desirable  to  minimise  the  extraction  time,  a  maximum  flow  of  0.5-2.0  mLmin-'  of  SF  leads 
to  limitations  in  the  size  of  the  extraction  vessel  and  thus  limitations  in  the  detection 
limits. 
1.2.10.1  LIQUJI)  (,  OLLECTION 
Liquid  collection  is  the  simplest  method  for  collecting  analytes  from  an  SFE  system.  The 
restrictor  is  simply  placed  into  a  vial  containing  solvent  as  indicated  in  Figure  1.7.  The 
analyte  is  trapped  in  the  solvent  while  the  decompressed  SF  vents  to  the  atmosphere.  The 
solvent  used  must  be  compatible  with  the  analytes  and  with  any  modifier  which  is  required 
for  the  extraction.  A  broad  range  of  solvents  have  been  used  for  SFE  including  methanol, 
methylene  chloride,  chloroform,  acetone  and  hexane.  57  Due  to  the  cooling  associated  with 
the  decompression  of  C02,  it  is  possible  for  the  trapping  solvent  to  freeze  and  for  small 
pieces  of  ice  to  clog  the  restrictor  tip.  For  this  reason,  the  restrictor  is  often  heated  or  the 
collection  solvent  maintained  at  a  constant  temperature.  However  the  advantage  of  this 
cooling  is  that  it  prevents  evaporation  of  the  collection  solvent  which  would  occur  due  to 
the  high  gas  flows.  8 
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1.2.10.2  DRY  DEPOSITION 
Here,  the  surface  of  a  solid  is  used  as  a  support  to  collect  the  analytes  of  interest.  The 
surface  may  be  cooled  cryogenically  using  liquid  nitrogen  or  carbon  dioxide  or  simply  by 
the  expansion  of  the  SF  at  the  flow  outlet.  Typical  solid  surfaces  which  have  been  used  are 
glass  vials,  stainless  steel  beads  and  glass  beads.  Once  trapped,  the  analytes  are  washed 
from  the  surface  and  collected  for  further  analysis.  With  this  method,  faster  flow  rates  (up 
to  4  mLmin  1)  may  be  used  however,  an  additional  washing  step  is  required  which  is  not 
necessary  with  liquid  trapping. 
1.2.10.3  SOLID  PHASE  SORPTION 
This  is  often  a  chromatographic  packing  material  which  traps  by  two  mechanisms.  The 
trap  is  cryogenically  cooled  again  either  by  an  external  source  or  by  the  expanding  SF  and 
the  analytes  are  absorbed  onto  the  packing  material.  The  analytes  can  then  be  washed  from 
the  packing  material  using  a  suitable  solvent.  As  with  dry  deposition,  flow  rates  up  to  4 
mL  min'  can  be  used,  again  an  additional  wash  step  is  required. 
1.2.11  APPLICATIONS  OF  SFE 
The  applications  of  SFE,  some  of  which  have  been  mentioned  in  the  course  of  this  report, 
are  very  varied.  In  general  the  applications  of  SFE  have  been  developed  as  faster,  less 
solvent-intensive  alternatives  to  traditional  extraction  schemes.  Some  of  the  categories  of 
compounds  have  been  analysed  by  SFE  are  summarised  in  Table  1.3. Chapter  One:  Introduction  to  Supercritical  Fluids  Page24 
Table  1.3:  Examples  of  Uses  of  SFE 
Explosives  and  propellants  Nitroglycerin 
Trinitrotoluene 
Di  ro  1  hthalate 
Polar  compounds  Phenols 
Pol  h  drox  benzoic  acids 
Flavours  and  fragrances  Red  and  black  pepper 
Citrus  oils 
Fossil  fuels  PAH's 
Coal  and  petroleum  itches 
Environmental  samples  Sediments/soils/sands 
Chlorinated  materials 
Pesticides  and  herbicides  4-nitro  phenol 
Natural  products  Dairy  produce 
Fats  and  oils  Triglycerides 
So  abean  oil 
Pigments  and  dyes  Carotene 
Porphyrins 
Metal  chelates 
Drugs  Pharmaceutical 
Drugs  of  abuse 
1.2.11.1  SFE  OFDRucs 
Of  the  applications  mentioned,  the  one  of  most  relevance  to  this  report  is  drugs.  Several 
methods  exist  in  the  literature  for  the  supercritical  analysis  of  drugs  but  these  are  mainly 
concerned  with  chromatography.  58,59,60 
The  SFE  of  alkaloids  has  been  reviewed  extensively  in  particular  caffeine  and  nicotine, 
both  of  which  are  of  great  interest  for  health  and  consumer  reasons.  61  The  extraction  of 
chemotherapeutic  pyrrolizidine  alkaloid  from  plant  substrates  has  been  described  by 
Schaeffer  et  al62  Pyrrolizidine  alkaloids  are  known  to  be  anti-tumour  active  and  more 
recently  have  become  of  interest  as  anti-cancer  agents.  They  occur  naturally  in  several 
plant  species  and  are  often  difficult  to  extract  and  isolate  without  degradation  or  the  use  of 
toxic  solvents.  Another  group  of  therapeutic  drugs  which  have  been  reviewed  are 
xenobiotics.  Nam  et  a163  applied  SFE  to  various  xenobiotics  in  biological  tissues  and 
fluids  and  achieved  good  recoveries  of  all  but  the  polar  solutes  when  CO2  was  used  alone. Chapter  One:  Introduction  to  Supercritical  Fluids  Page25 
Methods  also  exist  in  literature  for  the  subcritical  extraction  of  morphinic  alkaloids  in 
urine64,  the  supercritical  fluid  extraction  of  budesonide  from  blood  plasma65  and 
benzodiazepines  from  solid  dosage  forms66  and  more  recently  the  extraction  of  drugs  of 
abuse  (morphine,  cocaine)  from  drug  addict  hair.  67  As  these  drugs  are  mentioned  later  in 
this  report,  these  papers  will  be  reviewed  where  relevant. 
In  general,  despite  these  examples,  the  extraction  of  pharmaceutical  drugs  and  drugs  of 
abuse  using  supercritical  fluids  is  not  well  documented. 
1.3  INSTRUMENTATION  IN  SFE 
1.3.1  INTRODUCTION 
Inherently  SFE  is  a  simple  process.  The  SF  is  delivered  by  a  pumping  system  through  a 
thermostated  high  pressure  vessel,  containing  the  sample  of  interest,  and  a  flow  restrictor  to 
an  appropriate  analyte  collection  device.  Due  to  this,  the  instrumentation  for  SFE  has 
required  little  development  since  it  was  first  introduced.  Commercial  systems  are  available 
which  have  addressed  issues  like  automation,  multiple  extensions,  flow  restrictor  plugging, 
analyte  collection  and  interfacing. 
A  schematic  representation  of  the  instrumentation  required  for  SFE  is  given  in  Figure  I.  S. 
It  consists  of  three  basic  sections.  The  first  of  these  is  a  pumping  system  similar  to  that 
used  in  HPLC,  the  second  is  an  extraction  vessel  which  houses  the  matrices  from  which  the 
analytes  have  to  be  extracted  and  the  third  is  a  pressure  regulator. Chapter  One:  Introduction  to  Supercritical  Fluids 
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Figure  1.8:  Schematic  Representation  of  the  Main  Components  of  a  SF  System 
Two  other  important  components  of  the  SF  system  are  the  collection  device,  used  to  trap 
the  extracted  analytes  and  a  flow  restrictor  at  the  end  of  the  outlet  tubing  which  helps 
prevent  complete  depressurisation  of  the  SF  in  the  outlet  tubing.  A  detector,  generally  UV, 
can  also  be  used  to  monitor  the  extraction  effluent. 
1.3.2  SFE  Pumps 
The  pumps  used  for  SFE  are  derived  from  HPLC  pumps,  often  with  little  or  no 
modification.  One  useful  adaptation  is  to  cool  the  head  of  the  CO2  pump  so  that  the  CO2 
is  in  its  liquid  form  and  is  thus  highly  compressed.  '"  It  is  important  to  properly  insulate  the 
CO2  pump  cooling  system  to  prevent  excessive  air  moisture  condensation  and  loss  of 
cooling  efficiency.  Cut-to-fit  polystyrene  foam  can  be  used  with  expanded  polystyrene 
hoses  for  the  cooling  system  tubing. 
When  high  flow  rates  are  being  used,  reciprocating  pumps  are  preferred.  As  well  as 
having  the  advantage  of  delivering  unlimited  volumes  within  a  continuous  flow,  they  can 
easily  incorporate  a  gradient  system.  When  syringe  pumps  are  being  used  it  is  found  that 
they  take  a  long  time  to  fill  their  cylinder  if  only  the  CO,  vapour  pressure  displaces  the  liquid 
Pressure  Regulator Chapter  One:  Introduction  to  Supercritical  Fluids  Pa  e27 
into  the  pump.  Thus,  they  can  only  be  used  with  very  low  flow  rates  (pLmin  1  c.  f.  mLmin  1 
for  reciprocating  pumps).  The  problem  of  filling  the  syringe  barrel  can  be  reduced  by  the 
addition  of  helium  to  the  CO2  cylinder  (padded  cylinders).  The  addition  of  He  to  the 
cylinder  can  enhance  the  gas  head  pressure  to  110-175  bar.  One  advantage  of  using  syringe 
pumps  at  low  flow  rates  is  that  they  provide  pulseless  flow.  However,  in  most  SFE 
applications  reciprocating  pumps  are  used. 
1.3.3  CARBON  DIOXIDE 
The  C02,  which  is  usually  the  main  extraction  fluid,  is  provided  as  a  liquid-gas  mixture. 
For  analytical  SFE,  PT10  cylinders  containing  7.2  kg  of  CO2  are  used.  Regardless  of  the 
grade  of  the  CO2  used,  it  is  essential  that  a  full  length  dip  tube  is  installed  in  the  cylinder  as 
it  is  the  liquid  CO2  which  is  required  for  pumping.  At  room  temperature  CO2  has  a 
substantial  vapour  pressure  which  helps  displace  the  liquid  to  the  pump. 
1.3.4  MODERS 
Organic  modifiers  can  be  introduced  into  the  eluent  in  a  number  of  ways.  Cylinders  doped 
with  MeOH,  2-propanol  and  other  solvents  are  commercially  available.  Alternatively, 
various  mixtures  of  modifiers  in  CO2  can  be  made  by  mixing  the  components  together  in  a 
syringe  pump  or  by  having  a  two  pump  system  and  using  on-line  mixing  which  allows 
gradient  eluent  compositions. 
1.3.5  EXTRACTION  VESSEL 
The  high  pressure  sample  vessels  initially  used  for  SFE  were  made  using  empty  HPLC 
columns.  Subsequently,  vessels  designed  specifically  for  SFE  have  been  introduced. 
Unlike  HPLC,  where  only  the  inlet  fitting  is  under  pressure,  the  extraction  column  outlet 
fitting  is  also  under  pressure  and  must  withstand  the  maximum  operating  pressure  in 
general  at  least  4500  psi. 
Conveniently,  HPLC  fittings  can  be  used  for  SFE  systems,  but  great  care  must  be  taken 
regarding  the  pressure  resistance  of  such  components.  When  a  gas  is  compressed  to  a  high Chapter  One:  Introduction  to  Supercritical  Fluids  Page28 
pressure,  at  a  few  hundred  kg  cm'3,  a  considerable  amount  of  energy  is  stored  that  could  be 
explosively  released  if  the  vessel  is  damaged,  compared  with  liquids,  where  only  a  little 
energy  is  stored  due  to  their  lower  compressibility. 
Saito  et  a169  calculated  that  a  typical  HPLC  column  with  an  internal  diameter  (i.  d.  )  of  4.6 
mm  and  an  outer  diameter  (o.  d.  )  of  1/4"  (6.35  mm)  has  sufficient  mechanical  strength  for 
the  maximum  operating  pressure  of  4500  psi.  Furton  and  Rein70'71  studied  the  effect  of 
extraction  vessel  dimensions  for  the  SFE  of  PAH's.  They  found  that,  the  observed 
efficiencies  for  the  largest  PAH  studied  were  increased  by  more  than  a  factor  of  2  by 
increasing  the  vessel  diameter  :  length  from  1:  20  to  1:  1.  The  results  indicate  that  for  longer 
cells  inductive  effects  may  be  important  but  as  the  diameter  :  length  ratio  increases, 
diffusion  controlled  mechanisms  dominate  the  extractability  of  PAH's. 
Ong  et  a172  designed  an  extraction  cell  for  use  with  either  liquid  or  solid  samples  which 
yielded  an  extraction  efficiency  of  98%  for  cholesterol  spiked  equine  blood/serum. 
Another  approach  for  liquid  samples  is  to  absorb  the  liquid  onto  a  solid  material  prior  to 
extraction.  Hopper  and  King73  reported  the  use  of  calcified  diatomaceous  earth  to  increase 
the  permeability  of  the  sample  to  the  SF  extracting  solvent,  and  absorb  H2O  from  the 
sample. 
1.3.6  THE  BACK  PRESSURE  REGULATOR 
The  device  which  characterises  SF  instrumentation  is  the  back-pressure  regulator  (BPR). 
The  BPR,  pressurises  the  system  and  is  where  the  main  pressure  drop  of  the  system 
abruptly  occurs.  There  are  two  different  types  of  BPR  currently  used  in  SFE  and  SFC. 
1.  Simple  restrictor 
2.  Mechanical  or electronic  feedback  regulator 
A  simple  restrictor  is  a  capillary  tube  with  an  appropriate  length  for  the  required  back- 
pressure  and  flowrate.  This  type  of  restrictor  is  used  most  commonly  with  open-tubular 
capillary  SFC.  It  is  easy  to  assemble  and  has  a  small  dead  volume.  However,  in  order  to Chapter  One:  Introduction  to  Supercritical  Fluids  Page29 
change  the  back-pressure,  it  is  necessary  to  alter  the  flowrate  as  the  back-pressure  is 
produced  only  by  flow  resistance. 
A  mechanical/electrical  feedback  regulator  is  a  complex  device  consisting  of  a  pressure 
sensitive  mechanism  and  a  needle  valve.  The  regulator  can  control  back  pressure 
irrespective  of  the  mass  flowrate  of  the  fluid.  Therefore,  these  BPR's  are  more  convenient 
to  use  than  simple  restrictors  for  the  precise  examination  of  extraction  yield  versus  pressure 
in  SFE  and  other  parameters  which  require  measurement  under  the  same  mass  flowrate. 
However,  conventional  BPRs  have  a  high  dead  volume  and  thus,  must  be  placed  in  line  in 
the  system  post-detector. 
An  ideal  BPR  should  have  a  low  dead  volume  (<10  µl),  high  precision,  pressure  control 
independent  of  mass  flowrate  and  an  external  reference  signal  for  pressure/density 
programming.  Saito  et  a174  have  developed  a  new  style  BPR  based  on  a  totally  different 
operational  system  to  that  conventionally  used.  Flow  resistance  is  created  by  changing  the 
gap  size  between  a  needle  valve  and  a  valve  seat.  The  system  is  based  on  high  speed 
switching  of  the  fluid  flow  by  periodically  opening  and  closing  the  flow  path,  and  is  used 
in  conjunction  with  a  pressure  transducer  and  control  circuitry  for  the  regulation  of  back- 
pressure. 
1.3.7  DETECTION  IN  SFE 
Various  types  of  detector  have  been  used  for  SFE  and  SFC  including  ultra-violet  (UV), 
diode  array  (DAD),  flame  ionisation  (FID),  mass  spectrometry  (MS)  and  Fourier  transform 
infra-red  (FTIR).  Although  the  detector  is  an  integral  part  of  a  SFC  system  its  use  in  SFE 
is  advantageous  as  the  extraction  process  can  be  monitored. 
The  most  widely  used  type  of  detector  in  SFE  is  UV.  With  SFs  and  UV  detectors,  some 
noise  is  inherent  due  to  density  related  changes  in  the  highly  compressible  SF.  However, 
this  is  counteracted  by  the  fact  that  SF-CO2  is  transparent  even  at  190  nm,  which  is  the 
short  wavelength  cut-off  of  most  variable  wavelength  detectors.  Thus,  even  compounds 
which  are  thought  to  have  little  or  no  UV  absorbance,  e.  g.  lipids,  can  be  detected  by  UV  at 
wavelengths  of  <200  nm.  This  advantage  of  SF-CO2  is  revoked  by  the  addition  of Chapter  One:  Introduction  to  Supercritical  Fluids  Page30 
modifiers  to  the  SF  system  which  generally  have  cut-off  wavelengths  >200  nm  e.  g. 
methanol  -+  205  nm,  ethyl  acetate  -+  255  nm,  diethylether  -º  205  nm 
Although  fixed  wavelength  UV  detectors  have  been  the  detector  of  choice  for  analytical 
SFE,  photodiode  array  detectors  have  also  been  used.  By  using  multiwavelength 
photodiode  array  detectors,  it  is  possible  to  monitor  the  UV  spectra  of  an  analyte  as  a 
function  of  extraction  time. 
To  utilise  any  type  of  UV  detector  with  a  SF,  it  must  be  equipped  with  a  high  pressure  flow 
cell  which  can  withstand  pressure  of  at  least  4500  psi.  Metal  gaskets  of  lead  or  24  ct.  gold 
with  sapphire  windows  are  generally  suited  for  the  construction  of  high  pressure  flow  cells. 
However,  the  UV  cut-off  wavelength  of  sapphire  is  =220  nm  which  sacrifices  the  excellent 
transparency  of  SF-CO2.  Although  the  tensile  strength  of  quartz  is  several  times  lower  than 
that  of  sapphire  and  thus  the  window  must  be  substantially  thicker,  it  is  a  good  material  for 
use  when  monitoring  below  220  nm. 
1.3.8  FLOW  THROUGH  THE  SYSTEM 
The  CO2  remains  liquid  throughout  the  pumping  and  compression  zones  and  passes 
through  small  diameter  metal  tubing  as  it  approaches  the  column  (SFC)  or  extraction  cell 
(SFE).  A  preheated  injection  valve  before  the  column  or  extraction  cell  is  useful  so  that 
supercritical  conditions  are  applied  immediately  to  the  analyte  matrix.  The  flow  then 
passes  through  the  column/extraction  cell  at  a  rate  and  temperature  determined  during 
method  development.  The  mathematical  product  of  the  time  period  and  flow  rate  yields  a 
net  volume  of  CO2  analogous  to  partition  coefficients  and  total  retention  volumes  in  other 
types  of  extraction  and  chromatography.  Next,  the  SF  containing  the  extracted  analyte 
flows  through  additional  capillary  tubing  (via  the  detector)  until  it  reaches  the  restriction 
zone  at  the  BPR.  After  leaving  the  extraction  vessel,  the  fluid  can  return  to  liquid  state.  At 
this  point  retaining  supercritical  conditions  for  analyte  solubility  is  unnecessary.  Lower 
temperatures  increase  the  density  which  in  turn  causes  an  increase  in  intrinsic  saturation 
solubility.  At  the  restrictor  zone,  the  temperature  usually  increases  significantly.  Between 
the  pump  and  the  outlet  of  the  restrictor  the  pressure  is  deliberately  increased  to  a  very  high 
level.  As  the  fluid  passes  out  of  the  restrictor  the  conditions  are  no  longer  supercritical. Chapter  One:  Introduction  to  Supercritical  Fluids  Page31 
The  pressure  is  lowered  to  1  bar  in  a  short  period  of  time  over  a  short  linear  distance. 
Joule-Thomson  type  cooling  occurs  which  is  compensated  by  heating  the  restrictor  zone  to 
avoid  plugging  and  too  rapid  precipitation  of  the  analytes,  CO2  or  any  other  material 
present. 
Finally  the  analyte  either  goes  to  waste  or  is  collected  for  further  analysis.  There  are  three 
main  types  of  collection  device  as  described  in  section  1.2.8.  All  three  methods  are 
dependent  on  flow  restriction.  There  is  a  risk  of  plugging  due  to  co-extracted  or extraneous 
materials  due  to  the  sudden  decrease  in  pressure  at  the  flow  outlet.  This  can  be  prevented 
by  the  use  of  a  post-extraction  solvent  flush. 
1.4  SETTING  UP  OF  INSTRUMENTATION 
A  home-made  SFE  system  was  favoured  over  a  commercial  one,  as  many  of  the 
components  were  already  available.  A  schematic  representation  of  the  instrumentation 
used  for  this  study  is  shown  in  Figure  1.9.  The  system  consisted  of  the  following 
components. 
9  PT  10  CO2  cylinder  fitted  with  a  full  length  dip-tube  (7.2  kg  of  C02) 
"  Two  Gilson  1OSC  pumps  programmed  via  Gilson  715  software 
"A  Gilson  811B  dynamic  mixer 
"A  Gilson  805S  manometric  module 
"A  7125  Rheodyne  fitted  with  a  100  [il  injection  loop 
"A  Pye  Series  104  GC  oven 
"A  Kratos  Spectraflow  757  UV  detector 
"A  Rheodyne  7037  back-pressure  regulator Chapter  One:  Introduction  to  Supercritical  Fluids 
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Figure  1.9:  Instrumentation  Used  for  SFI 
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The  original  PTFE  (polytetrafluoroethylene)  check  valves  in  the  C02-IOSC  pumphead 
were  replaced  with  PVDF  (polyvinyldifluoride)  check  valves  as  these  are  more  resistant  to 
extremes  of  heat  and  cold.  This  pumphead  was  chilled  using  a  SFC3  refrigeration  unit. 
The  second  pumphead  was  used  with  the  PTFE  check  valves  and  was  used  to  pump 
modifier. 
The  pressure  at  the  pump  end  of  the  system  (i.  e.  before  the  extraction  cell)  was  measured 
by  the  Gilson  805S  manometric  module  and  monitored  on  the  Gilson  715  software 
package.  The  software  controller  allows  programming  of  up  to  four  pumps.  The  CO2  and 
modifier  were  premixed  by  the  Gilson  811  B  dynamic  mixer.  An  HPLC  7125  Rheodyne 
valve  fitted  with  a  100  µl  injection  loop  was  used  to  apply  the  samples  to  the  extraction 
vessel  and  this  was  placed  in  line  between  the  dynamic  mixer  and  the  extraction  cell  which 
was  housed  within  the  GC  oven.  Ideally  the  Rheodyne  should  be  placed  inside  the  oven  so 
that  supercritical  conditions  are  applied  directly  to  the  matrix  containing  the  analytes,  but 
with  the  initial  set  up  used,  this  was  not  mechanically  feasible. Chapter  One:  Introduction  to  Supercritical  Fluids  Page33 
The  extraction  vessels  were  originally  prepared  from  empty  HPLC  columns  which  had  the 
stationary  phase  removed.  The  dimensions  of  these  columns  were  4.6  mm  i.  d.  (0.25"  o.  d.  ) 
10  cm  length  and  they  were  made  of  stainless  steel. 
The  UV  detector  was  next  in  line  and  was  used  to  monitor  the  extractions.  The  original 
flow  cell  was  replaced  with  a  high  pressure  flow  cell  which  although  larger  than  the 
original  and  thus  liable  to  produce  more  noise,  provided  better  sensitivity  and  was  capable 
of  withstanding  the  high  pressure  required  for  SFE.  A  mechanical  BPR  was  placed 
downflow  of  the  detector  which  could  be  opened  and  closed  manually  with  the  use  of  a 
spanner  to  maintain  the  required  pressure.  The  BPR  had  a  gauge  attached  to  it  in  order  to 
monitor  the  pressure  at  this  end  of  the  system. 
An  additional  HPLC  column  (4.6  mm  i.  d.  x  10  cm)  loosely  packed  with  Lichoprep  60  was 
placed  in  the  system  between  the  CO2  cylinder  and  the  CO2  pumphead.  This  was  to 
prevent  deposits  from  the  CO2  cylinder  contaminating  the  system. 
It  is  essential  that  the  CO2  cylinder  is  not  allowed  to  be  pumped  dry  as  gaseous  CO2  will 
harm  the  check  valves  in  the  pumphead.  For  this  reason  in  order  to  monitor  the  amount  of 
liquid  CO2  remaining  in  the  cylinder,  it  was  placed  on  a  set  of  bathroom  scales. 
The  system  which  is  described  above  was  used  for  preliminary  method  development. 
Throughout  the  course  of  this  study  several  modifications  were  made  to  the  system 
however,  these  will  be  discussed  where  relevant  in  the  following  chapters. G. 
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2.  BENZODIAZEPINES 
2.1  INTRODUCTION 
Benzodiazepines  were  accidentally  discovered  in  1955  by  Dr.  Leo  Sternbach  in  the 
Hoffman  LaRoche  laboratories.  75  Initially,  it  was  thought  that  the  newly  discovered  drug 
belonged  to  the  quinazoline-N-oxide  group  of  compounds.  However,  further  investigation 
showed  effects  very  different  to  those  of  the  quinazolines.  On  administration,  the  new  drug 
was  found  to  have  calming  effects,  produce  muscle  relaxation  and  prevent  convulsions. 
Evaluation  of  the  chemical  structure  of  the  drug  showed  it  to  be  a  benzodiazepine  and  it 
was  given  the  name  chlordiazepoxide.  Chlordiazepoxide  is  now  marketed  under  the  name 
Librium®  and  is  prescribed  for  the  treatment  of  anxiety. 
2.2  PRESCRIPTION 
Since  the  development  of  chlordiazepoxide,  hundreds  of  benzodiazepines  have  been 
synthesised  and  at  present  16  are  available  by  prescription  in  the  United  Kingdom.  76'77 
These  16  drugs  along  with  some  of  their  proprietary  names  are  shown  in  Table  2.1. 
The  benzodiazepines  are  used  primarily  in  the  treatment  of  anxiety.  However,  some  are 
used  as  sleeping  aids,  some  as  antiepileptics  and  three  are  used  as  premedications. 
2.3  CHEMICAL  STRUCTURE 
After  the  discovery  of  chlordiazepoxide,  to  determine  which  aspects  of  its  chemical 
structure  were  related  to  its  pharmacological  effects,  several  other  benzodiazepines  were 
synthesised.  Most  were  found  to  have  effects  similar  to  chlordiazepoxide  however,  one 
was  found  to  be  much  more  potent.  This  drug  was  given  the  name  diazepam  and  was 
marketed  as  Valium®. 
The  basic  structure  of  benzodiazepines  is  detailed  in  Figure  2.1  and  the  10  of  the  prescribed 
benzodiazepines  with  this  basic  structure  are  indicated  in  Table  2.2. Chapter  Two  Benzodiazepines  Page35 
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Figure  2.1:  Basic  Structure  of  14-Benzodiazepines 
Table  2.1:  Currently  Prescribed  Benzodia  epz  ines 
Name  Pro  rieta  Name(s)  Treatment  Action 
Alprazolam  Xanax®  anxiolytic  PA 
Bromazepam  Lexotan®  anxiolytic  IA 
Chlordiazepoxide  Librium®,  Tro  ium®  anxiolytic  PA 
Clobazam  NA  anxiolytic,  anti-epileptic  PA 
Clonazepam  Rivotril®  anti-epileptic  - 
Clorazepate  Tranxene®  anxiolytic  PA 
Diazepam  Valium®,  Valclair 
, 
Diazemuls®,  Heminevrin  ® 
anxiolytic,  anti-epileptic, 
skeletal  muscle  relaxant, 
premed 
PA 
Flunitrazepam  Roh  pnolo  hypnotic  IA 
Flurazepam  Dalmane®  hypnotic  PA 
Loprazolam.  NA  hypnotic  IA 
Lorazepam  Ativar®  anxiolytic,  anti-epileptic, 
premed 
IA 
Lormetazepam  NA  hypnotic  IA 
Midazolam  H  novel®  light  sedative  (IV)  - 
Nitrazepam  Mogadon®,  Remnos®, 
Unisomnia® 
hypnotic  PA 
Oxazepam  NA  anxiolytic  IA 
Temazepam  Normison®  hypnotic,  premed  IA 
PA  Prolonged  action,  IA  Intermediate  action, 
The  activity  of  benzodiazepines  arises  from  the  substituent  on  the  7-position  of  the  1,4- 
benzodiazepine  structure.  8  This  is  generally  a  chloride  or  a  nitro  group  (R4).  Substitution 
of  chloride  or  fluoride  on  the  ortho  position  of  the  5-phenyl  ring  (R2)  usually  decreases  the 
half  life  and  almost  always  increases  the  potency.  Another  developmental  approach  was  to 
synthesise  new  1,4-benzodiazepines  which  were  extensively  metabolised  to 
desmethyldiazepam  i.  e.  pro-drugs.  Synthesis  of  the  newest  benzodiazepines  has  involved Chapter  Two  Benzodiazepines  Page36 
annelation  of  the  1,2-diazepine  position  -with  a  triazo  (alprazolam)  or  an  imidazo  ring 
(midazolam). 
Table  2.2:  Structural  Groups  of  Classic  Benzodiazepines 
Benzodiazepine  R1  R2  R1  R4 
Clonazepam  H  Cl  H  NO2 
Clorazepate  H  H  COOH  Cl 
Desmeth  ldiaze  am*  H  H  H  Cl 
Diazepam  CH3  H  H  Cl 
Flunitrazepam  CH3  F  H  NO2 
Flurazepam  C6H14N  F  H  Cl 
Lorazepam  H  Cl  OH  Cl 
Lormetazolam  CH3  Cl  OH  Cl 
Nitrazepam  H  H  H  NO2 
Oxazepam  H  H  OH  Cl 
Temazepam  CH3  H  OH  Cl 
*  metabolite  of  diazepam 
2.4  PHARMACOLOGY 
There  are  four  basic  pharmacological  properties  of  benzodiazepines.  75 
"  Anxiolytic 
"  Sedative-hypnotic 
"  Anticonvulsant 
"  Muscle  relaxant 
The  predominance  or  potency  of  these  effects  differs  from  drug  to  drug  and  therefore,  the 
use  of  a  specific  benzodiazepine  for  a  particular  ailment  depends  on  the  acceptability  of  the 
other  properties  as  side  effects,  e.  g.  in  sufficient  dosage,  all  benzodiazepines  act  as 
sedatives. 
Research  on  the  benzodiazepines  shows  that  these  drugs  attach  to  specific  receptors  named 
the  benzodiazepine  receptors.  All  benzodiazepines  shown  to  be  capable  of  reducing 
anxiety  are  also  capable  of  binding  to  the  receptors.  The  more  effective  the  anxiety  relief 
the  tighter  the  binding  is  found  to  be.  Other  drugs  which  are  capable  of  reducing  anxiety Chapter  Two  Benzodiazepines  Page37 
e.  g.  meprobamate,  barbiturates  and  alcohol  do  not  bind  to  these  receptors  and  hence  it 
seems  that  the  receptors  are  specific  to  benzodiazepines. 
Scientists  believe  that  the  body  itself  may  produce  compounds  which  act  on  the 
benzodiazepine  receptors  and  are  thus  working  on  isolating  and  identifying  a  natural 
anxiety-reducing  compound.  9 
2.5  METABOLISM 
The  metabolism  of  benzodiazepines  is  largely  predictable.  Classic  benzodiazepines  are 
metabolised  by  N-demethylation  (N-methyl  hydroxylation  followed  by  hydrolysis)  and  by 
hydroxylation  in  the  3-position  of  the  diazepine  ring.  This  is  known  as  phase  I  metabolism 
and  is  followed  by  conjugation  with  glucuronic  acid  (phase  II  metabolism).  Other 
metabolic  reactions  do  occur  but  these  are  minimal.  In  most  cases,  activity  is  maintained 
after  N-demethylation  (e.  g.  diazepam  desmethyldiazepam).  After  the  hydroxylation 
step,  the  metabolites  are  rapidly  conjugated  and  therefore  do  not  accumulate  in  the  blood. 
This  means  that  e.  g.  oxazepam,  the  hydroxylation  metabolite  of  diazepam,  rarely  achieves 
significant  concentrations  in  the  plasma  after  the  administration  of  diazepam.  Figure  2.2 
indicates  the  metabolic  routes  of  several  benzodiazepines. 
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Figure  2.2:  Metabolic  Route  of  Benzodiazepines79 Chapter  Two  Benzodiazepines  Page38 
2.6  PHARMACOKINETICS 
Benzodiazepines  exhibit  a  two  compartment  pharmacokinetic  model.  9  Central 
compartment  redistribution  is  rapid  with  a  second  phase  redistribution  to  adipose  and 
peripheral  tissue.  With  single  dose  administration,  the  redistribution  phase  determines  the 
duration  of  action  for  each  benzodiazepine,  with  lipid  solubility  being  an  important 
variable.  Highly  lipophilic  benzodiazepines  tend  to  be  redistributed  quicker  than  less 
lipophilic  ones.  With  multiple  dosing,  once  the  adipose  sites  are  saturated,  the  drug  is  not 
redistributed  so  quickly.  Accumulation  of  the  drug  may  occur  for  the  more  lipid  soluble 
drugs  which  are  extensively  metabolised.  Due  to  the  possibility  of  active  metabolites,  and 
the  large  redistribution  of  benzodiazepines  with  high  lipid  solubility,  the  characterisation  of 
benzodiazepines  according  to  the  elimination  half  life  of  the  parent  drug  is  not  a  reliable 
indication  of  the  duration,  onset  or  clinical  effects  of  the  drug.  A  better  indicator  of  the 
therapeutic  effect  of  benzodiazepines  is  the  time  which  benzodiazepines  exist  at  or  above 
their  therapeutic  concentration  at  the  intended  receptor  site. 
Some  of  the  pharmacokinetic  data  for  the  prescription  benzodiazepines  is  given  in  Table 
2.3. 
Table  2.3:  Pharmacokinetic  Data  for  Benzodiazepines80 
Drug  tuu2  (hr)  VD 
(Lk  "1) 
CL 
(ml  mink  ") 
Distribution 
in  blood 
Protein 
binding 
Al  razolam  6-20(12)  1  1  /  70 
Bromaze  am  8-19(12)  0.9  /  /  40-70 
Chlordiazepoxide  5-30(15)  0.3-0.6  0.5  P:  S  33  90-97 
Clobazam  10-58(25)  1  0.5  /  85 
Clonazepam  18-45  2-4  1  /  85 
Clorazepate  2  0.5-2.5  0.1-0.3  P:  WB  1.1  97 
Diazepam  20-100(48)  0.5-2.5  0.3-0.5  P:  WB  1.8  98-99 
Desmethyldiazepa  25-200(40- 
100) 
0.5-2.5  0.1-0.3  P:  WB  1.7  97 
Flunitrazepam  10-70(25)  4  2  P:  WB  0.75  78 
Flurazepam  2-3  97 
Loprazolam  4-11(7)  /  / 
Lormetazolam  10  5  4  /  90 
Lorazepam  2  0.5-2.0  2-8(5)  /  95 
Midazolam  9-24(14)  1-2  1  /  90 
Nitrazepam  18-38(28)  2-3  1  /  85-88 
Oxazepam  4-25(8)  0.5-2.0  1-2  P:  WB  0.9  95 
Temaze  am  3-38(10)  1  1-2  P:  WB  1.9  97 Chapter  Two  Benzodiazepines  Page39 
t112  =  elimination  half  life  from  blood  (bracketed  numbers  =  mean) 
P:  S;  Plasma  :  Saliva 
P:  WB;  Plasma  :  Whole  Blood 
2.7  PHARMACODYNAMICS 
Pharmacodynamically,  a  reverse  loop  hysterisis  has  been  seen  with  some  benzodiazepines. 
This  means  that  while  benzodiazepine  concentrations  remain  constant  or  increase,  the 
impairment  of  mental  functioning  improves  over  the  time  course  of  a  few  hours.  It  is 
unclear  why  this  happens,  but  it  is  thought  that  receptor  kinetics  and  adaption  are  more 
important  in  determining  the  pharmacodynamic  effects  of  the  benzodiazepines.  $' 
2.8  LEGAL  STATUS 
Benzodiazepines  are  prescription  only  medicines.  They  were  inserted  into  the  Misuse  of 
Drugs  Act  in  1985  and  are  controlled  under  Class  C  which  makes  them  illegal  to  supply. 
However,  it  is  legal  to  possess  them  in  the  medicinal  form  without  a  prescription. 
2.9  ANALYSIS  OF  BENZODIAZEPINES 
Reviewing  the  previous  literature  on  the  analysis  of  benzodiazepines  shows  an  increase  in 
the  reporting  of  SPE  compared  to  LLE  and  HPLC  and  GC/MS  compared  to  GC/FID  and 
GC/ECD.  In  his  handbook  on  benzodiazepines,  Schütz  reviewed  the  extraction 
methodology  of  the  late  1970's  and  early  1980's.  82  Of  21  reviews,  only  3  use  HPLC  as  the 
method  of  choice  for  analysis  and  only  one  reference  was  made  to  the  use  of  MS  as  a 
detector. 
The  most  recent  literature  has  been  concerned  with  the  GC/MS  analysis  of  benzodiazepines 
with  derivatisation.  In  1996,  Valentine  et  a!  94  compared  the  use  of  HPLC  versus  GC/MS 
for  the  quantitation  of  urinary  benzodiazepines.  They  conclude  by  stating  that  both 
methods  can  be  used  for  the  determination  of  benzodiazepines.  However,  HPLC  offers 
some  advantages  including  reduced  analysis  time  and  better  determination  of  some  of  the 
benzodiazepines  e.  g.  chlordiazepoxide.  Table  2.4  summarises  some  of  the  more  recent 
literature  detailing  the  type  of  extraction  and  analysis. Chapter  Two  Benzodiazepines  Page40 
Table  2.4:  Analysis  of  Benzodiazepines 
Year  Extraction 
Technique 
Analysis 
Technique 
Screen/ 
Quantitate 
Sample 
Volume 
Sample 
Type 
19911,  GC/MS/MS  SPE  Q  10  ml  Urine 
19911,  GC/NPD, 
HPLC 
LLE  S/Q  1  ml  Serum 
19911,  FPIA, 
HPLC 
LLE  S/Q  1  ml  Serum 
1994 
86  /  IA  S  /  Urine 
198987  GC/MS  SPE  2  ml  Urine 
1992  HPLC  SPE  1  ml  Blood 
1994  89  HPLC  LLE  I  ml  Blood 
199690  HPLC  SPE  Q  1  ml  Serum/ 
Plasma 
19959,  HPLC  LLE  S/Q  1  ml  Blood/SC/ 
Liver 
1995 
92  GC/MS  LLE  1  ml  Urine 
1997 
93  HPLC  SPE  Q  lg/2  ml  Tissue/ 
Blood 
1996 
94  GC/MS, 
HPLC 
LLE  Q  3  ml, 
1  ml 
Urine 
SC:  stomach  contents. 
2.10  SUPERCRITICAL  FLUID  ANALYSIS  OF  BENZODIAZEPINES 
As  with  most  drugs  of  abuse  there  is  a  severe  lack  of  literature  available  on  the  SFE  of 
benzodiazepines.  To  date  only  one  other  group  appear  to  have  investigated  the  extraction 
of  benzodiazepines  using  SF's.  Lawrence  et  al  used  SFE  to  extract  benzodiazepines  from 
95  their  solid  dosage  forms.  Their  method  used  CO2  with  2%  MeOH  as  a  modifier,  a 
temperature  of  65  °C  and  100  atmospheres  pressure  with  an  extraction  time  of  15  minutes 
(5  minutes  static,  10  minutes  dynamic).  The  drugs  analysed  represented  parent  drugs  and 
metabolites  (e.  g.  oxazepam  was  readily  extracted).  In  addition,  by  using  GCIMS,  no 
matrix  components  or  contaminants  were  found  to  be  extracted. 
2.11  CURRENT  METHODOLOGY 
The  methodology  used  at  present  in  the  routine  toxicology  laboratory  consists  of  SPE 
followed  by  HPLC  with  UV  detection.  The  SPE  method  is  detailed  in  section  2.11.1  and 
was  used  as  a  comparison  method  for  SFE.  The  HPLC  method  used  is  described  in 
Section  2.12.1.1. Chapter  Two  Benzodiazepines  Page4l 
2.11.1  SPE  OF  BENZODIAZEPINES 
A  10  ml  Plastipak  syringe  was  plugged  with  a  small  amount  of  glass  wool  and  3/4  filled 
with  dichloromethane  (DCM)  washed  Extrelut®  (diatomaceous  earth).  Three  types  of  vials 
were  prepared  as  follows: 
1) Standard  vial  containing:  100  µl  of  standard  mix  (temazepam,  triazolam, 
chlordiazepoxide,  desmethyldiazepam  and  diazepam,  all  3-5  mg/100  ml),  100  ml  of 
prazepam  (3  mg  /  100  ml),  0.9  ml  blank  blood,  250  µl  5%  NH3  and  phosphate  buffer 
(pH  7.4). 
2)  Blank  vial  containing:  100  µl  of  prazepam  (3  mg/100  ml),  1  ml  blank  blood,  250  µ15% 
NH3  and  1  ml  of  phosphate  buffer. 
3)  Sample  vial  containing:  100  µl  of  prazepam  (3  mg/100  ml),  1  ml  sample  blood,  250  µl 
5%  NH3  and  1  ml  of  phosphate  buffer. 
For  each  vial,  an  Extrelut®  column  was  prepared  and  a  labelled  8  ml  vial  placed  under  each 
column.  250  µl  of  5%  NH3  were  pipetted  onto  the  top  of  each  column  and  the  vortexed 
contents  of  each  vial  pipetted  onto  the  appropriate  column.  This  was  allowed  to  sit  for  5 
minutes  before  elution  with  diethylether  under  gravity.  Approximately  7  ml  were  eluted 
and  then  evaporated  to  dryness  under  a  stream  of  N2.  The  dried  residue  was  reconstituted 
in  180  µl  of  HPLC  mobile  phase. 
The  phosphate  buffer  added  to  the  vials  was  prepared  as  follows: 
A=  13.6  g  of  KH2PO4  /  500  ml  H2O 
B  =4  g  of  NaOH  /  500  m1  H2O 
450  ml  of  A  and  355  ml  of  B  were  mixed  and  the  pH  adjusted  to  pH  7.4  using  either  A  or 
B. 
2.12  HPLC  OF  BENZODIAZEPINES 
2.12.1  SEr-UP  OF  HPLC 
2.12.1.1  EXPERIMENTAL 
A  Gilson  HPLC  system  was  tested  to  ensure  that  the  analytical  results  produced  for  the 
separation  of  benzodiazepines  were  comparable  to  those  produced  in  the  routine Chapter  Two  Benzodiazepines  Page42 
laboratory.  The  system  consisted  of  a  Gilson  305,5SC  pump,  a  Gilson  805  manometric 
module,  and  a  Gilson  115  UV  detector  controlled  via  Gilson  715  software.  The  mobile 
phase  (0.01M  Na2HPO4  :  MeOH  (30  :  70  (v/v))  was  prepared  as  follows  and  allowed  to 
equilibrate  in  the  HPLC  system  for  30  minutes  before  recycling. 
1.78  g  of  Na2HPO4.2H20  (m.  wt.  177.99)  was  dissolved  in  1L  of  distilled  water  (dH2O). 
120  ml  of  this  was  added  to  280  ml  of  MeOH  and  degassed  with  helium  for  10  minutes  at 
room  temperature. 
The  flowrate  for  the  separation  was  1.0  ml  min''  which  gives  a  pressure  of  approximately 
2500  psi  through  a  25  cm  x  4.6  mm  i.  d.  Hypersil  ODS  column.  Injections  were  controlled 
via  a  7125  Rheodyne  fitted  with  a  20  µL  loop.  For  the  detection  of  benzodiazepines,  the 
wavelength  used  was  254  nm. 
Solutions  of  the  eleven  benzodiazepines  listed  in  table  2.5  which  had  been  prepared  for  the 
routine  laboratory  were  analysed  by  HPLC.  A1  ml  aliquot  of  each  standard  was  pipetted 
into  a  vial,  evaporated  to  dryness  under  N2  at  60  °C  and  reconstituted  in  1  ml  of  HPLC 
mobile  phase.  By  reconstituting  the  standards  in  mobile  phase,  the  solvent  front  and  peak 
distortions  are  minimised.  A  20  tl  injection  of  each  solution  was  made  into  the  HPLC  and 
the  chromatograms  recorded  on  a  Asea  Brown  Boveri  (ABB)  SE  120  chart  recorder. 
2.12.1.2  RESULTS  AND  DISCUSSION 
The  retention  times  and  capacity  factors  obtained  from  the  chromatograms  of  the  eleven 
benzodiazepines,  including  the  five  routinely  screened  for  (marked  *  in  Table  2.5),  with 
prazepam  as  an  internal  standard  are  shown  in  Table  2.5. Chapter  Two  Benzodiazepines  Page43 
Table  2.5:  Retention  Times  of  Selected  Benzodiazepines. 
Drug  Retention  time  (R.  T.  ) 
(minutes) 
Capacity  Factor  (k') 
Clonaze  am  4.4  0.96 
Nitrazepam  4.7,6.9)  1.19  (2.21) 
Clobazam  5.2  1.31 
Lo  razolam  5.6  1.49 
Lorazepam  6.0,  (9.9)  1.22  (2.67 
Triazolam  *  5.7  1.11 
Oxazepam  6.4  1.37 
Temaze  am  *  6.8  1.52 
Chlordiaze  oxide  *  7.1,  (8.3)  1.63  (2.07) 
Desmeth  ldiaze  am  *  7.7  1.85 
Diazepam  *  8.7  2.22 
Praze  am  14.3  4.30 
Each  of  the  benzodiazepines  chromatographed  had  separate  retention  times  and  capacity 
factors.  However,  for  several  of  the  drugs,  the  retention  times  and  capacity  factors  were 
close  e.  g.  loprazolam  (5.6  min)  and  triazolam  (5.7  min)  and  thus,  it  would  be  desirable  to 
have  a  separate  method  in  order  to  verify  which  drug  was  being  detected  in  an  unknown 
sample. 
It  was  essential  that  great  care  was  taken  while  preparing  the  mobile  phase.  The  elution  of 
benzodiazepines  is  extremely  sensitive  to  the  addition  of  excess  methanol  to  the  system. 
Inaccuracies  of  as  little  as  5  ml  in  a  litre  of  mobile  phase  was  found  to  cause  co-elution  of 
some  of  the  more  commonly  encountered  drugs  e.  g.  temazepam  and  chlordiazepoxide. 
2.12.2  DETERMINATION  OF  RETENTION  TIME  OF  CHLORDIAZEPOXIDE,  NITRAZEPAM  AND 
LORAZEPAM 
2.12.2.1  EXPERIMENTAL,  RESULTS  AND  DISCUSSION 
As  can  be  seen  in  Table  2.5,  the  injections  of  chlordiazepoxide,  nitrazepam  and  lorazepam, 
gave  two  peaks.  Fresh  standards  of  these  drugs  were  prepared  in  methanol  and  these  gave 
only  one  peak  per  drug  (the  retention  time  which  is  not  in  brackets).  Of  the  three, 
chlordiazepoxide  is  the  only  one  of  relevance  to  this  study,  as  nitrazepam  and  its Chapter  Two  Benzodiazepines  Page44 
metabolites  are  chromatographed  by  a  separate  method  and  lorazepam  is  only  analysed  for 
in  cases  where  the  subject  is  known  to  have  used  the  drug. 
2.12.3  CHLORDIAZEPOXIDE  STABILITY 
The  degradation  peak  of  chlordiazepoxide  elutes  between  desmethyldiazepam  and 
diazepam  and  for  the  normal  standard  mix  used  (triazolam,  chlordiazepoxide,  temazepam, 
diazepam,  desmethyldiazepam)  does  not  affect  the  chromatography  to  any  great  extent  so 
long  as  the  optimal  methanol  volume  is  not  exceeded.  Chlordiazepoxide  abuse  at  the  time 
of  this  initial  study  was  extremely  rare  and  on  the  occasions  where  positives  were 
observed,  a  fresh  standard  was  prepared  for  quantitation  purposes.  However,  the  situation 
in  1997  has  changed  with  reference  to  benzodiazepines  and  with  the  withdrawal  of 
temazepam  from  the  market,  more  chlordiazepoxide  is  found  in  case  samples. 
The  structure  of  chlordiazepoxide  is  shown  in  Figure  2.3. 
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Figure  2.3:  Structure  of  Chlordia  epoxide 
2.12.3.1  EXPERIMENTAL 
A  short  study  was  carried  out  to  see  how  quickly  the  chlordiazepoxide  decomposed.  A 
standard  mix  containing  all  five  of  the  standards  used  in  the  laboratory  was  prepared  by 
pipetting  5  ml  of  each  drug  standard  (5  mg/100ml)  into  a  vial,  evaporating  to  dryness  under 
N2  at  60  °C  and  reconstituting  in  5  ml  of  MeOH.  For  injection  onto  the  HPLC,  aliquots  of Chapter  Two  Benzodiazepines  Page45 
this  standard  mix  were  pipetted  into  a  vial,  evaporated  to  dryness  and  reconstituted  in  the 
appropriate  volume  of  mobile  phase. 
In  addition,  a  fresh  chlordiazepoxide  standard  was  prepared  by  dissolving  a5  mg  Librium 
tablet  into  100  ml  of  methanol  in  a  volumetric  flask.  The  study  was  carried  out  over  one 
week  to  determine  how  quickly  the  degradation  peak  appeared. 
2.12.3.2  RESULTS  AND  DISCUSSION 
The  relative  peak  heights  of  the  five  standards  to  prazepam  were  calculated  from  the  traces 
obtained  from  HPLC  injections  on  day  one  and  day  eight  and  are  shown  in  Table  2.6. 
Table  2.6:  Chlordiazepoxide  Stability  Study 
Peak  Retention  time 
(minutes) 
Relative  height 
Day  1 
Relative  height 
Day  8 
Triazolam  5.3  1.26  1.07 
Temaze  am  6.3  1.46  0.91 
Chlordiaze  oxide  6.7  1.14  0.20 
Desmeth  ldiaze  am  7.4  1.56  1.30 
Im  uric  7.8  0  0.74 
Diaze  pam  8.1  1.20  1.13 
Praze  am  13.4  1.00  1.00 
Although  none  of  the  relative  peak  heights  from  days  one  and  eight  have  remained 
constant,  the  one  which  has  shown  the  most  marked  decrease  is  chlordiazepoxide.  Over 
the  eight  days,  an  impurity  peak  has  appeared  which  elutes  between  desmethyldiazepam 
and  diazepam.  By  injecting  each  of  the  drugs  on  their  own,  it  was  confirmed  that  this  peak 
was  due  to  the  chlordiazepoxide  as  each  of  the  other  drugs  produced  only  one  peak  none  of 
which  corresponded  to  the  impurity  peak. 
For  the  chlordiazepoxide  on  its  own,  initially  (t=0  hours),  only  one  peak  was  observed.  At 
the  end  of  the  first  day  (t=2  hours)  an  additional  peak  was  observed  at  7.8  minutes  with  a 
height  of  0.6  cm.  After  18  hours  the  peak  height  had  increased  to  2.1  cm  and  after  4  days 
the  peak  height  was  8.5  cm  corresponding  to  a  1417%  increase  from  t=2  hours.  These 
results  are  shown  graphically  in  Figure  2.4. Chapter  Two  Benzodiazepines 
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Figure  2.4:  Increase  in  Height  of  '  Chlordia  epoxide  Impurity  Peak  with  Time 
As  chlordiazepoxide  rapidly  degrades,  it  is  essential  that  if  a  case  sample  is  positive,  a  new 
chlordiazepoxide  standard  is  prepared  prior  to  quantification.  It  should  be  noted  that  the 
relative  height  of  the  impurity  peak  to  chlordiazepoxide  could  not  be  calculated  as  in  order 
to  measure  the  height  of  the  impurity  peak,  the  sensitivity  of  the  detector  had  to  be 
increased  and  thus,  the  chlordiazepoxide  peak  was  off  scale  on  the  chart  recorder. 
The  HPLC  chart  recorder  traces  of  the  chlordiazepoxide  and  its  impurity  on  days  one  and 
four  are  shown  in  Figure  2.5. Chapter  Two  Benzodiazepines  Page47 
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Figure  2.5.  Chromatograms  of  Chlordiazepoxide  Peaks  on  Days  One  and  Four 
2.12.4  IDENTITY  OF  CHLORDIAZEPOXIDE  IMPURITY  PEAK 
2.12.4.1  EXPERIMENTAL 
A  fresh  standard  of  chlordiazepoxide  in  MeOH  was  prepared  (1  mg/5  ml).  This  was 
injected  into  HPLC  and  GC/MS  immediately  after  preparation.  Each  day  after,  further 
injections  were  made  on  both  instruments  and  the  impurity  peak  monitored.  The  solution 
was  made  concentrated  so  that  the  impurity  peaks  mass  spectrum  could  be  obtained  for 
quantification.  Several  small  impurity  peaks  were  observed  in  the  chlordiazepoxide  mass 
chromatogram.  Only  one  of  these  was  found  to  increase  in  area  with  time.  After  28  days 
at  room  temperature,  the  impurity  peak  was  larger  than  the  chlordiazepoxide  peak. 
The  mass  spectrum  obtained  for  the  impurity  peak  was  investigated  in  order  to  attempt  to 
identify  the  impurity.  The  mass  spectrum  obtained  is  shown  in  Figure  2.6. 
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Figure  2.6:  Mass  Spectrum  of  Chlordiazepoxide  Impurity 
As  it  was  not  possible  to  determine  the  structure  of  the  impurity  from  this  information,  an 
additional  study  was  carried  out.  Approximately  0.5  mg  of  chlordiazepoxide  was  dissolved 
in  H2O,  MeOH,  EtOH  and  deuterated  MeOH  (D3OD).  Again  the  solutions  were  injected 
on  day  one  and  consecutive  days  thereafter,  until  the  impurity  peak  mass  spectrum  could  be 
ascertained. 
The  mass  chromatograms  for  the  chlordiazepoxide  in  H2O  and  EtOH  showed  no  impurity 
peak  after  10  days.  The  chromatograms  for  chlordiazepoxide  in  MeOH  and  CD3OD 
showed  a  peak  at  the  same  retention  time  that  had  been  observed  for  the  experiment 
previously  carried  out  in  MeOH.  The  mass  spectra  of  these  impurity  peaks  are  shown  in 
Figure  2.7,  the  mass  spectrum  for  chlordiazepoxide  is  also  given  for  comparison. 
From  these  spectra  alone,  it  was  not  possible  to  identify  the  impurity.  It  can  be 
hypothesised  that  in  some  way  the  MeOH  (CD3OD)  is  adding  into  the  chlordiazepoxide 
structure  (from  the  m/z  313  in  the  MeOH  which  becomes  m/z  317  in  CD3OD)  possibly  at 
the  imino  amide  part  of  the  diazepine  ring. Chapter  Two  Benzodiazepines  Page49 
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Figure  2.7:  Mass  Spectra  of  CDP  Impurity  in  MeOH  and  D30D 
2.12.5  RETENTION  TIME  REPRODUCIBILITY 
2.12.5.1  EXPERIMENTAL 
The  remainder  of  this  study  was  carried  out  using  only  the  five  benzodiazepines  routinely 
screened  for  as  highlighted  in  Table  2.5.  Three  to  five  injections  of  each  of  the  standards 
were  made  in  order  to  check  the  retention  time  reproducibility  of  the  HPLC  system  for  an 
equilibrated  mobile  phase  (MP1).  An  injection  of  each  standard  was  also  made  using  a 
freshly  prepared  mobile  phase  (MP2)  to  ensure  reproducibility  in  the  mobile--phase 
preparation.  The  second  mobile  phase  was  equilibrated  in  the  system  overnight. 
2.12.5.2  RESULTS  AND  DISCUSSION 
The  retention  time  reproducibility  results  are  reported  in  Table  2.7,  where  xi  and  x2  are  the 
mean  retention  times  for  mobile  phases  1  and  1+2  respectively.  The  relative  standard 
deviation  (RSD)  for  each  set  of  means  was  computed  using  a  calculator. Chapter  Two  Benzodiazepines  Page5O 
Table  2.7:  Infection  Time  Reproducibility 
Sample  MP1  MP2  xl  X2  RSD1*  RSD2 
Triaz  5.3,  5.3,  5.2,  5.2,  5.3  5.2  5.3  5.3  1.04%  1.04% 
Temaz  6.4,  6.3,  6.3  6.2  6.3  6.3  0.91%  1.29% 
CDP  6.8,  6.8,  6.7,  6.7,  6.7  6.6  6.7  6.7  0.81%  1.12% 
DMD  7.4,  7.4,  7.4,  7.4,  7.4  7.3  7.4  7.4  0.00%  0.55% 
Diaz  8.1,  8.2,  8.1,  8.1,  8.1  8.2  8.1  8.1  0.55%  0.63% 
Praz  13.6,  13.4,13.4  13.4  13.5  13.5  0.86%  0.74% 
*For  calculation  of  RSD  see  Appendix  11. 
From  these  results  it  is  apparent  that  the  reproducibility  of  the  system  is  sufficient  for  use 
both  on  a  daily  basis  and  a  weekly  basis  which  requires  changing  of  the  HPLC  mobile 
phase.  There  is  little  variation  seen  in  the  retention  times  of  the  peaks  and  the  RSD  values 
are  low  (all  less  than  1.3%). 
2.13  SET  UP  OF  SFE  SYSTEM. 
2.13.1  INrrrAL  SET-up 
The  initial  SFE  set-up  is  described  in  Section  1.4.  A  start-up  check  list  was  devised  as 
indicated  below: 
"  Switch  on  the  chiller  unit,  the  detector  and  the  GC  oven 
9  Prime  the  modifier  pump  with  the  CO2  cylinder  closed 
"  Once  the  chiller  is  cold,  check  the  system  for  leaks  with  CO2  (Do  not  pump  CO2  until 
the  chiller  is  cold) 
"  Once  the  oven  is  at  the  correct  temperature,  switch  on  the  pumps  and  the  mixer 
"  Adjust  the  pressure  using  the  back-pressure  regulator 
"  Place  the  extraction  cell  into  the  oven 
"  Put  the  analyte  collection  device  in-line  (in  this  case  a6  ml  hypovial  containing  -2  ml 
of  MeOH) 
"  Start  the  run  using  the  Gilson  306  software 
"  Inject  the  matrix  containing  the  analytes  to  be  extracted  into  the  rheodyne 
9  Switch  the  rheodyne  valve  from  load  to  inject  and  remove  the  syringe Chapter  Two  Benzodiazepines  Page51 
After  extraction: 
"  Switch  the  rheodyne  valve  from  inject  to  load 
"  Remove  the  collection  vial 
"  Evaporate  the  MeOH  to  dryness 
"  Reconstitute  the  residue  in  HPLC  mobile  phase 
"  Inject  the  sample  onto  HPLC 
At  the  end  of  the  day: 
"  Stop  the  flow. 
"  Remove  and  clean  the  extraction  vessel. 
"  Isolate  the  two  halves  of  the  system  by  switching  the  rheodyne  to  the  middle  position 
and  letting  the  pressure  drop  on  the  oven  side. 
"  Unplug  the  chiller  unit. 
"  Switch  off  the  mixer,  the  oven  and  the  detector. 
"  Turn  off  the  CO2. 
2.13.1.1  EXPERIMENTAL 
In  order  to  check  that  the  system  had  no  mechanical  or  electronic  faults  and  that  there  were 
no  leaks,  an  ODS  Hypersil  (25  cm  x  4.6  mm  i.  d.,  5µ  particle  size)  HPLC  column  was 
inserted  into  the  GC  oven.  A  100  t1  injection  of  a  mixed  solution  of  the  five 
benzodiazepine  standards  was  made  under  the  following  conditions: 
1%-25%  MeOH  in  CO2  over  fifteen  minutes,  hold  for  two  minutes,  back  to  1%  MeOH 
over  one  minute  at  60  °C  and  0.5  ml  min''. 
2.13.1.2  RESULTS  AND  DISCUSSION 
All  six  peaks  were  found  to  elute  within  the  first  few  minutes  and  the  peak  shapes  were 
very  poor.  However,  on  injecting  blank  MeOH,  no  peaks  were  observed  other  than  a  slight 
solvent  front  indicating  that  the  system  was  functioning  and  improvement  of  the 
chromatography  could  be  achieved  with  simple  method  development. Chapter  Two  Benzodiazepines  Page52 
However,  the  purpose  of  this  study  was  SFE  and  thus,  as  the  system  was  functioning,  an 
extraction  vessel  was  prepared.  An  empty  HPLC  column  (10  cm  x  4.6  mm  i.  d.  )  was  half 
filled  with  DCM  washed  Extrelut°.  200  µl  of  the  benzodiazepine  standard  mixture  was 
loaded  into  this  and  the  column  inserted  into  the  oven  which  was  set  at  60  °C.  At  the  flow 
outlet,  a  hypovial  containing  MeOH  was  attached,  ensuring  that  the  end  was  immersed  in 
the  MeOH.  The  vial  was  sealed  using  a  butyl  rubber  septa  and  a  disposable  needle  was 
inserted  as  a  pressure  release  as  shown  in  Figure  2.8. 
From  SFE 
System 
Pressure 
Regulator 
i! 
Butyl  Rubber 
Septum 
sure 
gase 
Outlet 
Tubin, 
6  mI. 
Eiyp  ovial 
rlethanol 
Figure  2.8:  Collection  Device  for  SFE 
Initially  I%  MeOH  was  pumped  through  at  I  ml  min-',  however,  as  the  pressure  increased, 
the  flow  had  to  be  decreased  to  0.5  ml  min-1.  The  percent  of  MeOH  was  increased  stepwise 
to  25%  over  three  minutes.  Next,  the  ODS  column  was  reinserted  in  place  of  the 
extraction  vessel,  and  the  extract  injected.  All  previously  detected  peaks  were  found  to 
elute. 
These  two  experiments  indicated  that  the  SF  system  was  functioning  properly  and  thus  was 
suitable  for  use  for  the  SFE  of  benzodiazepines. Chanter  Two  Benzodiazepines  Page53 
2.14  METHOD  DEVELOPMENT:  SFE  OF  BENZODIAZEPINES 
Several  benzodiazepines  were  investigated  by  SFE,  namely  triazolam,  temazepam, 
diazepam,  desmethyldiazepam,  chlordiazepoxide  and  prazepam.  These  were  initially 
extracted  from  methanol  standards  by  loading  200  µl  of  the  mixed  drug  standard  onto 
DCM  washed  Extrelut®.  The  Extrelut®  was  chosen  as  an  extraction  media  as  this  is  the 
same  as  that  used  in  the  routine  SPE  method. 
2.14.1  SFE  OF  TRIAZOLAM 
2.14.1.1  EXPERIMENTAL 
As  opposed  to  extracting  all  five  benzodiazepines  at  once,  it  was  decided  to  investigate  one 
drug  and  then  apply  the  developed  conditions  to  all  five.  Triazolam  was  the  first 
benzodiazepine  to  be  investigated.  The  initial  conditions  used  were  5%  diethyl  ether,  1500 
psi,  0.5  ml  min  1  and  70  °C.  Again,  diethyl  ether  was  chosen  as  a  modifier  as  it  is  used  in 
the  SPE  of  benzodiazepines.  Using  these  conditions,  two  fractions  were  collected,  one 
from  0-5  minutes  and  the  other  from  5-10  minutes. 
The  extracts  were  collected  into  MeOH  at  the  flow  outlet,  evaporated  to  dryness  under  N2 
at  65  °C  and  reconstituted  in  100  µl  of  HPLC  mobile  phase. 
A  second  extraction  of  triazolam  was  carried  out  using  the  same  conditions  except  that  the 
pressure  was  increased  by  closing  the  pressure  regulator  to  a  pressure  of  3000  psi.  For  this 
extraction,  the  extract  fractions  were  collected  from  0-8  minutes  and  8-15  minutes. 
2.14.1.2  RESULTS  AND  DISCUSSION 
HPLC  of  the  first  extraction  fractions  showed  several  peaks  at  the  solvent  front  and  one 
peak  at  4.6  minutes.  This  peak  was  masking  two  other  peaks  at  4.2  minutes  and  5.1 
minutes.  On  injection  of  a  standard  solution  of  triazolam  this  was  found  to  have  a 
retention  time  of  5.4  minutes,  thus  no  triazolam  had  been  extracted.  On  HPLC  of  the 
second  extraction  extracts,  the  0-8  minutes  extract  showed  a  peak  at  5.3  minutes 
corresponding  to  triazolam.  The  recovery,  as  calculated  by  comparing  the  PH  of  the Chapter  Two  Benzodiazepines 
extracted  standard  to  that  of  an  unextracted  standard  at  the  same  concentration,  for  this 
part  of  the  extraction  was  very  low  (<5%).  The  8-15  minutes  extract  had  no  corresponding 
peaks. 
2.14.2  SFE  OF  TEMAZEPAM 
The  number  of  toxicology  cases  in  the  period  1992-1996,  which  were  positive  for 
benzodiazepines  was  investigated  and  yielded  the  bar  chart  shown  in  Figure  2.9.  No 
triazolam  positive  cases  were  found  in  this  time  period.  In  addition  to  this,  it  was  found 
that  the  most  commonly  encountered  benzodiazepine  in  toxicology  samples  in  the  period 
leading  up  to  this  study  in  1994  was  temazepam.  For  this  reason  it  was  decided  to  use 
temazepam  instead  of  triazolam  as  a  starting  drug. 
Temazepam 
   Diazepam 
   Desmethyl  diazepam 
   Chlordiazepoxide 
Q  Nitrazepam 
Figure  2.9:  Ben:  odia:  epine  Cases  1992-1996 
2.14.2.1  EXPERIMENI  AL 
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The  second  set  of  conditions  used  for  triazolam  (i.  e.  3000  psi,  5%  diethyl  ether,  0.5  ml 
min-',  70  °C)  were  used  for  the  extraction  of  temazepam.  The  pressure  was  difficult  to 
control  and  fluctuated  throughout  the  extraction.  For  this  reason  all  pressures  quoted 
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development  are  an  average  of  the  initial  and  final  pressures.  All  extractions  were  run  for 
fifteen  minutes  unless  otherwise  stated. 
2.14.2.2  RESULTS  AND  DISCUSSION 
At  an  average  pressure  (pa)  of  2502  psi,  temperature  at  70  °C  and  0.5  ml  min  1,  only  a  very 
small  amount  of  temazepam  was  extracted  (<I%).  At  the  same  temperature  and  pressure 
but  with  15%  diethyl  ether,  the  recovery  was  still  less  than  5%.  The  modifier  was  changed 
from  diethyl  ether  to  methanol  and  this  time  the  peak  height  of  the  extracted  temazepam 
increased  from  2.9  cm  to  20.8  cm  which  corresponded  to  an  approximate  recovery  of 
100%. 
2.14.3  SFE  OF  THE  STANDARD  MIX  +  INTERNAL  STANDARD 
2.14.3.1  EXPERIMENTAL 
As  the  15%  MeOH,  70  °C,  0.5  ml  min'  extraction  conditions  appeared  to  work  for 
temazepam,  a  mix  of  the  standards  and  the  internal  standard  was  extracted  at  15%,  10% 
and  5%  MeOH.  The  pressure  was  =  3000  psi,  the  flowrate  0.5  ml  miri  d,  and  the 
temperature  60  °C  in  all  cases.  Only  the  15%  and  10%  extractions  could  be  directly 
compared  as  the  5%  run  was  carried  out  using  a  different  standard  mix. 
2.14.3.2  RESULTS  AND  DISCUSSION 
The  results  obtained  for  the  SFE  of  the  five  standard  benzodiazepines  with  prazepam  as  the 
internal  standard  at  varying  percents  of  MeOH  are  shown  in  Table  2.8.  The  retention  times 
(R.  T.  )  are  in  minutes  and  the  peak  heights  (P.  H.  )  in  cm. Chapter  Two  Benzodiazepines  Page56 
Table  2.8:  Comparison  of  Extractions  at  Various  %  MeOH 
Drug  15%  MeO  H  10  %  MeO  H  5%  McO  H 
R.  T.  P.  H.  PHR  R.  T.  P.  H.  PHR  R.  T.  P.  H.  PHR 
Triaz  5.4  2.3  3.3  5.4  4.6  2.1  5.4  6.75  1.2 
Temaz  6.4  2.5  3.6  6.4  4.4  2.0  6.4  5.1  0.9 
CDP  6.8  0.9  1.3  6.9  1.8  0.8  6.9  1.8  0.3 
DMD  7.5  1.2  1.7  7.5  4.8  2.2  7.4  7.6  1.4 
Diaz  8.4  0.9  1.3  8.3  2.6  1.2  8.3  6.6  1.2 
Praz  14.1  0.7  1.0  14.1  2.2  1.0  14.1  5.5  1.0 
A  blank  extraction  of  MeOH  was  made  to  see  if  there  was  any  carry  over  of  the 
benzodiazepines  within  the  system.  Traces  of  all  the  benzodiazepines  were  observed  by 
HPLC.  A  second  blank  extraction  was  carried  out  this  time  using  diethyl  ether.  Again 
peaks  were  observed  by  HPLC.  Finally,  another  MeOH  blank  was  extracted.  This  time, 
no  peaks  were  observed  by  HPLC.  The  carry  over  peaks  indicate  that  either  the  extraction 
time  is  not  long  enough,  that  the  conditions  are  not  ideal  for  100%  recovery,  that  the  drugs 
have  an  affinity  for  the  stainless  steel  tubing  or  that  there  is  a  "cold-spot"  in  the  SFE 
system. 
From  the  results  in  Table  2.8,  it  appears  that  as  the  %  modifier  is  reduced,  the  peak  heights 
of  the  drugs  extracted  increases.  The  extraction  at  10%  was  repeated.  However  on 
injection  onto  HPLC  at  the  previous  sensitivity  of  0.05,  all  peaks  were  off  scale.  It  was 
noted  that  the  GC  oven  had  been  switched  off  and  therefore,  the  extraction  mixture  was  not 
supercritical.  As  a  result  of  this,  the  effects  of  temperature  on  the  extraction  were 
investigated. 
2.14.4  TEMPERATURE  EnEcrs. 
2.14.4.1  EXPERIMENTAL 
A  series  of  extractions  were  carried  out  on  the  standard  mix  at  ambient,  40  °C  and  60  °C. 
The  flow  was  set  to  0.5  ml  mini  1  with  MeOH  as  the  modifier  at  10%.  A  new  extraction 
column  was  put  in  place.  The  pressure  for  the  ambient  extraction  was  -  4500  psi  which 
was  too  high  and  thus  the  pressure  was  decreased  by  opening  the  regulator  until  a  pressure 
of  =  3500  psi  was  obtained  for  the  other  extractions.  To  ensure  that  there  was  no  carryover Chapter  Two  Benzodiazepines  Page57 
between  extractions,  blank  diethyl  ether  was  injected  between  each  extraction.  No  carry 
over  peaks  were  observed. 
2.14.4.2  RESULTS  AND  DISCUSSION 
The  %  recoveries  calculated  for  the  extraction  of  the  five  benzodiazepines  at  various 
temperatures  on  a  peak  height  basis  are  shown  in  Table  2.9. 
Table  2.9:  Recoveries  for  Standard  Benzodiazepines  at  Various  Temperatures 
Drug  Unextracted  Ambien  t  40  °C  60  °C 
P.  H.  PHR  P.  H.  %Rec  PHR  P.  H.  %Rec  PHR  P.  H.  %Rec  PHR 
Triaz  12.3  1.07  14.4  117  1.5  9.5  77  1.51  1.6  13  1.6 
Temaz  10.4  0.90  8.9  86  0.93  6.3  61  1.00  1.0  9.6  1.0 
CDP  2.3  0.20  2.1  91  0.22  1.4  61  0.22  0.2  43  0.2 
DMD  14.4  1.25  13.3  92  1.39  9.2  64  1.46  1.5  10  1.5 
Diaz  13.0  1.13  10.9  84  1.14  8.0  62  1.27  1.2  9.2  1.2 
Praz  11.5  1.0  9.6  83  1.0  6.3  55  1.0  1.0  8.7  1.0 
It  can  be  seen  that  as  the  temperature  increases  the  %  recovery  decreases,  but  at  low 
temperatures,  the  system  is  not  operating  in  the  supercritical  mode.  The  benzodiazepines 
seem  to  be  remaining  absorbed  on  the  Extrelut®  at  the  higher  temperatures. 
The  temperature  in  the  SFE  system  was  set  to  50  °C  and  the  extractions  run  at  10,15  and 
20%  MeOH.  The  pressure  and  flow  rate  were  left  at-  3500  psi  and  0.5  ml  min  1.  These 
conditions  did  not  improve  the  extraction  efficiency  and  it  was  thought  that  at  the  higher 
percents  of  MeOH  that  the  system  was  again  not  supercritical. 
2.14.5  CRITICAL  TEMPERATURE  OF  CO2  AND  MEOH  MIXTURES 
As  an  estimation  of  the  critical  temperature  at  various  %  modifiers,  a  straight  line  graph 
can  be  plotted  from  T,,  for  CO2  to  Tc  for  modifier.  Using  the  X-axis  for  %  modifier  from 
0-100%,  with  the  critical  temperatures  of  the  two  components  on  the  y-axes,  the  T,  of  the 
mixture  can  be  approximated.  In  practice,  due  to  forces  mentioned  in  section  1.1.2  of  the 
SF  introduction,  these  temperatures  may  not  be  supercritical  and  thus  a  temperature  of  5- 
10  °C  higher  is  suggested  as  a  good  starting  point  for  method  development. Chapter  Two  Benzodiazepines  Page58 
The  graph  in  Figure  2.10  shows  the  approximate  critical  temperatures  for  CO2  and  MeOH 
mixtures.  So  for  example  at  30%  MeOH  in  C02,  the  approximate  critical  temperature 
would  be  94  °C  and  the  starting  point  for  method  development  would  be  99  °C. 
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Figure  2.10:  Approximation  of  the  Critical  Temperature  ofMeOH  in  Supercritical  CO2 
2.14.6  CONTINUATION  OF  TEMAZEPAM  METHOD  DEVELOPMENT 
Instead  of  trying  to  further  continue  this  line  of  method  development  with  all  five 
benzodiazepines  plus  the  internal  standard,  it  was  decided  to  once  more  investigate 
temazepam  on  its  own.  The  conditions  developed  should  extract  the  other 
benzodiazepines  due  to  their  similar  structures. 
2.14.6.1  ExP  EwTAL 
The  initial  conditions  used  for  the  temazepam  extraction  were: 
"  Flow  rate:  0.5  ml  min  1 
9%  modifier:  20%  MeOH 
"  Temperature:  70  °C 
0  20  40  60  80  100 
%  MeOH Chapter  Two  Benzodiazepines  Page59 
"  p;:  4017 
"  Pf:  4075 
"  Pa:  4046 
The  extraction  was  recorded  and  the  profile  indicated  that  the  drug  is  extracting  between  3 
and  12  minutes  as  indicated  in  Figure  2.11. 
Injection  of  unextracted  temazepam  onto  the  HPLC  produced  a  peak  height  of  10.2  cm. 
Using  the  SFE  conditions  described,  a  peak  height  of  3.2  cm  was  obtained,  corresponding 
to  a  recovery  of  31  %. 
Figure  2.11:  Extraction  Profile  of  Tema  epam 
2.14.7  OPTIMISATION  OF  TEMAZEPANj  EXTRACTION. 
Optimisation  of  SFE  can  be  achieved  in  three  ways:  96 
----  ý.  ýý  JLV.  VV  tz.  VV  14.00 
TEMAZ1.001\DAT001.  DTI  Channel  A 
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"  Altering  the  modifier  /%  modifier 
"  Altering  the  temperature 
"  Altering  the  pressure 
2.14.8  EFFECT  OF  ALTERING  THE  %  MODIFIER. 
2.14.8.1  EXPERIMENTAL 
The  percent  of  MeOH  used  for  the  extraction  of  temazepam  was  varied  from  10-50% 
whilst  maintaining  the  pressure  at  -4000  psi  and  the  temperature  at  70  °C.  The  extractions 
were  carried  out  as  described  previously. 
2.14.8.2  RESULTS  AND  DISCUSSION 
The  average  pressures  are  indicated  in  Table  2.10  with  the  results  obtained  for  the 
extraction  of  temazepam  at  various  percent  of  MeOH. 
Table  2.10:  Variation  in  %  Recovery  with  Increasing  %  Modifier 
%  modifier  %  recovery  P  (psi) 
10  9.8  3894 
20  18  4126 
30  26  3828 
40  59.4  3640 
50  96  3718 
As  the  %  modifier  is  increased,  the  %  recovery  increases  but  again  the  conditions  will  not 
be  supercritical  (Tc  at  50%  MeOH  -  135  °C). 
2.14.9  REPRODUCIBILITY  OF  EXTRACTION  USING  MEOH  (40%)  AS  THE  MODIFIER 
2.14.9.1  EXPERIMENTAL 
Three  extractions  were  carried  out  at  40%  with  all  other  parameters  kept  constant.  The 
collected  extracts  were  injected  in  duplicate  ensuring  that  the  25  µl  loop  on  the  HPLC 
system  was  overfilled. Chapter  Two  Benzodiazepines  Page6l 
2.14.9.2  RESULTSAND  DISCUSSION 
The  results  for  the  reproducibility  test  are  shown  in  Table  2.11. 
Table  2.11:  Extraction  Reproducibility 
Injection  El  E2  E; 
1  8.297%  7.588%)  15.1>100%) 
2  10.4  (>100%)  11.2  (>100%)  15.9  (>100%) 
The  extraction  at  40%  showed  poor  reproducibility  by  HPLC,  both  intra-  and  inter- 
extraction  and  therefore,  a  peak  height  injection  reproducibility  test  was  carried  out  on  the 
HPLC. 
2.14.10  HPLC  SYSTEM  REPRODUCIBILITY 
2.14.10.1  EXPERIMENTAL 
The  temazepam  standard  in  MeOH  was  injected  five  times  onto  the  HPLC  at  a  sensitivity 
of  0.5.  The  peak  heights  obtained  were  measured  manually. 
2.14.10.2  RESULTS  AND  DISCUSSION 
The  peak  heights  obtained  for  the  five  injections  of  temazepam  were: 
8.4  cm,  8.8  cm,  8.4  cm,  9.8  cm,  8.4  cm. 
These  heights  give  a  mean  peak  height  of  8.76  and  a  RSD  of  6.9%.  It  would  appear  that 
the  9.8  cm  value  is  an  outlier,  however,  more  injections  would  be  required  in  order  to 
verify  this.  In  practice  only  a  maximum  of  three  injections  can  be  made  per  extraction  due 
to  the  reconstitution  volume  and  so  the  reproducibility  of  the  HPLC  system  is  unacceptable 
for  this  work. Chapter  Two  Benzodiazepines  Page62 
2.14.11  TEMAZEPAM  EXTRACTION  FROM  WHOLE  BLOOD 
2.14.11.1  EXPERIMENTAL 
Despite  the  conditions  at  70  °C  and  40%  MeOH  being  non-supercritical,  these  were 
yielding  reasonably  high  recoveries  and  thus  were  used  in  an  attempt  to  extract  temazepam 
from  a  spiked  blood  standard. 
A1  ml  aliquot  of  38.4  pg  ml'1  temazepam  standard  in  methanol  was  evaporated  to  dryness 
under  nitrogen,  reconstituted  in  1  ml  of  blank  blood  and  sonicated  for  three  minutes.  A 
fresh  extraction  vessel  was  inserted  into  the  GC  oven  and  the  system  was  set  for  0.5  ml 
min"',  40%  MeOH  and  70  °C.  A  100  µl  injection  of  the  blood  standard  was  made  followed 
by  an  injection  of  100  tl  of  distilled  water  (dH2O).  The  rheodyne  was  then  switched  back 
to  the  load  position  and  flushed  through  with  dH2O  until  it  ran  clear  and  after  one  minute  a 
further  injection  of  100  µl  dH2O  was  made  in  an  attempt  to  spread  the  blood  over  the 
Extrelut®  in  the  column. 
The  initial  pressure  was  3840  psi  and  the  final  pressure  was  4640  psi.  A  second  blood 
extraction  was  attempted.  This  time,  a  pressure  drop  of  -  1000  psi  was  seen  across  the 
system.  On  removing  the  column,  the  pressure  drop  was  found  to  be  due  to  the  injected 
blood  forming  a  clot  in  the  extraction  vessel,  thus  the  injections  of  dH2O  were  not 
spreading  the  blood,  over  the  contents  of  the  extraction  vessel.  In  addition,  the  collection 
solvent  turned  pale  brown  in  colour  which  was  possibly  due  to  the  water  carrying  blood 
through  to  the  collection  vial.  Two  further  extractions  were  carried  out  and  the  extraction 
vessel  changed  between  each  one  to  prevent  blocking. 
2.14.11.2  RESULTS  AND  DISCUSSION 
Results  for  the  first  extraction  and  the  two  further  extractions  were  obtained  by  HPLC  and 
are  reported  in  Table  2.12.  The  peak  height  of  the  unextracted  temazepam  was  10.9  cm. Chapter  Two  Benzodiazepines  Page63 
Table  2.12:  Reproducibility  for  3  Standard  Blood  Extractions 
Extraction  Recovery  (Peak  heig  ht  (cm)) 
Injection  Ext.  1  Ext.  2  Ext.  3 
1  53.2%*  (5.8)  86.2%  (9.4)  >100%  (11.2) 
2  99%  (10.8)  80.7%  (8.8)  >100%  (13.4) 
3  94.5  (10.3)  81.7  (8.9)  >100  (15.8) 
*  HPLC  mobile  phase  not  settled  down,  therefore,  peak  late. 
In  addition  to  the  temazepam  peak,  the  blood  extract  traces  were  showing  a  large  impurity 
peak  at  approximately  14  minutes.  This  will  probably  co-elute  with  the  internal  standard 
(prazepam)  once  it  is  introduced  to  the  system.  An  extraction  of  blank  blood  was  carried 
out  and  the  impurity  peak  was  still  present.  One  of  the  components  of  blood  which  could 
be  responsible  for  the  peak  was  cholesterol  and  thus,  an  injection  of  a  cholesterol  standard 
in  mobile  phase  was  made  in  order  to  determine  if  it  had  the  same  retention  time.  No 
peaks  were  observed  after  20  minutes.  An  alternative  possibility  for  the  peak  is  the 
anticoagulants  and  preservatives  added  to  blank  blood  at  the  hospital.  As  a  solution  of  the 
hospital  additives  was  not  available,  to  determine  if  the  peak  was  due  to  this,  a  post- 
mortem  sample,  which  contained  no  additives  and  was  known  to  be  negative  for 
benzodiazepines,  was  extracted.  No  corresponding  peak  at  14  minutes  was  observed  and 
the  MeOH  collection  solution  showed  no  breakthrough  blood. 
The  extraction  of  temazepam  from  spiked  hospital  blood  did  however  yield  good 
recoveries  using  the  conditions  described.  It  was  decided  to  continue  method  development 
by  altering  the  modifier  to  determine  if  the  extraction  could  be  made  more  effective  using  a 
different  modifier. 
2.14.12  EFFECT  OF  ALTERING  THE  TYPE  OF  MODIFIER 
As  stated  previously,  the  conditions  with  40%  MeOH  are  not  supercritical.  In  order  to 
make  the  conditions  supercritical  it  was  decided  to  use  a  different  modifier,  namely  ethyl 
acetate  (EtAc). Chapter  Two  Benzodiazepines  Page64 
2.14.12.1  EXPERIMENTAL 
The  following  conditions  were  set-up  and  both  standards  from  MeOH  and  blood  extracted. 
"  Flow  rate:  0.5  ml  miri  I 
"  Pressure:  =  3000  psi 
"  Temperature:  70  °C 
"  Modifier:  10%  EtAc 
2.14.12.2  RESULTS  AND  DISCUSSION  FOR  70  °C 
For  both  MeOH  and  blood  standards,  recoveries  of  >80%  were  achieved.  In  addition,  the 
peak  at  14  minutes  was  no  longer  observed  and  the  solvent  front  was  markedly  cleaner, 
indicating  better  selectivity.  In  order  to  decrease  the  harshness  of  the  conditions,  the 
temperature  was  decreased  to  50  °C  with  10%  EtAc  as,  at  this  temperature,  the  conditions 
are  still  supercritical.  In  addition,  in  order  to  decrease  the  extraction  time,  the  flow  rate 
was  increased  to  1.0  ml  mini  1. 
2.14.12.3  RESULTS  AND  DISCUSSION  FOR  50  °C 
At  10%  EtAc,  50  °C,  1  ml  min'  (p  =  2762  psi)  the  extraction  recovery  was  only  9.6%. 
The  EtAc  was  increased  to  15%  and  the  extraction  was  repeated  (p  =  3462  psi).  This  time, 
the  %  recovery  was  82.4%. 
2.14.13  EFFECT  OF  TEMPERATURE  WITH  ETAC  (15%)  AS  THE  MODIFIER 
2.14.13.1  EXPERIMENTAL 
The  percent  of  EtAc  was  set  to  15%  and  the  effect  of  altering  the  temperature  monitored 
whilst  keeping  the  pressure  constant. Chapter  Two  Benzodiazepines 
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2.14.13.2  RESULTS  AND  DISCUSSION 
At  60  °C,  15%  EtAc  (p  =  2974  psi)  the  recovery  was  100%  but  by  increasing  the 
temperature  further,  the  recovery  dropped  to  37%  at  70  °C,  20%  at  75  °C  and  27%  at  80 
°C.  These  results  are  plotted  in  Figure  2.12. 
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Figure  2.12:  %  Recovery  Vs  Temperature  for  Tema:  epam  at  15%  FtAc 
The  approximate  critical  temperature  plot  for  EtAc  in  CO2  is  shown  in  Figure  2.13. Chapter  Two  Benzodiazepines 
300 
250 
ö  200 
150 
E  100 
64. 
50 
0 
1'aýý  66 
º  -----v 
T  CO2 
F.  EtAc 
250  °C 
0  EtAc20  40  60  80  100 
%  EtAc 
Figure  2.13:  ('rilicul  "Temperature  Graph  for  CO,  -  EtAc  Mixtures 
The  critical  temperature  for  15%  EtAc  in  CO2  is  approximately  64  °C,  therefore  an 
additional  extraction  was  attempted  at  65  °C,  15%  EtAc,  3500  psi  and  0.5  ml  min-'  for  20 
minutes. 
The  extraction  at  these  conditions  was  attempted  several  times  without  success.  The  % 
modifier  and  flowrate  were  increased  as  problems  were  encountered  in  maintaining  the 
pressure  in  the  system.  The  head  pressure  of  the  CO2  cylinder  was  found  to  have  dropped 
from  Az700  psi  to  ;  500  psi.  This  decrease  in  head  pressure  was  enough  to  prevent 
sufficient  pressurisation  of  the  system,  and  it  was  thought  that  gaseous  CO2  was  being 
pumped  and  thus  a  new  cylinder  was  placed  in  the  system. 
Future  cylinders  were  checked  once  the  head  pressure  had  dropped  by  X150  psi  to 
determine  if  they  required  replacing.  This  method  was  found  to  be  more  effective  than 
weighing  the  cylinders,  and  thus  use  of  the  scales  mentioned  in  Chapter  1  was 
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2.14.14  ALTERATION  OF  EXTRACTION  CELL  LENGTH 
With  the  new  cylinder  in  place,  an  extraction  was  carried  out  at  5%  EtAc,  65  °C  and  2  ml 
min"'  as  these  were  the  last  conditions  tried  on  the  previous  cylinder.  The  recovery  was 
100%.  Until  this  point,  the  extractions  were  carried  out  in  a  10  cm  long  extraction  vessel. 
The  same  conditions  were  tried  using  a5  cm  long  extraction  vessel  and  again  the  recovery 
was  100%. 
2.14.15  CONFIRMATION  OF  ETAC  (5%)  AS  THE  MODIFIER  OF  CHOICE 
2.14.15.1  EXPERIMENTAL 
The  %  EtAc  was  further  decreased  to  1%  to  determine  if  the  solvent  in  the  system  could  be 
further  reduced  without  decreasing  the  recovery  of  temazepam.  The  extraction  at  5%  was 
also  repeated  three  times  using  a  freshly  prepared  temazepam  blood  standard  (4.42  mg/L) 
to  check  the  reproducibility  of  the  conditions. 
2.14.15.2  RESULTS  AND  DISCUSSION 
It  was  found  that  by  decreasing  the  %  EtAc  further  to  1%  reduced  the  recovery  to  -  20%. 
For  the  triplicate  extraction  of  temazepam  at  5%,  the  recoveries  were  96%,  98%  and  100% 
thus,  the  reproducibility  of  the  extraction  was  suitable. 
2.14.16  ADDITION  OF  OTHER  BENZODIAZEPINES  TO  THE  SYSTEM 
2.14.16.1  EXPERIMENTAL 
Using  the  same  extraction  conditions,  diazepam  and  desmethyldiazepam  were  extracted  on 
their  own,  however,  the  recoveries  were  very  low.  The  standard  mixture  was  then 
extracted  to  determine  the  effect  of  the  other  benzodiazepines  on  the  extraction  of 
temazepam. 
2.14.16.2  RESULTS  AND  DISCUSSION 
The  results  for  one  extraction  of  the  standard  mix  are  shown  in  Table  2.13. Chapter  Two  Benzodiazepines  Page68 
Table  2.13:  Effect  of  other  Benzodiazepines  on  Temazepam 
Unextracted  Extracted 
Drug  R.  T.  P.  H.  R.  T.  P.  H.  Recovery. 
Triaz  5.7  16  5.7  11  69% 
Temaz  6.8  11.7  6.8  11.6  99% 
CDP  7.1  1.8  7.1  1.6  89% 
DMD  7.8  16.9  7.8  20.2  120% 
Diaz  8.8  14.9  8.8  17.2  115% 
It  should  be  noted  that  the  extraction  conditions  also  yielded  100%  temazepam  at  a  flow  of 
1.0  mlmin'1  however,  by  using  a  flowrate  of  2.0  ml  min  I  the  extraction  time  is  reduced. 
With  the  exception  of  triazolam,  the  recovery  levels  of  all  the  drugs  are  acceptable. 
2.14.17  Ericr  of  PREssuRE 
In  order  to  investigate  the  effect  of  pressure  on  the  extraction,  it  was  decided  to  introduce 
the  internal  standard  (prazepam)  to  the  extractions.  For  the  optimum  conditions,  it  is 
essential  that  both  the  drug  of  interest  and  the  internal  standard  are  extracted  to  the  same 
extent  so  the  best  conditions  need  not  be  those  that  give  the  highest  recoveries  of 
temazepam. 
2.14.17.1  EXPERIMENTAL 
1  ml  of  prazepam  and  1  ml  of  temazepam  were  pipetted  into  a  vial,  evaporated  to  dryness 
under  nitrogen  and  reconstituted  in  1  ml  of  MeOH.  100  µl  aliquots  of  this  solution  were 
extracted.  The  extraction  was  carried  out  five  times  at  different  pressures. 
2.14.17.2  RESULTS  AND  DISCUSSION 
The  following  table  (2.14)  indicates  the  results  obtained  for  the  extraction  of  temazepam 
and  prazepam  at  various  pressures. Chapter  Two  Benzodiazepines 
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Mean  Pressure  (psi)  P.  H.  Temaz  PHR  %Rec.  Temaz 
1536  8.4  1.68  74% 
2016  6.2  2.48  55% 
2362  4.5  2.00  40% 
3096  7.7  2.33  68% 
3675  5.3  2.52  47% 
The  unextracted  PHR  was  2.06.  A  graph  of  pressure  versus  recovery  was  plotted  Figure 
2.14)  and  from  this  the  pressure  for  the  extractions  was  chosen  as  3000  psi  as  the  rate  of 
change  of  PHR  with  pressure  is  less  pronounced  at  this  pressure  and  the  recovery  is 
relatively  high. 
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Figure  2.14:  Variation  of  »HR  with  Pressure 
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2.14.18  VARIATION  OF  PRESSURE  WITHIN  THE  SFE  SYSTEM 
2.14.18.1  EXPERIMENTAL 
As  the  pressure  appears  to  have  such  a  pronounced  effect  on  both  the  PHR  and  the  % 
recovery  of  temazepam  and  prazepam,  a  study  on  the  variation  of  a  set  pressure  of  3000  psi 
for  20  minutes  was  carried  out. 
2.14.18.2  RESULTS  AND  DISCUSSION 
The  variation  in  pressure  of  the  SFE  system  at  a  set  pressure  of  3000  psi  is  shown  in  Table 
2.15. 
Table  2.15:  Variation  of  Pressure  set  at  3000  psi 
Time  (min)  Pressure  (psi)  Time  (min)  Pressure  (psi) 
0  2944  11  2770 
1  2688  12  2900 
2  2494  13  2770 
3  2248  14  3495 
4  2436  15  3118 
5  2436  16  3205 
6  1508  17  3683 
7  1523  18  3248 
8  1639  19  3321 
9  1392  20  3625 
10  1639 
0-10  2129  (RSD=26%)  11-20  3053  (RSD=19.5%) 
As  can  be  seen  from  these  results  there  is  very  little  pressure  control  in  the  system.  As  the 
CO2  did  not  require  changing,  this  variation  was  thought  to  be  due  to  the  check  valves  in 
the  CO2  pump  which  were  changed  and  the  experiment  repeated.  The  repeated  pressure 
results  are  given  in  Table  2.16. Chapter  Two  Benzodiazepines  Page71 
Table  2.16:  Variation  of  Pressure  Set  at  3000  psi  with  New  Check  Valves 
Time  (min)  Pressure  (psi)  Time  (min)  Pressure  (psi) 
0  2987  11  3045 
1  2625  12  3089 
2  2436  13  3002 
3  2306  14  3132 
4  2813  15  3045 
5  2944  16  3045 
6  3016  17  3060 
7  2944  18  3045 
8  2944  19  3074 
9  2987  20  3161 
10  3060 
0-10  2824  (RSD  =  9%)  11-20  3070  (RSD  =  1.5%) 
The  mean  pressure  for  the  twenty  minutes  was  2941  with  a  RSD  of  7.5%.  But,  if  five 
minutes  re-equilibration  time  is  allowed  for,  the  mean  pressure  is  3043  psi  with  a  RSD  of 
2.0%  which  is  acceptable. 
2.14.19  REPEAT  OF  EXTRACTION  AT  3000  PSI 
2.14.19.1  EXPERIMENTAL 
The  extraction  at  3000  psi  was  repeated  in  order  to  redetermine  the  PHR  and  recoveries  of 
temazepam  and  prazepam  at  this  pressure. 
2.14.19.2  RESULTS  AND  DISCUSSION 
The  results  for  the  repeat  extraction  at  3000  psi  are  shown  in  Table  2.17. 
Table  2.17:  Repeat  of  Extraction  at  3000  psi 
Temaz  Praz  PHR 
Unextracted  11.3  5.5  2.055 
Extracted  9.9  (88%)  5.2  (95%)  1.904 
It  can  be  seen  that  these  results  agree  well  with  those  obtained  during  the  optimum  pressure 
study  and  thus  it  was  decided  to  use  a  pressure  of  3000  psi  for  future  extractions. Chapter  Two  Benzodiazepines  Page72 
2.14.20  EFFECT  OF  TEMPERATURE 
2.14.20.1  EXPERIMENTAL 
A  temperature  study  at  3000  psi,  5%  EtAc  and  2  ml  min  1  was  carried  out.  Three 
extractions  were  made  at  each  temperature  and  the  initial  and  final  pressures  were  noted. 
Previous  studies  have  indicated  that  a  temperature  around  60  °C  should  be  ideal  and  thus 
the  temperature  was  varied  around  this  value.  It  should  be  noted  that  precise  control  of  the 
temperature  gauge  on  the  GC  oven  controller  was  difficult  so  the  exact  temperature 
measurements  were  made  by  placing  a  thermometer  into  the  oven.  - 
2.14.20.2  RESULTS  AND  DISCUSSION 
The  results  for  the  temperature  study  on  temazepam  and  prazepam  are  shown  in  Table 
2.18.  For  the  runs  at  62  °C,  the  EtAc  was  not  pumping  efficiently  which  explains  the 
relatively  low  recoveries  at  this  temperature.  This  was  found  to  be  due  to  faulty  modifier 
pump  check  valves  which  were  subsequently  changed. Chapter  Two  Benzodiazepines  Page73 
Table  2.18:  Temperature  Study  flor  Tema 
. epam  and  Prazepam 
Temaz 
%Rec. 
Mean 
(SD) 
Praz 
%Rec. 
Mean 
(SD) 
PHR  Mean  (SD)  Pressure  (psi) 
55  °C  1  .  947 
139  129  121  121  2.232  2.133  3169 
90  (61)  90  (31)  2.098  0.087)  3067 
160  151  2.070  2890 
60  °C  1  .  991 
73  103  76  99  1.929  2.047  3133 
123  (26)  117  (21)  2.092  (0.103)  3205 
112  105  2.120  3212 
62  °C  2.152 
41  37  44  41  2.022  2.332  3365 
56  (21)  68  (29)  1.775  (0.762)  3179 
14  10  3.200  3125 
64  °C  1.991 
90  106  92  103  1.951  2.042  3227 
114  (14)  110  (96)  2.066  (0.082)  3154 
114  107  2.109  3104 
66  °C  2.055 
72  107  73  105  2.025  2.043  3314 
178  (61)  174  (60)  2.000  (0.055)  3053 
71  69  2.105  2920 
2.14.21  EFFECT  OF  COLLECTION  SOLVENT  AND  CONTINUATION  OF  TEMPERATURE  STUDY 
2.14.21.1  EXPERIMENTAL 
It  has  been  suggested  in  literature  that  MeOH  is  a  poor  collection  solvent  and  that 
chloroform  should  give  better  recoveries.  97  For  the  rest  of  the  temperature  survey,  the 
extracts  were  collected  in  both  MeOH  and  CHC13  so  that  the  recoveries  for  each  could  be 
compared. 
2.14.21.2  RESULTS  AND  DISCUSSION 
The  results  for  the  extraction  of  temazepam  and  prazepam  using  chloroform  and  methanol 
as  collection  solvent  at  varying  temperatures  are  shown  in  Tables  2.18a  and  2.18b. Chapter  Two  Benzodiazepines  Page74 
Table  2.18a:  Temperature  Study  Using  Chloroform  as  a  Collection  Solvent 
Temazepam 
Recovery 
Prazepam  Recovery  Peak  Height  Ratio  Pressure 
64  °C  2.087 
121  99  2.549  2.323  3118 
73  133  (67)  69  122  (68)  2.225  (0.20)  3140 
206  198  2.196  3089 
65  °C*  2.743 
132  135  135  139  2.680  2.67  3003 
137  142  2.650  3089 
66  °C  1.815 
123  109  2.042  1.947  3161 
141  118(25)  128  110  (18)  2.000  (0.13)  3220 
92  93  1.800  3170 
70  °C  2.0  87 
17  15  2.467  3154 
Table  2.18b:  Temperature  Study  Using  Methanol  as  a  Collection  Solvent 
Temazepam 
Recovery 
Prazepam  Recovery  Peak  Height  Ratio  Pressure 
64  °C  2.087 
111  107  2.173  2.210  3261 
95  78(45)  95  75(45)  2.082  (0.15)  3118 
27  23  2.375  3111 
65  °C*  2.7  43 
101  104  119  110  2.341  2.644  3067 
107  100  2.946  3060 
66  °C  1.815 
127  118  1.915  3082 
91  109  (20)  93  103  (12)  1.780  1.895  3183 
92  93  1.800  (0.13)  3169 
126  109  2.085  3214 
70  °C  2.  087 
2.3  2.9  2.000  3075 
*  For  the  run  at  65  °C  a  more  concentrated  solution  was  injected  (25  mg/L  c.  f.  5  mg/L)  to 
see  if  a  smaller  injection  volume  would  improve  the  reproducibility. 
Although  the  intra-temperature  results  were  not  very  reproducible,  as  seen  from  Figure 
2.15,  the  optimum  temperature  with  least  variance  is  around  65  °C.  With  the  temperature 
gauge  on  the  GC  oven  programmer  set  to  65  °C,  the  temperature  reading  on  a  thermometer 
placed  in  the  oven  was  found  to  be  64  °C  which  is  satisfactory. Chapter  Two  Benzodiazepines  Page75 
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Figure  2.15:  Variation  of  PHR  with  Temperature 
2.14.22  EXTRACTION  OF  TEMAZEPAM  AND  PRAZEPAM  FROM  BLOOD 
2.14.22.1  EXPERIMENTAL 
Standards  of  temazepam  and  prazepam  were  prepared  in  blood,  however  post-restrictor 
blocking  became  problematic,  possibly  due  to  Joule-Thomson  cooling  of  extracted  water 
in  the  outlet  tubing.  A  column  containing  dried  silica  was  placed  in-line  before  the 
extraction  vessel  in  order  to  trap  the  water.  An  extraction  of  temazepam  and  prazepam  in 
methanol  was  carried  out  in  order  to  see  whether  or  not  the  silica  affected  the  extraction. 
This  was  followed  by  an  injection  of  MeOH. 
2.14.22.2  R  ,,  SIIL7SANI)  I)I.  SCUSSION 
The  results  for  the  effect  of  a  silica  drying  column  on  the  extraction  of  temazepam  and 
prazepam  are  shown  in  Table  2.19. 
54  59  64  69 
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Table  2.19:  Effect  of  Silica  on  Temazepam  MeOH  Standard  Extraction 
Area  Temaz  (%Rec)  Area  Praz  (%Rec)  PHR 
Unextracted  23.5  10.5  2.238 
Extracted  11.1  (47%)  7.1(68%)  1.563 
MeOH  flush  9.4  (40%)  5.7  (54%)  1.647 
Total  Extracted  20.5  (87%)  12.8  (122%)  1.602 
An  extraction  of  the  spiked  blood  standard  was  also  carried  out,  but  no  peaks  were 
observed.  The  low  recoveries  obtained  for  the  MeOH  standards  indicate  that  the  silica  may 
be  retaining  the  drugs  and  that  a  post  extraction  flush  might  be  necessary  for  high 
recoveries.  With  post-extraction  drying,  the  recoveries  dropped  again  (MeOH  extraction, 
Temaz  3.2  cm  (14%),  Praz  4.6  cm  (44%),  PHR  =  0.696).  A  blank  blood  extraction  after 
this  eluted  1.45  cm  (6%)  temazepam  and  0.5  cm  (5%)  prazepam  (PHR  =  2.900).  The 
spiked  blood  standard  was  extracted  again  but  only  trace  amounts  were  recovered. 
2.14.23  ALTERNATIVE  METHOD  OF  PREVENTING  RESTRICTOR  PLUGGING 
2.14.23.1  EXPERIMENTAL 
As  an  alternative  to  using  a  silica  column  to  dry  the  extracts,  the  outlet  tubing  was  coiled 
inside  the  oven  and  the  remaining  tubing  which  was  outside  the  oven  lagged.  Again  at  this 
point,  the  CO2  head  pressure  was  dropping  and  thus  the  cylinder  was  replaced. 
Several  injections  of  temazepam  and  prazepam  MeOH  and  blood  standards  were  made  into 
the  SFE  system. 
2.14.23.2  RESULTS  AND  DISCUSSION 
From  MeOH  the  recoveries  were  24%  and  60%  for  temazepam  and  prazepam  respectively 
however,  the  blood  extract  showed  recoveries  of  >100%  for  both  drugs  and  a  subsequent 
MeOH  flush  was  negative  indicating  that  the  blood  extract  had  removed  the  remaining 
temazepam  and  prazepam  from  the  MeOH  extraction.  It  was  not  possible  to  calculate  the 
recoveries  for  the  blood  extract,  as  the  concentrations  were  different  to  those  of  the  MeOH 
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2.14.24  PREPARATION  OF  STANDARD  TEMAZEPAM  AND  PRAZEPAM 
2.14.24.1  EXPERIMENTAL 
Fresh  standards  in  MeOH  and  blood  were  prepared  keeping  the  concentrations  constant  as 
follows.  4  ml  of  temazepam  (5.16  mg  /  100  ml)  and  4  ml  of  prazepam  (4.50  mg  /  100  ml) 
were  pipetted  into  two  vials  and  evaporated  to  dryness  under  N2  at  60  °C.  To  the  residue,  5 
ml  of  MeOH  or  5  ml  of  blood  was  added  and  the  vial  sonicated  for  three  minutes  in  an 
ultrasonic  bath.  The  concentrations  of  these  standards  were  41.3  mg/L  temazepam  and 
36.0  mg/L  prazepam.  The  unextracted  MeOH  standard  gave  peak  heights  of  13.7  cm  and 
7.2  cm  for  temazepam  and  prazepam  respectively  and  a  PHR  of  1.903. 
2.14.25  COMPARISON  OF  SFE  AND  SPE  FOR  TEMAZEPAM  AND  PRAZEPAM 
2.14.25.1  EXPERIMENTAL 
A  SPE  was  carried  out  on  the  blood  standard  for  comparison  with  SFE.  The  method  used 
was  as  described  in  Section  2.11.1  however,  only  100  t1  of  the  blood  standard  was 
extracted  for  a  direct  comparison  with  SFE. 
2.14.25.2  RESULTS  AND  DISCUSSION 
The  results  obtained  by  SPE  were  temazepam  13.3  cm  (97%)  and  prazepam  6.6  cm  (92%), 
PHR  2.015.  The  SFE  of  the  same  blood  standard  gave  5.2  cm  (38%)  temazepam  and  8.75 
(122%)  prazepam,  PHR  0.594  with  a  MeOH  flush  yielding  0.75  cm  (5%)  temazepam  and 
0.4  cm  (6%)  prazepam  indicating  that  the  extraction  set-up  was  still  not  robust. 
2.14.26  PROCEDURE  FOR  DRYING  OF  BLOOD  SAMPLES 
Due  to  the  many  problems  which  were  being  encountered  with  the  "wetness"  of  the  blood 
samples,  a  literature  search  on  the  problem  of  water  in  SFE  systems  was  carried  out  with 
suggestions  found  on  removing  the  water  prior  to  extraction  by  freeze  drying  followed  by 
SPE98  and  cryogenic  trapping  99  Alternatively,  a  modifier  could  be  selected  with 
sufficiently  strong  antifreeze  properties  to  counteract  the  Joule-Thomson  cooling  effect.  10° 
The  most  feasible  of  these,  which  would  cause  least  disruption  to  the  system,  would  be  the Chapter  Two  Benzodiazepines  Page78 
addition  of  antifreeze  either  as  or  in  the  modifier.  However,  as  the  extraction  conditions 
used  are  mild  and  provide  high  recoveries,  an  alternative  sample  loading  method  was 
investigated. 
Instead  of  injecting  the  samples  via  the  rheodyne  loop  onto  the  Extreluto  in  the  extraction 
vessel  (i.  e.  the  extraction  vessel  was  in  the  position  of  an  HPLC  column),  the  plumbing  of 
the  system  was  altered  and  the  extraction  vessel  was  placed  over  the  loop  position  of  the 
rheodyne.  This  has  the  following  advantages: 
"  The  extraction  vessel  can  be  changed  without  disturbing  the  equilibrium  of  the 
supercritical  fluid 
"  Reduction  in  blockages  in  loop  and  connective  tubing 
"  Reduced  chance  of  contamination  from  sample  to  sample  as  the  system  will  operate  in  a 
one  vessel  per  extraction  mode 
9  Reduce  time,  as  a  post  extraction  flush  will  not  be  required 
Initial  runs  with  this  system  gave  poor  recoveries,  possibly  as  the  drugs  needed  to  be 
extracted  twice,  as  the  original  vessel  was  still  in  line.  The  original  extraction  vessel  was 
removed  and  replaced  with  a  dead  volume  connector. 
The  first  blood  extraction  with  this  system  gave  good  recoveries  (100%)  with  a  PHR  of 
1.804  (c.  f.  1.652)  however,  pressure  fluctuations  were  still  problematic  throughout  the 
course  of  the  extraction.  It  was  decided  to  dry  the  blood  samples  on  the  Extrelut®  prior  to 
insertion  into  the  extraction  vessel.  Although  this  step  is  time  consuming  and  allows  for  an 
increased  chance  of  sample  loss,  the  importance  of  these  factors  is  counteracted  by  the 
following  three  points: 
"  Reduction  in  blockages  (increased  up-time) 
"  Multiple  samples  can  be  prepared  and  dried  overnight 
"  Prazepam  is  added  to  the  samples  and  thus  any  loss  of  sample  is  compensated  for Chapter  Two  Benzodiazepines  Page79 
The  components  for  the  initial  extraction  were  weighed  in  order  to  monitor  the  sample  loss. 
0.19  g  of  Extrelut®  and  0.10  g  were  weighed  onto  the  boat  and  dried.  0.22  g  of  this  were 
transferred  to  the  column.  Therefore,  without  taking  into  account  losses  due  to  drying  of 
the  sample,  the  recoveries  should  be  76%.  The  recoveries  obtained  were  95%  for 
temazepam  and  80%  for  prazepam  giving  a  PHR  of  2.051  (c.  f.  1.729  for  the  standard). 
Taking  into  account  the  variability  seen  for  the  unextracted  standards  and  errors  which 
might  occur  in  sample  preparation  of  both  the  unextracted  standards  and  the  blood 
standards,  this  method  was  chosen  for  use  on  authentic  forensic  samples,  validation 
pending. 
2.14.27  EFFECT  OF  ALTERING  THE  SUPPORT  MEDIUM 
2.14.27.1  EXPERIMENTAL 
In  addition  to  changing  the  temperature,  pressure  and  %  modifier  in  the  extraction,  the 
other  variable  which  was  investigated  was  the  effect  of  the  support  medium.  Until  now  all 
method  development  was  carried  out  using  Extrelut®.  Two  other  support  mediums, 
namely  C18  and  HCX  were  investigated  for  the  extraction  of  all  6  benzodiazepines. 
2.14.2Z2  RESULTS  AND  DISCUSSION 
From  Extrelut®  all  6  benzodiazepines  were  extracted  however,  the  other  two  support 
mediums  were  less  successful.  Using  C18,  triazolam,  temazepam,  chlordiazepoxide, 
desmethyldiazepam  and  diazepam  extracted  but  the  recoveries  were  very  low  and  the 
prazepam  did  not  extract.  Using  the  HCX  support  medium,  none  of  the  benzodiazepines 
extracted.  For  this  reason  the  support  medium  was  kept  as  Extrelut®. 
2.14.28  CONCLUSIONS  FROM  METHOD  DEVELOPMENT 
The  final  conditions  developed  for  the  extraction  of  temazepam  and  prazepam  are  as 
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"  Flow  Rate:  2.0  mlmin  1 
"%  EtAc:  5% 
"  Temperature  :  65  °C 
"  Pressure:  3000  psi 
"  Run  Time:  5  minutes 
"  Support  Medium:  Extrelut® 
The  SFE  system  was  set  to  equilibrate  at  the  above  conditions  and  samples  prepared  as 
follows.  A  100  µl  aliquot  of  the  sample  to  be  analysed  was  loaded  onto  Extrelut®  in  a 
weighing  boat  and  mixed  thoroughly.  This  was  allowed  to  dry  at  room  temperature  until  a 
friable  consistency  was  achieved  and  then  loaded  into  an  extraction  vessel.  The  extraction 
vessel  was  placed  into  the  equilibrated  SFE  system  and  the  extraction  commenced  by 
switching  the  Rheodyne  valve  from  load  to  inject,  allowing  the  flow  of  supercritical  fluid 
to  pass  through  the  extraction  vessel.  A  Hypovial®  containing  MeOH  placed  at  the  flow 
outlet,  trapped  the  extracted  analytes. 
2.15  METHOD  VALIDATION  FOR  TEMAZEPAM 
2.15.1  HIGH  CONCENTRATION  CALIBRATION  CURVES 
2.15.1.1  EXPERIMENTAL 
The  first  part  of  the  validation  was  carried  out  by  producing  high  concentration  calibration 
graphs  for: 
1)  MeOH  standards  straight  onto  HPLC  (Table  2.20) 
2)  MeOH  extracted  standards  (Table  2.21) 
3)  Blood  extracted  standards  (Table  2.22) 
The  range  of  concentrations  was  from  0-51.6  mg/L.  For  the  unextracted  standards,  100  µl 
of  temazepam  was  evaporated  to  dryness  and  reconstituted  in  100  µl  of  mobile  phase  and 
for  the  extractions,  either  100  µl  of  MeOH  standard  or  blood  standard  were  extracted  and 
the  collected  extract  evaporated  to  dryness  and  reconstituted  in  100  µl  of  mobile  phase. Chapter  Two  Benzodiazepines  Page8l 
2.15.1.2  RESULTS  AND  DISCUSSION 
The  peak  heights  of  temazepam  obtained  for  the  calibration  are  shown  in  Tables  2.20,2.21 
and  2.22.  The  %  recoveries  were  calculated  by  comparing  the  extracted  PH's  to  the 
extracted  PH  for  the  relevant  concentration.  The  equation  for  each  of  the  best  fit  lines  is 
given  as  y=  Bx  +  A. 
Table  2.20:  Unextracted  Standards 
Concentration  Peak  Height 
0  0 
10.32  3.1 
20.64  6.15 
25.80  8.4 
41.26  12.7 
51.60  17.05 
r2  =  0.995 
A=-0.469' 
B=  0.332 
Table  2.21:  MeOH  Extracted  Standards  (average  of  3) 
Concentration  Peak  Height  (%  Recovery) 
0  0 
10.32  3.2(103%) 
20.64  5.8(94%) 
25.80  9.3(111%) 
41.26  12.6  (99%) 
51.60  15.15(89%) 
r2=0.975 
A=0.494 
B=  0.291 
Table  2.22:  Blood  Extracted  Standards  (1  infection  one) 
Concentration  Peak  Height  (%  Recovery) 
0  0 
10.32  4.2(135%) 
20.64  6.0(98%) 
25.80  8.1(96% 
41.26  8.567% 
51.60  11.65  (68%) 
r2  =  0.919 
A=2.800 
B=  0.163 
At  this  point,  the  concentrations  of  the  standards  used  were  much  higher  than  those  seen 
from  therapeutic  and  even  overdose  levels  of  benzodiazepines  in  case  samples.  It  can  be 
seen  that  in  addition  to  the  poorer  correlation  seen  for  the  blood  extracted  standards  the 
concentration  range  appears  to  have  overloaded  the  range  for  extraction  (i.  e.  a  longer Chapter  Two  Benzodiazepines  Page82 
extraction  time  would  have  to  be  used  in  order  to  extract  this  amount  of  temazepam).  This 
is  also  the  case  for  the  51.6  mg/L  MeOH  extraction. 
In  terms  of  the  gradients  (B)  of  the  curves  produced,  it  can  be  seen  that  as  the  matrix 
effects  increase  (i.  e.  MeOH  to  blood)  compared  with  the  unextracted  standards,  a  decrease 
in  the  gradient  is  seen. 
The  injection  reproducibility  of  the  HPLC  system  was  checked  again.  Ten  injections  of  the 
51.6  µg  ml"  standard  were  made  and  the  peak  heights  were  found  to  range  from  16.9  cm  to 
18.3  cm  (mean  17.4  cm,  RSD  2.86%).  A  20  µl  loop  was  used  and  50  µl  was  injected  each 
time.  This  was  compared  to  five  25-30  µl  injections;  range  16.0-18.5  cm,  mean  17.2  cm, 
RSD  5.23%.  Thus,  the  injection  reproducibility  could  also  contribute  to  the  results 
obtained  as  the  blood  extraction  results  were  based  on  only  one  injection. 
2.15.2  EXTRACTIONS  WITH  INTERNAL  STANDARD 
2.15.2.1  EXPERIMENTAL 
The  MeOH  unextracted  and  extracted  calibrations  were  repeated  this  time  including 
prazepam  to  compensate  for  the  injection  reproducibility.  0.5  ml  of  each  standard  dilution 
plus  0.5  ml  prazepam  was  analysed  in  each  case  (N.  B.  prazepam  on  its  own  extracts 
100%). 
2.15.2.2  RES  ULTS  AND  DISCUSSION 
The  results  for  the  extractions  with  prazepam  and  temazepam  are  shown  in  Table  2.23. Chapter  Two  Benzodiazepines  Page83 
Table  2.23:  Extraction  with  Temazeyam  and  Prazepam 
[Temaz]  PHR  Ext.  PHR  Unext.  %Rec. 
Temaz 
%Rec.  Praz  %  Error 
0  0  0  na  na  na 
5.16  0.633  0.313  76  38  +103 
10.32  0.900  0.775  58  50  +11 
12.9  1.077  0.923  39  33  +17 
20.64  1.714  1.56  40  36  +10 
25.80  1.78  2.20  42  52  -19 
Unextracted:  r`:  0.990  Extracted:  r:  0.967 
A:  -0.174 
B:  0.089 
A:  0.316 
B:  0.060 
Again  at  the  higher  concentrations,  a  loss  of  temazepam  is  apparent  and  the  gradient  is less 
than  that  of  the  unextracted  standards. 
2.15.3  LINEARITY  OF  EXTRACTION  ABOVE  THE  THERAPEUTIC  CONCENTRATION 
2.15.3.1  EXPERIMENTAL 
A  fresh  standard  of  temazepam  was  prepared  by  weighing  1.28  mg  of  temazepam  standard 
into  a  100  ml  volumetric  flask  and  making  up  to  the  mark  with  MeOH  to  give  a 
concentration  of  12.8  mgL'I  This  was  sequentially  diluted  to  give  calibration  solutions  of 
0,1.28,2.56,3.84,6.40,12.8  mgL"I  of  temazepam  with  11.24  mgL"1  of  prazepam  in  each. 
Each  standard  type  was  extracted  by  SPE  and  SFE  for  comparison. 
2.15.3.2  RESULTS  AND  DISCUSSION 
The  unextracted  standard  calibration  was  carried  out  in  duplicate  in  order  to  check  the 
reproducibility.  The  results  are  shown  in  Tables  2.24  and  2.25. Chapter  Two  Benzodiazepines  Page84 
Table  2.24:  Unextracted  MeOH  Standards  1 
[Temaz]  mg  L''  Peak  Height  Ratio 
0  0 
1.28  0.164 
2.56  0.342 
3.84  0.559 
6.40  0.973 
12.80  1.892 
Table  2.25:  Unextracted  MeOH  Standards  2 
[Temaz]  mg  L"  Peak  Height  Ratio 
0  0 
1.28  0.158 
2.56  0.348 
3.84  0.538 
6.40  0.973 
12.80  1.908 
r2  =  0.999 
A=  -0.025 
B=0.151 
r2=0.999 
A=-0.036 
B=0.153 
From  these  results  it  can  be  seen  that  a  reproducible  calibration  graph  can  be  easily 
constructed  over  this  concentration  range. 
Using  the  system  as  described  previously  with  the  chart  recorder,  calibrations  for  MeOH 
SFE  standards  and  blood  SPE  standards  were  constructed  as  shown  in  Tables  2.26  and 
2.27. 
Table  2.26:  Extracted  MeOH  1-  SFE 
[Temazl  mg  L'  Peak  Height  Ratio 
0  0 
1.28  0.193 
2.56  0.409 
3.84  0.717 
6.40  1.047 
12.80  2.014 
r2  =  0.995 
A=0.038 
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Table  2.27:  Extracted  Blood  1-  SPE 
[Temaz]  mg  1;  1  Peak  Height  Ratio 
0  0 
1.28  0.220 
2.56  0.524 
3.84  0.682 
6.40  1.247 
12.80  2.567 
r2  =  0.998 
A=  -0.044 
B=0.203 
At  this  point  there  were  no  other  graphs  to  compare  these  to,  however,  the  correlation 
coefficients  are  high  and  in  the  case  of  the  MeOH  SFE  extracts,  the  gradient  is  similar  to 
that  of  the  unextracted  standards. 
2.15.4  CONTINUATION  OF  CALIBRATION  wim  SYSTEM  CONTROLLER 
2.15.4.1  EXPERIMENTAL 
At  this  point,  the  system  controller  was  modified  so  that  the  traces  could  be  directly 
compared  using  the  Gilson  software.  This  also  reduces  the  human  error  from  manually 
measured  peak  heights.  Injections  of  the  unextracted  MeOH  standards  and  extracted  blood 
and  MeOH,  SFE  and  SPE  extracts  were  continued  using  the  new  set-up. 
2.15.4.2  RESULTS  AND  DISCUSSION 
The  unextracted  MeOH  standard  calibration  was  repeated.  As  can  be  seen  from  the  results 
in  Tables  2.28,2.29,2.30,2.31  and  2.32  a  slightly  different  gradient  is  calculated  using  the 
system  controller  peak  areas  as  opposed  to  manually  measured  peak  heights. 
Table  2.28:  Unextracted  MeOH  Using  Gilson  Software  I  (n=3) 
[Temaz]  mg  U  Peak  Area  Ratio 
0  0 
1.28  0.103 
2.56  0.248 
3.84  0.384 
6.40  0.679 
12.80  1.331 
r2=0.999 
A=  -0.024 
B=0.107 Chapter  Two  Benzodiazepines  Page86 
During  the  course  of  the  SFE  extractions  it  was  noted  that  the  PTFE  check  valves  in  the 
modifier  pump  were  allowing  flow  back  of  CO2  into  the  solvent  reservoir.  These  were 
replaced  and  left  overnight,  however,  the  same  problem  was  noted  the  next  morning.  In 
order  to  check  whether  it  was  the  combination  of  PTFE  and  EtAc,  PVDE  check  valves 
were  inserted  into  the  modifier  pump.  These  did  not  hold  the  flow  at  all.  A  fresh  batch  of 
PTFE  check  valves  were  inserted  which  worked  well,  and  thus  the  problem  was  attributed 
to  a  faulty  batch  of  check  valves.  As  the  CO2  had  been  leaking  throughout  the  night,  a  new 
cylinder  was  placed  in  the  system. 
Table  2.29:  Extracted  MeOH  -  SFE  (3  extractions,  3  infection  each  n=9) 
[Temaz]  mg  L"  Peak  Area  Ratio 
0  0 
1.28  0.139 
2.56  0.304 
3.84  0.570 
6.40  0.758 
12.80  1.565 
r2  =  0.991 
A=0.015 
B=0.121 
Table  2.30:  Extracted  Blood  -  SFE  (2  extractions  3  infections  each  n=6) 
[Temaz]  mg  L'1  Peak  Area  Ratio 
0  0 
1.28  0.091 
2.56  0.449 
3.84  0.794 
6.40  0.851 
12.80  1.236 
r2  =  0.827 
A=0.220 
B=0.086 
Table  2.31:  Extracted  MeOH  -  SPE  (1  extraction,  3  infections  n=3) 
[Temaz]  mg  L'  Peak  Height  Ratio 
0  0 
1.28  0.127 
2.56  0.232 
3.84  0.403 
6.40  0.804 
12.80  1.406 
r2=0.989 
A=  -0.017 
B=0.114 Chapter  Two  Benzodiazepines  Page87 
Table  2.32:  Extracted  Blood  SPE  (2  extractions.  3  infections  n 
[Temaz]  mg  L"  Peak  Height  Ratio 
0  0 
1.28  0.074 
2.56  0.160 
3.84  0.207 
6.40  0.359 
12.80  0.966 
r2  =  0.981 
A=  -0.065 
B=0.078 
From  these  tables  it  can  be  seen  that  good  correlation  exists  over  the  range  1.28-12.80 
mg/L  temazepam  for  the  various  extractions. 
2.15.5  INTRA-  AND  INTER-DAY  REPRODUCIBILITY 
2.15.5.1  EXPERIMENTAL 
To  check  the  reproducibility  of  the  temazepam  extraction  throughout  the  course  of  one  day 
and  from  day  to  day,  sequences  of  extractions  of  the  same  standard  were  extracted  on  days 
one  and  two.  This  experiment  was  also  used  to  ensure  that  there  was  no  carry  over  of  the 
benzodiazepines  in  the  system.  5  extractions  of  temazepam  and  prazepam  were  carried  out 
on  day  one,  and  6  on  day  two  with  blank  extractions  in  between  to  ensure  no  carryover. 
The  temperature  in  the  oven  was  found  to  be  62  °C  instead  of  64  °C  as  previously  noted 
using  the  thermometer  in  the  oven. 
2.15.5.2  RESULTS  AND  DISCUSSION 
The  results  for  the  extractions  on  day  one  are  shown  in  Table  2.33. 
Table  2.33:  Extraction  of  Temazenam  and  Prazepam  "  Day  I 
Extraction  Area  Temaz  Area  Praz  PAR 
1  6102  9590  0.636 
2  5005  9477  0.528 
3  35583  57505  0.619 
4  31208  63479  0.492 
5  57152  113041  0.506 
Unext.  501961  602912  0.833 
X=0.556 
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NB:  The  sensitivity  of  the  HPLC  was  turned  up  for  the  injections  of  extracts  3,4  and  5  and 
the  unextracted  standard. 
The  results  for  the  extractions  on  day  two  are  shown  in  Table  2.34. 
Table  2.34:  Temazepam  and  Prazepam  Extraction;  Day  2 
Extract  Area  Temaz  Area  Praz  PAR 
1  108258  140896  0.768 
2  79817  123005  0.649 
3  32316  51446  0.628 
4  117640  190665  0.617 
5  44081  61156  0.721 
6  22548  39166  0.576 
Unext.  501961  602912  0.833 
x:  0.660 
RSD:  11% 
The  mean  PAR  over  the  two  days  was  0.613  with  a  RSD  of  13.9%.  Thus  the  variation 
from  day  to  day  is  no  greater  than  that  seen  within  the  same  day. 
Due  to  the  slight  variation  in  PAR  observed  between  extractions,  for  any  authentic  samples 
extracted,  the  standard  will  have  to  be  run  in  triplicate  at  least. 
2.15.6  ALTERATION  OF  OUTLET  RESTRICTION 
2.15.6.1  EXPERIMENTAL 
Problems  were  being  encountered  due  to  blockages  caused  by  precipitation  of  material 
within  the  flow  outlet  tubing.  This  was  causing  a  reduction  in  the  recoveries  at  the 
previously  optimised  conditions  and  was  thought  to  be  due  to  insufficient  restriction  being 
provided.  In  order  to  amend  this,  the  pressure  in  the  system  was  set  to  1500  psi  and  the 
end  of  the  outlet  tubing  crimped  until  an  increase  in  pressure  was  observed.  With  this  in 
place,  extractions  were  carried  out  at  10%  EtAc,  5%  EtAc  and  then  10%  EtAc  again. 
2.15.6.2  RESULTS  AND  DISCUSSION 
The  results  for  the  extractions  at  5  and  10%  EtAc  are  shown  in  Table  2.35. Chapter  Two  Benzodiazepines  Page89 
Table  2.35:  Temazepam  Extractions  With  Crimped  Outlet 
%  EtAc  Area  Temaz  (%  Rec)  Area  Praz  (% Rec)  PAR 
10/1  85455  (21)  251453  (51)  0.340 
5  136636  (33)  305927  (61)  0.447 
10/2  183388  (44)  333325  (67)  0.550 
Unext.  414021  497680  0.832 
The  recoveries  were  still  quite  low,  so  to  ensure  that  the  drugs  were  not  binding  to  matter 
which  had  adhered  to  the  inside  of  the  tubing,  all  of  the  tubing  in  the  system  was  replaced. 
Due  to  the  recent  problems  with  the  system,  the  extraction  conditions  for  benzodiazepines 
were  modified  slightly  to  10%  EtAc,  65  °C,  2.0  ml  min"  and  3000  psi.  Despite  the  fact 
that  the  use  of  10%  EtAc  decreases  the  selectivity  of  the  extraction  slightly,  it  was  found  to 
be  better  for  the  extraction  of  authentic  forensic  samples  perhaps  due  to  the  increased 
matrix  effects  as  compared  to  spiked  blood  samples. 
2.15.7  VITREOUS  HUMOR 
2.15.7.1  DEFINITION 
In  addition  to  analysing  blood  samples,  this  study  was  also  involved  with  the  extraction  of 
drugs  from  post-mortem  vitreous  humor  samples.  The  vitreous  humor  is  defined  as  a  clear, 
avascular,  gelatinous  body  which  comprises  two  thirds  of  the  volume  and  weight  of  the  eye 
and  fills  the  space  bound  by  the  lens,  retina  and  optic  disc.  101  It  consists  of  approximately 
99%  water  with  the  remaining  components  including  collagen  and  hyaluronic  acid  which 
give  it  its  specific  physical  character. 
The  gel  like  form  of  the  vitreous  is  due  to  a  loose  mass  of  long  chain  collagen  molecules 
capable  of  binding  up  to  200  times  their  own  weight  in  water.  The  hyaluronic  acid 
molecules  are  very  large,  loose  bundles  capable  of  binding  up  to  60  times their  own  weight 
in  water.  Combined  with  the  collagen  element,  they  account  for  the  physical 
characteristics  of  normal  vitreous. Chapter  Two  Benzodiazepines  Page90 
The  use  of  vitreous  humor  as  an  alternative  to  post-mortem  blood  is  of  particular 
importance  when  the  body  has  undergone  considerable  decomposition  or  burning.  102  In 
comparison  to  post-mortem  blood,  which  is  often  putrefied,  vitreous  humor  is  a  relatively 
simple  matrix  as  highlighted  in  Table  2.36.  It  is  also  much  less  susceptible  to  post-mortem 
changes.  The  transport  of  drugs  across  the  blood  /  vitreous  humor  barrier  is  limited  by  the 
lipid  solubility  of  the  drug  and  its  charge  at  physiological  pH.  '°3 
Table  2.36:  Composition  of  Putrefled  Blood  c.  f.  Vitreous  Humor'°2 
Putrefied  Blood 
(pH  4-9) 
Vitreous  Humor 
(pH7-7.8) 
Water  (20-70%)  Water  (98.0-99.7%) 
Lysate  Glucose 
Clots  -  denatured  &  bacterial  Hyaluronic  acid 
Denatured  protein  Simple  anions  &  cations 
Fat  droplets  Collagen 
Steroids 
Putrefactive  bases 
Protein  microagglutinates 
Enzymes 
2.15.8  ANALYSIS 
Most  studies  concerning  the  analysis  of  vitreous  humor  have  been  concerned  with  time- 
since-death  determinations  104  and  it  is  only  in  the  last  decade  that  interest  has  been  placed 
on  the  use  of  vitreous  humor  for  the  determination  of  drug  levels. 
Some  of  the  drugs  which  have  been  investigated  in  vitreous  humor  include  morphine,  105 
flurazepam,  106  methadone,  107  and  cocaine.  102  The  methodology  usually  involves  a  solid 
phase  extraction  followed  by  the  appropriate  analysis  technique. 
2.15.8.1  VITREOUS  HUMOR  ANALYSIS  FOR  BENZODIAZEPINES 
In  terms  of  this  study,  the  10%  EtAc  extractions  were  found  to  give  slightly  better 
recoveries  from  authentic  forensic  samples  than  the  5%  EtAc.  The  method  development 
for  vitreous  humor  is  taken  as  being  the  same  as  the  McOH  standard  method  development. 
The  reasons  for  this  are  twofold: Chapter  Two  Benzodiazepines  Page91 
"  No  blank  vitreous  humor  was  available  for  direct  comparison 
"  The  matrix  used  to  mimic  vitreous  humor  was  water,  however  as  the  samples  are  dried 
prior  to  extraction,  the  addition  of  water  to  the  Extrelut®  should  make  little  difference  to 
the  matrix  to  be  extracted. 
2.15.9  EXTRACTIONS  WITH  ETAC  (10%)  AS  THE  MODIFIER 
2.15.9.1  EXPERIMENTAL 
A  combination  of  various  standards  was  extracted  using  10%  EtAc  to  ensure  that  the 
system  was  functioning  and  that  the  10%  EtAc  produced  high  recoveries.  The  standards 
analysed  are  detailed  below. 
Extraction  1:  Triazolam 
Extraction  2:  Temazepam 
Extraction  3:  Chlordiazepoxide 
Extraction  4:  Diazepam 
Extraction  5:  Desmethyldiazepam 
Extraction  6:  Triazolam  +  Temazepam 
Extraction  7:  Temazepam  +  Diazepam 
Extraction  8:  Temazepam  +  Desmethyldiazepam 
Extraction  9:  Triazolam  +  Temazepam  +  Desmethyldiazepam  +  Diazepam 
Extraction  10:  All  5  standards 
2.15.9.2  RESULTS  AND  DISCUSSION 
The  results  are  shown  in  Table  2.37  on  page  92. Chapter  Two:  Benzodiazepines 
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From  Table  2.36  it  can  be  seen  that  the  extractions  work  well  with  good  recoveries 
and  thus  the  10%  EtAc  was  used  for  all  future  analyses. 
2.16  METHOD  VALIDATION  FOR  ALL  FIVE  STANDARDS 
2.16.1  LINEARITY  OF  DIAZEPAM,  DESMETHYLDIAZEPAM,  CHLORDIAZEPOXIDE  AND 
TRIAZOLAM  METHANOL  STANDARDS 
2.16.1.1  EXPERIMENTAL 
The  linearity  for  diazepam,  desmethyldiazepam,  chlordiazepoxide  and  triazolam  from 
methanol  standards  was  calculated.  Each  of  the  results  is  an  average  of  three 
extractions  and  three  injections  (n=9).  The  results  obtained  are  shown  in  Tables  2.38, 
2.3  9,2.40  and  2.41. 
2.16.1.2  RESULTS  AND  DISCUSSION 
Table  2.38:  Linearity  for  Diazepam;  Methanol  Standards 
Unex  tracted  Extracted 
Cone' 
(m  ) 
Area 
Diaz 
Area 
Praz 
PAR  Area 
Diaz 
Area 
Praz 
PAR 
0  0  376610  0  0  126320  0 
0.55  74593  174663  0.427  r2:  0.997  18454  55613  0.332  r2:  0.988 
1.10  111750  134850  0.829  A:  0.128  37460  63283  0.592  A:  -0.098 
1.66  151680  137650  1.102  B:  0.594  59210  65235  0.908  B:  0.662 
2.21  232840  160620  1.450  72608  51827  1.401 
2.76  269600  153270  1.759  189560  107760  1.759 
Table  2.39:  Linearity  for  Desmethyldia  enam"  Methanol  Standards 
Unextracted  Extracted 
Conch 
(m  ) 
Area 
DMD 
Area 
Praz 
PAR  Area 
DMD 
Area 
Praz 
PAR 
0  0  374379  0  0  308326  0 
0.42  91825  386670  0.237  r2:  0.999  99775  368763  0  271  r2:  0  989 
0.85  175928  384498  0.458  A:  0.007  167417  273455 
. 
0  612 
. 
A:  0  053 
1.27  275638  399624  0.690  B:  0.537  147918  161554 
. 
0  916 
. 
B:  0  630 
1.70  338065  370187  0.913  241397  215479 
. 
1  120- 
. 
2.12  424846  368959  1.551  532755  392761 
. 
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Table  2.40:  Linearity  for  Chlordiazepoxide:  Methanol  Standards' 
Unex  tracted  Extracted 
Conc° 
(m  ) 
Area 
CDP 
Area 
Praz 
PAR  Area 
CDP 
Area 
Praz 
PAR 
0  0  309210  0  0  197976  0 
0.84  20760  299681  0.069  r2:  0.980  39487  329021  0.120  r2:  0.989 
1.68  41073  315776  0.130  A:  -0.044  69464  317427  0.219  A:  0.042 
2.52  70073  300417  0.233  B:  0.112  109292  353057  0.310  B:  0.101 
3.36  95808  310848  0.308  159054  441691  0.360 
4.20  135004  299282  0.451  142440  300824  0.473 
Table  2.41:  Linearity  for  Triazolam:  Methanol  Standard 
Unextracted  Extracted 
Conc" 
(m  /L) 
Area 
Triaz 
Area 
Praz 
PAR  Area 
Triaz 
Area 
Praz 
PAR 
0  0  418840  0  0  89123  0 
0.71  33598  435380  0.077  r2:  0.936  15887  227390  0.077  r2:  0.985 
1.42  25112  172230  0.146  A:  0.034  30040  219200  0.137  A:  0.010 
2.12  38077  151910  0.251  B:  0.083  52818  265555  0.199  B:  0.089 
2.83  44259  163100  0.271  33474  138440  0.242 
3.54  58552  189810  0.308  36381  107300  0.339 
From  these  it  can  be  seen  that  the  linearity  over  the  range  studied  is  good  and  the 
gradients  of  both  the  unextracted  and  extracted  standard  curves  are  in  good  agreement 
for  all  drugs. 
2.16.2  LINEARITY  OF  DIAZEPAM  AND  DESMETHYLDIAZEPAm  BLOOD  STANDARDS 
2.16.2.1  EXPERIMENTAL 
For  blood  standards  only  diazepam  and  desmethyldiazepam  were  extracted  as  these 
and  temazepam  were  the  only  benzodiazepines  quantitated  in  the  authentic  blood 
samples  as  discussed  in  chapter  6. 
2.16.2.2  RESULTS  AND  DISCUSSION 
The  PAR's  obtained  for  three  extractions  and  three  injections  of  diazepam  and 
desmethyldiazepam  blood  standards  are  shown  in  table  2.42. Chapter  Two:  Benzodiazepines  Page95 
Table  2.42:  Linearity  for  Diazepam  and  Desmethyldiazepam:  Blood  Standards 
E  Diazepam  n  Desmeth  ldiaze  am 
Conch 
(m  ) 
Unext.  PA  Ext.  PAR  Conc4 
(mg  /L) 
Unext. 
PAR 
Ext.  PAR 
0  0  0  0  0  0 
0.55  0.427  0.180  r2:  0.919  0.42  0.237  0.380  r2:  0.881 
1.38  0.852  0.430  A:  -0.190  1.06  0.549  0.517  A:  0.231 
2.21  1.450  0.771  B:  0.508  1.70  0.913  0.606  B:  0.279 
L  2.76  0.759  1.364  2.12  1.151  0.903 
Although  the  correlations  are  poorer  for  the  blood  standards  than  the  MeOH 
standards,  the  gradients  are  still  in  good  agreement. 
2.16.3  PREPARATION  OF  FRESH  STANDARDS  AND  CALCULATION  OF  LIMITS  OF 
DETECTION 
2.16.3.1  EXPERIMENTAL 
Fresh  standard  benzodiazepines  were  prepared  at  the  following  concentrations: 
Temazepam:  3.44  mg/100  m1 
Diazepam:  3.17  mg/100  ml 
Desmethyldiazepam:  3.09  mg/100  ml 
Prazepam:  2.52  mg/100  ml 
The  limit  of  detection  was  calculated  for  temazepam,  diazepam  and 
desmethyldiazepam  using  these  standards  by  sequentially  diluting  the  stock  standards. 
2.16.3.2  RESULTS  AND  DISCUSSION 
The  limit  of  detection  results  obtained  are  shown  in  Table  2.43. Chapter  Two:  Benzodiazepines  Page96 
Table  2.43:  Linearity  for  Limit  of  Detection  .1 
Temaze  am  DMD  Diazepam 
Soli  m  /L  PAR  m  PAR  mg/Ll  PAR  AUFS 
1P  4.3  0.204  3.96  0.352  3.86  0.418  0.05 
2P  2.15  0.099  r2:  0.996  1.98  0.178  r2:  0.993  1.93  0.203  r2:  0.999  0.05 
3P  1.08  0.054  A:  0.002  0.99  0.104  A:  0.012  0.97  0.101  A:  0.003  0.05 
4P  0.54  0.035  B:  0.046  0.50  0.067  B:  0.086  0.48  0.062  B:  0.107  0.05 
5P  0.27  0.010  0.25  0.018  0.24  0.029  0.01 
6P*  0.14  0.012  0.13  0.036  0.12  0.023  0.002 
*The  prazepam  peak  in  6P  overloaded  the  detector  and  thus  the  PAR  for  these  values 
was  not  taken  into  account  for  the  linearity. 
New  standard  dilutions  were  prepared  using  a  more  dilute  prazepam  standard.  This 
time  the  concentrations  of  each  drug  were  quoted  in  absolute  nanogram  values 
injected  into  the  HPLC  system  as  this  way  the  limits  of  detection  can  be  more  easily 
converted  for  different  extraction  volumes.  The  results  are  shown  in  Table  2.44. 
Table  2.44:  Linearity  for  Limit  of  Detection  :2 
T  emaze  am  DMD  Diazepam 
Sol'  ng  PAR  ng  PAR  ng  PAR 
1  688  12.169  634  11.319  618  13.316 
2  344  7.470  r2:  0.989  317  6.996  r2:  0.987  309  7.825  r2:  0.993 
3  68.8  1.265  A:  0.174  63.4  1.038  A:  0.117  61.8  1.232  A:  0.08 
4  34.4  0.733  B:  0.018  31.7  0.578  B:  0.018  30.9  0.669  B:  0.02 
5  6.88  0.121  6.34  0.169  6.18  0.125 
6  3.44  0.094  3.17  0.063  3.09  0.080 
The  last  solution  (6)  was  diluted  further  as  the  limit  of  detection  had  not  been  reached, 
to  yield  the  following  nanogram  values  and  PAR's  for  each  drug: 
Table  2.45:  Linearity  for  Limit  of  Detection.  -  3 
Temazepam  DMD  Diaze  am 
Sol'  ng  PAR  ng  PAR  ng  PAR 
6a  3.44  0.087  3.17  0.076  3.09  0.084 
6b  2.29  0.051  2.11  0.038  2.06  0.062 
6c  1.72  0.043  1.59  -ve  1.55  0.049 
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From  this  the  limit  of  detection  was  taken  as  being  1.72  ng  for  temazepam,  2.11  ng  for 
desmethyldiazepam  and  1.55  ng  for  diazepam.  In  all  cases,  the  drugs  could  still  be 
distinguished  clearly  from  the  baseline  noise. 
2.17  CONCLUSIONS 
It  has  been  found  that  supercritical  fluid  extraction  can  be  used  successfully  for  the 
extraction  of  benzodiazepine  drugs  from  a  variety  of  matrices  loaded  onto  Extrelut®. 
This  method  which  was  developed  and  consequently  used  for  the  extraction  of 
Forensic  blood  and  vitreous  humor  samples  (see  Chapter  6),  is  described  below. 
Samples  were  prepared  by  loading  the  100  µl  of  sample  blood  or  vitreous  humor  onto 
approximately  19  g  of  Extrelut®.  To  this,  100  µl  of  internal  standard  was  added, 
mixed  and  allowed  to  dry.  Once  dry,  the  Extrelut®  was  transferred  to  an  extraction 
cell  which  was  sealed  and  placed  into  the  SEE  oven  at  65  °C.  The  SEE  system  which 
was  equilibrated  at  a  flow  of  2  ml  mini'  and  a  pressure  of  3000  psi  was  then  switched 
to  extract  and  the  extracted  analytes  collected  for  10  minutes  into  MeOH  at  the  flow 
outlet. 
The  methodology  was  found  to  be  reproducible  and  provide  high  recoveries  of 
temazepam,  desmethyldiazepam  and  diazepam  (80-100%),  the  three  most  commonly 
encountered  benzodiazepines  in  forensic  specimens  in  the  West  of  Scotland  over  the 
studied  period.  In  addition,  the  method  was  found  to  be  comparable  to  the  currently 
employed  SPE  method  but  was  less  solvent  intensive  (2  ml  of  EtAc  used  per 
extraction  c.  f.  -15  ml  of  diethylether  for  SPE). 1Lm  Sh4espeare;  Othello Chapter  Three:  Opiates  Page98 
3.  OPIATES 
3.1  INTRODUCTION 
The  opiates  are  a  group  of  drugs  derived  from  the  opium  poppy  (papaver  somniferum).  tos 
Their  use  as  analgesics  dates  back  as  early  as  the  7th  century  B.  C.  with  reference  to  the 
juice  of  the  poppy  in  the  Assyrian  medical  tablets.  109  By  the  16th  century  opium  was  well 
established  in  Western  European  medicine  and  many  of  the  physicians  of  the  time  stated 
that  they  could  not  practice  medicine  without  it.  At  the  beginning  of  the  19th  century,  the 
use  of  opium  was  still  thought  to  be  central  to  medicine  however,  its  widespread  use 
became  restricted  in  1868  when  the  first  Pharmacy  Act  became  law.  In  addition,  after 
World  War  One,  Britain  implemented  an  international  agreement  to  prohibit  non-medical 
use  of  opiates  due  to  the  large  number  of  post-war  addicts. 
Natural  opiates  which  are  found  in  the  opium  poppy  include  morphine  and  codeine,  both  of 
which  are  effective  as  painkillers.  Diamorphine  (heroin)  was  first  synthesised  from 
morphine  in  1874110  and  in  its  pure  form  is  a  white  fluffy  powder  which  is  more  than  twice 
as  potent  as  morphine.  It  was  initially  thought  to  be  a  safe  means  of  curing  morphine 
addiction  and  its  potential  for  abuse  was  largely  ignored.  A  number  of  other  synthetic 
opiates  have  been  manufactured  as  pain-killers  including  pethidine,  dipipanone  and 
methadone,  the  latter  of  which  will  be  discussed  more  fully  in  Chapter  4. 
In  order  to  monitor  the  size  of  the  national  heroin  problem,  a  Home  Office  Notification 
System  was  set  up  in  1968.  In  1993,  the  number  of  registered  addicts  was  27,976. 
However,  as  this  is  based  on  those  users  who  register  their  addiction  with  their  GP,  this 
number  is  an  under-estimation  and  the  number  of  actual  opiate  addicts  is  believed  to  be 
greater  than  125,000. 
3.2  PRESCRIPTION 
Opiates  are  generally  prescribed  as  painkillers,  however,  they  also  have  medical  uses  as 
cough  suppressants  and  anti-diahorrea  agents.  Table  3.1  lists  the  opiates  commonly Chapter  Three:  Opiates  Page99 
prescribed  along  with  their  proprietary  names  and  uses.  In  the  U.  K.,  morphine  is  the 
favoured  opiate  by  most  doctors  for  the  treatment  of  severe  pain. 
ll  t,  t  t2  Table  3.1:  Prescription  Opiates 
Name  Proprietary  Name(s)  Treatment 
Alfentanil  Ra  ifen®  Pain 
Buprenorphine  Tem  esic®  Pain,  premed. 
Codeine  Diarrest®,  Co- 
Codamol® 
Anti-diarrhoea,  pain 
Dextromoramide  Pallium®  Pain 
Dextropropoxyphene  Co-Proxamol®, 
Distal  esic® 
Pain 
Diamorphine  -  Pain  (IV),  cough 
Dihydrocodeine  DF118  Forte®  Pain 
Diphenoxylate  Lomotil®,  Tro  er  en®  Anti-diarrhoea 
Dipipanone  Diconal®  Pain 
Fentanyl  Duro  esic®  Pain 
Loperamide  Imodium°, 
Lo  era  en® 
Anti-diarrhoea 
Meptazinol  -  Pain 
Methadone  Ph  se  tone®  Pain,  cough 
Morphine  MST  Continus®, 
Kaolin®,  Oramorph 
SR®,  Sevredol® 
Pain,  cough,  dyspnoea 
Nalbuphine  Nubain®  Pain,  premed. 
Oxycodone  -  Pain 
Pa  averetum  -  Pain 
Pethidine  Pamer  an®  Pain 
Phenazocine  Na  hen®  Pain 
Phenoperidine  -  Pain 
Pholcodine  Copholco®, 
Galen  hol® 
Cough 
Tramadol.  Zydol  SR®  Pain 
3.3  CHEMICAL  STRUCTURE 
The  three  opiates  which  are  of  interest  to  this  study  are  diamorphine  (3,6-o- 
diacetylmorphine),  6-monoacetylmorphine  (6-MAM)  and  morphine  ((5aR,  5S,  7aR,  8R,  9cS)- 
4a,  5,7a,  8,9,9c-hexahydro-12-methyl-8,9c-iminoethanophenanthro[4,5-bcd]furan-3,5-diol). Chapter  Three:  Opiates  Page  100 
Methadone,  which  is  also  an  opiate  is  discussed  in  Chapter  4.  All  three  of  the  drugs  which 
will  be  discussed  here  have  the  same  basic  chemical  structure,  which  differs  only  in  the  Rl 
and  R2  groups  as  indicated  in  Figure  3.1  and  Table  3.2. 
2 
Figure  3.1:  Structure  of  opiates 
Table  3.2:  R1  and  Rz  Groups  for  Opiates  of  Interest 
Drug  R,  R2 
Diamorphine  COCH3  COCH3 
6MAM  H  COCH3 
Morphine  H  H 
3.4  PHARMACOLOGY 
Opiates  appear  to  share  some  of  the  properties  and  mimic  the  action  of  some  groups  of  the 
body's  naturally  occurring  chemicals  called  peptides  and  in  particular  the  endorphins, 
enkephalins  and  dynorphins.  Binding  studies  have  indicated  that  there  may  be  as  many  as 
eight  types  of  opiate  receptors  which  in  addition  may  all  have  sub-type  receptors.  113 
Opiates  directly  cause  a  large  number  of  actions: 
"  Effects  on  the  central  nervous  system 
"  Effects  on  the  peripheral  nervous  system 
"  Induced  histamine  release-related  effects 
9  Effects  for  which  there  is  no  identified  and/or  proven  causal  effect Chapter  Three:  Opiates_  Page  101 
The  main  pharmaceutical  uses  of  opiates  are  due  to  their  effects  on  the  CNS.  These 
include  pain  relief  and  cough  reflex  depression  as  well  as  some  of  the  less  desired  side 
effects  including  nausea,  vomiting,  and  respiratory  depression  which  is  the  main  cause  of 
opiate  related  deaths. 
Pain  relief  with  opiates  occurs  through  a  number  of  pain  reducing  mechanisms  and  altered 
perception  of  painful  stimuli.  Opiates  do  not  alter  the  sensitivity  of  the  nerve  endings  to 
pain,  but  instead,  interfere  with  the  transmission  of  signals  via  the  nervous  system  to  the 
brain  by  four  mechanisms: 
9  Decreasing  the  conduction  along  the  nerves  running  between  the  nerve  endings  and  the 
spine 
"  Preventing  production  of  chemicals  which  allow  signals  to  pass  between  the  nerves  and 
the  spinal  cord 
0  Stimulating  production  of  serotonin  (5HT)  and  noradrenaline  which  significantly 
reduces  the  pain  signals  reaching  the  brain 
9  Mimicking  the  action  of  endorphins  at  their  receptor  sites 
The  side  effect  which  is  responsible  for  the  national  opiate  addiction  problem  is  euphoria. 
Although  the  mechanism  by  which  opiates  produce  a  sense  of  euphoria  is  not  yet  agreed,  it 
is  thought  to  be  partly  via  action  on  part  of  the  brain  called  the  locus  cerulus,  which  is 
known  to  have  a  high  concentration  of  opioid  receptors.  114 
3.5  METABOLISM 
Diamorphine  is  the  active  ingredient  of  Heroin.  Post-administration,  it  is  readily  absorbed 
and  rapidly  hydrolysed  to  6-MAM  in  blood,  then  more  slowly  metabolised  to  morphine 
which  is  the  major  active  metabolite.  Normorphine  is  also  formed  to  a  lesser  extent.  All 
metabolites  may  be  conjugated  with  glucuronic  acid  to  form  the  glucuronide  derivatives. 
Morphine  itself  undergoes  considerable  first  pass  metabolism  and  is  widely  distributed  to 
the  kidneys,  liver,  lungs  and  spleen.  It  does  not  however  accumulate  in  the  tissues.  Figure 
3.2  shows  the  major  metabolic  pathway  of  diamorphine. Chapter  Three:  Opiates  Page  102 
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Figure  3.2:  Metabolic  Pathway  of  Diamorphine 
3.6  PHARMACOKINETICS 
Norcodeine 
H 
Due  to  the  short  half  lives  of  diamorphine  and  6MAM,  there  is  a  lack  of  pharmacokinetic 
data  on  these  drugs.  The  information  available  from  Clarkes  Identification  of  Drugs'  15  is 
summarised  in  Table  3.3.  As  can  be  seen  other  than  the  half  lives  of  diamorphine,  and 
6MAM,  no  pharmacokinetic  data  was  available  and  the  volume  of  distribution  (VD), 
clearance  (Cl)  and  protein  binding  quoted  for  these  drugs  refer  to  morphine. 
Table  3.3:  Pharmacokinetic  Data  for  Opiates 
Drug  Half  Life  VD  (Llkg)  Cl  (mImin/kg 
plas  a) 
Protein 
binding 
Diamorphine  -3  min  -  -  - 
6-MAM  -30  min  -  -  - 
Morphine  2-3  hr  3-5  15-20  20-30% Chapter  Three:  Opiates  Page103 
Diamorphine  is  difficult  to  detect  in  plasma  due  to  its  rapid  hydrolysis  to  6MAM.  An 
intravenous  dose  of  4-5  mg  declines  to  a  blood  concentration  of  0.01  mg/L  within  10 
minutes.  Therapeutic  morphine  plasma  concentrations  are  usually  in  the  range  0.01-0.07 
mg/L.  The  estimated  LD50  for  diamorphine  in  man  is  200  mg  however,  addicts  can  tolerate 
up  to  10  times  this  amount  and  fatalities  have  been  known  after  only  10  mg. 
3.7  LEGAL  STATUS 
Opium  is  one  of  the  few  drugs  in  the  Misuse  of  Drugs  Act  which  in  its  raw  form,  is  not 
authorised  for  medicinal  use  and  can  only  be  supplied,  possessed  or  administered  in 
accordance  with  a  Home  Office  Licence.  It  is  also  an  offence  to  frequent  a  place  used  for 
smoking  opium,  to  posses  utensils  used  for  smoking  and  preparing  opium  or  to  allow 
premises  to  be  used  for  smoking  or  preparing  opium. 
Dextromoramide,  dipipanone,  fentanyl,  heroin,  methadone,  morphine,  opium  and  pethidine 
are  all  Class  A  drugs.  Codeine  and  dihydrocodeine  are  Class  B  drugs  unless  prepared  for 
injection  in  which  case  they  are  Class  A  drugs.  Dextropropoxyphene  and  buprenorphine 
are  Class  C  drugs.  Dilute  mixtures  of  codeine,  morphine  or  opium  used  for  the  treatment 
of  coughs  or  diarrhoea  are  available  over  the  counter  from  pharmacies. 
3.8  ANALYSIS  OF  MORPHINE 
In  reviewing  the  available  literature  on  morphine  analysis  it  was  found  that  the  tissue  of 
choice  for  analysis  was  plasma.  Here  morphine  is  present  in  unconjugated  form  and  there 
is  little  else  in  the  matrix  likely  to  interfere  with  the  isolation  of  the  drug,  although  up  to 
30%  plasma  protein  binding  is  reported.  However,  plasma  is  seldom  available  in  most 
postmortem  cases  and  the  tissue  most  commonly  supplied  is  haemolysed,  often  putrefied, 
blood. 
Direct  analysis  of  body  fluids  and  tissues  is  impractical  and  usually  some  form  of  cleanup 
or  pre-concentration  is  required  before  chromatographic  methods  can  be  applied.  RIA  can 
be  performed  on  unprepared  samples  but  a  simple  extraction  into  MeOH  is  usually  carried Chapter  Three:  Opiates  Page  104 
out  to  eliminate  matrix  interference  and  increase  sensitivity.  Methods  which  have  been 
used  for  the  preparation  of  samples  to  be  analysed  for  morphine  include: 
1.  Protein  precipitation,  ultrafiltration  and  centrifugation  (Curry,  1969)116 
2.  Liquid/liquid  extraction  (Jones  et  al,  1985117  -  urine:  GC/MS;  Basett,  1980118  -  plasma: 
GC-ECD;  Todd  et  al,  1982119  plasma/CSF:  LC-EC;  White,  1979120  -  blood:  LC-EC) 
3.  SPE  (Mule,  1974121  urine:  GC,  Moore  et  al,  1984122  -  plasma:  LC-ED;  Fritschi  et  al, 
1985123  urine:  GC/MS/SIM;  Derko  et  al,  124 
-  urine:  LC-UV) 
In  terms  of  the  analysis  of  opiates,  the  method  of  choice  has  to  be  GC/MS  due  to  its 
sensitivity  and  selectivity  via  the  use  of  SIM.  The  use  of  GC/MS  for  opiates  is  well 
documented  and  recently  a  simultaneous  method  for  the  determination  of  acetylcodeine, 
monoacetylmorphine  and  other  opiates  in  urine  was  reported  by  O'Neal  and  Poklis.  125 
Other  popular  methods  for  the  analysis  of  opiates  are  summarised  in  Table  3.4. 
Table  3.4:  Opiate  Analysis  Methods 
Year  Analysis 
Technique 
Extraction 
Type 
Sample  Type  Sample 
Volume 
Derivatisation 
Required 
126 
1972  HPLC-UV  n/n  n/n  n/n  No 
198717.  HPLC-ED  n/n  Serum  n/n  n/n 
1984  GC/MS  n/n  n/n  n/n  Yes 
1991  GC 
-  n/n  Blood/  Bile  n/n  Yes 
1993 
129  GC/MS  On-line 
dialysis 
Plasma/ 
Blood 
n/n  Yes 
130  1994  GC/MS  SPE  Urine  0.5  ml  Yes 
1994 
131 
- 
GC-FID  n/n  Blood  stains  n/a  No 
199737  GC/MS  SPE  Saliva/ 
Blood/  Serum 
n/n  Yes 
1995 
133  Review  various  various  various  - 
1995  HPLC  SPE  Serum  200  1  No 
3.9  SFE  ANALYSIS  OF  MORPHINE 
The  super/sub  critical  analysis  of  opiates  has  been  reported  by  several  authors.  135,136  Janicot 
et  a1135  used  CO2  with  an  amine  polar  modifier  for  the  successful  separation  of  opium 
alkaloids  from  poppy  straw  extracts  and  Edder  et  al'36  reported  the  use  of  SF-CO2  with  a Chapter  Three:  Opiates  Page105 
polar  modifier  for  the  extraction  of  opiates  from  biological  matrices.  Indeed  this  second 
method  was  used  as  a  starting  point  for  the  SFE  of  morphine  as  described  in  section  3.13. 
3.10  STATUS  OF  CASES 
Figure  3.3  shows  the  number  of  toxicology  cases  in  which  morphine  was  found  over  the 
time  period  1992  to  1997.  It  should  be  noted  that  this  number  will  include  therapeutically 
administered  morphine  as  well  as  morphine  arising  from  heroin  related  deaths. 
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Figure  3.3:  Morphine  Related  Deaths 
It  can  be  seen  from  this  figure  that  over  the  period  1992  to  1995,  there  was  a  sharp 
increase  in  the  number  of  morphine  fatalities  whereas  from  1995-1997,  the  morphine 
related  deaths  appear  to  be  declining  in  number.  One  explanation  for  this  is  the 
introduction  of  the  methadone  maintenance  programmes.  This  will  be  discussed  in  more 
detail  in  the  next  chapter. 
3.11  CURRENT  METHODOLOGY 
At  the  time  of  this  work  the  method  of  extraction  employed  in  the  routine  laboratory  made 
use  of  solid  phase  extraction  as  described  below. 
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Samples  and  blanks  were  prepared  by  pipetting  1  ml  of  O.  1M  ammonia  buffer,  1  ml  of 
sample  or  blank  blood  and  50  µl  of  d3-morphine  (1µg/ml)  into  a  vial.  In  the  case  of 
standards,  50  µl  of  morphine  (1µg/ml)  was  also  added.  Two  extraction  columns  were 
required  for  each  extraction.  The  first  was  prepared  by  plugging  a  small  amount  of  glass 
wool  into  a  10  ml  plastic  syringe  and  filling  to  the  10  ml  mark  with  EtOH  /  MeOH  washed 
Extrelut®.  The  other  extraction  columns  were  Bond  Elut  SCX.  In  each  case  the  extraction 
columns  were  labelled  with  the  appropriate  sample  number. 
The  contents  of  the  sample,  standard  and  blank  vials  were  pipetted  onto  the  corresponding 
Extrelut®  column  and  allowed  to  stand  for  10  minutes.  The  Extrelut®  columns  were  then 
washed  with  5  ml  of  hexane  and  put  to  one  side.  The  SCX  columns  were  placed  on  the 
vac-elut  system  and  conditioned  with  2  ml  of  methanol,  followed  by  2  ml  of  water  and 
finally  1  ml  of  ethyl  acetate  :  isopropanol  (9:  1  v/v).  The  Extrelut®  columns  were  then 
placed  on  top  of  the  SCX  columns  via  an  adapter  and  eluted  using  12  ml  of  EtAc:  IPA  (9:  1 
v/v)  under  a  vacuum  of  approximately  5  psi.  The  Extrelut®  columns  were  then  discarded 
and  the  SCX  columns  washed  using  5  ml  of  MeOH  :  ACN  (l:  lv/v).  Labelled  tubes  were 
placed  under  the  appropriate  columns  on  the  vac-elut  system  and  2  ml  of  10%  ammonia  in 
MeOH  :  ACN  (1:  1  v/v)  was  passed  through  and  collected.  The  collected  extracts  were 
transferred  into  small  vials  and  evaporated  to  dryness  under  nitrogen.  50µ1  of  BSTFA  (1% 
TMCS)  were  added  to  each  vial  which  was  then  sealed  and  heated  at  90  °C  for  15  minutes. 
For  GC-MS  analysis,  1  µl  of  the  derivatised  extract  was  injected. 
3.12  GC/MS  METHODOLOGY 
The  GC/MS  for  both  morphine  and  methadone  (chapter  4)  was  carried  out  using  a  Fisons 
GC  8000  series  gas  chromatograph  with  a  MD  800  mass  spectrometer.  The  GC  was  fitted 
with  a  HP!  capillary  column  (30  mx0.25  mm  x  0.25  µm  film  thickness). 
For  the  analysis  of  morphine  and  6MAM,  the  temperature  programme  was  as  follows: 
Initial  Temperature:  100  °C 
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Temperature  Ramp:  10  °C/min 
Final  hold  Time:  5  minutes 
Injector  Temperature:  225  °C 
The  detector  was  run  in  the  selected  ion  monitoring  mode  (SIR)  and  the  mass  to  charge 
ratios  (m/z)  detected  were  414  and  429  for  morphine  and  432  for  d3-morphine.  The 
6MAM  was  investigated  at  a  later  stage  and  the  m/z  which  were  used  are  discussed  in 
section  3.14. 
It  should  be  noted  that  morphine  peaks  at  m/z  :  414  and  m/z  :  429  are  only  defined  as  being 
positive  when  the  m/z  ratio  of  414/429  is  between  0.4  and  0.85.  The  value  obtained  is 
usually  close  to  0.5,  however  alterations  in  the  tuning  of  the  instrument  give  some 
variation. 
3.13  EXPERIMENTAL 
Initially,  a  literature  review  on  previous  methodology  was  carried  out.  Several  papers  were 
noted  to  use  CO2  as  an  extractant  for  the  quantitation  of  opiates  as  previously 
mentioned.  136,137  The  first  of  these  to  be  reviewed  was  the  subcritical  extraction  method  for 
morphine,  published  by  Edder  et  a1.29  This  method  makes  use  of  a  ternary  phase  extractant 
which  at  the  low  temperatures  used  will  be  sub-critical  and  not  supercritical.  The 
conditions  used  for  the  extraction  were  as  follows: 
"  Support  medium:  C18  silica 
"  Extraction  phase:  C02:  MeOH  :  Et3N  (90:  8.5  :  1.5  (v/v)) 
"  Pressure:  25  MPa  (3625  psi) 
"  Temperature:  40  °C 
"  Time:  30  minutes 
"  Flowrate:  0.5  ml  miri  1 Chapter  Three:  Opiates  Page  108 
3.13.1  SUB-CRITICAL  Rum  EXTRACTION  OF  MORPHINE 
3.13.1.1  EXPERIMENTAL 
Four  extractions  of  morphine  and  d3-morphine  in  MeOH  were  carried  out  using  a  variety  of 
C18  supports.  In  each  case,  100  µl  of  morphine  and  d3-morphine  (10  mg/L)  were  pipetted 
onto  a  C18  support  and  allowed  to  dry  at  room  temperature.  In  addition  to  the  MeOH 
extracts,  an  additional  extraction  (1/1)  was  carried  out  using  a  blood  spiked  standard  (10 
mg/L).  Again  100  µl  of  the  standard  containing  morphine  and  d3-morphine  were  loaded 
onto  the  C18  support. 
In  their  paper,  Edder  et  a1136  suggest  that  a  small  amount  of  water  added  to  the  extraction 
vessel  may  aid  the  extraction  and  thus  10.  tl  of  dH2O  was  added  to  two  of  the  four  MeOH 
extracts.  A  further  two  blood  standard  extractions  (2/1,2/2)were  carried  out  the  following 
day,  this  time,  one  (2/2)  had  10  µl  of  dH2O  added. 
The  actual  conditions  used  were  slightly  modified  from  the  original  conditions  used  by 
Edder  et  a1136  as  follows: 
"  Extraction  phase:  CO2  :  MeOH  :  Et3N  (90:  8.5:  1.5  (v/v)) 
"  Pressure:  3500  psi 
"  Temperature:  45  °C 
"  Time:  30  minutes 
"  Flowrate:  1.0  ml  min" 
3.13.1.2  RESULTS  AND  DISCUSSION 
The  extraction  support  phase  was  varied  as  only  limited  amounts  of  C18  from  any  one 
supplier  was  available.  The  phases  used  are  detailed  below. 
MeOH  Extraction  1:  Shandon  5µ  ODS 
MeOH  Extraction  2:  As  for  Extraction  1  (10  µl  dH2O  added) 
MeOH  Extraction  3:  Spherisorb  C18 
MeOH  Extraction  4:  Glass  Appliances  5µ  ODS Chapter  Three:  Opiates  Page109 
Blood  Extractions:  Hypersil  ODS 
The  results  obtained  for  the  four  MeOH  extractions  are  shown  in  Table  3.5.  Area  based  % 
recoveries  were  calculated  for  each  of  the  monitored  ions. 
Table  3.5:  Morphine  MeOH  Extractions  :  Modification  of  method  by  Edder  et  al 
Ilk-  Area  % 
m/z:  432 
Area  % 
m/z:  429 
Area  % 
m/z:  414 
m/z  ratio  m/z  ratio 
414/429  429/432 
Area  Unext.  64431052  84183768  47162980  0.560  1.307 
Ext.  1  77  70  67  0.536  1.178 
Ext.  2  180  147  145  0.553  1.064 
Ext.  3  31  27  27  0.552  1.145 
Ext.  4  42  30  30  0.570  0.926 
The  results  obtained  for  the  blood  extractions  on  days  one  and  two  are  shown  in  Table  3.6. 
Table  3.6:  Morphine  Blood  Extractions 
Area  % 
m/z:  432 
Area  % 
m/z:  429 
Area  % 
m/z:  414 
m/z  ratio 
414/429 
m/z  ratio 
429/432 
Day  One 
Ext.  1/1  176  172  151  0.529  1.243 
Area  Unext.  64431052  84183768  47162980  0.560  1.307 
Day  Two 
Ext.  2/1  348  314  400  0.576  1.077 
Ext.  2/2  618  619  707  0.518  1.193 
Area  Unext.  37501364  44641888  20241124  0.453  1.190 
Although  in  both  cases  (blood  and  MeOH)  the  %  area  recoveries  vary  widely  from 
extraction  to  extraction,  good  comparison  with  the  unextracted  standard  in  terms  of  the 
429/432  ratio  is  observed.  Some  of  the  variation  in  the  areas  can  be  attributed  to  the 
derivatisation  procedure  as  highlighted  in  section  3.13.7. Chapter  Three:  Opiates  Pagel  10 
3.13.2  EXTRACTION  AT  VARIOUS  VOLUMES  OF  MORPHINE/D3-MORPHINE 
3.13.2.1  EXPERIMENTAL 
The  same  conditions  which  were  applied  in  section  3.13.1,  were  used  for  the  extraction  at 
various  volumes  of  morphine  and  d3-morphine  from  0  to  1.0  ml.  Both  extracted  and 
unextracted  MeOH  standards  were  run  through  the  GCIMS. 
3.13.2.2  RESULTSANDDISCUSSION 
The  results  obtained  for  the  subcritical  extraction  of  various  volumes  of  morphine  and  d3- 
morphine  are  shown  in  Table  3.7. 
The  volumes  of  standard  used  cover  a  range  from  1.1  to  11.0  mg/L  of  morphine 
hydrochloride.  The  case  samples  which  have  been  received  for  analysis  by  SPE  to  date  are 
in  the  concentration  range  0.03  to  1.1  mg/L  by  SPE  followed  by  GC/MS,  thus  a  ten-fold 
dilution  of  these  samples  will  have  to  be  carried  out  in  order  to  check  the  linearity  over  this 
range. 
Table  3.7:  Subcritical  Extraction  at  Various  Volumes  of  Morphine  and  dr-Morphine 
Unextracted  m/z  ratio  Extracted  m/z  ratio  Apparent 
Vol.  (ml)  429/432  414/429  429/432  414/429  Concn 
0  0.0033  13.89  0.0044  10.42  -ve 
0.1  0.9298  0.582  1.1176  0.574  1.32 
0.2  1.0457  0.597  1.2016  0.570  1.26 
0.3  1.0337  0.628  1.1390  0.575  1.21 
0.4  1.0116  0.632  1.1340  0.577  1.23 
0.5  1.0578  0.602  Extract  solidified 
0.75  1.0576  0.795  1.0475  0.551  1.19 
1.0  1.0130  0.795  0.9504  0.678  1.03 
Mean  429/432 
RSD  429/432 
1.021 
4.4% 
1.098 
7.9% 
As  the  volumes  of  morphine  and  d3-morphine  being  analysed  were  the  same,  the  m/z 
429:  432  ratio  should  remain  constant.  From  the  results  obtained  in  this  and  the  previous 
sections,  it  is  noticeable  that  the  429/432  m/z  ratio  of  morphine  for  unextracted  standards 
varies  from  0.93  to  1.44  on  a  day  to  day  basis.  For  this  reason  it  is  essential  that  where 
possible,  an  unextracted  standard  is  run  on  the  same  day  as  the  extracted  standards. Chapter  Three:  Opiates  Pagel  11 
3.13.3  LINEARrrx  of  MoR  HiNE  ExTRACn0N 
3.13.3.1  EXPERIMENTAL 
An  11  mg/L  morphine  hydrochloride  standard  solution  was  diluted  1:  10  to  give  a  stock 
concentration  of  1.1  mg/L.  In  real  samples,  the  morphine  being  analysed  will  not  be  as  the 
hydrochloride,  therefore  the  concentrations  were  adjusted  for  morphine  only,  to  give  a 
stock  solution  concentration  of  0.98  mg/L.  Aliquots  of  this  solution  were  pipetted  into  a 
vial  with  200  µl  of  d3-morphine,  blown  to  dryness  under  a  stream  of  nitrogen,  reconstituted 
in  50  µl  of  BSTFA  (1%  TMCS)  and  derivatised  for  15  minutes  at  90  °C.  The  same 
volumes  of  morphine  and  d3-morphine  were  also  extracted  by  pipetting  the  appropriate 
volumes  of  morphine  and  d3-morphine  onto  C18,  drying,  extracting  and  derivatising  as 
detailed  above.  The  derivatised  samples  were  then  injected  onto  the  GGMS. 
3.13.3.2  RESULTS  AND  DISCUSSION 
The  results  for  various  concentration  of  morphine  at  constant  d3-morphine  concentration 
are  shown  in  Table  3.8. 
Table  3.8:  Morphine  Linearity  over  the  range  0.049  to  0.98  mQ/L 
Unextracted  m/z  ratio  Extracted  m/z  ratio 
Vol.  (1)  Concn  429/432  414/429  429/432  414/429 
0  0  0  0  0  0 
50  0.049  0.256  0.702  0.224  0.681 
100  0.098  0.553  0.581  0.475  0.589 
200  0.196  1.144  0.535  0.957  0.632 
300  0.294  1.698  0.519  1.567  0.559 
400  0.392  2.310  0.513  2.354  0.521 
500  0.490  2.754  0.504  2.962  0.498 
600  0.588  3.216  0.504  3.186  0.558 
700  0.686  3.620  0.501  3.589  0.603 
800  0.784  4.036  0.501  3.964  0.540 
900  0.882  4.590  0.497  4.479  0.503 
1000  0.980  4.932  0.498  4.877  0.536 
For  the  unextracted  standards:  r2:  0.995,  A:  0.165,  B:  5.0  19. 
For  the  extracted  standards:  r2:  0.987,  A:  0.110,  B:  5.041. unapter  Three:  Opiates  Page  112 
The  morphine  m/z  414  and  mlz  429  peaks  for  the  0.049  mg/L  standard  were  still  easily 
detectable  by  GCAIS  as  shown  in  Figure  3.4. 
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Figure  3.4:  Mass  Chromatogram  of  0.049  mg/L  Morphine 
3.13.4  SUPERCRITICAL  FLUm  EXTRACTION  METHOD 
3.13.4.1  EXPERIMENTAL 
An  additional  method  for  the  supercritical  fluid  extraction  of  morphine  was  investigated.  137 
This  method  was  designed  for  the  extraction  of  hair  samples  but  it  was  attempted  in  a 
modified  form  for  the  extraction  of  morphine  from  MeOH  and  blood  standards.  '  The 
original  method  uses  the  following  conditions: 
"  Temperature:  100  °C 
Flowrate:  2.0  ml  min" 
"  Pressure:  25  Mpa  (3625  psi) 
"  Modifier:  McOH:  Et3N:  H20  (2:  2:  1  v/v) 
317772 
1L.  19. 
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The  conditions  were  maintained  with  the  exception  of  the  modifier  which  was  kept  as  the 
MeOH  :  Et3N  used  in  the  initial  extraction  method  by  Edder  et  al.  136 
Fresh  standards  of  morphine  and  d3-morphine  were  prepared  in  methanol  as  follows: 
Morphine:  1.35  mg  of  morphine  hydrochloride  was  weighed  into  a  100  ml  volumetric 
flask  and  made  up  to  the  mark  with  methanol.  As  the  morphine  is  as  the  hydrochloride,  the 
actual  concentration  of  morphine  -*  1.20  mg/100  ml 
d3-morphine:  1.01  mg of  d3-morphine  were  weighed  into  a  volumetric  flask  and  prepared 
as  above. 
For  d3-morphine  the  absolute  concentration  does  not  have  to  be  calculated.  It  is  only 
important  that  the  concentration  is  approximately  the  same  as  the  morphine  concentrations 
being  investigated  and  that  it  is  kept  constant  for  all  samples  and  standards. 
An  extraction  calibration  curve  with  these  standards  diluted  1:  10  was  carried  out.  1000  tL 
of  d3-morphine  was  added  for  each  extraction. 
3.13.4.2  RESULTS  AND  DISCUSSION 
The  results  for  the  calibration  using  the  new  extracted  standards  are  shown  in  Table  3.9  and 
Figure  3.5. 
Table  3.9:  Calibration  with  New  Standards 
Volume  added 
(1) 
Conc" 
(mg/L) 
429/432 
m/z  Ratio 
414/429 
m/z  Ratio 
0  .0  4.5*  10"  10.31 
100  0.12  0.202  0.879 
200  0.24  0.387  0.826 
300  0.36  0.550  0.838 
400  0.48  0.879  0.681 
500  0.60  0.957  0.806 
750  0.90  1.337  0.819 
1000  1.20  1.762  0.768 
r2:  0.989 
A:  0.070 
B:  1.432 Chapter  Three:  Opiates  Pagel  14 
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Figure  3.5:  Linearity  of  Morphine  over  the  Runge  0.12-1.20  mg  1, 
The  new  standards  yielded  a  better  correlation  coefficient  for  the  extraction.  The  gradients 
of  the  two  calibrations  could  not  be  directly  compared  as  the  amount  of  internal  standard 
added  was  different  (1000  µl  c  .f 
200  µl).  In  order  to  check  that  the  two  sets  of  standards 
were  however  providing  reproducible  results,  the  PAR's  were  plotted  against  each  other  as 
shown  in  Figure  3.6. 
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Figure  3.6:  Comparison  of  Old  and  New  Morphine  Standards 
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As  the  concentrations  were  different  for  the  two  sets  of  standards,  the  points  for  the  old 
standard  were  calculated  using  the  equation  of  the  best  fit  line  (y=5.019x+0.165).  For  the 
two  sets  of  standards,  the  coefficient  of  correlation  was  calculated  as  0.989  and  the 
equation  of  the  line  was  y=3.465x-0.045,  indicating  that  similar  results  would  be  obtained 
using  either  standard. 
3.13.5  LINEARrry  of  MORPHINE  EXTRACTION 
3.13.5.1  EXPERIMENTAL 
The  linearity  test  with  the  new  standards  was  repeated,  this  time  reducing  the  concentration 
to  0.012  mg/L  morphine  for  MeOH  and  blood  standards.  Each  set  of  MeOH  standards  was 
injected  into  both  GC/MS's  to  ensure  that  both  instruments  were  producing  the  same 
results. 
3.13.5.2  RESULTS  AND  DISCUSSION 
The  results  obtained  for  the  MeOH  extractions  on  both  GC/MS's  and  for  the  blood 
standards  are  shown  in  Table  3.10. 
Table  3.10:  Linearity  After  One  Hundred-Fold  Dilution  of  Standards 
GC/MS  A:  MeOH  GC/MS  B:  MeOH  Blood 
Conc"  429/432  414/429  429/432  414/429  429/432  414/429 
0  0  0  0  0  0  0 
0.012  no  429  no  429  no  morphine 
0.018  no  429  no  429  no  morphine 
0.024  no  429  0.027  0.886  no  morphine 
0.06  0.054  1.506  0.040  0.792  no  morphine 
0.12  0.097  1.687  0.075  0.750  no  mo  hine 
0.18  0.201  1.190  0.224  0.682  0.213  0.623 
0.24  0.183  1.040  0.183  0.691  0.363  0.578 
0.60  0.351  1.202  0.423  0.571  0.745  0.643 
1.20  0.777  1.103  1.042  0.518  1.362  0.518 
Although  the  detection  limit  for  the  method  appears  quite  high  it  should  be  noted  that  the 
extractions  are  based  on  only  100  µI  of  blood  or  MeOH  being  extracted  instead  of  the  1  ml Chapter  Three:  Opiates  Pagel  16 
used  in  SPE.  Thus,  if  for  example  500  tl  were  extracted,  the  detection  limit  should  be 
decreased  by  a  factor  of  five. 
From  the  results  in  Table  3.10  it  is  apparent  that  the  results  from  the  two  GC/MS's  are  not 
comparable.  For  GC/MS  A,  the  r2  value  was  0.983  with  a  gradient  of  0.604  and  for 
GC/MS  B,  the  r2  value  was  0.981  with  a  gradient  of  0.839.  In  addition,  the  LOD  using 
GC/MS  B  is  0.024  compared  to  0.06  using  GC/MS  A  for  MeOH  standards. 
In  theory,  all  method  development  should  be  carried  out  using  the  same  GCIMS,  however 
this  was  not  always  possible.  The  linearity  (indicated  by  r)and  limits  of  detection  are 
however,  good  enough  for  use  with  the  samples  involved  in  this  study. 
3.13.6  COMPAusON  of  SFE  AND  SPE 
3.13.6.1  EXPERIMENTAL 
A  comparison  between  SFE  and  SPE  was  made  to  check  that  the  same  results  were 
achieved  for  the  extraction  of  blood  using  the  two  methods. 
A  stock  blood  standard  was  prepared  by  pipetting  5  ml  of  1.2  mg/L  morphine  and  5  ml  of 
the  1:  10  diluted  d3-morphine  internal  standard  into  a  vial  and  evaporating  to  dryness  under 
a  stream  of  nitrogen.  Once  dry,  5  ml  of  blank  blood  was  pipetted  into  the  vial  and 
sonicated  at  room  temperature  for  three  minutes.  Three  extractions  were  carried  out  for 
each  method  (SFE  and  SPE)  using  the  methods  previously  described.  The  same 
concentration  was  extracted  in  each  case  and  an  unextracted  standard  in  MeOH  also 
injected  for  comparison. 
3.13.6.2  RESULTS  AND  DISCUSSION 
The  results  shown  in  Table  3.11  are  averages  of  three  injections  for  each  of  the  triplicate 
extracts. Chapter  Three:  Opiates  Pagel  17 
Table  3.11:  Comparison  of  SFE  and  SPE  for  the  Extraction  of  Morphine  from  Whole 
Blood 
m/z  ratio  429/432  m/z  ratio  414/429 
Unext.  Std.  1.186  0.549 
SFE  1  1.124  0.555 
SFE  2  1.152  0.554 
SFE  3  1.136  0.554 
SPE  1  1.292  0.561 
SPE  2  1.242  0.549 
SPE  3  1.121  0.535 
SFE  +  unextracted:  x=1.150±0.03,  RSD=2.34% 
SPE  +  unextracted:  x=1.210±0.07,  RSD=6.08% 
x=1.137±0.01 
RSD=1.24% 
x=1.218±0.09 
RSD=7.24% 
Both  methods  were  found  to  produce  similar  results  with  SFE  yielding  slightly  better 
reproducibility. 
3.13.7  EFFEcr  OF  DEtrvATTSATION  TIME 
3.13.7.1  EXPERIMENTAL 
The  effect  of  derivatisation  time  on  the  areas  of  morphine  and  d3-morphine  was 
investigated.  An  unextracted  standard  was  prepared  by  pipetting  100  µl  of  both  morphine 
and  d3-morphine  into  a  vial,  evaporating  to  dryness  and  adding  50  µ1  of  BSTFA  (1% 
TMCS).  After  15  minutes  of  derivatisation  at  90  °C,  an  injection  of  the  standard  was  made 
onto  the  GC/MS.  The  same  standard  was  reinjected  after  a  total  derivatisation  time  of  1 
hour. 
3.13.7.2  RESULTS  AND  DISCUSSION 
The  results  for  the  effect  of  derivatisation  on  the  peak  areas  of  morphine  and  d3-morphine 
are  shown  in  Table  3.12.  The  last  row  shows  the  relative  %  increase  in  peak  area  obtained 
by  increasing  the  derivatisation  time  from  15  minutes  to  1  hour. Chapter  Three:  Opiates  Pagel  18 
Table  3.12:  Effect  of  Derivatisation  Time 
Time  m/z  432  m/z  429  m/z  414  m/z  ratio 
429/432 
m/z  ratio 
414/429 
15  min.  2696164  3090318  1607642  1.146  0.520 
1  hour  84656264  100363992  58051708  1.186  0.578 
lhr/15min  3140%  3248%  3610% 
Although  the  414/429  and  429/432  m/z  ratios  are  the  same  for  the  two  derivatisation  times, 
and  thus  would  yield  the  same  analytical  results,  an  increase  of  greater  than  3000  %  is  seen 
simply  by  leaving  the  standards  derivatising  for  1  hour  as  opposed  to  the  stated  15  minutes. 
In  practice  this  is  not  always  practical  as  it  is  time  consuming  and  in  some  cases,  the 
samples  were  found  to  dry  in  the  vials  and  thus,  had  to  be  reconstituted  before  injection. 
This  step  incurs  a  decrease  in  the  recovery  of  the  samples. 
3.13.8  CONCLUSIONS  ON  METHOD  To  USE 
As  both  of  the  methods  investigated  yielded  good  results  for  the  extraction  of  both  MeOH 
standards  and  blood  standards,  it  was  decided  to  use  the  supercritical  method  as  opposed  to 
the  subcritical  method.  The  final  conditions  used  for  the  extraction  are  detailed  below: 
Extractant  Fluid:  C02:  MeOH:  Et3N  (90:  8.5:  1.5) 
Pressure:  3500  psi 
Temperature:  100  °C 
Support  Medium:  EtOH:  MeOH  washed  Extrelut® 
Flow  Rate:  2.0  ml  min' 
Extraction  Time:  20-30  minutes 
Collection  Solvent:  MeOH 
3.14  INTRODUCTION  OF  6MAM  INTO  THE  SFE 
As  the  purpose  of  this  study  was  to  investigate  heroin  related  deaths,  it  was  decided  to  look 
at  one  of  the  more  confirmatory  metabolites  of  diamorphine  namely,  6- 
monoacetylmorphine  (6MAM),  as  a  means  of  determining  if  the  death  was  heroin  or 
morphine  related. Chapter  Three:  Opiates  Pagel  19 
A  concentrated  solution  of  6MAM  was  prepared  by  pipetting  5  ml  of  a  13.3  mg/L  solution 
of  6MAM  in  MeOH  into  a  vial,  evaporating  to  dryness  under  N2  and  reconstituting  in  50  µl 
of  BSTFA  (1  %  TMCS).  This  solution  was  then  derivatised  for  15  minutes  at  90  °C  and 
run  full  scan  on  the  GC/MS  using  the  morphine  GC  parameters  to  determine  the  best  peaks 
to  look  for.  The  mass  spectrum  of  the  6MAM  peak  is  shown  in  Figure  3.6  and  from  this 
the  ions  m/z  340  and  m/z  400  were  initially  chosen. 
￿ 
5i:  6-MONOACETYLMORPHIME  +  BSTFA 
Formula: 
3.99 
3O 
73  /400  Y.  FS  43  287 
342  ?5i34 
253  { 
343  1.819  4 
r-2161 
M/z  100  200  300  400 
Figure  3.6:  Mass  Spectrum  of  BSTFA  Derivatised  6-Monoacetylmorphine 
3.14.1  DETERMINATION  OF  M/z  340/400  RATIO  FOR  VERIFICATION  PURPOSES 
3.14.1.1  EXPERIMENTAL 
A  set  of  standards  at  varying  concentrations  of  6MAM  from  0.67-2.66  mg/L  were  run 
through  the  GUMS  in  order  to  determine  the  ratio  of  340:  400  for  confirmation  of  positive 
6MAM.  d3-morphine  was  included  as  an  internal  standard  in  order  to  plot  a  calibration 
curve  for  the  concentrations  investigated. 
3.14.1.2  RESULTS  AND  DISCUSSION 
The  results  obtained  are  shown  in  table  3.13. Chapter  Three:  Opiates  Page  120 
Table  3.13:  Calculation  of  340/400  for  6MAM 
Vol.  (1)  m/z  ratio  400/432  m/z  ratio  340/400 
0  0  0 
50  0.135  2.34 
100  0.371  2.32 
150  0.513  2.28 
200  0.686  2.10 
From  this,  the  m/z  ratio  of  340/400  was  estimated  as  2.2. 
r2:  0.989 
A:  0.024 
B:  0.270 
This  experiment  was  also  carried  out  for  extracted  standards.  However,  the  samples  had  to 
be  left  in  the  refrigerator  for  one  week  while  routine  maintenance  was  carried  out  on  the 
GC/MS  and  on  analysis,  morphine  peaks  were  observed.  A  second  batch  of  6MAM 
standards  were  extracted  to  ensure  that: 
1)  The  6MAM  was  not  breaking  down  to  morphine  during  the  extraction 
2)  The  6MAM  was  not  effecting  the  extraction  of  morphine 
3.14.2  STABu.  rrY  OF  6MAM  IN  THE  SFE  SYSTEM  AND  ITS  EFFECT  ON  MORPHINE 
3.14.2.1  EXPERIMENTAL 
Two  sets  of  standards  were  prepared  as  previously  described.  The  first  had  the  various 
concentrations  of  6MAM  and  100  µl  of  d3-morphine  and  the  second  was  as  above  but  also 
had  100  µL  of  morphine  added  to  each  sample. 
3.14.2.2  RESULTS  AND  DISCUSSION 
The  results  for  the  extractions  are  shown  in  Table  3.14. Chapter  Three:  Opiates  Page  121 
Table  3.14:  Extraction  of  6MAM  With  and  Without  Morphine 
Without  Morphine 
Concc 
(m  /L) 
m/z  ratio 
340/400 
m/z  ratio 
400/432 
m/z  ratio 
429/432 
m/z  ratio 
414/429 
0  0  0  - 
0.67  Sample  dried  in  vial 
1.33  2.860  0.148  0  - 
2.00  2.757  0.340  0  - 
2.66  2.792  0.629  0  - 
With  Morphine 
0  -  -  0.896  0.555 
0.67  2.735  0.169  0.925  0.560 
1.33  2.729  0.224  0.990  0.548 
2.00  2.699  0.672  0.934  0.553 
2.66  2.453  0.996  0.837  0.562 
For  the  three  points  obtained  for  the  6-MAM  without  morphine:  r2:  0.986,  A:  -0.349,  B: 
0.361 
For  the  extractions  with  morphine:  r2:  0.932,  A:  -0.220,  B:  0.441 
The  presence  of  6MAM  does  not  appear  to  effect  the  extraction  of  morphine.  In  addition, 
no  morphine  was  observed  for  the  6MAM  and  d3-morphine  extractions  and  thus,  the 
extraction  conditions  are  not  causing  the  6MAM  to  degrade  to  morphine. 
3.14.3  INVESTIGATION  OF  MORPHINE  GLUCURONIDE 
In  addition  to  investigating  the  6MAM  it  was  also  decided  to  see  whether  or  not  the 
morphine  glucuronide  was  being  broken  down  to  morphine  during  the  SFE  process.  This 
degradation  could  result  in  artificially  high  results  obtained  by  SFE  compared  to  the  SPE 
method  which  does  not  break  down  the  glucuronide. 
3.14.3.1  EXPERIMENTAL 
A  200  µl  aliquot  of  a  7.65  mg/L  morphine  glucuronide  sample  prepared  in  water,  was 
loaded  onto  Extrelut®  and  extracted.  The  extract  was  dried  under  nitrogen,  derivatised  and 
injected  onto  the  GC/MS. Chapter  Three:  Opiates  Page  122 
3.14.3.2  RESULTS  AND  DISCUSSION 
Peaks  for  both  morphine  and  d3-morphine  were  observed.  As  no  d3-morphine  had  been 
added  to  the  standard  at  any  stage  it  was  assumed  that  either  the  glucuronide  standard  was 
contaminated  or  the  system  was  contaminated  as  had  been  observed  previously  for  the 
benzodiazepines.  The  outlet  tubing  of  the  system  was  changed.  The  replacement  tubing 
had  a  narrower  internal  diameter  and  thus  provided  additional  restriction  at  the  flow  outlet. 
A  second  standard  of  morphine  glucuronide  from  a  fresh  bottle  was  also  prepared.  This 
time  the  concentration  was  5.76  mg/L 
3.14.4  EXTRACTION  WITH  FRESH  MORPHINE  GLUCURONIDE 
3.14.4.1  EXPERIMENTAL 
A  blank  MeOH  extraction  was  carried  out  to  determine  if  there  was  any  carry  over  in  the 
remainder  of  the  instrumentation.  As  this  was  negative,  an  extraction  of  200  µ1  of  the  new 
morphine  glucuronide  standard  was  carried  out.  No  peaks  were  seen  for  morphine  or  d3- 
morphine  thus,  the  glucuronide  is  not  being  broken  down  to  free  morphine  by  the 
extraction  process  and  the  results  obtained  from  SFE  and  SPE  should  be  directly 
comparable. 
Several  case  samples  were  run  to  see  whether  the  results  which  were  being  obtained  were 
in  agreement  with  those  seen  by  SPE.  The  results  are  shown  in  section  6.4.1.2. 
3.14.5  CHECK  OF  SFE  CONDITIONS  FOR  THE  DETERMINATION  OF  MORPHINE  AND  6MAM 
3.14.5.1  EXPERIMENTAL 
The  following  samples  were  prepared  for  extraction  in  order  to  check  for  carryover  and  as  a 
final  check  on  whether  or  not  the  6MAM  was  being  broken  down  to  morphine  and/or 
effecting  the  morphine  results: 
A)  6MAM:  0,50,100,150,200  µl  +  100  µl  d3-morphine 
B)  6MAM:  0,50,100,150,200  µl  +  100  µl  morphine  +  100µl  d3-morphine 
C)  Morphine:  0,50,100,150,200  µl  +  100  µl  d3-morphine. Chapter  Three:  Opiates  Page  123 
3.14.5.2  RESULTS  AND  DISCUSSION 
The  results  from  these  sets  of  extractions  are  shown  in  Table  3.15  on  page  132.  As  can  be 
seen  from  the  results  there  is  significant  carryover  from  extraction  to  extraction  as 
indicated  in  bold.  The  system  was  again  flushed  out  and  an  extraction  of  morphine  and  d3- 
morphine  was  carried  out  successfully  with  no  carryover  6MAM  peaks. 
In  addition  to  flushing  out  the  system,  the  outlet  tubing  was  further  investigated.  The 
narrower  bore  tubing  was  not  providing  a  sufficient  restriction  (which  is  indicated  by  the 
collection  solution  becoming  cold).  In  order  to  achieve  better  restriction,  it  would  be  ideal 
to  use  GC  capillary  tubing  as  a  restrictor.  GC  capillary  tubing  was  housed  inside  a  piece  of 
stainless  steel  tubing  and  connected  to  the  flow  outlet.  By  using  this  method,  it  was  easier 
to  change  the  outlet  tubing  more  frequently  thus  decreasing  any  contamination  risk. Chapter  Three:  Opiates 
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3.14.6  INVESTIGATION  OF  M/Z  399  PEAK  FOR  VERIFICATION  PURPOSES 
3.14.6.1  EXPERIMENTAL 
In  addition  to  the  m/z  400  peak,  the  6MAM  also  has  a  m/z  399  peak  which  is  stronger  than 
the  m/z  400  peak.  As  opposed  to  the  m/z  340  and  m/z  400  being  used  for  the  quantitation 
of  6MAM,  the  m/z  399  and  m/z  340  peaks  were  investigated.  The  following  mixes  of 
standards  were  analysed  by  GC/MS.  Both  unextracted  and  extracted  standards  were 
injected. 
A)  6MAM  only 
B)  6MAM  +  d3-morphine 
C)  Morphine  glucuronide  only 
D)  Morphine  glucuronide  +  d3-morphine 
E)  Morphine  only 
F)  Morphine  +  d3-morphine 
3.14.6.2  RESULTS  AND  DISCUSSION 
The  results  obtained  for  the  six  standard  mixes  are  shown  in  Table  3.16. 
Table  3.16:  Unextracted  and  Extracted  Standard  Mixes 
Unextracted 
Run  m/z 
432 
m/z 
429 
m/z 
414 
m/z 
399 
m/z 
340 
429/ 
432 
414/ 
429 
340/ 
399 
340/ 
432 
A  -  -  -  161349  141142  -  -  0.875  - 
B  599159  -  26044  157900  147965  -  -  0.937  0.247 
C  -  -  -  -  -  -  -  D  38703  -  -  -  -  - 
E  8632  293200  137351  -  -  33.97  0.468  -  -  F  427511  345231  182786  -  -  0.808  0.529  -  - 
Extracted 
A 
B  31013  -  -  17501  16879  -  -  0.964  0.544 
C  -  8279  8603  -  -  -  1.039  -  -  D  7228  13359  7163  -  -  1.848  1.284  -  -  E  -  9166  17840  -  -  -  0.855  -  -  F  13317  15139  6208  -  -  1.137  0.410  -  - Chapter  Three:  Opiates  Page126 
From  these  results  it  appears  that  the  contamination  problems  have  been  reduced.  The  only 
carry  over  peak  appears  to  be  in  the  unextracted  morphine  run.  d3-morphine  is  observed  at 
a  low  concentration.  The  extracted  6MAM  yielded  no  peaks,  however  a  high  pressure 
blockage  occurred  during  the  extraction  and  thus  some  sample  may  have  been  lost.  Peaks 
were  seen  at  414  and  429  for  both  glucuronide  extracts.  However,  the  ratio  of  the  peaks 
were  found  to  be  1.039  and  1.284  which  means  that  they  are  not  due  to  morphine.  No 
corresponding  peaks  were  seen  in  the  unextracted  glucuronide. 
3.14.7  LINEARrrY  AvD  LOD  FOR  6MAM 
3.14.7.1  EXPERIMENTAL 
The  linearity  and  limit  of  detection  were  calculated  for  6MAM.  The  initial  stock  standard 
had  a  concentration  of  1.33  mg/100  ml.  This  was  diluted  1:  10  with  methanol  and  this 
solution  (1.33  mg/L)  was  used  as  the  starting  concentration  for  the  linearity  with  100  tL  of 
d3-morphine.  Serial  dilutions  of  this  solution  were  made  down  to  a  concentration  of  0.665 
µg/L. 
3.14.7.2  RESULTSAND  DISCUSSION 
The  results  obtained  for  the  linearity  of  6MAM  are  given  in  Table  3.17. 
Table  3.17:  Linearity  and  Limit  of  Detection  for  6MAM 
6-MAM 
(m  /L) 
m/z  ratio 
340/432 
m/z  ratio 
340/399 
0.000665  -  - 
0.00133  -  - 
0.00655  0.00142  0.323 
0.0133  0.00293  0.587 
0.0655  0.0113  0.606 
0.133  0.0282  0.627 
0.655  0.1084  0.641 
1.33  0.421  0.599 Chapter  Three:  Opiates  Page127 
From  these  results  the  limit  of  detection  (where  no  399  ion  is  present)  was  taken  as  1.33 
ng/ml  and  the  limit  of  quantitation  as  6.65  ng/ml.  The  range  of  linearity  is  from  6.65  -  665 
ng/ml  (r2  =  0.999,  y=0.157  x+0.003,  (y=Bx+A)) 
3.15  CONCLUSIONS 
From  the  work  carried  out  in  this  section  the  conditions  chosen  for  the  extraction  of 
morphine  and  6-monoacetylmorphine  were  as  follows: 
Support  medium:  Extrelut® 
Extractant  Phase:  C02:  MeOH  :  Et3N  (90:  8.5:  1.5) 
Temperature:  100  °C 
Pressure:  3500  psi 
Flowrate:  2.0  ml  min-' 
Extraction  Time:  30  minutes 
Collection  Solvent:  MeOH 
Analysis  Technique:  GC/MS  (SIM) 
Derivatisation:  BSTFA  (1  %TMCS)  at  90  °C  for  15  minutes 
The  samples  were  prepared  as  for  the  benzodiazepines  by  loading  100  µl  of  the  samples 
onto  Extrelut®  and  drying.  The  method  was  found  to  be  reproducible  and  yield  high 
recoveries.  Again,  the  solvent  usage  was  reduced,  this  time  the  total  volume  required  per 
extraction  was  6  ml  (c.  f.  27  ml  for  the  SPE  method).  The  results  of  case  samples  analysed 
using  this  methodology  are  given  in  Chapter  6. 711111'a  ickr-picult-LI 
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4.  METHADONE 
4.1  INTRODUCTION 
The  discovery  of  methadone  has  been  attributed  to  two  German  scientists  Max  Bockmühl 
and  Gustav  Ehrhart.  138  The  drug  was  first  created  in  1937  and  was  initially  given  the  name 
Hoechst  10820  which  was  later  changed  to  polamidon.  The  patent  application  for 
methadone  was  filed  in  September  1941.  Although,  the  new  compounds'  structure  had  no 
resemblance  to  morphine,  its  analgesic  and  spasmolytic  properties  were  ascertained  in  1942 
when  it  was  handed  over  to  the  military  under  the  code  name  Amidon®.  At  this  point  its 
use  was  not  exploited  to  a  great  extent  due  to  side  effects,  which  were  later  attributed  to  the 
dosage  being  too  high.  139 
In  1947,  Isbell  et  al  published  experimental  work  on  methadone  stating  that  morphine 
addicts  responded  very well  to  the  properties  of  methadone,  but  unless  the  manufacture  and 
use  were  controlled,  then  addiction  to  it  would  become  a  serious  health  problem.  140 
Despite  this,  early  advertisements  in  the  UK  claimed  little  chance  of  addiction  and  the 
general  consensus  was  that  it  was  a  better  analgesic  than  morphine. 
In  1955,  the  Home  Office  were  aware  of  only  21  methadone  addicts  with  this  figure  rising 
to  60  in  1960.141  In  1968  with  the  introduction  of  the  Home  Office  Notification  System, 
297  methadone  addicts  were  registered  and  an  even  larger  increase  was  observed  by  1969 
with  the  introduction  of  new  drug  clinics  (1687  addicts  registered).  Prior  to  the  1970's, 
addiction  maintenance  was  mainly  in  the  form  of  prescribing  the  abused  drug  to  the  patient 
at  clinics.  However,  the  dramatic  increase  in  the  number  of  heroin  addicts  throughout  the 
1970's  and  1980's  promoted  a  change  from  this  to  the  prescription  of  oral  methadone  as  a 
means  of  addiction  maintenance.  142  At  present  in  the  UK,  most  Health  Authorities  have  a 
methadone  prescribing  service  of  some  kind.  All  GP's  have  the  right  to  prescribe 
methadone  and  more  than  half  of  all  methadone  addicts  known  to  the  Home  Office  are  via 
GP's. Chapter  Four:  Methadone  Page  129 
4.2  PRESCRIPTION 
Methadone  is  prescribed  mainly  for  the  treatment  of  opiate  addiction,  *  however  it  is 
available  as  a  linctus  which  is  used  for  the  treatment  of  coughing  in  terminal  illness.  There 
are  five  preparations  of  methadone: 
"  Liquid  Methadone  lmg/lml 
This  is  the  treatment  of  choice  for  opiate  dependency.  '43  It  is  available  as  a 
pre-prepared  solution  or  as  concentrate  which  is  diluted  at  the  pharmacy. 
9  Methadone  Linctus  2mg/5m1 
9  This  is  a  general  medicine  licensed  in  the  UK  for  the  treatment  of  coughing  in 
terminal  illness.  It  is  not  usually  prescribed  for  the  treatment  of  opiate  dependency. 
"  Methadone  5mg  tablets  -  Physeptone® 
This  is  not  licensed  for  the  treatment  of  opiate  dependency  and  prescription  is 
discouraged  due  to  the  possibility  of  crushing  and  injecting  the  tablets. 
9  Methadone  Suppositories 
These  are  rarely  used  in  the  treatment  of  dependency  again  due  to  the  possibility  of 
injection 
"  Injectable  Methadone  10mg/ml 
This  is  prescribed  for  subcutaneous  or  intramuscular  injection.  However,  when 
obtained  illicitly  it  is  usually  used  intravenously. 
4.3  CHEMICAL  STRUCTURE 
Methadone  (6-dimethylamino-4,4-diphenyl-3-heptatone)  has  a  relatively  simple  structure 
and  has  a  complex  and  powerful  range  of  effects  on  those  who  take  it.  The  structure  of 
methadone  is  shown  in  Figure  4.1. 
CH3-  CH2-  C  -C  -9  CH2-CH-  N/CHF 
U 
0  CH3 
SCH:, 
Methadone 
Figure  4.1:  Structure  of  Methadone Chapter  Four:  Methadone  Page  130 
Structurally,  methadone  appears  to  have  two  active  regions: 
"  The  nitrogen  atom,  which  is  thought  to  act  on  the  peripheral  nervous  system 
"  The  two  phenyl  rings,  which  are  thought  to  be  necessary  for  its  opiate  like  action  on  the 
central  nervous  system. 
4.4  PHARMACOLOGY 
The  pharmacology  of  methadone  is  very  similar  to  that  of  the  opiates  (section  3.4).  When 
used  for  the  treatment  of  opiate  addiction,  the  feeling  "on  methadone"  is  often  described  as 
an  absence  of  withdrawal  symptoms.  The  increase  in  anxiety  and  psychological  discomfort 
experienced  by  many  detoxification  programme  patients,  compared  to  methadone 
maintenance  patients,  suggests  that  methadone  contributes  to  a  sense  of  relief  from  distress. 
4.5  METABOLISM 
Methadone  is  rapidly  absorbed  following  oral  administration  and  is  widely  distributed  in 
tissues  with  higher  concentrations  in  the  liver,  lungs,  kidneys  and  spleen  than  in  the  blood. 
It  undergoes  extensive  first  pass  metabolism  and  the  main  metabolic  reaction  is  N- 
demethylation,  which  results  in  a  substance  which  instantly  cyclizes  to  form  methadones' 
two  major  metabolites,  2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine  (EDDP)  and  2- 
ethyl-5-methyl-3,3-diphenyl-l-pyrrolidine  (EMDP),  neither  of  which  is  active. 
Hydroxylation  to  methadol  followed  by  N-demethylation  to  normethadol  also  occurs  to 
some  extent.  Other  minor  metabolic  reactions  also  occur  and  there  are  at  least  8  known 
metabolites. 
The  principle  metabolic  route  of  methadone  is  shown  in  Figure  4.2. Chapter  Four:  Methadone  Page  131 
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Figure  4.2:  Metabolic  Route  of  Methadone 
4.6  PHARMACOKINETICS 
In  subjects  on  methadone  maintenance,  20-60%  of  a  dose  is  excreted  in  urine  within  24 
hours  with  up  to  33%  as  unchanged  methadone,  43%  as  EDDP  and  5-10%  as  EMDP.  The 
half  life  of  methadone  is  very  much  dependant  on  the  type  of  dosing  due  to  its  high  affinity 
for  tissue  in  the  lungs,  kidneys  and  liver.  For  a  single  dose,  the  half  life  of  methadone  is 
between  12-18  hours  (mean  15  hours)  and  for  multiple  dosing  the  half  life  is  between  13- 
47  hours  (mean  25  hours).  144  The  estimated  LD50  for  methadone  is  50  mg,  however 
tolerance  to  the  drug  may  build  up,  albeit  slowly  compared  to  the  other  opiates,  and  doses 
of  200  mg  or  more  may  be  withstood.  Other  pharmacokinetic  parameters  for  methadone 
are  given  below: 
VD:  5  L/kg 
Cl:  2  mUmin/kg  plasma 
Plasma  :  whole  blood  distribution:  1.3 
Protein  binding:  up  to  90% Chapter  Four:  Methadone  Page  132 
4.7  LEGAL  STATUS 
Methadone  (Physeptone)  is  a  Class  A  drug  which  is  listed  under  Schedule  2  of  the  Misuse 
of  Drugs  Act.  This  means  that  it  is  illegal  to  possess  methadone  without  a  prescription  or 
other  authority. 
4.8  ANALYSIS  OF  METHADONE 
As  with  the  other  two  groups  of  drugs,  a  literature  review  was  carried  out  on  previously 
used  methadone  extraction  and  analysis  methods.  As  with  the  analysis  for  diamorphine 
and  its  metabolites,  the  method  of  choice  for  the  analysis  of  methadone  is  GC/MS  with 
SIM. 
Table  4.1  provides  a  review  of  the  analysis  and  extraction  methods  for  methadone. 
Table  4.1:  Methadone  Analysis 
Year  Analysis 
Technique 
Extraction 
Technique 
Sample  Type  Sample  Volume 
145  1972  GC-FID  LLE  Plasma/  Urine  4/0.5-2  ml 
1975 
146  GC-ECD  LLE  Serum  <2  ml 
1977 
147  GC-FID  LLE  Blood/  Urine/ 
Stomach  contents/ 
Bile/  Tissue 
5/5/2.52.5  ml/ 
2.5g 
148  1977  GC/MS  LLE  Plasma/  Urine  1  ml  149  1981  GC-NPD  LLE  Blood/  Plasma/  Urine  1  ml 
19,82  GC-MS  LLE  Plasma/  Saliva/  Urine  0.5/0.5/1  ml  151  1987  HPLC  LLE  Blood/  Liver/  Brain  2  ml/250/500  mg 
1996 
152  HPLC  SPE  Serum  5  ml 
1996 
153  LC-MS  SPE  Blood  1  ml 
1997  CE  LLE  Serum/  Urine/  Hair  1/1  ml/50  m 
4.9  SFE  ANALYSIS  OF  METHADONE 
No  methodology  was  found  to  be  available  on  the  supercritical  analysis  of  methadone  or  its 
metabolites  other  than  for  hair.  This  will  be  discussed  in  Chapter  5 Chapter  Four:  Methadone 
4.10  STATUS  OF  CASES 
Page  l 
Figure  4.3  shows  the  number  of  toxicology  cases  in  which  methadone  was  found  over  the 
time  period  1992  to  1997. 
a) 
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Figure  4.3:  Methadone  Related  Deaths 
In  comparing  this  to  the  previous  morphine  related  death  figures,  a  trend  between  the 
decrease  in  morphine  fatalities  and  the  onset  of  methadone  maintenance  programmes  is 
apparent. 
4.11  CURRENT  METHODOLOGY 
For  the  analysis  of  methadone,  the  routine  method  used  in  the  Forensic  Science  Laboratory 
was  liquid-liquid  extraction  as  detailed  below.  This  methodology  was  used  as  a 
comparison  with  SFE. 
Into  a  screw  capped  test-tube,  I  ml  of  pH  10  carbonate  buffer  (1  M  Na-,  COz,  IM  NaHCO1), 
1  ml  of  blood,  100  µl  of  cyclizine  standard  and  5  ml  of  EtAc  were  pipetted.  The  test-tube 
was  capped  and  rock  and  rolled  for  15  minutes  then  centrifuged  for  10  minutes.  The  EtAc 
layer  was  then  transferred  to  a  clean  test-tube  and  2  ml  of  0.2  M  HCl  added.  This  test-tube 
was  then  rocked  and  rolled  and  centrifuged  as  before.  The  EtAc  layer  was  then  discarded. 
The  acid  layer  was  basified  by  the  addition  of  2  ml  of  pH  10  carbonate  buffer.  3  ml  of 
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EtAc  were  also  added  at  this  stage.  The  rock  and  roll,  centrifuge  step  was  again  repeated. 
Finally,  the  EtAc  layer  was  transferred  to  a  vial  and  evaporated  to  dryness  under  N2  and  the 
residue  reconstituted  in  20  µl  of  EtAc.  A1  µl  aliquot  of  this  was  injected  onto  GC. 
4.12  EXPERIMENTAL 
4.12.1  ANALYSIS  INSTRUMENTATION 
Methadone  method  development  was  initially  carried  out  using  a  Hewlett  Packard  5890 
Series  II  GC  with  flame  ionisation  detection  (FID)  using  cyclizine  as  the  internal  standard. 
The  GC  conditions  were  as  follows: 
Column:  HP5 
Initial  Temperature:  100  °C 
Rate:  10  °C/min 
Final  Temperature:  300  °C 
Injection  Temperature:  280  °C 
Detector  Temperature:  300  °C 
Equilibration  Time:  0.2  minutes 
Using  these  conditions,  the  methadone  eluted  at  19  minutes  which  meant  that  the  run  time 
was  very  long.  For  this  reason,  the  initial  temperature  was  changed  to  120  °C  which  eluted 
the  methadone  at  15.4  minutes  and  the  cyclizine  at  13.9  minutes  which  is  still  too  long. 
The  run  time  was  decreased  by  changing  the  conditions  to  the  following: 
Initial  Temperature:  150  °C  for  1  minute 
Rate:  10  °C  /minute 
Final  Temperature:  300  °C  for  5  minutes 
The  injector  and  detector  temperatures  and  the  equilibration  time  were  kept  constant. Chapter  Four:  Methadone  Page135 
With  these  conditions,  the  methadone  eluted  at  12.8  minutes  and  the  cyclizine  at  11.6 
minutes  which  was  satisfactory. 
4.12.2  GC  INJECTION  REPRODUCIBILITY 
4.12.2.1  EXPERIMENTAL 
In  order  to  check  the  injection  reproducibility  of  the  GC-FID  system,  five  injections  of 
methadone  (10.4  . tg/m1)  and  cyclizine  (10.1  tg/m1)  were  made. 
4.12.2.2  RESULTS  AND  DISCUSSION 
The  injection  reproducibility  results  for  five  injections  are  shown  in  Table  4.2. 
Table  4.2:  Injection  Reproducibility  for  Methadone  and  Cyclizine 
Methadone  Area  Cyclizine  Area  PAR  (Meth/C  cl) 
8306  10569  0.786 
7142  9141  0.781 
7210  6426  0.765 
6779  8690  0.780 
5414  7276  0.744 
For  the  results  in  't'able  4.2,  the  mean  PAR  was  0.771  with  an  RSD  of  2.2%  which  is 
acceptable  for  this  work  at  present. 
4.12.3  ExTRACTIoN  OF  METHADONE  USING  E'rAc  AS  A  MODIFIER 
4.12.3.1  EXPERIMENTAL 
Extractions  were  carried  out  using  ethyl  acetate  as  a  modifier  at  0%,  1%,  5%  and  10%  in 
CO2.  For  each  percentage  of  EtAc,  100  µl  of  methadone  (10.4  µg/ml)  and  cyclizine  (10.1 
µg/ml)  in  MeOH  were  loaded  onto  C18  and  Extrelut®  and  extractions  carried  out  from  each 
support.  The  pressure  for  the  extractions  was  2500  psi,  the  temperature  60  °C  and  the 
flowrate  2.0  ml  mini  1.  The  extraction  time  was  30  minutes.  The  collected  extracts  were 
evaporated  to  dryness  under  N2  and  reconstituted  in  20  µl  of  EtAc. Chapter  Four:  Methadone  Page136 
4.12.3.2  RESULTS  AND  DISCUSSION 
The  runs  at  0,1  and  5%  were  negative  for  both  methadone  and  cyclizine.  The  run  at  10% 
gave  small  peaks  for  both  drugs  from  both  Extrelut  and  C18.  The  standard  methadone  and 
cyclizine  had  to  be  reconcentrated  before  being  observed  on  the  FID  therefore,  if  the 
extraction  efficiency  is  poor  then  no  peaks  would  be  observed  even  if  they  were  present. 
The  unextracted  standards  were  concentrated  10:  1  compared  to  the  reconstitution  of  the 
extracted  standards:  500  µl  -+  20  µl  (5:  1). 
4.12.4  EXTRACTION  OF  METHADONE  BY  SFE  USING  MEOH  AS  A  MODIFIER 
4.12.4.1  EXPERIMENTAL 
The  modifier  was  changed  to  MeOH  and  extractions  carried  out  at  0,2,4,6,8  and  10% 
MeOH  in  CO2.  These  extractions  were  carried  out  using  C8  as  a  support  medium.  500  µl 
of  methadone  (10.4  µg/ml)  and  cyclizine  (10.1  µg/ml)  were  loaded  onto  the  contents  of  a 
C8  SPE  column  and  dried  at  room  temperature.  The  pressure  for  the  extractions  was  3500 
psi,  at  a  temperature  of  60  °C  and  a  flowrate  of  2.0  ml  min  1  for  30  minutes.  The  collected 
extracts  were  evaporated  to  dryness  and  reconstituted  in  20  µl  of  EtAc. 
4.12.4.2  RESULTS  AND  DISCUSSION 
The  results  for  the  extraction  of  methadone  and  cyclizine  using  MeOH  as  a  modifier  at 
various  percentages  in  CO2  are  shown  in  Table  4.3. 
Table  4.3:  Extraction  of  Methadone  and  Cvclizine  Usim  MeOH  as  a  Modifier 
Run  R.  T. 
Methadone 
(min) 
Area 
Methadone 
R.  T.  Cyclizine 
(min) 
Area  Cyclizine 
Unextracted  12.792  7738  11.559  9585 
0%  McOH 
2%  McOH  /  /  /  / 
4%  MeOH  /  /  11.570  1220 
6%  MeOH  /  /  11.590  483 
8%  McOH  /  /  /  / 
10%  McOH  /  /  11.603  1109 Chapter  Four:  Methadone  Page  137 
As  can  be  seen  from  these  results,  the  extraction  conditions  are  not  of  use  for  the  extraction 
of  methadone  or  cyclizine. 
4.12.5 
- 
EXTRACTIONS  FROM  C8 
4.12.5.1  EXPERIMENTAL 
Four  extractions  were  carried  out  using  C8  as  a  support  medium.  In  each  case  the  pressure 
was  2500  psi,  the  temperature  60  °C  and  the  flowrate  2.0  ml  miri  1.10%  MeOH  was  used 
as  a  modifier. 
4.12.5.2  RESULTS  AND  DISCUSSION 
The  results  are  shown  in  Table  4.4. 
Table  4.4:  Extractions  from  C$  at  2500  psi 
Run  Area 
Methadone 
R.  T. 
Methadone 
Area 
Cyclizine 
R.  T. 
Cyclizine 
PAR  (M/C) 
1  1445  12.836  1032  11.597  1.400 
2  5144  12.883  506  11.596  10.167 
3  0  /  1604  11.582  0 
4  2085  12.815  8578  11.571  0.243 
From  Table  4.4  it  can  be  calculated  that  the  PAR  of  the  unextracted  standard  is  (0.807), 
thus  the  method  is  not  extracting  methadone  and  cyclizine  to  the  same  extent.  A 
requirement  of  the  developed  method  is  that  the  drug  of  interest  (methadone  in  this  case) 
and  the  internal  standard  (cyclizine)  are  extracted  to  the  same  extent  and  thus,  further 
method  development  was  necessary. 
In  addition,  the  GC  traces  were  very  dirty  and  thus  the  peaks  seen  at  12.8  and  11.6  minutes 
may  not  be  due  to  methadone  and  cyclizine. Chapter  Four:  Methadone  Page138 
4.12.6  DETERMINATION  OF  INTERFERING  SYSTEM  PEAKS 
4.12.6.1  EXPERIMENTAL 
Two  EtAc  blanks  were  extracted  using  these  same  conditions  to  determine  if  the  peaks  at 
11.6  and  12.8  minutes  could  be  due  to  the  support  medium.  The  extraction  traces  were  still 
quite  dirty  but  no  peaks  were  seen  which  would  coelute  with  methadone  or  cyclizine. 
In  order  to  clean  up  the  extraction  and  determine  how  long  the  extraction  would  have  to  be 
run  for,  collections  were  made  from  0-5  minutes,  5-10  minutes  and  then  for  0-10  minutes 
for  comparison. 
4.12.6.2  RESULTS  AND  DISCUSSION 
The  0-5  minutes  extract  showed  peaks  at  11.566  minutes  (PA:  2066)  and  12.802  minutes 
(PA:  2102)  which  would  correspond  to  cyclizine  and  methadone  respectively.  The  PAR  of 
methadone  to  cyclizine  was  1.017.  In  total  9  peaks  were  integrated,  with  the  trace  being 
less  noisy  than  previously  seen. 
The  5-10  minutes  extract  again  had  peaks  at  11.547  minutes  (PA:  5398)  and  12.802  minutes 
(PA:  3633)  and  this  time  only  5  peaks  were  integrated  and  the  PAR  of  methadone  to 
cyclizine  was  0.673. 
The  combined  areas  for  0-5  and  5-10  minutes  were  7464  for  cyclizine  and  5734  for 
methadone  giving  a  PAR  of  0.768.  This  compares  well  to  the  unextracted  standard  ratio  of 
0.807. 
The  0-10  minute  extraction  recovered  less  than  the  5-10  minute  extraction  but  more  than 
the  0-5  minutes  extraction  with  cyclizine  at  11.552  minutes  (PA:  4352)  and  methadone  at 
12.789  minutes  (PA:  2383)  and  a  PAR  of  0.548  Nine  peaks  were  integrated  and  there  was 
more  baseline  noise  than  with  the  0-5  minute  extraction. Chapter  Four:  Methadone  Page  139 
4.12.7  EXTRACTION  OF  METHADONE  USING  THE  BENZODIAZEPINE  SFE  CONDITIONS 
4.12.  %1  EXPERIMENTAL 
Methadone  and  cyclizine  were  extracted  using  the  benzodiazepine  extraction  conditions 
but  at  a  temperature  of  58  °C  Three  extractions  were  carried  out  and  injected  onto  the  GC 
along  with  an  unextracted  standard  at  the  same  concentration. 
4.12.7.2  RESULTSAND  DISCUSSION 
Large  peaks  were  observed  at  14.7  minutes  and  16.0  minutes  but  none  corresponding  to  the 
methadone  (12.811  minutes,  PA  5731)  and  cyclizine  (11.584  minutes,  PA  :  7687)  of  the 
unextracted  standard  (PAR  :  0.746). 
It  was  initially  thought  that  the  methadone  and  cyclizine  had  deteriorated  as  they  had  been 
loaded  onto  the  C8  for  4  days.  Fresh  standards  were  prepared  on  C8  and  these  were 
extracted  under  the  same  conditions.  However,  the  same  two  peaks  were  observed  and  no 
peaks  at  11.6  or  12.8  minutes. 
C8  was  extracted  on  its  own  to  see  if  the  peaks  were  due  to  the  support  medium.  The  peaks 
were  again  observed.  However,  as  the  peaks  are  not  coeluting  with  the  methadone  or 
cyclizine  its  was  decided  to  keep  using  the  C8  as  a  support  medium  as  it  had  yielded  the 
best  results  to  date. 
4.12.8  EXTRACTIONS  USING  ETAC  AND  C8 
4.12.8.1  EXPERIMENTAL 
A1  ml  aliquot  of  each  of  the  standards  was  loaded  onto  the  contents  of  three  C8  SPE 
columns,  which  had  been  emptied  into  a  weighing  boat.  Five  extractions  were  carried  out 
using  this  support. 
(1)  10%  EtAc,  1  ml  miri  1,65  °C,  3000  psi 
(2-5)  5%  EtAc:  2  ml  mini  1,65  °C Chapter  Four:  Methadone  Page140 
For  extractions  1,2,3  and  4,  the  extraction  vessels  were  filled.  For  extraction  5  there  was 
only  enough  silica  to  half  fill  the  extraction  vessel.  No  methadone  or  cyclizine  was 
extracted  for  any  of  the  runs. 
4.12.9  Ex  RAc  0NS  wrFH  ETAC  AND  C8  CONTINUED 
4.12.9.1  EXPERIMENTAL 
The  following  extractions  were  run  in  duplicate  with  100  tl  methadone  and  cyclizine 
standards  from  C8: 
(1)  5%  EtAc:  2  ml  miri  1,65  °C,  3000  psi 
(2)  10%  EtAc,  2m1  mini',  65  °C,  3000  psi 
(3)  15%  EtAc,  2  ml  miri  t,  65  °C,  3000  psi 
Again,  no  methadone  or  cyclizine  were  recovered. 
4.12.10  EXTRACTIONS  USING  ALTERNATIVE  SUPPORTS 
4.12.10.1  EXPERIMENTAL 
The  next  set  of  duplicate  extractions  were  carried  out  using  various  different  supports  at 
5%  EtAc: 
(1)  DCM  washed  silica  gel 
(2)  Unwashed  silica  gel 
(3)  C8 
(4)  DCM  washed  Extrelut® 
None  of  these  extractions  recovered  methadone  or  cyclizine. Chapter  Four:  Methadone  Pagel4l 
4.12.11  CHECK  OF  SFE  SYSTEM 
At  this  point  the  benzodiazepines  extraction  was  checked  to  see  if  the  system  was 
functioning.  The  drugs  were  extracting  but  the  recoveries  were  poor.  Modifications  to  the 
system  were  made  using  the  benzodiazepines  (see  section  2.15.6)  and  once  it  was 
functioning  satisfactorily,  method  development  of  methadone  was  continued  as  follows. 
4.12.11.1  EXPERIMENTAL 
Two  methadone  and  cyclizine  extractions  were  carried  out  at  67  'C,  3000  psi  and  5%  EtAc 
and  four  at  10%  EtAc. 
4.12.11.2  RESULTS  AND  DISCUSSION 
The  results  are  shown  in  Table  4.5 
Table  4.5:  Extractions  at  67  °C.  3000  psi  and  5%  EtAc 
%  EtAc  R.  T. 
Methadone 
(minutes) 
Area 
Methadone 
R.  T. 
Cyclizine 
(minutes) 
Area 
Cyclizine 
PAR 
Std  12.785  40660  11.341  41472  0.980 
5  12.773  21327  11.341  37754  0.565 
5  /  0  11.618  16316  / 
10  12.805  7423  11.365  13341  0.556 
10  12.672  10970  11.369  14194  0.773 
10  /  0  11.321  5758  / 
10  /  0  11.346  6844  / 
The  first  10%  EtAc,  3000  psi,  67  °C  extraction  gave  the  closest  PAR  to  the  unextracted 
standard  with  27%  and  34%  recoveries  for  methadone  and  cyclizine  respectively.  The 
other  two  10%  EtAc  extractions  were  unsuccessful. 
4.12.12  SYSTEM  FLUSH 
After  being  left  over  the  weekend,  the  SFE  was  flushed  with  EtAc  to  see  if  there  was  any 
remaining  methadone  or  cyclizine  in  the  system.  The  flush  was  very  dirty  with  23  peaks Chapter  Four:  Methadone  Page142 
observed  and  small  peaks  were  seen  corresponding  to  methadone  (12.818  minute  PA: 
1540)  and  cyclizine  (11.318  minutes  PA:  1580). 
4.12.13  NEW  RETENTION  TIMES  FOR  METHADONE  AND  CYCLIZINE 
4.12.13.1  EXPERIMENTAL 
The  retention  time  of  the  methadone  and  cyclizine  had  changed  due  to  the  head  pressure 
being  altered  as  the  flows  had  been  switched  off.  The  methadone  was  now  eluting  at  14.5 
minutes  and  the  cyclizine  at  13.2  minutes.  The  column  head  pressure  was  set  to  10  psi,  the 
air  at  40  psi,  the  H2  at  20  psi  and  the  carrier  gas  to  35  psi.  The  previous  pressure  had  not 
been  noted. 
Three  methadone  and  cyclizine  extractions  were  carried  out  at  5%  EtAc,  67  °C  and  3000 
psi,  3500  psi  and  2500  psi. 
4.12.13.2  RESULTS  AND  DISCUSSION 
The  runs  at  3000  psi  and  2500  psi  had  high  pressure  errors  in  the  middle  of  the  extractions. 
However  some  peaks  were  observed  for  methadone  and  cyclizine.  The  results  are  shown  in 
Table  4.6. 
Table  4.6:  Extractions  at  5%  EtAc 
%  EtAc  Pressure  R.  T. 
Methadone 
Area 
Methadone 
R.  T. 
Cyclizine 
Area 
Cyclizine 
PAR 
Std  /  14.517  1714  13.248  2214  0.774 
5  2500  14.528  16482  13.240  4373  3.769 
5  3000  14.477  19785  13.197  14923  1.326 
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4.12.14  REPEAT  OF  EXTRACTIONS  WTTH  NEW  PRESSURE  REGULATOR 
4.12.14.1  EXPERIMENTAL 
The  pressure  restrictor  in  the  SFE  system  was  replaced  as  it  was  not  holding  pressures 
above  2000  psi.  With  the  new  restrictor  in  place,  extractions  of  methadone  and  cyclizine 
were  carried  out. 
4.12.14.2  RESULTS  AND  DISCUSSION 
The  following  results  were  obtained  at  5%  EtAc  and  3000  psi  (Table  4.7). 
Table  4.7:  Methadone  Extraction  Results  with  new  Pressure  Regulator 
Methadone  Cyclizine 
Sample  Area  R.  T.  (min)  Area  R.  T.  (min)  PAR 
Unext.  1714  14.517  2214  13.248  0.774 
Ext.  1  2757  14.496  3508  13.216  0.786 
Ext.  2  11003  14.472  22619  13.190  0.486 
The  recoveries  were  better  than  had  previously  been  seen  and  in  the  case  of  the  first 
extraction,  the  PAR  was  comparable  to  the  unextracted  standard. 
4.12.15  EXTRACTIONS  AT  VARIOUS  PRESSURES 
4.12.15.1  EXPERIMENTAL 
More  methadone  extractions  were  carried  out  at  various  pressures  from  2500-4000  psi  at 
5%  EtAc  and  67  T. 
4.12.15.2  RESULTS  AND  DISCUSSION 
The  results  for  the  extraction  of  methadone  and  cyclizine  at  various  pressures  are  shown  in 
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Table  4.8:  Recoveries  of  Methadone  at  Various  Pressures 
Methadone  Cycl  izine 
a  (Si)  Area  %Rec  Area  %Rec  PAR 
HP  error  1470  6.86  1463  6.88  1.005 
3000  1737  8.11  5989  28.20  0.290 
3000  0  0  0  0  - 
4000  3  682  17.19  2465  11.59  1.494 
4000  0  0  0  0 
2500  0  0  2257  10.61  0 
2500  0  0  0  0  - 
Unext.  21422  -  21276  -  1.007 
Once  again  it  can  be  seen  that  the  extraction  method  is  not  appropriate. 
4.12.16  INVESTIGATION  OF  pKA 
The  method  development  so  far  was  carried  out  using  the  same  modifiers,  temperatures 
and  pressure  that  had  been  used  for  the  temazepam  method  development.  The  pKa  values 
of  the  drugs  being  investigated  was  examined. 
Methadone  pKa:  8.3 
Morphine  pKa:  8.0,9.9 
Temazepam  pKa:  1.6 
Thus  the  pKa  of  methadone  is  more  like  morphine  than  temazepam  so  the  effect  of  adding 
Et3N  which  works  well  in  the  extraction  of  morphine  was  investigated. 
4.12.17  EXTRACTION  USING  MORPHINE  CONDITIONS 
4.12.17.1  EXPERIMENTAL 
C18  was  tried  as  a  support  instead  of  the  Extrelut®  used  for  the  extraction  of  morphine  at 
the  following  pressures:  3400,3200,2800,3300,2700,3000  psi.  500  µl  of  methadone  and 
cyclizine  were  extracted  in  each  case.  The  extractions  were  run  for  20  minutes  at  65  °C, 
90%  C02:  9%  McOH:  1%  Et3N  at  1  ml  min''. Chapter  Four:  Methadone 
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The  results  obtained  are  shown  in  Table  4.9. 
Pa  el4 
Table  4.9:  hxtraction  of'Methadone  Using  Morphine  Modifier  at  Various  Pressures 
Pressure  R.  T.  Cycl. 
(min) 
Area 
C  cl. 
%  Rec 
C  cl. 
R.  T.  Meth. 
(min) 
Area 
Meth. 
%  Rec. 
Meth. 
PAR 
Unext  13.195  150387  /  14.463  183047  /  1.217 
3400  13.186  26011  17  14.447  25794  14  0.992 
3200  13.178  3798  2.5  14.442  3033  1.7  0.799 
2800  13.166  7674  5  14.429  5332  3  0.695 
3300  13.172  2636  1.7  14.430  2579  1.4  0.978 
2700  13.177  1172  0.8  14.431  1200  0.7  1.024 
3000  /  0  0  /  0  0  0 
The  effect  of  pressure  on  the  PAR  and  recovery  of  methadone  is  shown  graphically  in 
Figure  4.4. 
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In  general  the  recoveries  for  the  extraction  are  higher  at  higher  pressures  and  the  PARs  are 
closer  to  that  of  the  unextracted  standard. 
4.12.18  MORPHINE  MODIFIER  METHADONE  EXTRACTION 
4.12.18.1  EXPERIMENTAL 
The  conditions  used  for  the  extraction  of  morphine  (3.13)  were  repeated  for  the  extraction 
of  methadone  and  cyclizine  standards  at  various  concentrations.  MeOH  and  Et3N  (85:  15 
v/v)  were  mixed  with  CO2  at  10%.  The  temperature  for  the  extraction  was  40  °C,  the 
pressure  3600  psi  and  the  flowrate  0.5  mlmin'.  The  extractions  were  run  for  25  minutes. 
Seven  vials  were  prepared  in  duplicate  containing  1.0,0.75,0.5,0.4,0.3,0.2  and  0.1  ml  of 
methadone  (10.4-1.04  µg/m1)  and  cyclizine  (10.1-1.01  µg/m1)  to  ensure  that  the  PAR  of 
methadone  :  cyclizine  remained  constant  at  all  concentrations  and  that  the  concentrations 
were  linear  over  the  range  being  studied.  At  each  concentration  the  contents  of  one  vial 
were  extracted  and  the  other  vial  was  evaporated  to  dryness  under  a  stream  of  nitrogen  at 
60  °C,  reconstituted  in  50  µl  of  EtAc  and  injected  directly  onto  GC-FID. 
4.12.18.2  RESULTSANDDISCUSSION 
The  results  from  the  linearity  of  methadone  and  cyclizine  using  the  conditions  described  in 
Section  3.13  are  shown  in  Table  4.10. 
Table  4.10:  Methadone  linearity 
Unextracted  Extracted 
Vol. 
(ml) 
Area 
Meth. 
Area 
C  cl. 
PAR  Area 
Meth. 
Area 
C  cl. 
PAR  %Rec 
Meth. 
%Rec 
C  cl. 
0  0  75427  0  0  71978  0  0  95 
0.1  17698  16531  1.071  14089  14755  0.955  89  80 
0.2  41858  29106  1.438  0  0  0  0  0 
0.3  44902  29351  1.530  61015  43740  1.395  136  149 
0.4  72076  54014  1.335  58995  50815  1.1  11  82  94 
0.5  100726  88014  1.144  11450  8268  1.385  11  9.4 
0.75  146326  130282  1.121  168548  121128  1.392  115  93 
1.0  296935  264296 
, 
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From  these  results  it  is  obvious  that  the  addition  of  the  internal  standard  is  of  utmost 
importance.  The  PAR's  are  comparable  in  all  cases  where  a  result  was  obtained,  but  where 
the  unextracted  standard  areas  are  linear  over  the  range  for  both  methadone  (r2=0.925)  and 
cyclizine  (r2=0.915),  no  linearity  is  seen  for  the  extracted  standards  using  these  conditions. 
4.12.19  LINEARITY  OF  METHADONE  WTTH  CYCLIZINE  AS  THE  INTERNAL  STANDARD 
4.12.19.1  EXPERIMENTAL 
A  calibration  graph  for  methadone  with  cyclizine  as  the  internal  standard  was  carried  out 
over  the  concentration  range  187.2  µg/ml  to  1.04  p.  g/ml.  Two  separate  curves  were  drawn 
on  from  208  -  10.4.  tg/ml  with  cyclizine  at  40.4  pg/ml  and  the  other  from  20.8  -  1.04  pg/ml 
with  cyclizine  at  4.04  pg/ml.  For  the  first  set  of  standards,  11  vials  were  prepared 
containing  1000,900,800,700,600,500,400,300,200,100  and  0  µl  of  methadone 
methanol  standard  with  200  t1  of  cyclizine.  The  contents  of  each  vial  was  evaporated  to 
dryness  under  nitrogen  at  60  °C  and  reconstituted  in  50  µl  of  EtAc  to  yield  the 
concentrations  shown  in  Table  4.10.  For  the  second  set  of  standards,  a  1:  10  dilution  was 
made  of  the  methadone  stock  standard  (10.4  µg/ml  -,,  0.104  µg/ml)  which  was  then  used  in 
the  same  way  as  the  concentrated  stock  standard  to  prepare  17  vials. 
4.12.19.2  RESULTS  AND  DISCUSSION 
The  results  from  the  calibration  curves  for  methadone  and  cyclizine  are  given  in  Table 
4.11. 
Two  separate  linear  ranges  were  plotted  as  shown  in  Figures  4.5  and  4.6.  From  Figure  4.5 
(0-208  mg/L),  r2=0.989;  A=0.110  and  B=0.024.  From  Figure  4.6  (0-20.8  mg/L),  the  graph 
was  found  to  be  linear  over  the  range  0.82-20.8  mg/L  (r2=0.981;  A=0.754;  B=0.299.  Thus 
by  using  cyclizine  as  the  internal  standard  and  GC-FID  as  the  analysis  technique,  the  limit 
of  detection  of  methadone  is  approximately  1  mg/L. Chapter  Four:  Methadone  Page  148 
Table  4.11:  Calibration  of  Methadone  with  Cyclizine  as  the  Internal  Standard 
Methadone  Conc' 
(  /m1) 
Area  Methadone  Area  Cyclizine  PAR 
208  193128  35148  5.495 
187.2  215655  45211  4.770 
166.4  209796  54360  3.859 
145.6  211982  58894  3.599 
124.8  109939  36884  2.981 
104  95235  36122  2.636 
83.2  66454  31957  2.079 
62.4  78870  51204  1.540 
41.6  57141  50441  1.133 
20.8  20391  30837  0.661 
10.4  20129  36228  0.556 
0  0  20073  0 
20.8  7397  1006  7.353 
18.72  16979  2700  6.289 
16.64  10832  1957  5.535 
14.56  11967  2532  4.726 
12.48  9558  2296  4.163 
10.40  5512  1192  4.13 
8.32  10575  3647  3.400 
6.24  4717  1735  2.719 
4.16  1720  717  2.400 
2.08  485  492  1.586 
1.04  1284  2249  0.971 
0.832  532  947  0.562 
0.624  744  1214  0.613 
0.416  877  1438  0.610 
0.208  1702  2032  0.835 
0.104  1669  2510  0.665 
0  0  2736  0 Chapter  Four:  Methadone 
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Figure  4.5:  Methadone  Linearity  Over  the  Range  0-208  mg,  I. 
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4.12.20  GC/MS  ANALYSIS  OF  METHADONE 
4.12.20.1  EXPERIMENTAL 
Method  development  was  now  changed  to  the  GC/MS  with  d3-methadone  as  the  internal 
standard.  The  GC/MS  was  the  same  as  that  described  in  section  3.12.  The  GC  conditions 
for  the  analysis  of  methadone  are  shown  below. 
Initial  Time  :  1  minute 
Initial  Temperature:  150  °C 
Final  Temperature:  300  °C 
Temperature  Ramp:  15  °C/min 
Final  Hold  Time:  5  minutes 
Injector  Temperature:  250  °C 
The  detector  was  run  in  the  SIR  mode  and  the  mass  to  charge  ratios  (m/z)  detected  were  72 
and  165  for  methadone  and  75  for  d3-methadone.  For  confirmation  of  a  positive 
methadone  peak,  the  ratio  of  m/z  165/72  should  be  less  than  0.1. 
Extracted  MeOH  standards  and  blood  standards  were  compared  to  unextracted  MeOH 
standards  to  ensure  that  they  gave  comparable  results. 
4.12.20.2  RESULTS  AND  DISCUSSION 
The  results  for  the  extraction  of  methadone  and  d3-methadone  for  MeOH  and  blood 
standards  are  shown  in  Table  4.12. Chapter  Four:  Methadone 
Table  4.12:  Methadone  and  d3-Methadone  MeOH  and  Blood  Extractions 
Page]  51 
Conc'  (m  7  L)  Unext  MeOH  PAR  Ext.  MeOH  PAR  Ext.  Blood  PAR 
0  0  0  0 
0.0107  0.185  0.161  0.201 
0.0153  0.204  0.216  0.226 
0.0214  0.245  0.237  0.274 
0.0535  0.345  0.398  0.398 
0.107  0.515  0.503  0.503 
0.153  0.623  0.619  0.619 
0.214  0.759  0.727  0.782 
0.535  1.129  1.132  1.249 
1.07  1.568  1.614  1.473 
r` 
A 
B 
0.930 
0.307 
1.290 
0.942 
0.302 
1.327 
0.887 
0.340 
1.222 
From  these  results  a  calibration  graph  was  plotted,  however  only  the  lower  concentrations 
were  linear.  The  highest  concentration  in  each  case  was  omitted  from  the  calibration  as  at 
this  value,  the  graph  levelled  off.  The  graph  produced  is  shown  in  Figure  4.7. 
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Using  GC/MS,  a  100  fold  reduction  in  the  limit  of  detection  was  found  with  the  calibration 
being  linear  over  the  range  0.0107  to  0.214  mg/L  (r2  =  0.989,  y=2.842x+0.177  unextracted; 
r2  =  0.964,  y=2.709x+0.186  MeOH  extracted;  r2  =  0.986,  y=2.749x+0.203  blood 
extracted). 
4.13  CONCLUSIONS 
Initially  method  development  for  methadone  was  carried  out  using  GC-FID.  Using  this 
apparatus  and  the  conditions  developed  for  the  extraction  of  morphine  in  Chapter  3,  a  limit 
of  detection  of  approximately  1  mg/L  was  obtained.  A  the  majority  of  samples  being 
analysed  for  methadone  will  contain  less  than  1  mg/L,  the  methodology  was  changed  and 
GCIMS  was  used  as  the  analysis  method.  By  this  method,  the  limit  of  detection  was 
decreased  100  fold  to  0.01  mg/L. 
The  conditions  for  the  extraction  are  the  same  as  those  developed  for  the  extraction  of 
morphine  from  blood  and  vitreous  humor  (p127)  and  indeed,  both  extractions  can  be  run 
simultaneously  by  adding  both  internal  standards  to  the  Extrelut®  prior  to  the  extraction. 
The  reduction  in  the  use  of  solvent  was  not  as  pronounced  in  this  case  (6m1  for  SFE  and  8 
ml  for  LLE),  however  the  SFE  extracted  less  endogenous  material  to  provide  a  cleaner 
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5.  HAIR  ANALYSIS 
5.1  INTRODUCTION 
The  analysis  of  hair  is  becoming  increasingly  accepted  as  a  tool  for  the  determination  of 
use  and  abuse  of  drugs  of  forensic  interest.  lss  The  importance  of  hair  analysis  stems  from 
the  fact  that,  at  present,  no  toxicological  method  is  available  for  the  confirmation  of  long 
term  drug  use.  Drugs  pass  into  the  hair  from  body  fluids  and  remain  there,  thus  each  hair 
strand  should  provide  a  fixed  record  of  past  use.  156  Hair  analysis  cannot  pinpoint  the  actual 
dose  of  drug  consumed  but,  by  carrying  out  a  segmental  analysis,  it  can  provide 
information  regarding  the  approximate  period  of  time  of  drug  usage  which  cannot  be 
determined  from  blood  or  urine. 
Since  1979,  hair  has  been  used  to  document  chronic  drug  exposure.  157  To  date  more  than 
400  articles  concerning  hair  analysis  have  been  published  with  applications  in  clinical  and 
forensic  toxicology.  The  main  practical  advantage  of  testing  hair,  compared  to  blood  or 
urine,  is  its  longer  surveillance  window  (weeks  to  months  depending  on  length  compared 
to  2-4  days  for  fluid  analysis).  158  For  practical  purposes,  the  two  compliment  each  other  in 
that  biological  fluid,  analysis  yields  short  term  information,  whereas  hair  analysis  provides 
long  term  histories  of  drug  use.  The  severity  and  pattern  of  an  individuals  drug  use  can 
also  be  determined  without  many  of  the  problems  associated  with  conventional  analysis. 
The  accumulation  of  drugs  in  hair  of  drug  users  has  been  confirmed  by  several  independent 
laboratories  in  the  US,  Japan  and  Europe.  159,160,161,162,163 
with  the  drugs  investigated 
including  cocaine,  heroin,  amphetamines  and  phencyclidine.  In  addition  to  its  obvious 
utility  in  the  drug  abuse  area,  hair  analysis  also  offers  applications  in  the  monitoring  of 
compliance  of  medication  intake,  164  establishing  toxic  chemical  exposure'58  and  for 
monitoring  the  control  of  diabetes  by  measuring  the  glycosylation  of  hair  proteins.  '65 
The  main  advantages  of  hair  analysis  are  summarised  below.  166 
"  The  test  cannot  be  thwarted  by  temporary  abstention  from  drug  use  or  adulteration  of 
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9  Hair  can  be  collected  under  close  supervision  without  embarrassment. 
"A  second  sample  can  be  collected  and  compared  to  the  first  by  its  appearance,  by 
microscopic  examination  and  by  DNA  analysis. 
9  The  specimen  and  analytes  are  stable  even  under  adverse  environmental  conditions  and 
can  be  stored  almost  indefinitely  without  refrigeration. 
9  The  test  provides  information  on  the  temporal  pattern  and  severity  of  drug  use. 
In  conjunction  with  the  wide  detection  window,  hair  analysis  is  therefore  much  more 
efficient  than  biological  fluid  analysis  for  the  identification  of  drug  abusers. 
5.2  STRUCTURE  OF  HAIR 
5.2.1  INTRODUCTION 
Head  hair  grows  at  approximately  1  cm  per  month  and  the  identification  of  a  drug  in  hair 
depends  on  the  length  and  type  of  hair.  Its  analysis  can  reveal  drug  use  from  one  week  to 
months  prior  to  sampling166  depending  upon  the  length  of  the  hair. 
In  order  to  interpret  the  results  of  hair  analysis  tests  accurately,  and  to  understand  the 
appropriate  role  of  hair  analysis  in  drug  abuse  testing,  it  is  necessary  to  have  a  basic 
understanding  of  hair  biology. 
5.2.2  ANATOMY  OF  HAIR 
Hair  is  a  complex  structure,  the  biology  of  which  is  only  partly  understood.  167  It  is 
composed  of  cylindrical  structures  or  shafts  made  up  of  tightly  compacted  cells  that  grow 
from  small  sac-like  organs  called  follicles.  168  In  man,  the  diameter  of  these  shafts  may 
range  from  15-120  gm  depending  on  the  type  of  hair  and  the  region  of  the  body.  Hair 
contains  a  family  of  sulphur-rich  proteins  known  as  keratins  which  form  long  fibrils  in  the 
shaft  which  become  tightly  bound  through  the  replacement  of  S-H  bonds  with  S-S  bridges. 
These  bridges  produce  a  tough,  highly  stable  structure. Chapter  Five:  Hair  Analysis  Page  155 
5.2.3  CHEMICAL  COMPOSITION  OF  HAIR 
Hair  is  essentially  a  cross-linked,  partially  crystalline,  oriented  polymeric  network 
containing  a  number  of  functional  chemical  groups  (e.  g.  acid,  base,  peptide)  which  have 
the  potential  to  bind  small  molecules.  Depending  on  the  moisture  content,  human  hair  is 
between  65-95%  protein,  5-35%  water  and  1-9%  lipids.  Mineral  content  is  between  0.12- 
0.95%  on  a  dry  weight  basis.  Essential  trace  elements  and  heavy  metals  can  also  be 
found.  168 
The  lipid  material  in  hair  is  derived  from  sebum  and  apocrine  secretions.  It  consists  of  free 
fatty  acids,  mono-,  di-,  and  tri-glycerides,  wax  ethers,  hydrocarbons  and  alcohols.  Human 
hair  contains  relatively  large  amounts  of  side-chain  amino-acids  (e.  g.  glycine,  threonine, 
cysteine). 
169 
5.2.4  THE  HAIR  FOLLICLE 
This  is  a  highly  complex  skin  appendage  consisting  of  both  epithelial  (matrix  and  outer 
root  sheath)  and  dermal  (dermal  papilla  and  connective  tissue  sheath)  tissues  and  may  be 
considered  as  a  miniature  organ.  There  are  approximately  80,000-100,000  hair  follicles  on 
the  head  and  the  number  decreases  with  age.  170  The  structure  of  the  hair  follicle  is  shown 
in  Figure  5.1. 
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The  follicles  are  embedded  in  the  epidermal  epithelium  of  skin  approximately  3-4  mm 
below  the  surface.  They  are  closely  related  to  the  sebaceous  and  apocrine  glands  . 
In  most 
body  parts,  the  hair  follicle  and  the  sebaceous  gland  are  fused  both  anatomically  and 
functionally  into  a  pilosebaceous  unit.  The  ducts  of  both  sebaceous  and  apocrine  glands 
empty  into  the  follicle.  171 
There  are  three  functional  zones  along  the  hair  shaft:  169 
"  The  innermost  zone  in  and  around  the  bulb  is  the  site  of  biological  synthesis  of  hair 
cells. 
"  The  keratinogenous  zone  where  keratinization  of  the  cells  occurs  is  directly  above  the 
bulb.  Here  hair  undergoes  hardening  and  solidification. 
"  The  region  of  permanent  hair.  Here  the  hair  shaft  consists  of  dehydrated  cornified  cells 
which  have  formed  fibrils  fused  by  intercellular  binding. 
Hair  growth  begins  in  cells  located  in  a  germination  centre  (matrix)  located  at  the  base  of 
the  follicle.  As  the  cells  divide,  increase  in  volume  and  elongate,  they  move  up  the  hair 
shaft  to  the  keratinogenous  zone  where  melanin  is  synthesised.  Long  fibrils  are  formed 
through  cross-linking  of  sulfhydryl  groups  in  the  amino-acids.  Gradually  the  cells  die, 
decompose  by  elimination  of  the  nucleus  and  water,  and  coalesce  into  a  dense  "horny" 
mass. 
5.2.5  SECRETORY  GLANDS 
Secretions  by  glands  bathe  the  hair  shaft  and  therefore,  may  be  possible  sources  of  trace 
elements  in  the  hair  and  vehicles  for  the  transfer  of  drugs  into  hair.  168  The  linkage  between 
various  types  of  glands  and  the  hair  fibre  is  indicated  in  Figure  5.2. Chapter  Five:  Hair  Analysis  Page  157 
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5.2.5.1  SEBACEOUS  GLANDS 
These  glands  are  present  over  the  entire  body  surface  except  on  the  palms  and  the  soles  and 
dorsum  of  the  feet.  168  They  are  located  just  below  the  surface  of  the  skin  and  their  ducts 
exit  directly  into  the  tunnel  of  the  hair  follicle.  This  means  that  the  permanently  formed 
hair  shaft  is bathed  in  serum  just  before  it  emerges  from  the  skin.  The  exception  to  this  is 
the  beard  follicle  whose  complimentary  sebaceous  gland  has  a  duct  which  opens  directly 
onto  the  skin  surface.  Sebaceous  glands  are  at  their  largest  and  most  numerous  on  the 
scalp,  forehead,  cheeks  and  chin.  The  sebum  which  they  secrete  gives  unwashed  hair  its 
oily  appearance. 
The  composition  of  the  sebum  depends  on  its  anatomical  area  but  in  general  consists  of  one 
third  aqueous  as  free  fatty  acid,  one  third  as  combined  fatty  acid  and  one  third  as 
unsaponifiable  material  e.  g.  squalene,  cholesterol  and  waxes. Chapter  Five:  Hair  Analysis  Page  158 
5.2.5.2  APOCRINE  GLANDS 
These  are  localised  in  the  axilla,  external  auditory  meatus,  eyelids  and  perennial  region.  168 
They  are  different  from  the  sweat  glands  on  the  scalp  in  that  they  secrete  by  the  separation 
of  cytoplasm  from  secretion  cells.  They  discharge  directly  onto  the  hair  follicle  rather  than 
the  skin  surface.  Apocrine  gland  secretions  are  oily,  colourless,  odourless  substances  about 
which  little  is  known  other  than  that  their  bacterial  breakdown  results  in  body  odour. 
5.2.5.3  SWEAT  GLANDS  (ECCRINE  OR  MEROCRINE) 
These  are  distributed  all  over  the  body  surface  and  originate  in  the  dermal  layer.  168  Their 
ducts  exit  near  to  the  follicles  but  they  are  not  directly  in  contact  with  them.  They  exist  as 
simple  tubules  consisting  of  a  coiled  segment  in  the  dermis  and  a  straight  duct  which  opens 
onto  the  epidermis. 
The  quantity  and  concentration  of  fluid  secretions  from  sweat  glands  varies  largely 
depending  on  the  individual  and  the  environment.  The  principal  ingredients  of  the  fluid  are 
water,  salts  (sodium  and  potassium),  urea,  amino-acids,  lactate  and  pyruvate. 
5.2.6  THE  DERMAL  PAPILLA  AND  BLOOD  SUPPLY  TO  THE  FOLLICLE 
The  main  source  for  the  transport  and  delivery  of  blood  elements  to  hair  is  the  vascularized 
dermal  papilla  which  contains  a  population  of  fibroblast-like  cells  and  endothelial  cells.  167 
Due  to  the  enormous  amount  of  amino  acids,  lipids  and  carbohydrates  required  to  produce 
hair  and  its  sheaths,  fenestrated  vessels  with  thin  diaphragm  type  membrane  areas  for 
accelerated  transport  are  present.  173  As  in  many  tissues  the  common  source  of  energy  in 
the  hair  follicle  is  glucose,  which  becomes  phosphorylated  and  directed  through  the  major 
pathways  like  Embden  Meyerhof,  the  pentose  cycle  and  the  tricarboxylic  cycle.  The  major 
activity  of  glucose-6-phosphatdehydrogease  is  found  in  the  matrix  and  upper  bulb  region. 
Most  drugs  undergo  metabolic  transformations  including  oxidative,  reductive,  hydrolytic 
and  conjugative  reactions  in  the  body.  The  main  site  of  drug  transformation  is  the  liver, 
but  other  tissues  like  the  hair  follicle  may  also  participate.  It  was  found  that  a  mono- 
oxygenase  system  is  operative  in  the  hair  follicles  which  is  comparable  to  the Chapter  Five:  Hair  Analysis  Page159 
corresponding  system  in  the  liver.  The  fact  that  the  follicle  contains  cytochrome  P-450 
may  be  interesting  for  toxification  reactions.  These  findings  present  strong  evidence  that 
biotransformations  in  drugs  of  forensic  interest  may  also  occur  within  the  hair  follicle, 
prior  to  fusion  in  the  hair  shaft.  174 
Hair  follicles  are  surrounded  by  two  dense  capillary  networks,  whose  patterns  are  different 
in  active  and  quiescent  follicles.  168  The  lower  third  of  an  actively  growing  follicle  is 
surrounded  by  a  rich  vascular  plexus  composed  of  long  parallel  vessels  connected  by  cross- 
shunts.  The  second  network  is  located  at  the  level  of  the  sebaceous  glands  and  extends  to 
the  skin  surface.  Therefore,  both  the  growing  hair  bulb  and  the  sebaceous  glands  are  richly 
vascillarized.  The  two  networks  are  connected  by  a  simpler  parallel  system  of  larger 
vessels  which  descends  along  the  sides  of  the  follicle. 
5.2.7  STRUCTURE  OF  THE  HAIR  SHAFT 
Each  shaft  consists  of  three  types  of  cell: 
5.2.7.1  OUTER  CUTICLE 
This  consists  of  a  single  layer  of  elongated  overlapping  individual  cells  each  between  0.5- 
1.0  tm  long.  168  Its  function  is  to  anchor  the  hair  shaft  in  the  follicle  and  protect  the  interior 
fibre.  The  cuticle  can  become  damaged  or  destroyed  by  chemicals,  heat  light  or 
mechanical  injury  and  as  a  result  becomes  less  intact  towards  the  distal  end  of  the  shaft  and 
may  become  frail  and  fall  apart. 
Assuming  that  drug  substances  are  mainly  located  inside  the  hair  fibre,  the  fact  that  the 
weight  contribution  of  the  cuticle  depends  on  the  fineness  of  the  hair,  may  imply  possible 
minor  variations  of  the  drug  content  in  hair  analysis  as  a  function  of  the  hairs  diameter. 
5.2.7.2  CENTRAL  CORTEX 
The  cortex  forms  the  bulk  of  the  hair  shaft  and  is  composed  of  long  keratinized  cells  which 
form  into  long  fibrils  approximately  100  µm  long.  168  They  are  held  together  by  a  special Chapter  Five:  Hair  Analysis  Page160 
chemical  cement.  Between  the  cells  are  very  small  air  spaces  called  fusi.  In  the  living 
portion  of  the  hair  roots,  these  are  fluid  filled  but  as  the  hair  grows,  the  fluid  dries  out  and 
is  replaced  with  air.  Pigment  granules  are  also  found  in  the  cortex  and  their  alignment  give 
hair  its  colour.  As  with  the  skin  and  eyes,  melanin  is  the  main  pigment.  It  is  synthesised  in 
special  organelles  known  as  melanosomes.  These  are  located  within  the  hair  bulb  in  small 
bodies  called  melanocytes  where  the  enzyme  tyrosinase  acts  on  tyrosine  to  produce 
melanin. 
The  associated  proteins  forming  the  cortex  matrix  consist  of  two  large  families  of 
nonhelical  proteins,  the  "high  sulphur"  and  the  "high  glycine/tyrosine"  proteins  167,175  The 
intermediate  filaments  of  a  cortex  cell  are  embedded  in  a  matrix  of  globular  proteins  with 
the  interactions  of  the  molecular  chains.  The  space  in  the  matrix  for  small  molecules  is 
limited  by  the  globular  proteins  and  it  has  been  demonstrated  for  water  molecules  that  the 
microfibrils  or  intermediate  filaments  absorb  much  more  water  than  the  interfilament 
associated  proteins  of  the  matrix.  176  In  the  polypeptide  chains  of  the  intermediate  filaments 
and  in  the  associated  protein,  a  large  number  of  binding  sites  (including  hydrogen  bonding, 
ionic,  amide,  disulphide  and  electrostatic)  are  present.  Thus,  different  drug  substances  may 
be  easily  built  in  during  the  keratinization  process  of  the  cortical  cells.  Since  the  cortex 
makes  up  the  main  part  of  the  hair  fibre  both  by  weight  and  volume,  drug  binding  within 
the  cortex  is  believed  to  dominate  the  analytical  results,  but  this  is  not  yet  proven.  '77 
5.2.7.3  CENTRAL  MEDULLA 
Medullar  cells  are  initially  loosely  packed  but  as  the  hair  grows  they  dehydrate  leaving  a 
series  of  vacuoles  along  the  fibre  axis.  168  In  general,  the  number  of  medullar  cells  increases 
as  the  fibre  diameter  increases.  In  human  hair  the  medullar  cells  comprise  only  a  small 
percent  of  the  mass  of  the  hair  and  in  some  cases  may  be  totally  absent,  continuous  along 
the  centre  or  discontinuous. 
The  hair  medulla  is  difficult  to  isolate  and  has  an  insoluble  fraction.  178  It  seems  to  be  rich 
in  proteins  and  lipids  and  has  been  shown  to  have  E(-glutamyl)lysine  cross  linkages.  It  also 
contains  cutrulline,  has  a  very  low  cystine  and  sulphur  content  and  consists  of  relatively 
large  amounts  of  acidic  and  basic  amino  groups  and  hydroxyamino  acids.  169  Drug Chapter  Five:  Hair  Analysis  Pagel6l 
substances  have  been  found  in  the  medulla  thus,  it  can  be  speculated  that  the  type  of 
medullation  and  the  medullary  index  (ratio  of  width  of  medulla  to  hair  diameter)  in  a  hair 
sample  may  also  have  an  influence  on  the  analytical  results.  167 
5.2.8  THE  MELANIN  GRANULE 
Melanin  granules  are  the  cell  components  of  melanocytes,  which  are  situated  at  the  apex  of 
the  dermal  papilla.  167  They  release  branches  filled  with  melanin  granules  during  the  anagen 
phase  of  the  growth  cycle.  The  matrix  cells,  which  are  to  become  cortex  cells  later, 
actively  phagocytose  the  granules  as  they  pass  by  the  melanocyte  region  on  their  way 
upwards  to  the  keratinization  region.  As  the  cortical  cells  harden  during  keratinization,  the 
melanin  granules  become  fixed  between  the  ketatinous  fibrils.  Melanin  granules  are  spread 
throughout  the  cortex  but  are  more  concentrated  towards  the  periphery.  They  are  observed 
in  the  medulla,  are  rarely  present  in  the  spaces  between  the  cortical  cells  and  are  usually 
absent  in  the  hair  cuticles.  179 
Hair  colour  depends  on  the  number  of  melanin  granules  present,  their  size,  arrangement 
and  distribution  in  the  hair  shaft  and  their  melanin  composition.  When  pigment  is  deficient 
or  lacking,  the  hair  appears  grey  or white. 
Melanins  are  polymers  which  are  basically  composed  of  indole-5,6-quinone  units  which 
can  occur  in  different  stages  of  oxidation  with  units  of  5,6-dihydroxyindole  carboxylic 
acids  present.  The  macromolecules  are  formed  by  condensation  on  active  sites  in  a  soluble 
protein  matrix  of  the  immature  melanin  granule  within  the  melanocytes  and  they  are 
extremely  conjugated.  180  They  act  as  unique  biological  absorbers.  In  vitro  experiments 
demonstrate  that  even  high  concentrations  of  different  drugs  can  be  taken  up  by  isolated 
granules. 
167  The  melanin  affinity  for  drugs  is  dependent  on  the  drugs  chemical  nature.  The 
maximum  affinity  group  is  characterised  by  the  presence  of  a  series  of  highly  conjugated 
double  bonds  as  seen  in  chloroquinine.  The  loading  of  pigment  granules  also  seems  to  be 
influenced  by  the  quantity  of  pigment  and  the  concentrations  of  the  offered  drug  as  well  as 
the  morphology  and  chemical  composition  of  the  granules  themselves.  '8'  The  molecular 
binding  mechanism  is  not  well  known.  It  is  believed  to  be  a  type  of  adsorption  in  which 
forces  occur  which  may  be  due  to  charge  transfer  reactions,  the  melanin  being  the  electron Chapter  Five:  Hair  Analysis  Page  162 
acceptor,  as  well  as  electrostatic  forces.  For  many  drugs  which  are  present  as  cations  at 
physiological  pH's  with  known  melanic  affinity,  ionic  attraction  also  occurs  between  the 
positively  charged  molecules  and  the  anionic  carboxyl  groups  of  the  melanin  polymer.  182 
This  means  that  the  measurement  of  drugs  in  hair  may  be  biased  by  its  pigmentation,  thus 
the  results  should  be  interpreted  in  light  of  particular  drug  interactions  with  melanin 
polymers. 
5.2.9  THE  GROW  M  CYCLE 
Hair  growth  is  cyclic  in  humans  and  is  asynchronous  and  varies  in  its  rate  depending  on  the 
follicle  type  from  0.1-0.45  mm  per  day.  167  The  rate  shows  vestiges  of  seasonal  changes 
and  is  affected  by  endocrine  dysfunctions,  metabolic  and  genetic  disorders,  nutrition, 
hormones  and  drugs  which  target  the  follicular  segments  and  interfere  with  the  cell  kinetic 
of  hair  growth. 
5.2.9.1  ANALEN  PHASE 
The  length  of  this  phase  determines  the  length  and  type  of  hair.  The  onset  of  the  anagen 
phase  is  accompanied  by  an  increase  in  the  metabolic  activity  of  the  matrix  cells  located  at 
the  base  of  the  follicle  just  above  the  papilla.  168  The  bottom  of  the  follicle  is  pushed  more 
deeply  into  the  dermis  by  continual  cell  division.  New  hair  begins  to  grow  as  new  cells 
elongate  and  form  a  thin  filament  then  push  their  way  upward  into  the  follicular  canal. 
Here  the  hair  cells  differentiate  into  cuticle,  cortex  and  medullar  types  and  the 
keratinization  process  begins.  183  It  is  thought  that  drugs  and  trace  elements  are 
incorporated  into  hair  at  this  time.  When  radioactive  compounds  e.  g.  35S  labelled  cysteine 
are  administered,  appreciable  radioactivity  is  seen  in  the  keratinogenous  zone  but  little 
activity  is  seen  in  the  follicular  bulb.  When  radioactive  glucose  is  administered,  the 
opposite  is  observed.  This  implies  that  the  hair  follicle  receives  nutrients  from  the  vessels 
surrounding  the  bulb  but  other  chemicals  are  incorporated  at  the  keratinogeneous  level. Chapter  Five:  Hair  Analysis  Page  163 
5.2.9.2  CATAGEN  PHASE 
This  is  the  transitional  phase.  Cell  division  stops  and  the  base  of  the  shaft  becomes  fully 
keratinized  and  forms  the  dry,  white  node  characteristics  of  a  club  hair.  The  bulb  begins  to 
degenerate  and  the  follicle  becomes  considerably  shorter.  168 
5.2.9.3  TELOGEN  PHASE 
The  follicle  enters  a  quiescence  or  resting  period  in  which  the  hair  shaft  stops  growing  and 
is  retained  in  the  upper  portion  of  the  follicular  canal  where  it  can  be  easily  removed  by 
pulling.  The  length  of  this  period  depends  on  the  body  area  and  the  age  of  the  individual. 
For  scalp  hair  this  period  is  relatively  short  (-  10  weeks)  compared  to  the  general  body 
surface  (2-6  years).  '  84 
5.2.9.4  SUMMARY 
Each  hair  follicle  has  its  own  growth  cycle.  The  percent  of  hairs  growing  compared  to  the 
percent  resting,  varies  depending  on  the  area  of  the  body.  The  longer  the  type  of  hair,  the 
longer  the  growing  phase.  On  the  scalp,  approximately  15%  of  the  hairs  are  resting  and  the 
remaining  85%  are  growing.  This  process  can  be  complicated  by  disease  states,  nutritional 
deficiencies  and  pregnancy. 
5.2.10  RATEof  GROwrt 
Hair  usually  grows  at  1  cm/month.  This  is  an  oversimplification  as  not  all  hair  is  in  the 
growing  phase  at  any  one  time  and  the  percent  of  follicles  in  the  growing  phase  varies  with 
anatomical  location  and  age.  The  range  of  growth  is  from  0.6  cm/month  to  3.36  cm/month. 
Hair  type  and  anatomical  region  are  the  most  important  factors.  Scalp  hair  grows  faster 
than  pubic  or  axillary  hair  which  grows  faster  than  beard  hair.  Caucasian  hair  grows  faster 
than  Asian  hair.  In  general  the  rate  decreases  with  age.  All  of  these  factors  are  important 
when  considering  where  to  take  a  sample  of  hair  from.  Usually  hair  in  the  vertex  region  of 
the  scalp  is  chosen  as  the  best  specimen,  as  it  has  the  largest  amount  of  hair  in  the  telogen 
phase  and  the  fastest  growth  rate.  168 Chapter  Five:  Hair  Analysis  Page164 
Provided  that  exogenous  factors  have  neither  removed  or  added  to  the  drug  in  the  hair,  the 
presence  of  a  drug  at  a  particular  distance  from  the  scalp  should  reflect  that  the  drug  was 
available  to  the  hair  at  that  time  of  formation  and  keratinization  of  that  hair  section.  Thus, 
analysis  of  the  hair  segments  as  recording  filaments  at  different  distances  from  the  scalp 
should  provide  retrospective  information.  If  sufficient  information  on  the  rate  of  growth  is 
available,  a  rough  correlation  between  the  distance  of  a  section  from  the  scalp  and  the  time 
interval  since  that  section  was  in  the  follicle  can  be  made.  172 
New  hairs  take  about  three  weeks  to  reach  the  surface  of  the  scalp.  167  Thus,  if  a  sample  of 
hair  is  taken  by  cutting  as  opposed  to  plucking,  the  first  segment  of  the  hair  strand  was 
formed  more  than  four  weeks  earlier  and  does  not  represent  the  drug  uptake  in  the  month 
prior  to  sampling. 
5.2.11  SCALP  HAIR  V  BEARD  HAIR  V  PUBIC  HAIR  AS  A  SPECIMEN168 
5.2.11.1  SCALP  HAIR 
This  type  of  hair  is  the  easiest  to  collect  but  there  exists  considerable  variation  in  growth 
rates  in  the  various  regions  which  makes  the  choice  of  sampling  area  important.  Scalp  hair 
has  the  highest  growth  rate  of  all  the  hair  types  therefore  is  probably  the  most  variable. 
Also,  as  the  ducts  of  the  sebaceous  glands  discharge  directly  into  the  hair  follicles,  the  hair 
shaft  is  exposed  directly  to  sebaceous  secretions  before  it  emerges  from  the  skin.  Scalp 
hair  is  exposed  also  to  sweat  and  external  contamination.  Finally  the  chemistry  and 
physiology  of  scalp  hair  may  be  modified  by  the  use  of  cosmetic  treatments  whose  impact 
on  hair  analysis  is  not  yet  fully  understood  (e.  g.  bleach,  perm  lotions). 
5.2.11.2  BEARD  HAIR 
Beard  hair  is  thick  and  its  follicles  in  comparison  to  other  types  are  enormous.  It  has  the 
slowest  growth  rate.  The  fact  that  the  hair  shaft  and  sebaceous  gland  ducts  exit  from  the 
skin  in  two  separate  channels  means  that  this  hair  is  less  likely  to  be  contaminated  by 
sebaceous  excretions.  However,  when  beard  hair  is  obtained  by  shaving,  it  may  contain 
parts  of  the  epidermis.  External  contamination  is  as  likely  here  as  it  is  with  scalp  hair. Chapter  Five:  Hair  Analysis  Page  165 
5.2.11.3  PUBIC  HAIR 
This  type  of  hair  has  the  apparent  advantage  in  that  it  may  be  less  contaminated  through 
environment  exposure  or  cosmetic  treatment.  However,  contamination  due  to  urine  is  an 
important  issue  which  must  be  considered.  Hair  in  the  axillae  and  pubic  region  is  curled 
rather  than  straight  which  makes  segmental  analysis  difficult.  Pubic  hair  is  exposed  to 
sebum  and  sweat  secretions  and  to  the  secretions  of  the  apocrine  glands  which  are  present 
in  significant  numbers  only  in  the  axilla  and  pubic  areas.  These  glands  discharge  their 
secretions  directly  into  the  follicle.  Pubic  hair  grows  slower  than  scalp  hair  and  has  a 
longer  resting  period. 
5.2.12  SUMMARY 
Hair  is  quite  an  attractive  indicator  in  forensic  science  because  it  is  easy  to  obtain  and 
easily  stored.  Nevertheless,  it  is  a  very  complex  material  which  requires  sophisticated 
analytical  techniques  and  profound  knowledge  to  interpret  the  results.  For  hair  analysis, 
the  formation  and  the  morphology  of  the  hair  fibre  are  suggested  to  be  key  structures  but 
much  more  information  than  already  available  is  needed  to  answer  the  open  questions  and 
to  evaluate  hair  analysis  in  an  adequate  manner. 
5.3  TRANSFER  OF  DRUGS  INTO  HAIR 
The  precise  mechanism(s)  involved  in  the  incorporation  of  drugs  into  hair,  or  the  factors 
influencing  it,  have  yet  to  be  determined.  172  The  generally  accepted  mechanism  is  one  in 
which  chemicals  present  in  blood  move  via  passive  diffusion  into  the  rapidly  growing  cells 
of  the  hair  follicle.  '  85  As  the  cells  die  and  fuse  to  form  hair  strands,  the  drugs  become 
trapped. 
It  has  been  suggested  that  the  passive  diffusion  of  drugs  into  growing  cells  may  be 
augmented  by  the  drugs  binding  to  intracellular  components  of  the  hair  cells,  e.  g.  pigment. 
This  is  especially  so  for  amphetamine  and  methamphetamine  which  are  chemically  similar 
to  tyrosine  and  DOPA  (3,4-dihydroxyphenylalanine),  the  precursors  of  melanin.  This 
mechanism  is  probably  not  too  important  as  drugs  may  be  found  in  the  hair  of  albinos  and 
only  a  small  amount  of  drug  is  found  in  the  melanin  fraction  of  hair.  '  86  Bonding  of  the Chapter  Five:  Hair  Analysis  Page166 
drugs  to  hair  could  also  be  due  to  sulfhydryl  containing  amino  acids,  especially  for  drugs 
which  can  form  stable  direct  covalent  bonds  e.  g.  divalent  cations. 
5.3.1  SIMPLE  PASSIVE  TRANSFER  MODEL 
This  is  the  simplest  model  to  describe  drug  binding  in  hair.  Drugs  move  by  passive 
diffusion  from  the  bloodstream  into  the  growing  cells  at  the  base  of  the  follicle,  then 
become  tightly  bound  in  the  interior  of  the  hair  shaft  during  keratogenesis.  The  model  is 
dependent  on  the  concentration  of  drug  in  blood  and  thus  the  quantity  of  the  drug 
administered.  Figure  5.3  is  a  schematic  representation  of  this  model. 
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Figure  5.3:  Simple  Passive  Transfer  Model  172 
Hair  is  assumed  to  grow  at  a  constant  rate,  thus  the  position  of  the  drugs  along  the  hair 
shaft  can  be  correlated  with  the  time  that  the  drug  was  in  the  bloodstream.  This  model  also 
forms  the  basis  for  segmental  analysis.  As  techniques  for  hair  analysis  improve,  newer 
findings  suggest  that  this  model  is  somewhat  oversimplified. 
5.3.2  PROBLEMS  WITH  THE  SIMPLE  PASSIVE  TRANSFER  MODEL 
Some  elements/drugs  have  shown  good  correlation  between  the  concentration  of  ingested 
drug'  87  and  the  concentration  of  drug  in  hair,  others  correlate  badly.  188  Although,  some  of Chapter  Five:  Hair  Analysis  Page167 
this  can  be  put  down  to  external  contamination,  it  has  been  proposed  that  another  possible 
method  involved  is  "pooling".  172  This  introduces  the  concept  of  multiple  equilibria  and 
steady  states.  This  proposal  is  element  and  exposure  dependent,  but  only  after  transfer 
from  pool  to  pool  via  multiple  equilibria  and  steady  states.  It  has  not  yet  been  verified 
experimentally. 
5.3.2.1  CORRELATION 
Baumgartner  et  al  have  reported  a  positive  correlation  between  self  reported  drug  use  and 
concentration  in  hair  for  heroin,  189  marijuana,  19'  cocaine'9'  and  PCP  (phencyclidene)'92  by 
RIA  (radioimmunoassay).  More  recent  studies  using  GC-MS  have  also  shown  a  positive 
correlation  e.  g.  Nakahara  et  a1193  found  good  correlation  between  methoxyamphetamine 
intake  and  hair  concentration.  In  a  two  person  study  by  Cone  et  al194  good  correlation 
between  opiate  dose  and  concentration  in  beard  hair  was  found.  Puschel  et  a1195  also 
analysed  opiates  in  the  hair  of  cancer  patients  on  morphine  and  found  poor  correlation  with 
the  highest  concentration  corresponding  to  patients  who  had  received  the  lowest  doses. 
Poor  correlation  has  also  been  shown  for  cocaine  and  its  metabolites  in  hair,  urine,  blood 
and  sweat.  172  However,  in  general  with  cocaine  the  concentration  found  in  hair  increases 
with  dose.  Intersubject  variability  has  been  found  to  be  high,  therefore  the  estimation  of 
dose  is  very  difficult  to  make.  This  variability  cannot  be  assigned  solely  to  plasma 
pharmacokinetics. 
5.3.2.2  DRUG  METABOLITE  RATIOS 
Perhaps  the  greatest  challenge  to  the  passive  transfer  model  is  the  relatively  high  parent 
drug  to  metabolite  ratio  e.  g.  heroin  is  highly  metabolic  and  6-MAM  which  is  a  relatively 
short  lived  metabolite  is  found  in  high  concentrations  in  hair.  196 
5.3.2.3  TIME  COURSE  OF  DRUG  INCORPORATION 
Two  assumptions  are  made  for  segmental  analysis 
1)  Hair  grows  at  a  constant  rate  of  -1  cm/month 
2)  No  diffusion  occurs  along  the  hair  shaft Chapter  Five:  Hair  Analysis  Page168 
Some  investigators  have  shown  that  the  presence  of  drug  does  correspond  to  the  time  of 
injection,  194  but  not  all.  This  leads  to  the  belief  that  a  more  complex  multicompartment 
model  exists.  For  example,  hair  obtained  after  a  single  administration  of  deuterated 
cocaine  showed  that  the  position  of  the  d5-cocaine  along  the  hair  shaft  did  not  always 
correlate  with  the  time  of  drug  injection.  172 
5.3.3  MULTIc0MPARTMENr  MODE. 
A  suitable  model  to  describe  the  incorporation  of  drugs  into  hair  would  have  to  explain 
findings  such  as: 
"  Why  drug  and  metabolite  ratios  in  hair  are  different  from  those  in  blood. 
"  Why  the  time  for  drugs  to  appear  in  hair  varies  between  subjects. 
"  Why  the  distribution  along  the  hair  shaft  is  not  always  consistent  with  what  is  predicted 
from  hair  growth. 
"  Why  the  drug  and  metabolite  concentrations  in  hair  vary  to  a  great  extent  between 
subjects  receiving  the  same  dose. 
5.3.4  PROPOSED  MODEL 
This  involves  three  pools172  as  indicated  in  Figure  5.2,  Section  5.2.5. 
a)  Blood  during  formation  of  the  hair  shaft. 
b)  Sweat  and  sebum  after  formation  of  the  hair  shaft. 
c)  External  contamination  after  formation  of  the  hair  shaft  and  after  hair  has  emerged 
from  the  skin. 
In  addition,  the  drugs  and  metabolites  may  be  transferred  from  multiple  body 
compartments  or  pools  in  the  tissues  surrounding  the  hair  follicle. 
5.3.4.1  TRANSFER  VIA  SWEAT,  SEBACEOUS  AND  APOCRINE  GLANDS 
Nearly  all  drugs  of  abuse  have  been  found  in  sweat,  often  in  concentrations  higher  than 
those  found  in  blood.  172  In  order  to  determine  the  contribution  of  drugs  in  sweat  to  drugs Chapter  Five:  Hair  Analysis  Page  169 
in  hair,  Henderson  carried  out  an  experiment  where  subjects  who  had  ingested  cocaine 
under  supervision  held  uncontaminated  hair  in  their  hands  two  hours  after  ingestion. 
Subsequent  analysis  showed  significant  amounts  of  cocaine  in  the  hair,  in  some  cases  even 
after  washing.  In  the  experiment,  the  inter-subject  variability  was  found  to  be  high  and 
therefore,  this  contribution  is  more  significant  for  some  individuals  than  others. 
Contributions  due  to  sweat  and  sebaceous  excretions  in  the  hair  are  not  separable  and 
therefore,  inter-individual  differences  of  drug  levels  in  subjects  consuming  known  amounts 
of  a  particular  drug  may  be  partially  explained  by  this.  This  phenomena  also  goes  some 
way  to  explaining  the  apparent  band  broadening  seen  in  some  individuals  known  to  have 
used  drugs  over  a  certain  time  period,  i.  e.  excretions  in  the  sweat  may  explain  why  drugs 
are  found  in  longer  areas  of  hair  than  expected.  If  glandular  secretions  are  significant 
routes  for  incorporation,  interlaboratory  variability  in  washings  and  extraction  procedures 
could  also  result  in  variable  findings. 
5.3.4.2  TRANSFER  FROM  THE  EXTERNAL  ENVIRONMENT 
External  contamination  can  come  from  a  variety  of  media  including  air,  water  and  cosmetic 
treatments  and  is  possibly  the  reason  why  it  is difficult  to  establish  a  baseline  concentration 
for  trace  elements  in  hair.  '72  For  example,  hair  analysis  cannot  distinguish  smokers  from 
non-smokers.  External  contamination  in  addition  to  coating  the  hair  can  be  intradermally 
transferred  especially  for  highly  lipid  soluble  drugs. 
5.3.4.3  TRANSFER  FROM  DEEP  COMPARTMENTS  IN  THE  SKIN 
Skin  has  been  shown  to  act  as  a  reservoir  for  certain  drugs,  especially  lipophiles.  t72  More 
specifically  this  occurs  in  the  epidermis  and  hypodermis.  When  drugs  penetrate  from  the 
external  environment  across  the  skin,  they  are  retained  by  the  lipid  layers  of  the  stratum 
corneum  and  are  released  slowly  into  the  bloodstream.  Conversely,  when  drugs  move  from 
the  systemic  circulation  to  the  surface  they  are  retained  primarily  by  the  adipose  tissue  of 
the  hypodermis  and  secondarily  by  the  stratum  corneum.  Both  the  stratum  corneum  and 
the  hypodermis  are  in  intimate  contact  with  the  hair  follicle  and  its  associated  glands  and Chapter  Five:  Hair  Analysis  Page  170 
the  capillaries  surrounding  the  hair  bulb  could  maintain  an  equilibrium  between  these 
structures  and  any  pool  in  the  adjacent  tissues. 
5.4  ANALYSIS 
5.4.1  QUANwATTVE  ASPECTS  OF  HAIR  ANALYSIS 
Figure  5.4  represents  the  change  in  concentration  of  a  drug  with  time  for  various  sample 
types.  158  For  body  fluid  analysis  (BFA),  the  area  under  the  curve  correlates  to  the  amount 
of  drug  taken.  The  figure  indicates  that  BFA  can  be  used  for  a  set  time  period  and  there  is 
no  way  of  monitoring  whether  the  sample  was  taken  on  the  ascending  or  descending  part  of 
the  curve  and  thus  there  is  no  relation  to  amount  taken  (i.  e.  small  amount  recently  or  large 
amount  some  time  ago).  Therefore,  this  is  not  very  practical  for  long  term  drug  screening. 
With  hair  analysis,  the  drug  recirculates  in  the  bloodstream  in  direct  proportion  to 
concentration.  In  this  respect,  hair  acts  as  an  integrating  monitor.  The  concentration  in  the 
bloodstream  depends  on  the  amount  taken,  the  mode  of  administration,  the  metabolic  rate, 
the  excretion  rate  and  the  distribution  coefficient. 
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The  most  important  considerations  in  developing  a  hair  analysis  method  are:  162 
"  Washing  and  digestion  (extraction). 
"  Measurement  of  the  metabolite  :  drug  ratio. 
"  Reproducibility  of  results  with  a  second  sample. 
Wash  procedures  are  used  to  remove  external  contamination  and  are  based  on  the 
following  properties  with  respect  to  exogenously  applied  drugs. 
"  Cocaine,  opiates,  amphetamines  and  marijuana  (and  their  respective  metabolites)  do 
not  bind  strongly  to  keratin  proteins  and  therefore  are  readily  removed  by  washing. 
"  Metabolites  are  not  formed  by  contact  with  hair. 
"  Deposition  of  endogenous  and  exogenous  drugs  in  the  hair  involves  three  hair  domains: 
0  Surface  domain 
This  is  readily  accessible  to  exogenous  drugs,  e.  g.  from  vapours  and  powders. 
However  these  will  be  loosely  bound  and  readily  accessible  to  even  non  hair- 
swelling  solvents  e.  g.  EtOH  and  are  removable  in  this  way. 
0  Accessible  interior  domain 
This  is  located  in  the  interior  structures  of  the  hair  and  offers  moderate  resistance 
to  penetration  of  exogenous  drugs.  These  are  not  easily  removed  by  non-hair- 
swelling  solvents  but  are  readily  removed  by  water.  As  this  section  of  the  hair 
also  contains  endogenous  drugs  these  too  may  be  removed.  However  the 
percentage  of  endogenous  drug  will  be  small  in  comparison  to  that  found  in  the 
inaccessible  interior  domain.  Therefore,  washing  will  not  have  a  significant  effect 
on  the  overall  result. 
0  Inaccessible  interior  domain 
This  is  very  rarely  accessible  to  exogenous  drugs  and  aqueous  solvents  under 
realistic  conditions,  and  endogenous  drugs  cannot  be  easily  removed  from  it  with 
the  use  of  solvents.  In  general,  it  is  the  largest  of  the  three  domains  and  depends Chapter  Five:  Hair  Analysis  Page172 
on  the  type  of  hair  and  its  condition.  Endogenous  drugs  are  usually  released 
from  this  domain  by  liquefaction  of  the  hair  specimen. 
The  high  resistance  of  the  inaccessible  domain  to  exogenous  drugs,  their  ready  removal 
from  the  accessible  interior  domain  and  surface  domain  and  the  absence  of  metabolic 
formation  by  contact,  all  combine  to  greatly  reduce  the  possibility  of  evidentiary  false 
positives.  In  contrast,  the  probability  of  evidentiary  false  positives  with  BFA  is  greatly 
increased  by  active  inhalation  of  drug  vapours,  by  ineffective  barriers  to  drug  penetration  in 
the  lung  and  gastrointestinal  tract,  and  by  the  formation  of  metabolites. 
5.4.2  WASH  PROCEDURES 
Two  types  of  wash  procedure  are  adopted  in  hair  analysis:  162 
is  Extended  wash 
"  Truncated  wash 
Extended  washes  are  continual  washes  which  are  carried  out  until  a  plateau  drug 
concentration  has  been  reached.  The  duration  and  number  of  washes  is  determined  by  the 
results  obtained  with  a  particular  hair  specimen  and  therefore,  involves  the  analysis  of 
wash  solutions  while  the  wash  procedure  is  being  performed. 
Truncated  wash  procedures  involve  a  fixed  number  of  washes  over  a  fixed  duration.  The 
results  can  be  mathematically  related  to  the  extended  criteria.  This  type  of  wash  is  used  for 
mass  production  testing  whereas,  the  extended  wash  procedure  is  used  for  individual 
forensic  specimens. 
In  general,  wash  procedures  consist  of  two  steps.  A  solvent  wash  is  carried  out  first 
(usually  with  an  alcohol  e.  g.  MeOH,  EtOH)  to  ensure  that  and  oils  or  greasy  hair 
applications  do  not  diminish  the  efficacy  of  the  wash  procedure  and  to  remove  loosely 
adhering  drugs  from  the  surface  domain.  This  is  followed  by  aqueous  washings,  which 
allow  the  hair  to  swell  and  thus  allow  penetration  into  the  accessible  interior  domain.  A 
final  rinse  in  solvent  may  be  advisable  as  this  will  facilitate  drying  of  the  hair. Chapter  Five:  Hair  Analysis  Page173 
5.4.3  DIGESTION  /  EXTRACTION  PROCEDURES 
The  rate  of  extraction  is firstly  due  to  the  solubility  of  the  analyte  in  the  supercritical  fluid 
and  secondly  due  to  transfer  of  the  mass  of  the  solute  outside  of  the  matrix.  There  are  four 
mechanisms  of  mass  transport. 
1.  Diffusion  of  analyte  across  internal  volume  of  sample. 
2.  Desorption  from  surface  of  sample. 
3.  Diffusion  of  analyte  across  boundary  layer  on  surface  of  sample. 
4.  Transfer  into  core  of  supercritical  fluid. 
If  step  1  is  predominant  then  the  extraction  is  dependant  on  particle  size  and  therefore 
pulverisation  will  consequently  increase  the  rate  of  extraction.  If  steps  2  or  3  are  more 
important  then  the  extraction  will  be  improved  by  addition  of  a  more  polar  modifier. 
The  typical  analysis  is  therefore  a  four  stage  process: 
1.  Wash  -  elimination  of  contamination. 
2.  Pre-treatment  e.  g.  elution  by  aqueous  solvent,  hydrolysis. 
3.  Extraction  e.  g.  LLE,  SPE. 
4.  Analysis  e.  g.  GC/MS. 
If  solvent  extraction  procedures  are  used,  complete  extraction  of  the  drugs  from  the  hair 
cannot  be  guaranteed  since  the  extraction  efficiency  depends  on  the  physical  properties  of 
the  hair.  The  amount  of  melanin  present,  may  give  rise  to  racial  or  colour  biases  especially 
if  the  major  portion  of  the  drug  is  in  the  melanin  granules.  In  some  digestion  methods  the 
melanin  is  removed  and  the  drugs  are  not  released  from  this  fraction  during  digestion.  197 
Sample  preparation  techniques  and  procedures  for  hair  analysis  are  often  time  consuming, 
costly  and  can  require  the  use  of  toxic  solvents.  For  example:  198 
"  Acid  hydrolysis  requires  an  18  hour  incubation  period. 
Enzymatic  methods  use  ß-glucuronidase  and  aryl-sulphatase  which  are  expensive. Chapter  Five:  Hair  Analysis  Page  174 
"  The  presence  of  6-MAM  is  conclusive  proof  of  heroin  intake  however  6-MAM  is 
hydrolysed  to  morphine  under  alkaline  conditions  meaning  that  it  is  not  possible  to 
distinguish  between  drug  abuse  and  medical  intake. 
"  Direct  methanolic  extraction  requires  5  hours  sonication. 
As  an  alternative  to  the  current  wet  extraction  methods,  there  has  been  an  increasing 
interest  in  the  use  of  SFE  for  the  extraction  of  drugs  from  hair  samples.  By  using  an  SFE 
system  for  the  analysis  of  drugs  washing,  pretreatment,  extraction  and  final  analysis  can  be 
carried  out  using  the  same  apparatus,  thus  minimising  many  of  the  potential  problems 
associated  with  other  techniques.  199 
5.4.3.1  BENZODIAZEPINE  HAIR  ANALYSIS 
The  detection  of  benzodiazepines  in  human  hair  (the  most  abused  pharmaceuticals  world- 
wide)200  appears  mostly  undocumented.  At  the  time  of  this  study,  only  five  papers  were 
found  to  report  their  detection.  Diazepam  was  readily  found  in  hair  samples,  201,202 
however,  alprazolam  and  lorazepam  were  not  detected  in  patients  receiving  therapeutic 
doses  of  these  drugs.  203  Yegles  et  a120°  detected  diazepam,  desmethyldiazepam,  oxazepam, 
flunitrazepam,  lormetazepam  and  lorazepam  in  the  hair  of  deceased  polydrug  addicts. 
Other  benzodiazepines  which  have  been  detected  include  flunitrazepam  and 
alprazolam. 
204,205 
5.4.3.2  OPIATES  HAIR  ANALYSIS 
Hair  analysis  for  opiates  has  been  around  for  almost  three  decades  however,  it  was  not  until 
1985  that  RIA  findings  could  be  supported  by  a  second  independent  method  as  demanded 
by  the  courts.  206  Initially,  it  was  assumed  that  the  hair  had  to  be  totally  dissolved  and  then, 
the  drugs  determined  quantitatively  in  order  to  differentiate  between  heroin  and  codeine 
consumption.  The  hair  samples  were  dissolved  in  NaOH  and  then  treated  in  the  same  way 
as  urine  samples.  However,  not  all  illegal  drugs  can  withstand  NaOH  treatment  therefore, 
a  method  was  developed  whereby  the  hair  was  completely  dissolved  using  enzymes  and  the 
solution  extracted  using  Bond  Elut  Certify®  columns.  More  recently,  procedures  have  been 
developed  where  the  hair  is  only  partially  dissolved.  Several  methods  for  this  exist  in  the Chapter  Five:  Hair  Analysis  Page  175 
literature.  Of  these,  two  are  used  routinely,  one  developed  by  Moeller  and  Fey207  and  the 
other  developed  by  Kauert  et  a1.208 
5.4.3.3  METHADONE  HAIR  ANALYSIS 
Hair  analysis  with  methadone  is  of  extreme  importance  as  it  provides  a  means  of 
monitoring  the  compliance  of  patients  on  methadone  maintenance  programmes  and  also 
allows  for  the  detection  of  other  non-prescribed  drugs.  In  the  case  of  urinalysis  a  positive 
morphine  in  urine  may  indicate  that  a  small  amount  of  heroin  was  used  by  the  patient  the 
night  before  the  test  or  that  the  patient  had  been  regularly  using  heroin  but  had  thought  it 
wise  not  to  do  so  for  a  few  days  leading  up  to  the  test.  By  using  hair  analysis,  the 
difference  between  these  two  patterns  of  use  can  be  determined. 
Hair  analysis  for  methadone  in  maintenance  clinics  has  been  incorporated  since  the  early 
1990's.  209  Recent  literature  on  the  methodology  usually  involves  a  basic  hydrolysis 
procedure  with  GCIMS  as  the  favoured  analysis  technique.  210 
5.4.3.4  SFE  HAIR  ANALYSIS 
The  use  of  supercritical  fluids  in  the  extraction  of  drugs  from  hair  was  first  reported  in 
1992  by  Sachs  and  Uhl.  211.  The  quantitative  determination  of  opiates  in  hair  using  SFE 
was  also  first  investigated  by  Sachs.  212  Hair  was  collected  from  sixteen  subjects  who  had 
died  after  a  fatal  heroin  overdose.  Levels  of  morphine  detected  ranged  from  0.17-1.54 
(0.69)  ng/mg  and  6-MAM  0.15-14.90  (3.78)  ng/mg.  Cocaine  and  cannabinoids  were  also 
extracted  using  the  same  procedure.  In  1994,  Edder  et  a1213  also  investigated  the  possible 
use  of  SFE  for  the  extraction  of  opiates  from  drug  addict  hair  samples  while  Morrison  et 
a1214  investigated  their  use  for  the  extraction  of  cocaine.  Both  types  of  drugs  were 
extracted  effectively  with  high  recoveries.  More  recently,  in  1995,  a  method  for  the 
supercritical  fluid  extraction  of  opiates  form  hair  was  also  investigated  by  Cirimele  et  al.  198 
They  extensively  investigated  the  effect  of  parameters  such  as  temperature  and  modifier 
volume  on  the  extraction  recovery  of  morphine  and  6-MAM.  In  1996,  Staub  et  al'99 
applied  a  modified  version  of  the  method  by  Edder  et  a1213  to  the  extraction  of  opiates  and Chapter  Five:  Hair  Analysis  Page  176 
methadone.  Three  cases  were  successfully  analysed  for  the  presence  of  morphine  6-MAM 
and  methadone. 
5.4.4  Avomuvc  FALSE  PosmvEs 
5.4.4.1  CONTAMINATION 
Hair  analysis  allows  a  trilevel  reporting  system  to  be  used. 
"  No  drug  use. 
"  Drug  use. 
"  Contaminated  but  no  drug  use. 
This  is  useful  in  criminal  justice  type  situations  where  neither  drug  use  or  being  in  the 
presence  of  drugs  is  permissible  for  parolees  or  probationers. 
Contamination  can  be  divided  into  two  subsections 
a)  Trivial  contamination 
This  is  characterised  by  contamination  levels  exceeding  the  endogenous  cut-off  values  by  a 
small  amount  and  is  reported  as  being  either  zero  or  trivial.  This  situation  may  arise  when 
non-drug  user  is  constantly  in  the  presence  of  drug  users 
b)  Extensive  contamination 
This  is  characterised  by  contamination  levels  exceeding  the  cut-off  levels  by  a  large 
margin.  This  situation  arises  from  individuals  who  are  frequently  exposed  to  high  levels  of 
drugs  e.  g.  non-drug  using  drugs  dealers  or  manufacturers. 
5.4.4.2  MEASUREMENT  OF  METABOLITES 
This  is  used  in  conjunction  with  the  other  methods  to  avoid  evidentiary  false  positives. 
Metabolites  can  sometimes  be  formed  by  non-metabolic  processes  (e.  g.  the  hydrolysis  of 
cocaine  to  benzoylecgonine)  therefore,  the  preferred  method  is  to  measure  the  metabolite  : Chapter  Five:  Hair  Analysis  Page177 
drug  ratios  rather  than  simply  the  concentration  of  the  metabolite.  Thus,  the  use  of  the 
wash  procedures  is  still  very  important  and  allows  monitoring  of  the  contribution  that  the 
hydrolysis  process  may  make  in  the  digestion.  In  the  case  of  cocaine,  a  hydrolysis  control 
is  always  included.  215 
With  opiates,  a  number  of  metabolic  approaches  may  be  taken  to  distinguish  between 
external  contamination  and  drug  use.  Morphine  is  a  metabolite  of  heroin  and  the  presence 
of  monoacetyl  morphine  has  been  reported  in  hair.  The  most  convenient  and  sensitive 
metabolite  procedure  is  based  on  the  detection  of  morphine  glucuronide.  This  involves  the 
measurement  of  the  increase  in  free  morphine  following  hydrolysis  by  glucuronidase. 
Due  to  the  unfavourable  signal  to  noise  ratio  of  endogenous  :  exogenous  cannabinoids  in 
hair,  wash  procedures  have  no  use.  Instead,  the  use  of  cannabis  is  determined  by  the 
presence  of  11-nor-09-tetrahydrocannabinol-9-carboxylic  acid  (09-THCCOOH)  which  has 
not  been  found  to  be  present  in  marijuana  smoke. 
It  is  important  to  realise  that  the  determination  of  accurate  metabolite  :  drug  ratios  as  well 
as  the  endogenous  cut-off  levels,  depend  critically  on  effective  wash  procedures  therefore, 
the  measurement  of  metabolites  is  not  a  substitute  for  effective  washings.  Similarly,  good 
wash  procedures  critically  determine  the  reproducibility  of  results  with  a  newly  collected 
specimen.  Reproducibility  of  results  is  a  very  important  criteria  for  excluding  external 
contamination  since  contamination  is  usually  characterised  by  highly  variable  results. 
5.5  METHOD  DEVELOPMENT  FOR  HAIR  ANALYSIS 
Method  development  of  hair  samples  was  carried  out  using  hair  samples  obtained  from 
persons  known  not  to  have  used  any  drugs  being  investigated  in  this  study.  The  hair 
samples  were  prepared  and  spiked  with  the  appropriate  standards  as  described  in  the 
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5.5.1  PREPARATION  OF  HAIR  STANDARDS. 
5.5.1.1  WASH  PROCEDURE 
In  order  to  remove  grease  and  cosmetic  preparations,  which  might  be  present  in  the  hair 
samples,  they  were  first  of  all  washed  using  distilled  water  (dH2O),  MeOH,  dH2O  and 
CHC13.  At  each  wash  stage,  the  appropriate  solvent  was  added  to  the  hair  and  sonicated  for 
15  minutes  at  room  temperature.  The  solvent  was  then  decanted  off  and  the  next  solvent 
added.  Once  the  CHC13  wash  had  been  carried  out,  the  samples  were  dried  overnight  in  an 
oven  at  60  °C. 
5.5.1.2  GRINDING  PROCEDURE 
In  order  to  maximise  the  extraction  from  authentic  forensic  hair  samples,  it  was  decided  to 
grind  the  hair  samples  to  provide  the  largest  possible  surface  area  to  particle  size  ratio. 
Several  methods  were  attempted  for  this.  The  first  method  which  was  tried  was  the  use  of 
an  electric  razor.  This  method  was  found  to  be  extremely  time  consuming  and  wasteful  of 
sample.  In  addition,  the  best  method  for  "fixing"  the  hair  in  order  to  facilitate  shaving  was 
to  glue  the  ends  of  the  hair  to  a  piece  of  card  meaning  that  this  part  of  the  hair  was 
unavailable  for  analysis.  Some  of  the  case  samples  were  to  be  segmented  and  this  method 
would  mean  that  the  shortest  length  which  could  be  analysed  would  have  to  be  at  least  5 
cm  long  and  thus,  no  roots  could  be  ground  for  analysis. 
As  an  alternative  method  of  grinding,  a  Janke  and  Kunkel  electric  grinder  was  tested. 
However,  when  hair  samples  were  placed  in  the  grinding  chamber,  they  wound  round  the 
central  axis  and  did  not  grind.  After  consulting  with  the  manufacturers,  a  star  shaped  cutter 
was  purchased  which  when  used  with  C02(s)  produced  a  fine  powder  which  was  similar  to 
that  achieved  by  the  shaving  method  but  was  less  wasteful  of  sample  and  less  time 
consuming.  Approximately  5g  of  blank  powdered  hair  were  obtained  using  this  method. 
Additional  hair  for  standards  was  obtained  from  the  beard  shavings  of  a  person  also  known 
not  to  use  any  of  the  drugs  of  interest  to  this  study.  Although  this  hair  was  from  a  different 
source  and  may  be  contaminated  with  some  skin  fragments,  the  wash  procedure  developed Chapter  Five:  Hair  Analysis  Page179 
for  it  was  more  rigorous  including  two  additional  MeOH  washes  and  a  DCM  wash.  The 
results  obtained  from  spiked  samples  were  the  same. 
5.5.2  HAIR  SPIKING  PROCEDURE 
The  powdered  hair  samples  were  spiked  with  MeOH  standards  of  the  drugs  of  interest  as 
follows. 
For  a  ing/mg  standard,  100  µl  of  the  standards  to  be  used  (e.  g.  temazepam,  diazepam  and 
desmethyldiazepam  for  the  benzodiazepines  in  hair)  at  a  concentration  of  1  mg/L  was 
added  to  the  powdered  hair  (100  mg)  in  a  glass  vial.  500  µl  of  MeOH  was  added  to  ensure 
that  all  the  hair  was  coated  and  the  vial  sealed  and  sonicated  before  being  placed  in  an  oven 
at  60  °C  for  30  minutes.  The  vial  was  then  sonicated  again  at  room  temperature  for  10 
minutes  and  left  to  soak  overnight.  The  vial  was  then  opened  and  the  hair  allowed  to  dry  at 
room  temperature. 
Although  the  use  of  this  method  of  spiking  was  not  ideal  as  most  of  the  drug  would  be  on 
the  surface  of  the  hair  and  not  incorporated  into  the  hair  structure,  an  additional  wash  step 
was  not  used  as  this  would  mean  that  the  exact  concentration  of  the  drugs  in  the  hair 
standards  would  not  be  known. 
Internal  standards  were  used  for  all  extractions  (prazepam  for  the  benzodiazepines,  d3- 
morphine  for  opiates  and  d3-methadone  for  methadone)  and  were  added  to  the  hair  either 
prior  to  insertion  of  the  hair  into  the  extraction  cell  or  at  the  modified  static  extraction  step 
as  discussed  later. 
5.6  EXTRACTION  METHODOLOGY 
For  the  analysis  of  benzodiazepines,  opiates  and  methadone  in  hair,  the  method  reported  by 
Cirimele  et  al198  for  the  determination  of  opiates  in  hair  was  attempted  and  found  to  be 
successful.  The  next  sections  detail  how  this  method  was  introduced  to  the  system  and 
describes  the  method  development  which  was  subsequently  carried  out. Chapter  Five:  Hair  Analysis  Page  180 
5.7  METHOD  DEVELOPMENT  FOR  THE  EXTRACTION  OF  BENZODIAZEPINES  FROM  HAIR 
5.7.1  PRELIMINARY  EXTRACTIONS 
5.7.1.1  EXPERIMENTAL 
For  this  section  the  same  three  benzodiazepines  which  had  been  determined  in  blood  and 
vitreous  humor  were  investigated.  Spiked  hair  samples  were  prepared  at  -20  ng/mg  by 
pipetting  100  µl  of  20  µg/ml  standards  onto  100  mg  of  hair. 
Once  dried,  these  hair  standards  were  extracted  as  follows: 
Cleanup:  CO2  pumped  for  20  minutes 
Extraction:  MeOH  :  Et3N  (85:  15  v/v)  introduced  at  10%  for  30  minutes. 
Temperature:  100  °C 
Pressure:  3500  psi 
Flowrate:  2.0  ml  min-1 
As  before,  the  extracts  were  collected  into  MeOH  in  a  HypoVial®  at  the  flow  outlet.  The 
extracts  were  then  evaporated  to  dryness  under  a  stream  of  nitrogen  and  reconstituted  in 
100  µl  of  mobile  phase.  25  µl  was  then  injected  onto  the  HPLC  system  using  the 
previously  described  conditions  (Section  2.12). 
5.7.1.2  RESULTS  AND  DISCUSSION 
Some  pressure  problems  were  encountered  with  the  modifier,  possibly  due  to  the  added 
water  in  the  system.  However,  by  opening  and  closing  the  pressure  regulator  throughout 
the  extraction  it  was  possible  to  keep  the  pressure  reasonably  constant. 
The  first  run  of  temazepam  from  hair  was  done  without  the  addition  of  prazepam  to  the 
extraction.  An  area  of  367611  units  was  obtained  for  temazepam  extracted  from  hair  as 
compared  to  the  unextracted  standard  at  357771  units  corresponding  to  a  recovery  of 
103%.  This  high  recovery  indicated  that  the  extraction  was  sufficiently  successful.  It 
should  also  be  noted  that  the  initial  extractions  were  carried  out  without  the  use  of  static Chapter  Five:  Hair  Analysis  Page181 
mode  and  the  extractions  were  15  minutes  with  CO2  only  and  25  minutes  with  C02: 
MeOH:  Et3N  (90:  8.5:  1.5). 
5.7.2  EXTRACTION  OF  TEMAZEPAM,  DESMETHYLDIAZEPAM  AND  DIAZEPAM 
5.  %2.1  EXPERIMENTAL 
Spiked  benzodiazepine  hair  (105.2  mg)  was  prepared  at  23.0  ng/mg  temazepam,  20.2 
ng/mg  desmethyldiazepam  and  26.2  ng/mg  diazepam.  Two  aliquots  of  this  hair  (37.7  mg 
and  26.6  mg)  were  analysed  using  the  aforementioned  method  with  the  static  mode  in 
operation  as  described  later  in  section  5.8.  No  drugs  were  seen  to  elute  in  the  CO2  extracts. 
The  prazepam  was  added  with  the  modifier  to  the  extraction  cell.  An  unextracted  standard 
of  the  benzodiazepines,  at  the  concentration  the  hair  was  spiked  at,  was  also  injected  onto 
HPLC  in  order  to  calculate  the  recovery  of  each  of  the  drugs 
5.7  2.2  RESULTS  AND  DISCUSSION 
The  results  obtained  for  the  extraction  of  temazepam,  desmethyldiazepam  and  diazepam 
are  shown  below  in  Table  5.1. 
Table  5.1:  Extraction  of  Temazepam,  DMD  and  Diazepam  from  Spiked  Hair 
Temazepam  PAR  DMD  PAR  Diazepam  PAR 
Std  1:  37.7  mg  0.197  0.155  0.320 
Std  2:  26.6  mg  0.118  0.091  0.216 
Unextracted  0.958  0.802  1.198 
[Std  1]  13.2  n  /m  10.9  n  /m  19.6  n  /m 
[Std  2]  11.2  ng/mg  9.1  ng/mg  18.7  n  /m 
[Mean] 
%  Recovery 
12.2±1  ng/mg 
53±4  % 
9.97±0.9  ng/mg 
49.5±4.5  % 
19.14±0.4  ng/mg 
73±1.5  % 
It  should  be  noted  that  the  standards  were  added  to  the  hair  after  the  initial  weight  had  been 
recorded  but  prior  to  weighing  into  the  extraction  vessel  and  thus,  the  weights  reported  will 
be  for  the  hair  in  addition  to  the  drugs  and  any  residual  MeOH.  A  check  of  the 
contribution  of  the  weight  of  drug  was  carried  out  by  adding  100  µl  of  temazepam  to  a 
blank  hair  sample  which  had  been  weighed  at  32.6  mg.  On  reweighing,  the  hair  weight 
was  found  to  be  34.9  mg  which  corresponds  to  an  increase  of  2.3  mg.  If  this  is  taken  into Chapter  Five:  Hair  Analysis  Page  182 
account  for  all  three  drugs  being  added  the  approximate  error  in  weight  is  6.9  mg  (6.6  %). 
Thus,  the  weight  of  the  Ist  standard  will  be  35.2  mg  and  the  2nd  standard  24.9  mg  making 
the  recoveries  for  temazepam,  DMD  and  diazepam  57  %,  53  %  and  78  %  respectively. 
5.7.3  EFFECT  OF  TEMPERATURE  ON  THE  EXTRACTION  OF  TEMAZEPAM  FROM  HAIR 
5.7  3.1  EXPERIMENTAL 
A  temperature  recovery  study  was  carried  out  for  temazepam  and  prazepam  at  60,70,80, 
90  and  100  °C.  In  addition  to  using  MeOH:  Et3N:  H20  as  a  modifier,  EtAc  was  attempted  at 
each  temperature.  In  each  case  300  µl  of  modifier  were  added  directly  to  the  extraction 
vessel. 
5.  Z3.2  RESULTS  AND  DISCUSSION 
The  results  for  the  extraction  of  temazepam  from  hair  using  MeOH:  Et3N:  H20  (mod)  and 
EtAc  as  modifiers  are  shown  in  Table  5.2. 
Table  5.2:  Effect  of  Temperature  and  Modifier  on  the  Extraction  of  Temazepam 
Run  Peak  Height 
Temazepam 
Peak  Height 
Praze  am 
Temaz/Praz  %  Recovery 
Temazepam 
Unext.  Std.  10.30  7.15  1.44  n/a 
60  Mod  5.10  4.90  1.04  49.5 
60  EtAc  2.05  0.95  2.16  19.9 
70  Mod  1.20  2.15  0.56  11.7 
70  EtAc  5.65  3.20  1.77  54.9 
80  Mod  1.10  1.30  0.85  10.7 
80  EtAc  10.40  7.00  1.49  101 
90  Mod  4.00  3.30  1.21  38.8 
90  EtAc  4.10  1.60  2.56  39.8 
100  Mod  0.35  0.25  1.40  3.4* 
100  EtAc  2.80  1.75  1.60  27.2 
i:  nua-uvu  .  wa%,. 
From  the  results  in  Table  5.2,  the  best  extraction  conditions  appear  to  be  80  °C  with  EtAc 
as  a  modifier  and  60  °C  with  MeOH:  Et3N:  H20  as  a  modifier.  However,  during  the  100  °C Chapter  Five:  Hair  Analysis  Page  183 
extraction  with  the  latter  modifier  a  leak  occurred  in  the  extraction  cell  and  some  of  the 
modifier  escaped. 
5.7.4  EFFECT  OF  TEMPERATURE  ON  THE  EXTRACTION  OF  BENZODIAZEPINES  FROM  HAIR 
WITH  ETAc  AS  A  MODHMR 
5.74.1  EXPERIMENTAL 
The  temperature  study  previously  carried  out  for  temazepam  and  prazepam  only  was 
carried  out  for  temazepam,  desmethyldiazepam  and  diazepam  using  EtAc  as  a  modifier. 
5.  Z4.2  RESULTS  AND  DISCUSSION 
The  results  are  shown  in  Table  5.3 
Table  5.3:  Recoveries  of  Temazepam.  DMD  and  Diazepam  at  Various  Temperatures  with 
EtAc  as  the  Modifier 
PAR 
Temazepam 
PAR 
DMD 
PAR 
Diaze  am 
Recovery 
Temazepam 
Recovery 
DMD 
Recovery 
Diazepam 
R 
0.938  0.954  1.266  65/33  72/37  85/44 
0.541  0.579  1.043  37/13  44/15  70/25 
0.733  0.851  1.083  50/26  64/33  73/25 
r  2.307  2.453  1.493  159/57  185/69  101/38 
100  °C  1.387  1.100  1.600  95/95  83/85  108/104 
Unext.  1.453  1.327  1.483  n/a  n/a  n/a 
Recoveries  x/y:  x=  recovery  nasea  on  FAX,  y=  recovery  based  on  area 
From  these  results  it  can  be  seen  that  for  all  three  drugs  the  recoveries  in  terms  of  PAR  and 
area  are  best  at  100  °C. 
5.7.5  EFFECT  OF  TEMPERATURE  ON  THE  EXTRACTION  OF  BENZODIAZEPINES  FROM  HAIR 
WITH  MEOH:  ET3N:  H2O  AS  A  MODIFIER 
5.7.5.1  EXPERIMENTAL 
The  experiment  in  section  5.3.4  was  repeated  using  MeOH:  Et3N:  H20  as  the  modifier. Chapter  Five:  Hair  Analysis  Page  184 
5.  Z5.2  RESULTS  AND  DISCUSSION 
The  results  are  shown  in  Table  5.4 
Table  5.4:  Recoveries  of  Temazepam,  DMD  and  Diazepam  at  Various  Temperatures  with 
McOH:  Et3N:  H2O  as  the  Modifier 
Run  PAR 
Temazepam 
PAR 
DMD 
PAR 
Diazepam 
Recovery 
Temazepam 
Recovery 
DMD 
Recovery 
Diaze  am 
50  0.948  0.472  1.339  64/48  35/26  86/66 
56  0.798  0.482  1.316  54/40  36/27  84/64 
60  0.958  1.335  1.543  64/134  100/208  99/206 
86  1.024  0.979  1.423  69/147  73/138  91/173 
103  0.773  0.197  0.735  52/30  58/10  47/33 
Unext.  1.490  1.340  1.560  n/a  n/a  n/a 
This  time  the  best  recoveries  appear  to  be  at  60  °C,  however,  the  extractions  previous  to 
the  60  °C  extraction  were  very  low  in  recovery  and  thus  the  high  recoveries  were  possibly 
due  to  carryover.  For  this  reason,  the  extraction  at  86  °C  was  chosen  to  be  the  best  for 
using  the  MeOH:  Et3N:  H20  modifier. 
5.7.6  EXTRACTION  OF  AN  AUTHENTIC  HAIR  SAMPLE 
5.7  6.1  EXPERIMENTAL 
An  extraction  of  an  authentic  hair  sample  was  carried  out  using  both  100  °C  with  EtAc  and 
86  °C  with  MeOH:  Et3N:  H20.  The  extraction  at  86  °C  worked  but  the  one  at  100  °C  with 
EtAc  did  not,  indicating  that  the  EtAc  is  not  a  strong  enough  modifier  to  remove  the  drugs 
from  within  the  hair  matrix. 
The  same  case  was  extracted  at  86  °C  and  100  °C  with  the  MeOH:  Et3N:  H20  for  a 
comparison  at  these  two  temperatures.  The  results  which  were  obtained  at  100  °C  were 
better  fitting  to  results  published  in  the  literature  and  showed  less  endogenous  material 
being  extracted.  Thus,  although  the  recoveries  appeared  to  be  less  at  100  °C,  this 
temperature  was  chosen  for  running  authentic  samples  as  it  was  thought  that  the  drugs 
being  extracted  were  more  likely  to  be  from  within  the  hair  sample  then  that  at  80  °C. Chapter  Five:  Hair  Analysis  Page  185 
5.7.7  LINEARITY  FOR  THE  EXTRACTION  OF  BENZODIAZEPINES  FROM  HAIR 
5.7.7.1  EXPERIMENTAL 
Sets  of  hair  spikes  were  prepared  for  temazepam,  desmethyldiazepam  and  diazepam  over 
the  concentration  range  of  0.1  to  100  ng/mg  in  order  to  determine  the  linearity  over  this 
range  for  the  extraction  method.  All  three  drugs  were  extracted  in  the  same  run  and 
samples  were  run  in  triplicate. 
5.7.7.2  RESULTS  AND  DISCUSSION 
The  linearity  results  for  the  extraction  of  temazepam,  desmethyldiazepam  and  diazepam  for 
spiked  hair  samples  is  shown  in  Table  5.5. 
Table  5.5:  Extraction  of  Temazenam,  Desmethyldiazenam  and  Diazepam  for  Spiked  Hair 
Sam 
Temaze  am  Desmeth  ldiaze  am  Diazepam 
Conch 
n  /m 
PAR  Conc" 
n  /m 
PAR  Cone' 
-EL/mg 
PAR 
103.2  15.612  95.1  14.564  92.7  17.394 
68.8  11.436  63.4  10.713  61.8  12.596 
34.4  5.741  r2:  0.996  31.7  4.871  r2:  0.996  30.9  6.489  r2:  0.997 
17.2  3.102  A:  0.170  15.9  2.703  A:  0.083  15.5  3.410  A:  0.259 
8.6  1.258  B:  0.155  7.9  1.305  B:  0.157  7.7  1.594  B:  0.190 
3.44  0.461  3.17  0.444  3.09  0.582 
1.15  0.198  1.06  0.174  1.03  0.237 
0.57  -ve  0.52  -ve  0.52  -ve 
0.29  -ve  0.26  -ve  0.26  -ve 
From  this,  very  good  linearity  was  seen  over  the  full  range.  The  lower  two  concentrations 
in  each  case  were  not  detected,  thus  based  on  a  50  mg  hair  sample,  the  limits  of  detection 
for  the  three  drugs  are  as  follows: 
Temazepam:  1.15  ng/mg 
Desmethyldiazepam:  1.06  ng/mg 
Diazepam:  1.03  ng/mg. Chapter  Five:  Hair  Analysis  Page186 
5.8  METHOD  DEVELOPMENT  FOR  THE  EXTRACTION  OF  MORPHINE  FROM  HAIR 
5.8.1  PRELIMINARY  CHECK  OF  METHODOLOGY 
Three  extractions  of  morphine  spiked  hair  were  carried  out  using  the  same  methodology  as 
was  used  for  the  initial  extraction  of  temazepam. 
All  3  CO2  cleanup  extracts  were  found  to  be  negative  for  morphine.  For  the  three  modified 
extracts,  the  following  results  were  obtained  as  shown  in  Table  5.6. 
Table  5.6:  Preliminary  Morphine  Extractions 
Extraction  m/z  ratio  429/432  m/z  ratio  414/429 
1  0.839  0.605 
2  0.594  0.652 
3  0.687  0.643 
Extraction  three  yielded  the  largest  areas  which  may  be  as  a  result  of  the  extraction  being 
run  for  a  longer  time  due  to  a  high  pressure  error  during  the  extraction. 
At  this  point  the  system  was  set  up  for  use  in  the  static  mode.  The  Rheodyne  set  up  for 
operation  of  the  static  mode  is  shown  in  Figure  5.5. 
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When  the  first  (top)  Rheodyne  is  at  the  load  position,  flow  passes  from  position  2  to 
position  3  and  bypasses  the  second  Rheodyne.  When  the  first  Rheodyne  is  in  the  inject 
position,  flow  is  diverted  from  position  2  to  position  1  and  then  to  position  2  in  the  second 
(bottom)  Rheodyne.  In  order  to  carry  out  a  static  extraction,  the  Extraction  cell  is 
pressurised  by  placing  the  second  Rheodyne  in  the  inject  position.  Once  the  required 
pressure  has  been  reached,  the  second  Rheodyne  is  switched  to  the  load  position  and  flow 
is  diverted  back  to  position  4  in  the  first  Rheodyne,  via  position  3  to  the  pressure  regulator 
and  the  collection  vessel.  Once  the  static  extraction  has  been  carried  out  for  the  required 
length  of  time,  the  second  Rheodyne  is  put  to  the  load  position  and  the  supercritical  fluid 
and  any  extracted  material  from  the  extraction  cell,  flushed  out. 
5.8.2  EFFECT  OF  TEMPERATURE  ON  THE  EXTRACTION  OF  MORPHINE  FROM  HAIR  (INTERNAL 
STANDARD  ADDED  PRE-EXTRACTION) 
5.8.2.1  EXPERIMENTAL 
A  temperature  investigation  was  carried  out  for  the  extraction  of  morphine  from  spiked 
hair.  10  spiked  hair  samples  were  prepared  with  100  µl  of  morphine  and  d3-morphine  and 
extractions  carried  out  in  duplicate  at  60,70,80,90  and  100  °C. 
5.8.2.2  RESULTS  AND  DISCUSSION 
The  results  are  shown  in  Table  5.7.  It  should  be  noted  that  the  hair  was  not  added  to  the 
extraction  column  for  the  second  extraction  at  100  °C  and  therefore  no  result  has  been 
reported. Chapter  Five:  Hair  Analysis  Page188 
Table  5.7:  Temperature  Recovery  Study  for  Morphine  Spiked  Hair 
Relative  Recovery  (Ext/U  next)  n=3  Ratio  Average 
Run  m/z  432  m/z  429  m/z  414  m/z  ratio 
414/429 
m/z  ratio 
429/432 
Unext.  Std.  na  na  na  0.520  1.146 
60/1  14  5  10  1.105  0.403 
60/2  19  15  16  0.587  0.866 
70/1  126  106  105  0.535  0.967 
70/2  40  33  37  0.592  0.946 
80/1  75  60  64  0.582  0.909 
8012  163  146  137  0.509  1.021 
90/1  30  26  28  0.504  0.975 
90/2  42  39  40  0.556  1.065 
100/1  103  98  98  0.541  1.095 
From  these  results,  although  the  best  recoveries  appear  to  be  at  80  °C,  at  100  °C  the 
recoveries  are  still  high  and  the  ratios  more  comparable  to  the  unextracted  standard. 
5.8.3  EFFECT  OF  TEMPERATURE  ON  THE  EXTRACTION  OF  MORPHINE  FROM  HAIR  (INTERNAL 
STANDARD  ADDED  POST-EXTRACTION) 
5.8.3.1  EXPERIMENTAL 
This  study  was  repeated  but  this  time  the  internal  standard  was  added  post  extraction  to 
obtain  absolute  recoveries.  It  should  be  noted  that  when  the  internal  standard  is  added 
directly  to  the  weighed  hair,  losses  in  transferring  the  hair  to  the  extraction  vessel  do  not 
effect  the  results.  However,  transfer  losses  will  decrease  the  recoveries  when  the  internal 
standard  is  added  post  extraction. 
5.8.3.2  RESULTS  AND  DISCUSSION 
The  results  are  shown  in  Table  5.8. Chapter  Five:  Hair  Analysis  Page  189 
Table  5.8:  Temperature  Study  Results  with  d?  -Morphine  Added  Post-Extraction 
Run  m/z  ratio  414/429  m/z  ratio  429/432  %  Recovery 
Unext.  Std.  0.498  1.252  n/a 
60/1  0.754  0.114  9.1 
60/2  0.858  0.095  7.6 
70/1  0.703  0.158  12.6 
70/2  0.651  0.194  15.5 
80/1  0.678  0.166  13.3 
80/2  0.660  0.146  11.7 
90/1  4.750  0.008  -ve 
90/2  0.702  0.148  11.8 
100/1  0.586  0.229  18.3 
100/2  0.847  0.196  15.7 
Again  from  these  results,  the  extraction  at  100  °C  gives  the  best  recoveries.  Based  on  these 
results  and  the  results  in  Table  5.7,  it  would  appear  that  the  losses  on  transport  are  high  and 
thus  the  internal  standard  should  be  added  directly  to  the  weighed  hair. 
5.8.4  DIRECT  COMPARISON  OF  PRE  AND  POST  ADDING  OF  INTERNAL  STANDARD 
5.8.4.1  EXPERIMENTAL 
A  comparison  of  d3-morphine  added  pre  and  post-extraction  was  carried  out  to  compare  the 
two  on  the  same  day  in  the  same  GC/MS  run. 
5.8.4.2  RESULTS  AND  DISCUSSION 
The  results  are  shown  in  Table  5.9.  These  extractions  were  only  run  once  in  order  to 
extract  all  samples  within  the  same  day. Chapter  Five:  Hair  Analysis  Page190 
Table  5.9:  Pre-  and  Post-Extraction  dg-Morphine  Addition 
Run  m/z  ratio  414/429  m/z  ratio  429/432  %  Recovery 
Unext.  0.501  0.865  n/a 
60Post  0.626  0.258  29.8 
60Pre  0.433  0.101  11.7 
70Post  0.518  0.103  11.9 
70Pre  0.472  1.081  125 
80Post  0.518  0.103  11.9 
80Pre  0.662  0.417  48.2 
90Post  0.473  0.857  99.1 
90Pre  0.521  1.681  194 
l00Post  0.504  0.879  102 
10OPre  0.513  0.946  109 
The  pre-extraction  recoveries  represent  how  well  the  PAR  of  the  extracted  and  unextracted 
standards  compare  and  the  post-extraction  recoveries  represent  the  actual  recoveries  for  the 
extraction.  Again  from  this  it  was  decided  to  stay  with  a  temperature  of  100  °C  for  the 
morphine  hair  extractions. 
5.8.5  INTRODUCTION  of  6MAM  To  HAIR  EXTRACTIONS 
5.8.5.1  EXPERIMENTAL 
At  this  point,  6MAM  was  introduced  to  the  system.  A  spiked  hair  sample  was  prepared  as 
previously  described  by  pipetting  100  µl  of  morphine  (8.5  mg/L)  and  100  µl  of  6MAM 
(13.3  mg/L)  onto  100  mg  of  hair.  This  sample  was  split  into  three  portions  which  were 
then  extracted  using  the  developed  conditions  at  100  °C. 
5.8.5.2  RESULTS  AND  DISCUSSION 
The  results  for  the  extraction  of  morphine  and  6MAM  from  spiked  hair  samples  are  shown 
in  Table  5.10. Chapter  Five:  Hair  Analysis  Pagel9l 
Table  5.10:  Extraction  of  Morphine  and  6MAM  from  Spiked  Hair 
Extract  m/z  ratio 
340/399 
m/z  ratio 
340/432 
%Rec.  m/z  ratio 
414/429 
m/z  ratio 
429/432 
%Rec. 
Unext.  0.875  1.304  na  0.543  1.097  na 
1  0.792  1.216  93  0.468  0.855  78 
2  0.843  1.143  88  0.410  1.139  104 
3  0.894  1.197  92  0.525  0.991  90 
From  this  it  can  be  seen  that  the  extraction  conditions  yield  good  recoveries  of  the  6MAM 
from  spiked  hair.  In  addition  to  this,  a  spiked  6MAM  sample  with  no  morphine  was 
prepared  and  extracted  as  before  to  determine  if  the  extraction  was  hydrolysing  the  6MAM 
to  morphine.  The  ratio  of  340/399  was  found  to  be  0.742  and  the  ratio  of  340/432  1.079. 
No  morphine  was  recovered. 
5.8.6  LINEARITY  OF  MORPHINE  AND  6MAM 
5.8.6.1  EXPERIMENTAL 
Morphine  and  6MAM  spikes  were  prepared  at  0.085  ng/mg  to  85ng/mg  and  0.133  to  133 
ng/mg  respectively  in  order  to  determine  if  the  extraction  was  linear  over  this  range  and  to 
determine  the  limit  of  detection  for  each  of  the  drugs.  In  each  case  the  drugs  were  spiked 
onto  approximately  50  mg  of  hair  and  the  d3-morphine  concentration  was  approximately  5 
ng/mg. 
5.8.62  RESULTS  AND  DISCUSSION 
The  results  for  the  linearity  and  limit  of  detection  for  morphine  and  6MAM  are  shown  in 
Table  5.11. Chapter  Five:  Hair  Analysis  Page192 
Table  5.11:  Linearity  and  Limit  of  Detection  for  Morphine  and  6MAM 
Concentration 
n  /m 
m/z  ratio 
414/429 
m/z  ratio 
429/432 
m/z  ratio 
340/399 
m/z  ratio 
340/432 
0.085.0.133  no  peaks  -ve  no  peaks  -ve 
0.17/0.27  no  peaks  -ve  0.698  0.084 
0.34/0.53  1.239  -ve  0.853  0.135 
0.85/1.33  0.653  0.264  0.842  0.279 
2.13/3.33  0.649  0.634  0.796  0.446 
4.25/6.65  0.558  1.147  0.742  0.983 
8.5/13.3  0.524  2.367  0.831  1.992 
17.0/26.6  0.613  4.597  0.739  3.675 
25.5/39.9  0.598  6.861  0.856  7.268 
34.0/53.2  0.499  10.394  0.816  9.883 
85/133  0.515  25.468  0.875  19.684 
For  morphine,  r2=0.999  and  the  equation  of  the  line  is  y=0.301x  -  0.200.  For  6MAM, 
r2=0.987  and  the  equation  of  the  line  is  y=0.152x  +  0.211.  The  limits  of  detection  for 
morphine  and  6MAM  were  taken  as  0.85  ng/mg  and  0.27  ng/mg  respectively  for  a  50  mg 
hair  sample.  Both  sets  of  drug  concentrations  were  found  to  be  linear  over  the  range 
studied. 
5.9  METHOD  DEVELOPMENT  FOR  THE  EXTRACTION  OF  METHADONE  FROM  HAIR 
At  this  point  methadone  method  development  was  still  being  carried  out  using  the  FID  and 
not  GC/MS.  This  caused  problems  due  to  extracted  endogenous  material  which  the  FID 
was  sensitive  to  as  highlighted  in  Figure  5.6.  It  should  be  noted  that  the  methadone  and 
cyclizine  elute  between  10  and  15  minutes  and  thus,  unless  they  were  present  in  high 
concentrations,  they  would  not  be  seen  above  the  background. Chapter  Five:  Hair  Analysis  Page  193 
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Figure  5.6:  GC/FID  Trace  of  Background  Noise  for  Methadone  Extraction 
This  endogenous  material  did  not  interfere  with  the  morphine  on  the  GC/MS  or 
benzodiazepines  on  the  HPLC/UV.  At  this  point  the  modifier  was  being  added  using  the 
second  pump  and  not  directly  to  the  extraction  cell.  By  extracting  the  modifier  on  its  own, 
most  of  the  endogenous  peaks  were  still  being  observed  and  thus,  method  development  for 
methadone  was  switched  to  the  GC/MS.  In  addition,  as  the  hair  had  already  been  spiked 
with  cyclizine  this  was  used  as  the  internal  standard  and  was  not  detected  in  any  of  the 
traces.  Three  extractions  were  carried  out  using  the  methodology  described  previously  and 
methadone  was  found  in  all  three  modified  hair  extracts.  As  with  the  morphine  extracts, 
the  CO2  cleanup  extracts  were  negative. 
When  the  internal  standard  for  methadone  was  first  attempted  with  d3-methadone,  it  was 
discovered  that  the  wrong  internal  standard  had  been  ordered  from  Sigma  (deuterated  at  the 
wrong  part  of  the  molecule).  Two  spiked  samples  were  extracted  and  methadone  was 
observed  in  both  cases.  However,  the  methadone  peak  will  contain  contributions  from 
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both  the  methadone  and  the  d3-methadone  and  thus  even  area  based  recoveries  could  not  be 
calculated. 
As  the  method  development  for  the  benzodiazepines  and  for  the  morphine/6MAM  had 
been  successful  and  these  drugs  were  both  extracted  efficiently  by  the  same  method,  it  was 
decided  to  use  the  method  for  all  three  types  of  drug.  A  recovery  study  was  carried  out 
over  the  range  0.112  to  71.68  ng/mg  methadone.  The  results  obtained  are  shown  in  Table 
5.12. 
Table  5.12:  Linearity  of  Methadone  in  Hair 
Concentration  (n  /m)  m/z  ratio  72/75  m/z  ratio  72/165 
0.112  -ve  no  165 
0.56  0.105  0.096 
1.12  0.186  0.064 
2.24  0.349  0.063 
5.60  0.507  0.073 
11.2  0.794  0.054 
22.40  2.169  0.037 
33.60  3.947  0.051 
44.80  5.671  0.029 
56.0  7.931  0.039 
For  methadone  over  this  concentration  range,  the  coefficient  of  correlation  was  found  to  be 
0.982  with  the  equation  of  the  line  as  y=0.135x  -  0.599.  The  limit  of  detection  for  a  50  mg 
hair  sample  was  0.56  ng/mg. 
5.10  CONCLUSIONS 
For  the  extraction  of  benzodiazepines,  morphine  and  methadone  from  hair  samples,  the 
SFE  method  developed  by  Cirimele  et  a1198  was  successfully  applied.  Good  reproducibility 
was  found  within  extractions  of  the  same  concentration  of  spiked  standard  and  high 
recoveries  were  obtained. 
The  actual  conditions  used  for  the  extraction  of  the  hair  samples  is  detailed  below: Chapter  Five:  Hair  Analysis  Page195 
In  order  to  maximise  the  surface  area,  the  hair  samples  were  prepared  by  grinding  under 
liquid  nitrogen  to  produced  a  fine  powder.  The  hair  to  be  analysed  was  weighed  and 
transferred  to  the  extraction  vessel.  The  extraction  consisted  of  two  stages.  First  of  all  a 
clean  up  step  was  employed  to  remove  exogenous  compounds  from  the  surface  of  the  hair. 
This  consisted  of  running  the  SFE  in  the  static  mode  for  10  minutes  followed  by  a  dynamic 
extraction  for  15  minutes.  The  extraction  cell  was  then  removed  from  the  SFE  and  300  µl 
of  modifier  (MeOH:  Et3N:  H20  2:  2:  1)  and  100  µl  of  the  internal  standard  added.  Once  the 
extraction  cell  had  been  replaced  in  the  SFE  system,  a  second  static  extraction  was  carried 
out  for  15  minutes.  This  was  followed  by  a  dynamic  extraction  for  20  minutes  and  the 
analytes  were  collected  in  to  MeOH  at  the  flow  outlet. 
For  all  steps,  the  flowrate  was  2.0  ml  miri  I,  the  pressure  was  3500  psi  and  the  temperature 
100  °C. 
Linearity  over  a  wide  range  was  seen  for  benzodiazepines  analysed  by  HPLC  and  for 
morphine  and  methadone  analysed  by  GC/MS.  The  detection  limits  are  low  enough  to 
permit  detection  of  the  drugs  in  hair  even  when  the  sample  size  is  relatively  small 
(temazepam:  1.15  ng/mg,  desmethyldiazepam:  1.06  ng/mg,  diazepam:  1.03  ng/mg, 
morphine:  0.85  ng/mg,  6MAM:  0.27  ng/mg,  methadone:  0.1  ng/mg  based  on  a  50  mg  hair 
sample). 
It  terms  of  comparison  with  other  methodology  for  the  extraction  of  drugs  from  hair,  the 
method  offers  several  advantages.  Firstly,  all  three  drug  types  were  extracted  using  the 
same  method  without  degradation.  In  addition  the  total  extraction  time  was  1  hour  which 
makes  the  extraction  much  quicker  than  conventional  methods  e.  g.  acid  hydrolysis  requires 
an  18  hour  incubation  and  methanolic  extractions  require  5  hours  sonication. Mr  Justice  Avovq,  I924 Chapter  Six:  Case  Results  Page196 
6.  CASE  STUDIES 
6.1  INTRODUCTION 
The  ultimate  aim  of  any  method  developed  for  toxicological  analysis  is  its  application  to 
authentic  samples.  Method  development  for  the  extraction  of  an  analyte  from  a  spiked 
sample  is  the  best  way  of  imitating  an  authentic  sample  however,  in  reality,  other  factors 
will  come  into  effect  when  an  authentic  sample  is  put  through  the  developed  extraction 
process.  Of  particular  importance  to  SFE  is  the  effect  that  other  analytes  or  matrix 
artefacts  will  have  on  the  extraction  efficiency  of  the  analyte  of  interest. 
6.2  CASE  INFORMATION 
For  this  study  48  post-mortem  cases  were  investigated.  Samples  were  obtained  for 
suspected  drug  abuse  cases  from  the  pathologist  in  charge  of  the  postmortem.  Blood, 
vitreous  humor  and  hair  samples  were  requested  and  in  most  of  the  cases  all  three  sample 
types  were  made  available.  Summary  information  on  each  of  the  cases  investigated, 
including  the  samples  made  available  is  given  in  Table  6.1.  A  more  detailed  description  of 
the  circumstances  surrounding  the  death  is  given  in  section  6.2. 
Hair  samples  were  taken  from  the  posterior  vertex  and  were  about  the  thickness  of  a  pencil. 
Initially  the  roots  and  tips  of  the  hair  samples  were  not  kept  aligned  and  this  made 
sectioning  of  the  hair  very  time  consuming.  After  a  visit  to  the  mortuary  it  was  decided 
that  the  easiest  way  to  keep  the  roots  of  the  hair  together  was  to  tie  a  piece  of  string  round 
the  centre  of  the  sample  which  had  been  pulled  and  then  place  the  tied  hair  sample  in  a 
glass  universal  container. 
Blood  and  vitreous  humor  samples  were  also  collected  in  glass  universal  containers 
however,  no  information  was  made  available  on  the  site  of  blood  sampling  and  whether  the 
vitreous  came  from  one  or  two  eyes. Chapter  Six:  Case  Results  Page  197 
Table  6.1:  Case  Summary  Information 
Case  Age/Se  #Days  Cause  of  Death  Suspected  Drugs  Hair  Vit.  Blood  #  of  Alc 
Died-PM  (As  PM  re  ort)  Humor  Drugs 
K96  01  241F  12.1.96  a)PO  &C  propanolol,  ￿  X.  x  2  x 
b)Prothiaden  cannabis, 
and  propanolol  prothiaden, 
OD  speed,  Valium 
K96  0  26/M  6  a)I.  G.  C.  temazepam,  ￿  ￿  ￿  I  ￿ 
b)Morphine  and  procyclidine,  0 
alcohol  intox.  em  esic,  heroi 
K96  0  34/M  12.1.96  a)AFDL  b)acute  cocaine,  heroin,  V  V  V  3  ￿ 
alcohol  intox.  alcohol  0 
K96  0  23/M  12/1/96  a)PO  &C  Librium®,  V  x  ￿  5  V 
b)Drug  related  nitrazepam,  OB 
death  DHC,  oxazepam 
diazepam, 
insulin 
K96  0  36/M  16/1/96  a)Pneumonia  methadone,  V  x  x  I  x 
b)  IVDA  heroin,  M 
benzodiaze  ines 
K96  0  22/M  17.1.96  )I.  G.  C.  nitrazepam,  ￿  X.  X.  1  X. 
DHC,  heroin,  M 
cannabis 
K96  0  34/F  3  a)PO  &C  heroin,  Diconal"  V  V  ￿  3  X 
)Heroin  and  temazepam,  OB 
temaz.  intox.  Librium®, 
methadone 
K96  0  39/M  5  )Septis  methadone,  ￿  ￿  ￿  3  X. 
yndrome  diazepam,  BM 
Chronic  IVD  cocaine 
K96  0  29/M  16.2.96  a)Morphine  and  heroin  ￿  x  x  2  x 
emaz.  intox.  BM 
K96  1  38/M  6  a)PO  &C  alcohol,  ￿  ￿  ￿  1  x 
Heroin  intox.  cannabis,  heroin  0 
K97  11  27/F  21.3.96  a)I.  G.  C.  heroin  V  V  ￿  4  x 
b)Drug  related  OB 
death 
1(9  11  30/M  21.3.96  a)PO  &C  solvents,  ￿  ￿  ￿  1  x 
b)Morphine  sulpiride  0 
intox. 
K96  13  25/M  18.7.96  a)PO  &C  diazepam,  heroin  ￿  V  ￿  4  ￿ 
b)  Drug  related  BMT 
eath 
K96  1  25/M  6  )PO  &C  none  ￿  V  ￿  3  ￿ 
)Heroin  intox.  OB 
K96  1  35/F  9  a)PO  &  C;  methadone,  V  V  V  4  ￿ 
b)Methadone  cannabis,  heroin  BM 
intox. 
K96  1  30/F  29.7.96  )PO  &  C;  heroin  ￿  ￿  ￿  2  x 
,b 
)Heroin  intox.  0 
K96I  26/M  3  )Morphine  heroin,  ￿  V  ￿ 
I 
1  ￿ 
overdose  procyclidine,  0 
de  ixol,  losac 
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Case  Age/Se  #Days  Cause  of  Death  Suspected  Drug  Hair  Vit.  Blood  #  of  Alc 
Died-PM  (As  PM  report)  Humor  Drugs 
K96  18  33/M  7  a)Morphine  heroin,  ￿  ￿  ￿  4  X. 
overdose  temazepam,  OBM 
methadone 
K9619  32/M  3  a)I.  G.  C.  heroin  x  ￿  ￿  1  x 
b  )Heroin  intox.  O 
K96  20  39/M  7  a)PO  &  C;  cannabis,  heroin  ￿  ￿  ￿  3  X. 
b  )heroin  intox.  OB 
K96  21  29/F  5  a)PO  &C  methadone,  ￿  ￿  ￿  5  X. 
b)Heroin  intox.  heroin,  OBM 
temazepam, 
diazepam 
K96  22  27/F  7  a)PO.  methadone,  ￿  ￿  ￿  4  X. 
b)Heroin  and  heroin  OBM 
temaz  intox. 
K96  23  171M  4  a)I.  G.  C.  DHC,  Valium®,  ￿  ￿  ￿  4  ￿ 
b)Methadone,  cannabis,  BM 
iaz.,  cannabis  &  alcohol 
alcohol  intox. 
K96  24  20/F  21.10.96  a)Methadone,  methadone,  ￿  ￿  ￿  4  X. 
diazepam  &  temazepam,  BM 
emazepam  heroin, 
intoxication  paroxetine, 
diazepam, 
ibuprofen, 
loprazolam 
K96  25  25/M  7  a)I.  G.  C.  heroin,  Valiums  ￿  ￿  ￿  3  x 
b)Morphine  &  Librium®,  DHC,  OB 
iaz.  intox.  LSD,  cannabis, 
temgesic, 
temaze  am 
K96  26  24/M  3  a)Asphyxia  due  heroin  ￿  ￿  ￿  0  x 
to  hanging 
K96  27  261M  8  a)Morphine  &  heroin,  DHC,  ￿  ￿  ￿  4  ￿ 
temaz.  intox.  temazepam,  OB 
methadone 
K96  28  21/M  4  a)PO  &C  oxazepam,  ￿  ￿  ￿  3  x 
)Morphine  nitrazepam  OB 
intox. 
K96  29  33/M  5  a)AGC  temazepam,  ￿  ￿  ￿  3  x 
)Heroin  and  heroin  OB 
temaz.  intox. 
K96  30  17/F  10.12.96  a)I.  G.  C.  related  heroin,  ￿  ￿  ￿  3  x 
b)Drug  related  temazepam,  B 
death  iazepam 
K97  01  37/F  12  a)Gastro-  heroin,  alcohol  ￿  x  x  2  ￿ 
intestinal  M 
haemorrhage: 
b)Methadone 
intox 
K97  02  35/M  5  )Methadone,  diazepam,  ￿  x  x  5  x  heroin,  temaz.  &  methadone  OBM 
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Case  Age/Se  #Days  Cause  of  Death  Suspected  Drug  Hair  Vit.  Blood  #  of  Alc 
Died-  (As  PM  report)  Humor  Drugs 
PM 
K97  03  23/M  14  a)I.  G.  C.  methadone,  ￿  x  ￿  2  x 
b)Methadone  and  Valium®  M 
CE  intox 
K97  04  24/M  12  a)PO  &C  heroin,  ￿  x  ￿  1  x 
)Heroin  intox  diazepam,  0 
Voltarol®, 
Remedeine® 
K97  05  19/M  10  )Hanging  None  ￿  ￿  ￿  1  ￿ 
K97  06  26/M  7  )PO  &C  trazodone,  ￿  ￿  x  5  ￿ 
)Heroin  &  cannabis,  OB 
emazepam  temazepam, 
intoxication  Valium® 
K97  07  40/F  8  a)PO&C  heroin  ￿  ￿  ￿  1  ￿ 
Heroin  intox.  O 
K97  08  29/M  4  Unascertained  heroin,  ￿  ￿  x  5  ￿ 
methadone  OB 
K97  09  32/F  6  a)PO  &C  alcohol,  heroin  ￿  ￿  ￿  2  ￿ 
)Heroin  &  OB 
temaz.  intox 
K97  10  30/M  5  a)Drug  related  cannabis,  ￿  ￿  ￿  9  x 
death  cocaine,  OB 
temaze  am 
K97  11  30/F  5  a)Chlor.,  diaz.  &  heroin,  x  ￿  ￿  4  x 
morphine  temazepam,  OB 
(heroin)  intox.  diazepam 
K9712  29/M  11  a)PO&C  heroin,  ￿  x  ￿  3  ￿ 
b)Heroin,  diaz.  methadone,  OB 
alcohol  intox.  diazepam 
K97  13  18/M  5  )I.  G.  C.  methadone,  ￿  ￿  ￿  2  ￿ 
heroin  M 
K97  14  271F  7  a)A.  G.  C.  heroin  ￿  ￿  ￿  2  x 
OB 
K97  15  29/M  6  a)A.  G.  C  alcohol,  DHC,  ￿  ￿  ￿  2  ￿ 
b)Heroin  intox.  Coproxamol,  0 
Codydramol 
K97  16  20/M  4  )Heroin  &  diaz.  heroin,  x  ￿  ￿  3  x 
intox.  amitryptiline  OB 
K97  17  35/M  12.6.97  )Alcohol,  diaz.  heroin,  alcohol  x  ￿  ￿  2  ￿ 
&  heroin  intox.  OB 
K97  18  36/M  12.6.97  a)Heroin  &  heroin  x  ￿  ￿  1  x 
methadone  intox.  M 
Abbreviations:  M:  male;  F:  female;  PO&C:  pulmonary  oedema  and  congestion;  AFDL: 
acute  fatty  degeneration  of  the  liver;  A/IGC:  aspiration/inhalation  of  gastric  contents; 
DHC:  dihydrocodeine;  0:  opiate;  B:  benzodiazepines;  M:  methadone;  #:  number;  Alc: 
alcohol;  ￿:  detected;  x:  not  detected 
A  graph  of  the  range  of  ages,  for  each  sex  was  plotted  and  is  given  in  Appendix  III. Chapter  Six:  Case  Results  Page200 
6.3  CIRCUMSTANCES  SURROUNDING  DEATH  AND  OTHER  RELEVANT  INFORMATION 
The  following  section  summarises  the  information  available  from  the  post-mortem  and 
police  reports  for  each  of  the  cases  examined. 
K96  01 
Multiple  needle  puncture  marks  (NPMs)  on  right  side  of  neck  (post-mortem),  front  of  right 
shoulder,  groin,  and  arms.  History  of  taking  cannabis  and  speed.  Use  of  harder  drugs 
denied.  Diabetic  (perhaps  explains  needle  marks).  Recently  prescribed  Valium®.  On 
night  of  death  swallowed  most  of  the  contents  of  Propanolol  and  Prothiaden  bottles.  Taken 
to  hospital  hypotensive  and  unresponsive.  Given  Gelofusion  and  Inotrapses  to  raise  blood 
pressure  and  Boprenailin,  adrenaline  and  Sluragon  intravenously.  Resuscitation  proved 
unsuccessful.  Died  in  hospital. 
K96  02 
History  of  long-standing  schizophrenia.  Known  intravenous  drug  abuser  (IVDA). 
Admitted  injecting  temazepam  and  temgesic  6  years  ago.  Denied  the  use  of  other  drugs  at 
this  time.  On  Procyclidine  for  schizophrenia  (5  mg,  twice  daily).  Thought  to  have  been 
supplied  heroin.  Two  possible  fine  needle  marks  on  right  antecubital  fossa.  Died  at  home 
with  syringe  still  in  hand.  Last  seen  previous  evening. 
K96  03 
Known  to  have  abused  heroin  for  14  years  and  also  thought  to  abuse  cocaine.  Alcohol 
abuse  for  5  years.  Previous  heroin  overdose.  Not  on  any  medication  at  time  of  death.  No 
evidence  of  needle  puncture  marks.  Drinking  heavily  on  day  of  death  and  complaining  of 
stomach  pains.  Returned  home  1900  drunk  and  left  to  sleep  in  the  recovery  position. 
Found  dead  in  the  morning  0855. 
K96  04 
Diagnosed  diabetic.  Severe  insulin  dependence.  Recently  admitted  to  hospital  with 
diabetes  ketoacidosis,  but  failed  to  go  back  for  check  ups.  Received  one  months  supply  of 
insulin  and  Valium,  ®  did  not  reattend  clinic  for  more.  Records  show  the  deceased  to  be  a 
registered  drug  abuser  as  late  as  one  month  prior  to  death.  No  evidence  of  needle  puncture Chapter  Six:  Case  Results  Page201 
marks.  Complained  of  feeling  unwell  night  before  death  but  refused  medical  attention. 
Found  dead  the  next  morning  in  bed. 
K96  05 
Infected  injection  site  on  right  arm.  Thrombosed  veins  on  left  arm.  Signs  of  injection  in 
both  sides  of  groin.  Previous  year  admitted  to  hospital  with  abscesses  and  blood  clots  in 
legs  and  groin.  General  poor  health  due  to  drugs.  On  a  series  of  programmes  for  12  years 
to  curtail  drug  problem.  On  methadone  programme  but  failed  to  pick  up  last  prescription. 
Admitted  still  abusing  heroin  and  benzodiazepines.  Last  seen  16  days  before  being  found 
dead  at  home.  Hypodermic  syringe,  needles,  sterilised  pads,  Abdine  powders  and  heroin 
found  in  the  vacinity. 
K96  06 
No  fresh  or  old  needle  puncture  marks  identified.  Thought  to  smoke  heroin  and  cannabis 
but,  not  an  IVDA.  Six  months  prior  to  death  attended  surgery  with  respect  to  drug 
dependency  problem  with  heroin  and  cannabis.  Administration  of  dihydrocodeine  (DHC) 
since  then.  Thought  to  be  overcoming  drug  problem.  One  month  prior  to  death,  suffered 
sleeping  difficulties  and  prescribed  nitrazepam.  On  night  of  death,  went  to  bed  at  around 
2130.  Found  dead  in  bed  the  next  morning 
K96  07 
No  petechial  haemorrhages.  Needle  marks  and  scarred  sinuses  in  groins.  Recent  NPM  on 
right  side.  Both  lungs  oedematous  and  congested.  Rigor  beginning  to  wear  off.  In  prison 
for  three  weeks,  released  two  days  prior  to  death.  IVDA  for  17  years.  Abused  heroin, 
Diconal  and  heroin/temazepam.  Took  overdose  of  heroin  two  years  ago.  Recently 
prescribed  methadone  and  Librium.  "'  On  day  of  death,  took  drugs  between  1400  and  1430 
hours  then  became  unwell.  Found  dead  at  1610  hours  with  a  syringe  in  close  proximity. 
K96  08 
No  petechial  haemorrhages.  Marked  oedema  in  lungs.  Needle  puncture  marks  on  both 
sides  of  neck.  Evidence  of  old  puncture  marks  at  groin  and  possibly  on  arms.  Signs  of 
chronic  IVDA  on  shins  and  ankles.  Prescribed  methadone  (50  ml  daily)  and  diazepam  (15 Chapter  Six:  Case  Results  Pa  ege2202 
ml  daily).  Complained  of  swollen  testicles  as  the  result  of  an  assault  and  attended  hospital. 
Swelling  thought  to  be  due  to  injection  on  the  right  side  of  the  groin,  but  could  have  been 
due  to  assault.  Further  investigation  found  cellulitus  of  the  abdominal  wall,  infection  under 
the  skin  round  the  groin  due  to  long  term  injection.  Resulted  in  sceptic  shock.  Died  in 
hospital.  Thought  to  have  been  off  heroin  for  about  two  years,  but  had  started  snorting 
cocaine. 
K96  09 
Body  badly  burned  and  hair  singed.  Needle  and  syringe  clasped  in  right  hand.  80%  burns. 
No  obvious  signs  of  chronic  drug  abuse.  No  violence  evident.  History  of  drug  abuse. 
Abused  heroin  regularly.  Thrombosis  in  right  leg  prior  to  death.  Appears  to  have 
overdosed  and  fallen  onto  a  fire.  Life  pronounced  extinct  at  1410.  Burning  post  mortem 
therefore  cause  of  death  is  overdose  and  not  fire  (no  CO  in  blood). 
K96  10 
Known  drug  abuser.  Last  seen  alive  in  the  afternoon  three  days  before  being  found  dead. 
May  have  been  seen  on  video  surveillance  camera  night  before  death.  Needle  and  syringe 
in  hand  (still  injected).  History  of  alcohol  abuse  and  smoked  cannabis.  Reported  using 
"smack".  No  medical  records  of  drug  use,  but  treated  for  alcoholism  and  asthma.  Vene- 
puncture  mark  on  back  of  left  hand. 
K9611 
No  fresh  needle  marks  although  some  old  ones  possibly.  Taking  drugs  for  11  years  and 
most  recently  heroin.  Overdose  seven  years  ago.  One  week  before  death  given  sick  line 
from  doctor  for  nervous  debility.  Released  from  prison  8  days  before  death.  On  day  of 
death,  said  to  have  been  "sniffing".  Fell  asleep  at  1900.  Found  collapsed  on  the  floor  at 
2030.  Ambulance  called  but  no  signs  of  life. 
K9612 
No  sign  of  chronic  IV  use  but  one  puncture  mark  on  the  left  antecubital  fossa  perhaps  due 
to  resuscitation.  Suffered  from  mental  illness  and  was  on  medication.  Diagnosed  psychotic Chapter  Six:  Case  Results  Page203 
on  sulpiride.  Known  solvent  abuser.  Last  thought  to  be  alive  at  around  2130.  Found  two 
hours  later.  Needles,  syringe  and  suicide  note  found  in  the  vacinity. 
K96  13 
Died  in  hospital.  Taken  in  as  having  problems  breathing.  Resuscitation  carried  out. 
Adrenaline,  atropine,  diazepam,  streptokinase  and  intravenous  fluids  given.  Condition 
deteriorated.  Died  at  2157.  Four  needle  puncture  marks  in  right  antecubital  fossa  (two 
with  bruising)  three  on  front  of  right  wrist,  one  on  front  of  right  ankle,  one  on  right  side  of 
left  ankle.  Suggestion  of  scarring  on  both  sides  of  groin.  Being  assessed  for  suitability  for 
rehabilitation  and  treatment  at  a  Drug  Clinic.  Extensive  evidence  of  IVDA.  No 
medication  at  time  of  death 
K96  14 
Possible  needle  marks  on  right  forearm  at  the  elbow  and  left  arm  just  above  the  elbow. 
Fresh  needle  mark  on  the  back  of  the  left  hand.  Rigor  mortis  established.  Lungs 
oedematous  and  highly  congested.  Last  seen  by  family  doctor  two  months  previously 
suffering  from  anxiety  neurosis.  Seen  at  1500  in  apparently  good  health.  Found  dead  at 
home  at  2000  with  syringe  in  close  proximity. 
K9615 
Petechiae  confined  to  areas  of  hypostasis.  Early  decomposition  setting  in.  Rigor  mortis 
diminished.  Lungs  congested  and  oedematous.  Right  arm,  three  old  healed  puncture 
marks.  History  of  drug  abuse.  Known  drug  abuser  for  eight  years.  Registered  drug  abuser. 
Not  known  what  medication  she  was  on  at  time  of  death.  Released  from  prison  day  before 
death  after  a  three  month  sentence.  Overdosed  on  methadone  at  fpm  on  day  of  release  and 
admitted  to  hospital.  Treated  with  Narcan  and  discharged  at  2.30  p.  m.  At  around  8  p.  m., 
at  friends  house  drinking  heavily  and  smoking  cannabis.  Went  to  bed  at  10  p.  m.  Found  to 
be  dead  at  9  am  following  morning. 
K9616 
No  petechial  haemorrhages.  Rigor  mortis  diminished.  Lungs  congested  and  oedematous. 
Left  front  forearm,  two  healing  puncture  marks.  Back  of  left  forearm,  1  healing  puncture Chapter  Six:  Case  Results  Page204 
mark.  Two  puncate  abrasions  on  back  of  left  hand.  On  maintenance  prescription  in  the 
form  of  painkillers  to  treat  serious  bums  received  three  years  earlier.  Two  months  prior  to 
death,  admitted  to  hospital  due  to  heroin  overdose.  Needle  marks  found  on  groin  and  arm. 
At  2pm  on  day  of  death,  started  drinking  heavily.  8.30pm,  returned  home  and  continued 
drinking  then  fell  asleep.  Found  dead  in  living  room  at  11.15pm 
K96  17 
Petechial  haemorrhages  noted  in  left  anterior  axillary  fold  and  the  adjacent  axilla.  Rigor 
mortis  well  established.  Moderate  to  severe  oedema  and  congestion  in  lungs.  Possible 
recent  puncture  mark  on  left  antecubital  fossa.  Past  medical  history  of  schizophrenia  and 
known  IVDA.  Prescribed  procyclidine,  depixol  and  Losec.  Referred  to  a  Drugs  Centre 
one  month  before  death.  Last  seen  by  doctor  two  weeks  before  death  and  prescribed 
procyclidine.  Collapsed  suddenly  at  home  after  injection  of  heroin.  Resuscitation  attempts 
failed.  Seized  syringe  from  outside  flat. 
K9618 
No  petechial  haemorrhages.  Rigor  mortis  wearing  off.  Moderate  to  severe  oedema  and 
congestion  of  the  lungs.  Recent  puncture  mark  on  radial  border  of  left  wrist.  Pock  mark 
scarring  in  groin  region.  Thought  to  have  become  involved  with  drugs  eight  years  ago. 
Had  drug  counselling  as  part  of  probation.  Abused  heroin  and  temazepam.  First  medical 
history  of  drug  abuse  seven  years  ago.  On  methadone  for  one  year,  45  ml  daily.  Last 
prescribed  five  months  previously.  Registered  drug  addict.  On  night  of  death  went  to 
friends  at  about  10.15  p.  m.  Went  out  for  alcohol  (20  minutes)  then  watched  video  till  0230 
before  going  to  bed.  At  1430  the  next  day  found  dead  (1-2  hours  only).  Found  blood  filled 
syringe  on  floor,  shoelace  round  left  wrist,  spoon  and  open  Abdine  health  drink  sachet. 
K9619 
A  few  petechial  haemorrhages  on  the  conjunctivae.  Mouth  filled  with  vomit.  Limbs  still 
rigid.  Lungs  showed  haemorrhage  and  oedema  consistent  with  death  in  cardiac  failure  with 
superimposed  inhalation  changes.  Fresh  needle  puncture  mark  on  dorsum  of  right  hand 
plus  some  small  similar  old  wounds.  No  fresh  needle  marks  anywhere  else  on  the  body. 
Known  IVDA.  In  prison  for  several  weeks  prior  and  released  two  days  before  death.  First Chapter  Six:  Case  Results  Page205 
note  of  IVDA  four  years  before  death.  Attending  drugs  counselling  since  then.  Known  to 
have  Hepatitis  B.  At  around  lpm  on  night  before  death  visited  friends  with  heroin  and 
appropriate  drug  paraphernalia,  apparently  under  the  influence  of  drugs.  From  then  till 
midnight,  smoked  hash.  Fell  asleep  around  midnight.  Found  dead  0945  the  next  morning 
with  syringe  and  needle  in  right  hand. 
K96  20 
No  conjuctival  petechial.  Possible  needle  puncture  mark  on  back  of  right  hand.  No  other 
fresh  or  recent  NPMs.  Rigor  mortis  diminished.  Lungs  markedly  congested  and 
oedematous.  History  of  alcohol  and  drug  abuse  for  18  years.  Previous  overdose. 
Prescribed  methadone  one  year  prior  to  death.  Only  prescribed  once  as  doctor  felt  he  no 
longer  needed  it.  Prescribed  GNT  spray  for  angina  five  months  before  death.  Also  on 
ventalin.  Regular  smoker  of  cannabis  and  heroin.  Not  known  to  inject  over  the  past  two 
years.  On  night  of  death,  went  to  bed  drunk.  In  morning  found  dead  in  bathroom  with 
hypodermic  syringe  and  other  drug  paraphernalia  on  the  floor  (-7am).  Possible  needle 
puncture  mark  on  back  of  right  hand.  No  other  fresh  or  recent  needle  puncture  marks. 
K96  21 
Hypostatic  petechiae  on  right  upper  eyelid.  Rigor  mortis  diminished.  Lungs  congested  and 
oedematous.  Lower  limbs  showed  multiple  old  healing  needle  puncture  marks  of  varying 
ages  with  associated  purple  and  greenish  bruising.  Scabbed  sinus  in  left  groin  with  fresh 
needle  puncture  mark  and  blood  dot  at  its  base  with  tissue  paper  attached  to  it.  Multiple 
skin  popping  marks  round  knees  and  calves  of  both  legs.  Long  history  of  drug  abuse.  On 
methadone  treatment  and  obtained  prescription  of  9x  10  mg  diazepam  prescribed  day 
before  death  which  was  consumed  at  the  pharmacists.  Three  days  before  death  found 
collapsed  after  injecting  herself  with  drugs  in  the  toilet.  Recovered  sufficiently  to  refuse 
treatment  by  the  time  the  ambulance  had  arrived.  Last  seen  alive  1700.  Following 
morning  found  dead  in  room  with  trousers  and  pants  at  knees  and  syringe  nearby.  Been  on 
several  detox  programmes  but  resumed  habit  on  leaving.  On  diazepam  on  daily  dispensing 
reducing  course  for  temazepam  addiction.  Week  before  death  requested  methadone  detox. 
Suffered  seizures  due  to  temazepam  abuse  and  thrombosis  in  legs  due  to  IV  injection  in Chapter  Six:  Case  Results  Page206 
groins.  Seized  from  the  premises:  paper  fold  containing  white  powder,  used  syringe,  2 
syringes,  spoon  with  substance  thereon. 
K96  22 
Multiple  fine  petechiae  on  the  upper  eyelids  and  the  congunctivae.  Rigor  mortis 
diminished.  Lungs  showed  oedema  on  sectioning.  Needle  puncture  marks  on  breasts, 
arms,  thighs,  shins,  and  ankles.  History  of  drug  abuse  for  nine  years.  At  the  time  of  death, 
was  on  methadone  treatment.  Last  seen  at  0930.  Didn't  pick  up  methadone  from  the 
chemists.  At  about  1215,  witness  became  concerned  and  investigated  bedroom.  Found 
lying  in  a  semicrouched  position  on  the  floor  with  needle  and  syringe  inserted  into  left  leg. 
Ambulance  called,  but  found  to  be  dead. 
K96  23 
No  fresh  needle  marks  on  body.  Two  years  prior  to  death,  told  doctor  he  had  a  problem 
with  temazepam  and  was  referred  to  drug  abuse  clinic.  Failed  to  turn  up.  Overdosed  on 
alcohol  and  diazepam  seven  months  prior  to  death.  Seen  to  take  5  double  strength 
dihydrocodeine  and  7  yellow  Valium®  tablets  at  party  night  before.  Also  seen  to  drink 
lager  and  smoke  cannabis.  Walked  dog  at  0430,  and  returned  to  flat.  1030  found  dead. 
Small  amount  of  blood  emitting  from  nose. 
K96  24 
No  recent  needle  puncture  marks  or  evidence  of  old  scars  around  groin  areas.  No  recent 
needle  puncture  marks  on  arms.  Known  drug  abuser  but  not  intravenous  injection.  Said  to 
have  had  a  slight  drug  problem  -  taking  temazepam  when  depressed.  Suffered  from 
anxiety,  depression  and  panic  attacks  and  prescribed  Paroxetine  4/96.  Not  on  any 
medication  at  time  of  death.  Week  before  death  admitted  to  taking  Valium,  ®  temazepam 
and  smoking  heroin.  Night  before  death,  having  withdrawal  symptoms.  Returned  home  at 
2100.  Went  to  bed  around  0300  next  morning.  Around  0940  found  to  be  dead.  Seized:  48 
ml  bottle  of  methadone  mixture  -  empty,  5  mg  diazepam  tablets  bottle  -  empty,  400  mg 
ibuprofen  tablets,  400  mg  ibuprofen  tablets  and  1  mg  Loprazolam  tablets. Chanter  Six:  Case  Results  Paze207 
K96  25 
Face  and  conjunctivae  congested  with  a  few  small  petechial  marks.  Limbs  still  rigid. 
Lungs  extremely  congested  and  oedematous.  Right  arm  showed  small  crusted  wound  over 
the  medial  aspect  of  the  front  of  the  elbow  joint.  No  signs  of  recent  or  chronic  drug  abuse 
on  arms.  Both  legs  showed  pitted  scars  on  linear  aspect  of  the  shins  consistent  with  healed 
ulcerated  lesions  associated  with  IVDA.  No  evidence  of  fresh  needle  marks.  History  of 
chronic  IVDA.  Recently  in  prison.  Released  day  before  death.  Two  months  prior  to 
death,  given  a  prescription  for  Librium®  and  dihydrocodeine.  Before  this  had  been 
prescribed  DHC  on  several  occasions  and  admitted  to  having  a  £30  per  day  heroin  habit. 
Five  years  prior  to  death  noted  to  be  using  heroin  and  temgesic.  Overdose  seven  years 
prior  to  death.  Claims  to  have  used  LSD,  cannabis,  temazepam,  DHC  and  temgesic.  On 
release  from  prison,  went  home.  Thought  to  be  under  the  influence  (Valium®).  Later,  left 
house  to  buy  drugs.  Returned  home  0730  and  went  to  bed.  Last  seen  returning  home 
around  1530  apparently  well.  Around  2140,  witness  found  deceased  slumped  in  a  sitting 
position  with  string  tied  round  right  arm  and  needle  lying  next  to  him.  Appeared  to  have 
been  dead  for  several  hours.  Several  drug  related  items  were  removed  from  the  locus  (not 
noted  in  police  report). 
K96  26 
Ligature  mark  round  neck.  Fresh  needle  puncture  mark  on  antecubital  fossa  of  left  arm. 
Admitted  to  prison.  No  drug  use  for  one  week  although  known  to  be  an  IVDA.  Found 
hanging  within  cell  at  around  at  1100.  IV  abuse  of  heroin  (£60-80  per  day).  Moderate 
drinker  and  smoker. 
K96  27 
Eyes  congested  with  some  large  petechiae  in  right  sclera  and  conjunctivae.  Rigor  mortis 
worn  off.  Lungs  congested  and  oedematous.  Greenish  discoloration  of  the  abdomen  due 
to  decomposition.  Possible  recent  puncture  mark  over  radial  border  of  left  mid  forearm. 
Known  IVDA.  Two  weeks  prior  to  death,  found  unconscious  with  syringe  in  arm.  Day  of 
death  at  0020  returned  home.  At  about  0900  found  in  room  sitting  on  bed  apparently  dead. 
Large  amount  of  blood  and  vomit  on  the  floor.  Syringe  still  injected  in  arm.  Various  items 
of  drug  paraphernalia  seized  from  the  locus.  Admitted  to  hospital  due  to  drug  abuse  for Chapter  Six:  Case  Results  Pa  ee208 
first  time  ten  years  previously  for  IVDA  of  heroin.  Continued  to  abuse  heroin  and  other 
drugs.  Admitted  to  drug  dependency  three  and  a  half  years  prior  to  death.  At  this  stage 
also  suffering  from  epilepsy.  On  release  continued  to  abuse  methadone,  dihydrocodeine, 
temazepam  and  heroin  intravenously.  Admitted  to  various  hospitals  due  to  overdoses. 
Attended  psychiatric  unit  for  drug  abusers,  but  still  continued  to  abuse  drugs. 
K96  28 
Scleral  haemorrhage  in  left  eye.  Many  incorporated  petechial  haemorrhages  within 
hypostasis  on  face  and  trunk.  Rigor  mortis  passed  off.  Moderate  congestion  and  oedema 
in  lungs.  Possible  venepuncture  mark  on  left  antecubital  fossa  with  associated  bruising. 
No  other  venepuncture  marks.  Suffered  from  anxiety  and  had  a  drink  and  drug  problem. 
Prescribed  oxazepam.  and  nitrazepam.  Last  seen  1700  hours.  Three  days  later  at  1400 
found  dead  in  bed  with  flex  tied  round  left  arm.  Bloody  fluid  coming  out  of  mouth  and 
nostrils.  Syringe  and  white  substance  found  at  the  locus. 
K96  29 
No  petechial  haemorrhages.  No  recent  puncture  marks  on  either  arm.  Lungs  oedematous. 
Four  heeling  needle  puncture  marks  overlying  right  groin  with  faint  bruising.  Multiple 
recent  and  fresh  puncture  marks  overlying  left  groin  with  surrounding  bruising,  several 
with  overlying  blood  clots.  Long  history  of  drug  abuse.  Lunchtime,  day  of  death, 
purchased  temazepam  and  heroin.  Seen  to  swallow  5  temazepam  tablets  then  prepared 
heroin  and  injected  himself.  Went  to  sleep  until  around  1430  when  witnesses  noted  blue 
coloration  and  vomit.  Resuscitation  attempts  were  unsuccessful. 
K96  30 
Possible  old  needle  puncture  mark  on  right  forearm.  Day  before  death  purchased  £10  bag 
of  heroin  and  shared  half  then  fell  asleep.  Woke  up  in  morning  and  smoked  other  half  then 
went  back  to  sleep  again.  Found  later  on  "foaming  at  the  mouth".  Resuscitation  attempts 
failed.  Known  drug  abuser  for  2  years.  Smoked  heroin  daily.  Attempted  suicide  two  years 
prior  to  death  -  temazepam.  Previous  overdose  on  diazepam  -  temporary  coma  and 
pneumonia.  In  months  leading  to  death,  attending  Drug  Dependency  Unit.  Seized  2  rolled 
cigarette  papers  and  1  piece  of  tinfoil  with  brown  substance  thereon. Chapter  Six:  Case  Results  Page209 
K97  01 
No  fresh  needle  puncture  marks  on  either  arm.  Known  IVDA.  Cirrhosis  of  the  liver 
recently  diagnosed.  On  methadone  treatment  at  time  of  death.  Aneurism  due  to  IVDA  on 
right  femural  artery  requiring  treatment.  Last  seen  by  doctor  two  weeks  prior  to  death  for 
methadone.  Last  seen  alive  three  days  prior  to  death  heavily  under  the  influence  of  alcohol. 
Found  dead  at  home. 
K97  02 
No  fresh  needle  puncture  marks.  Puckered  scarring  on  left  groin.  Suspected  hepatitis  C. 
15  year  drug  history.  Attending  various  clinics  for  drug  abuse  with  mixed  results. 
Prescribed  diazepam  and  methadone  daily.  Last  seen  alive  2200.  Found  dead  1430 
following  day.  Syringes  found  in  bedroom. 
K97  03 
Medical  needle  puncture  marks  on  both  sides  of  neck.  Fresh  needle  puncture  mark  on 
radial  aspect  of  right  antecubital  fossa.  No  evidence  of  old  scarring  or  needle  puncture 
marks.  Drug  abuser  for  2/3  years.  Attending  rehabilitation  and  prescribed  methadone  and 
valium.  Not  known  IVDA  but  police  found  fresh  needle  puncture  mark  on  left  arm.. 
Escorted  home  by  police  at  2000  as  heavily  under  the  influence,  ambulance  summoned. 
Attempts  made  at  resuscitation.  2126  arrived  at  the  hospital  after  having  an  apparent 
cardiac  arrest.  Never  regained  consciousness.  Pronounced  dead  2142. 
K97  04 
Foamy  white  froth  in  mouth.  No  petechial  haemorrhages,  Lungs  congested  and  markedly 
oedematous.  Fresh  needle  puncture  mark  at  front  of  right  elbow.  Healing  needle  puncture 
marks  on  right  arm  above  wrist  crease  and  radial  wrist  crease.  No  needle  puncture  marks 
on  left  arm.  Two  possible  needle  puncture  marks  at  right  ankle.  History  of  asthma  and 
known  to  smoke  heroin.  On  voltarol,  remedeine  and  diazepam  at  time  of  death.  Last  seen 
alive  1600.2300  following  day,  found  fully  clothed,  dead  on  bed.  Medication  at  time  of 
death:  Voltarol,  Remedeine,  Diazepam.  Drug  paraphernalia  seized  from  locus. Chapter  Six:  Case  Results  Page210 
K97  05 
No  petechial  haemhorrages.  ECG  monitoring  pads  on  chest  and  front  of  right  elbow. 
Dressing  over  therapeutic  puncture  mark.  Ligature  mark  on  neck  with  several  linear 
petechial  bruises  along  the  axis.  Multiple  healing  excoriated  abrasions  with  small  circular 
scars  over  whole  body  due  to  scabies.  Therapeutic  puncture  mark  on  front  of  right  elbow. 
Multiple  healing  needle  puncture  marks  on  right  forearm  overlying  vein.  On  left  arm,  outer 
side  of  elbow,  needle  puncture  mark,  four  at  the  front  of  the  elbow  and  one  on  the  back  of 
the  hand.  Rigor  mortis  diminished.  Hypostasis  on  back  of  body.  Lungs  oedematous  with 
congested  lower  lobes.  Arrested  day  before  death.  Taken  into  custody  and  given  7  days  in 
prison.  Ate  meal  at  1630,  heard  talking  to  inmates  in  next  cell  at  1730  and  found  hanging 
in  cell  at  1930.  Heroin  addict  suffering  from  withdrawal  symptoms  when  last  seen. 
Inmates  next  door  heard  scrapping  of  bed  across  floor  and  banging  of  pipes  at  -1900. 
Found  by  guard  on  duty  at  1930.  Resuscitation  attempts  failed. 
K97  06 
Needle  puncture  mark  due  to  post-mortem  sampling  on  left  side  of  neck.  Front  of  right 
elbow,  overlying  antecubital  fossa,  needle  puncture  mark  with  medical  dressing.  Front  of 
left  antecubital  fossa,  fresh  needle  puncture  mark  with  associated  bruising.  Rigor  mortis 
diminishing.  History  of  drug  abuse.  Last  seen  by  doctor  one  month  prior  to  death. 
Complained  of  sleeping  difficulty  said  to  be  using  cannabis,  temazepam  and  Valium.  ` 
Asked  for  methadone,  but  told  this  was  not  available  until  blood  tests  had  been  carried  out. 
Following  tests,  prescribed  one  months  supply  of  trazodone.  Given  weeks  supply  but 
didn't  pick  up  the  rest.  Night  before  death  went  drinking.  Found  the  following  morning 
still  sitting  on  the  couch.  Called  ambulance  but  resuscitation  attempts  unsuccessful.  Life 
pronounced  extinct  1010. 
K97  07 
No  petechial  haemorrhages.  Front  of  right  arm  several  circular  skin  popping  scars. 
Multiple  circular  and  oval  skin  popping  scars  over  both  lower  limbs,  thighs  and  lower  legs. 
Right  groin,  scarred  sinus  with  fresh  blood  clot  related  to  needle  puncture  mark.  Left 
groin,  old  healed  scarred  sinus  overlying  femoral  vein.  Rigor  diminished.  Lungs 
congested  and  oedematous.  Ten  year  history  of  heroin  IVDA.  Admitted  for  detox Chapter  Six:  Case  Results  Pa  eý  211 
rehabilitation  in  previous  year  for  two  months.  Following  treatment,  said  only  to  smoke 
heroin  occasionally.  Went  to  bed  2300  and  found  following  morning  found  at  0820  dead 
on  living  room  floor.  Syringe,  spoons  and  Abdine  powder  nearby.  Fresh  injection  site 
noted  in  left  groin. 
K97  08 
No  petechial  haemorrhages.  Mouth  full  of  black  fluid.  Advanced  signs  of  decomposition. 
Not  possible  to  identify  recent  needle  puncture  marks  in  either  antecubital  fossa,  groins  or 
ankles.  Rigor  mortis  worn  off.  Internal  organs  showed  moderate  decomposition  changes. 
Moderate  oedema  in  lungs.  Registered  drug  abuser.  Previous  heroin  overdose.  Previously 
prescribed  methadone.  Released  from  prison  one  month  prior  to  death.  Last  seen  alive 
three  days  prior  to  death.  On  day  found  dead,  strange  smell  coming  from  room.  Found 
dead  inside  with  trousers  round  ankles  and  used  needle  nearby.  Life  pronounced  extinct  at 
1340.  Due  to  decomposition,  insufficient  blood  to  carry  out  full  drug  screen.  Overall 
findings  consistent  with  drug  related  death,  probably  heroin. 
K97  09 
No  petechial  haemorrhages.  Post-mortem  needle  puncture  mark  on  left  side  of  neck. 
Single  tiny  fresh  needle  puncture  mark  on  left  arm  at  the  front  of  the  elbow.  Old  scarred 
sinus  in  both  groins  overlying  femoral  veins.  No  fresh  needle  puncture  marks  on  groins. 
Rigor  mortis  diminished.  Lungs  congested  and  oedematous.  History  of  drug  abuse. 
Heavy  drinker.  In  prison  for  11  days.  On  day  before  release  was  overheard  saying  she  was 
going  for  a  hit  as  soon  as  she  got  out.  Following  day  arrived  at  train  station  at  0902.  Found 
dead  within  cubicle  of  toilets  at  1350.  Syringe  and  needle,  teaspoon  and  paper  fold  with 
white  granules  seized  from  locus.  Drug  dependant  for  12  years. 
K9710 
Petechial  haemorrhages  over  mid  chest  and  clavicles.  No  evidence  of  needle  puncture 
marks  or  scars  in  groins.  No  fresh  marks  injuries  or  fresh/old  needle  puncture  marks  on 
arms.  Lungs  bulky,  congested  and  oedematous.  History  of  long  term  drug  abuse.  Known 
to  abuse  cannabis,  cocaine  and  temazepam  but  not  known  to  be  an  IVDA.  Last  seen  alive 
1700.  Following  night  found  dead  in  bed. Chapter  Six:  Case  Results  Page212 
K9711 
No  needle  puncture  marks  in  arms  or  groins.  Limbs  flaccid.  Both  lungs  congested  and 
oedematous.  History  of  drug  abuse.  Known  to  have  taken  temazepam  and  had  suffered 
seizures  as  a  result  therefore  prescribed  chlordiazepoxide  at  this  point.  At  one  point  treated 
with  diazepam  to  control  seizures.  Taking  sleeping  tablets  and  temazepam  in  the  days 
leading  up  to  death.  Not  seen  by  family  since  9pm  two  days  prior  to  death.  Forced  entry 
into  flat  and  found  her  lying  face  down  in  the  bedroom.  Telephoned  for  ambulance  but 
found  to  be  dead  1910.  When  last  seen,  suspected  to  have  been  smoking  heroin. 
K9712 
Face  and  conjunctivae  congested.  Needle  puncture  marks  on  both  sides  of  neck  (PM). 
Circled  needle  puncture  marks  on  both  groins.  Right  arm,  needle  puncture  mark  in  outer 
aspect  of  antecubital  fossa  (circled).  Rigor  mortis  wearing  off.  Methadone  addict.  Known 
drug  abuser  for  10-15  years.  Released  from  prison  month  before  death.  Prescribed  10  mg 
x4  diazepam  daily.  Known  to  use  heroin.  1740,  forced  entry  and  found  deceased  face 
down  on  bedroom  floor  unconscious.  Tried  resuscitation  and  phoned  ambulance. 
Resuscitation  unsuccessful.  Seized  2  spoons,  belt  fastened  as  a  tourniquet  and  brown 
resinous  material  in  silver  foil. 
K9713 
No  petechial  haemhorrages.  Rigor  mortis  worn  off.  No  needle  puncture  marks.  Lungs 
contained  food,  oedematous  and  congested.  On  methadone  maintenance  programme. 
Smoked  heroin  for  approximately  one  year.  Prescribed  methadone  but  didn't  return  for 
repeat  prescriptions.  Three  months  prior  to  death  recommenced  on  methadone 
maintenance  programme  and  one  month  prior  to  death  had  daily  amount  increased  from 
50-60  mg.  Taken  at  chemists.  Last  spoken  to  at  1245.1545  witness  checked  on  him  and 
thought  to  be  asleep.  Checked  again  at  2200  before  going  to  bed  and  still  "sleeping".  0930 
tried  to  wake  him  but  couldn't.  Second  witness  found  him  to  be  dead  and  covered  in 
vomit. Chapter  Six:  Case  Results  Page2l3 
K97  14 
No  petechial  haemorrhages.  PM  needle  puncture  marks  on  neck.  Two  old  pale  circular 
scars  on  front  of  right  elbow  overlying  vein.  No  recent  needle  puncture  marks  on  either 
arm.  Old  circular  scars  overlying  vein  on  left  elbow.  Lower  limbs,  innumerable  small 
bruises,  some  overlying  veins,  many  associated  with  overlying  healing  small  needle 
puncture  marks.  Multiple  old  circular  and  oval  slightly  depressed  scars.  Front  of  left 
thigh,  2  cm  above  the  medial  edge  of  the  kneecap,  fresh  needle  puncture  mark.  Rigor 
mortis  diminishing.  Lungs  congested  and  oedematous.  Widespread  aspiration  of  gastric 
contents  into  airways.  Long  history  of  drug  and  alcohol  abuse.  Attended  drug 
rehabilitation  but  thought  to  have  recently  relapsed.  Last  seen  by  doctor  one  month  prior  to 
death.  Day  of  death  found  by  cleaner  in  toilets  of  health  centre  on  all  fours.  Found  needle 
and  syringe  inserted  just  above  left  knee. 
K9715 
Intravenous  line  in  right  elbow.  Possible  tiny  needle  puncture  mark  at  front  of  left  elbow. 
Rigor  mortis  diminished.  Hypostasis  on  back.  Lungs  congested  and  oedematous.  Heavy 
drinker.  Known  to  abuse  painkillers.  Previous  overdose  of  co-dydramol.  Day  before 
death  prescribed  100  co-proxamol  in  relation  to  back  pain.  Also  recently  prescribed 
dihydrocodeine  and  still  on  co-dydramol.  Not  known  if  IVDA  or  not.  1800  found 
kneeling  with  face  on  floor  appeared  to  be  dead  but  tried  resuscitation  anyway.  Ambulance 
arrived  1806  and  continued  resuscitation  to  no  avail.  Found  prescribed  drugs  and  syringe 
in  bin  near  deceased's  right  hand. 
K9716 
Few  petechiae  in  conjunctivae  of  left  lower  eyelid.  No  evidence  of  IVDA.  Lungs 
congested  and  oedematous.  Rigor  still  present  in  some  parts  of  the  body.  Referred 
psychiatric  hospital  -  five  years  prior  to  death  and  revealed  drug  and  alcohol  problem.  Six 
months  prior  to  death  saw  psychiatrist.  Said  to  be  depressed.  Doctors  prescribed 
amytriptyline  10  mg/day  due  to  back  pain.  Night  before  death  appeared  to  be  under  the 
influence  of  drugs.  0725  following  morning  found  in  living  room,  obviously  dead.  Dead 
some  time.  Rigor  still  evident.  Drug  paraphernalia  seized  from  locus. Chapter  Six:  Case  Results  Paae214 
K97  17 
Needle  puncture  mark  in  right  anticubital  fossa.  No  previous  signs  of  IVDA.  Rigor  still 
present.  Lungs  congested.  Said  to  be  a  binge  drinker  and  heroin  user.  Six  months  prior  to 
death,  prescribed  4  week  course  of  antidepressants.  1745,  appeared  to  be  under  the 
influence  of  alcohol.  1750  bought  some  heroin  (2x£10  bags)  to  share  with  friend. 
Prepared  heroin,  both  injected  at  same  time  from  the  same  solution.  Deceased  closed  eyes 
almost  immediately  after,  but  thought  to  be  OK.  1940  found  apparently  unconscious  in  the 
same  position.  Attempted  basic  first  aid  but  no  success.  Called  ambulance  but  found  to  be 
dead. 
K97  18 
Conjunctivae  congested.  Multiple  needle  puncture  marks  in  right  groin  (medical  ?  ).  Small 
sinus  in  left  groin  consistent  with  chronic  IVDA.  Right  groin  bleeding  with  5  needle 
puncture  marks.  Rigor  still  present.  Lungs  congested  and  oedematous.  Heroin  abuser  for 
13  years.  1015,  awake  in  bed.  Got  up  -1100  and  out  at  1145.1250  found  lying  face  down 
on  the  living  room  floor  with  head  in  rubbish  bag  and  jeans  pulled  down  below  groin  area, 
syringe  sticking  out  of  groin.  Not  breathing  and  blood  coming  from  mouth  and  nose. 
Tried  resuscitation.  Phoned  ambulance.  Arrived  1303.  Taken  to  hospital  but  resuscitation 
unsuccessful.  Found  spoon  and  paper  fold  in  kitchen. 
6.4  RESULTS  AND  DISCUSSION 
6.4.1  BLOOD  AND  VITREOUS  HUMOR 
6.4.1.1  BENZODIAZEPINES 
6.4.1.1.1  Analysis  of  PM  and  RTD  Blood  Samples 
In  addition  to  the  48  post-mortem  cases  previously  described,  15  post-mortem  (PM)  and 
road  traffic  drug  (RTD)  blood  samples  which  had  been  analysed  in  the  routine  laboratory, 
were  extracted  by  SFE.  The  results  were  then  compared  to  those  obtained  using  SPE  for 
temazepam  only.  In  both  cases  the  analyses  were  carried  out  using  the  same  standards 
(temazepam:  4.04  mg/100  ml,  prazepam  4.89  mg/100  ml)  for  direct  comparison  of  the 
results  and  the  samples  were  extracted  at  approximately  the  same  time. Chapter  Six:  Case  Results  Page2l5 
In  most  cases  the  analyses  were  carried  out  in  triplicate.  The  results  are  shown  in  Table 
6.2  and  a  correlation  graph  of  these  results  is  shown  in  Figure  6.1.  An  example  of  the 
method  used  to  determine  the  concentration  of  drug  present  in  the  extracts  is  given  in 
Appendix  I. 
Table  6.2:  Case  Blood  Analysis  for  Tema:  epum 
Case  SFE  Ter  mL  SPE  Ter  m7L 
RTD1  3.17  3.96 
RTD2  1.34  1.18 
RTD3  8.04  7.57 
RTD4  2.38  2.13 
RTD5  1.85  1.89 
RTD6  3.20  3.23 
RTD7  1.08  1.22 
PM  I  3.08  3.42 
PM2  2.01  2.41 
PM3  1.97  2.07 
PM4  2.52  2.65 
PM5  2.04  2.26 
PM6  4.51  4.51 
PM7  1.89  1.58 
PM  8  5.02  5.94 
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For  the  15  cases  analysed,  good  correlation  was  found  between  SFE  and  SPE.  The 
equation  of  the  best  fit  line  through  the  points  was  calculated  as  y=0.97x  +  0.06.  For  both 
methods  to  be  extracting  the  temazepam  to  the  same  extent,  the  gradient  of  the  line  should 
be  1.0.  From  the  equation  of  the  line  it  is  therefore  apparent  that  there  is  no  significant 
difference  between  the  values  obtained  by  the  two  techniques. 
6.4.1.1.2  Blood  and  Vitreous  Humor  Case  Samples  by  EIA  and  RIA 
Before  commencing  with  SFE  of  the  blood  and  vitreous  humor  samples,  it  was  decided  to 
screen  the  cases  by  enzyme-immunoassay  and  radio-immunoassay  to  determine  which  of 
the  drugs  of  interest  were  present.  Table  6.3  shows  the  results  obtained. 
Table  6.3:  EIA  and  RIA  Blood  and  Vitreous  Humor  Results 
Case  Meth 
Blood 
Meth 
Vit 
Benzo 
Blood 
Benzo 
Vit 
Morph 
Blood 
Morph 
Vit 
Opiate 
Blood 
Opiate 
Vit 
K96  01  na  /  na  /  na  /  na  / 
K96  02  -  IS  -  IS  +  IS  +  IS 
K96  03  -  -  +  +  -  -  -  + 
K96  04  -  na  +  na  +  na  +  na 
K96  05  na  /  na  /  na  /  na  / 
K96  06  na  /  na  /  na  /  na  / 
K96  07  -  -  +  +  +  -  +  - 
K96  08  +  +  +  +  -  +  -  + 
K96  09  na  /  na  /  na  /  na  / 
K9610  -  -  -  -  +  +  +  + 
K9611  -  -  +  +  +  +  +  + 
K9612  -  -  -  -  +  -  +  + 
K9613  +  +  +  +  -  -  +  + 
K9614  -  -  +  +  -  +  +  + 
K9615  +  +  +  +  -  -  +  + 
K9616  -  -  -  -  +  +  +  + 
K9617  -  -  -  -  +  +  +  + 
K9618  -  /  +  +  / 
K9619  -  -  -  -  -  +  +  + 
K96  20  -  -  +  +  +  /  +  + 
K9621  +  +  +  +  +  /  +  + 
K96  22  +  +  +  +  +  /  +  + 
K96  23  +  -  +  +  -  -  +  + 
K96  24  +  +  +  +  -  -  -  -  K96  25  -  -  +  +  +  +  +  + 
K96  26  -  -  +  -  -  -  -  - Chapter  Six:  Case  Results  Page217 
Table  6.3  continued 
Case  Meth 
Blood 
Meth 
Vit 
Benzo 
Blood 
Benzo 
Vit 
Morph 
Blood 
Morph 
Vit 
Opiate 
Blood 
Opiate 
Vit 
K96  27  -  -  +  +  +  -  +  + 
K96  28  -  n/1  +  n/I  +  n/1  +  n/1 
K96  29  -  -  +  +  +  /  +  + 
K96  30  -  -  +  +  -  /  +  + 
K97  01  na 
1(97  02  + 
K97  03  na  /  +  /  -  /  -  / 
K97  04  -  /  +  /  +  /  +  / 
K97  05  -  -  +  -  /  /  -  - 
K97  06  -  -  +  +  +  /  +  + 
K97  07  -  -  +  +  -  /  +  + 
K97  08  -  -  +  +  -  /  +  + 
K97  09  -  -  +  +  +  /  +  + 
K9710  -  +  +  +  +  /  +  + 
K9711  -  -  +  +  +  /  +  + 
K9712  -  /  +  /  +  /  +  / 
K9713  +  +  +  -  -  /  -  - 
K9714  -  -  +  +  +  /  +  + 
K9715  -  -  +  -  /  /  +  + 
K9716  -  -  +  +  /  /  +  + 
K9717  -  -  -  -  /  /  +  + 
K9718  +  +  -  -  /  /  +  + 
+:  Positive  result  as  determined  as  a  results  of  any  deviation  from  the  negative  calibrator. 
-:  Negative  result. 
The  cases  from  Table  6.3  which  were  positive  for  benzodiazepines  were  extracted  by  SFE 
to  determine  the  concentration  of  benzodiazepine  drugs  present.  Both  blood  and  vitreous 
humor  samples  were  extracted  where  applicable.  For  comparison,  some  of  the  samples 
were  also  extracted  by  SPE. 
Although,  all  cases  had  been  previously  analysed  in  the  laboratory,  these  results  were  not 
used  for  comparison  as  the  samples  used  for  this  study  were  taken  separately  at  post- 
mortem  (and  possibly  from  a  different  site).  In  addition,  there  was  a  time  delay  in  the 
analysis  by  the  two  techniques  of  up  to  one  year. 
Table  6.4  shows  the  results  obtained  for  blood  by  SFE  and  SPE  and  for  vitreous  humor. 
Where  more  than  one  analysis  was  carried  out  the  number  of  extractions  is  indicated  in 
brackets. Chapter  Six:  Case  Results  Page218 
Table  6.4:  Benzodiazepine  Blood  SFE  and  SPE  and  Vitreous  Humor  Results 
Case  SFE  Blood  SFE  Vitreous  SPE  blood  Blood  Vitreous 
mg/L  mg/L  mg/L  EIA/RIA  EIA/RIA 
n  /m  n  /m 
K96  02  Temaz:  1.22  Temaz:  1.19  NA  NA  NA 
Diaz:  0.18 
K96  03  Temaz:  0.20(2)  *  NA  1255  181 
DMD:  0.31 
Diaz:  0.17 
K96  04  Temaz:  0.27(4)  *  Temaz:  0.22  >2500 
DMD:  0.53  DMD:  0.50 
Diaz:  0.49  Diaz:  0.42 
K96  07  Temaz:  0.72(6)  Temaz:  0.71(2)  Temaz:  0.60  >2500  1015 
DMD:  0.06  DMD:  0.42  DMD:  0.06 
Diaz:  1.98  Diaz:  0.63  Diaz:  0.94 
K96  08  DMD:  0.14(3)  DMD:  0.17  DMD:  0.23  >2500  1751 
Diaz:  0.44  Diaz:  0.39  Diaz:  0.25 
K9611  Temaz:  0.48  -  Temaz:  0.35  >2500  616 
DMD:  0.47  DMD:  0.39  DMD:  0.55 
Diaz:  1.01  Diaz:  0.74  Diaz:  0.76 
K96  13  DMD:  0.55(3)  -  NA  +  >2500 
Diaz:  0.47  Diaz:  0.47 
K9614  DMD:  0.29(2)  -  NA  +  638 
Diaz:  0.15  Diaz:  0.15 
K96  15  DMD:  0.20  DMD:  0.37  DMD:  0.44  +  1368 
Diaz:  0.29  -  Diaz:  0.27 
K96  18  Temaz:  1.24  *  Temaz:  0.99  + 
DMD:  1.54  DMD:  0.85 
Diaz:  0.08  - 
K96  20  DMD:  0.38  *  DMD:  0.51  +  646 
Diaz:  0.39  Diaz:  0.44 
K96  21  Temaz:  0.01  -  -  +  91 
DMD:  0.39  DMD:  0.35  DMD:  0.54 
Diaz:  0.55  -  Diaz:  0.77 
K96  22  Temaz:  1.30  Temaz:  0.76  Temaz:  0.92  +  3353 
DMD:  0.68  DMD:  0.27  DMD:  0.46 
-  Diaz:  0.62  - 
K96  23  DMD:  0.18  DMD:  0.025  DMD:  0.19  >2500  731 
Diaz:  0.45  Diaz:  0.068  Diaz:  0.40 
K96  24  Temaz:  0.25(2)  Temaz:  0.08  Temaz:  0.20  +  >2500 
DMD:  0.29  DMD:  0.10  DMD:  0.24 
Diaz:  0.03  Diaz:  0.01  Diaz:  0.10 
K96  25  DMD:  0.08  DMD:  0.07  DMD:  0.03  +  713 
Diaz:  0.27  Diaz:  0.10  Diaz:  0.35 
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Table  6.4:  Continued 
Case  SFE  Blood  SFE  Vitreous  SPE  blood  Blood  Vitreous 
mg/L  mg/L  mg/L  EIA/RIA  EIA/RIA 
n  /m  n  /m 
K96  27  Temaz:  0.78  Temaz:  0.35  Temaz:  0.81  >2500  1056 
DMD:  0.22  DMD:  0.12  DMD:  0.18 
Diaz:  0.08  Diaz:  0.10  Diaz:  0.08 
K96  28  Temaz:  0.11  Temaz:  0.11  NA  >2500  NA 
DMD:  0.11  - 
Diaz:  1.51.  Diaz:  1.25 
K96  29  Temaz:  0.36(3)  Temaz:  0.17(2)  NA  +  529 
DMD:  0.52  DMD:  0.52 
K96  30  Temaz:  0.23(3)  Temaz:  0.19(3)  NA  +  497 
DMD:  0.20  DMD:  0.28 
Diaz:  2.62  Diaz:  2.48 
K97  02  Temaz:  0.20  *  NA  +  * 
DMD:  0.44 
K97  04  Temaz:  0.38  *  NA  + 
DMD:  0.26 
Diaz:  1.13 
*  Vitreous  not  available  for  analysis 
NA  Not  analysed 
+  Some  of  the  EIA/RIA  results  were  for  the  laboratory  samples.  Where  this  was  the  case,  + 
has  been  inserted  as  opposed  to  the  value  to  indicate  that  the  result  was  positive. 
As  can  be  seen  by  looking  at  the  results  obtained  by  HPLC  and  EIA/RIA,  there  is  no 
correlation  between  the  results.  For  this  reason  none  of  the  EIA  or  RIA  results  were 
displayed  graphically. 
The  results  obtained  by  SFE  for  blood  and  vitreous  humor  were  graphed  to  determine  if 
any  correlation  existed  as  shown  in  Figure  6.2. Chapter  Six:  Case  Results 
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From  this,  the  coefficient  of  correlation  (r2)  for  temazepam  in  blood  and  vitreous  is  0.692 
indicating  that  there  is  some  correlation  between  the  two  extraction  media.  The  gradient 
of  the  best  fit  line  through  the  results  was  0.75  indicating  that  the  level  of  temazepam  in 
vitreous  is  generally  lower  than  the  corresponding  level  in  blood. 
It  should  be  noted,  that  in  some  cases,  larger  blood  samples  were  analysed  (up  to  500  µL). 
Due  to  the  small  amount  of  vitreous  humor  available,  only  100  pL  were  analysed  at  any 
one  time.  This  means  that  in  some  of  the  samples  where  only  a  small  amount  of 
temazepam  was  present,  the  level  may  have  been  too  small  to  be  detected. 
The  correlation  between  the  blood  levels  of  temazepam  determined  by  SFE  and  SPE  was 
also  graphed  and  is  illustrated  in  Figure  6.3. 
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From  this,  the  coefficient  of  correlation  was  found  to  be  0.949  with  a  gradient  of  1.23 
indicating  that  the  SFE  method  is  extracting  more  temazepam  than  the  SPE  method. 
The  blood  versus  vitreous  and  SPE  versus  SFE  graphs  for  temazepam  were  repeated  for 
desmethyldiazepam  and  diazepam  as  shown  in  Figures  6.4-6.7. 
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Figure  6.7:  Correlation  Between  SFE  and  SPE  for  Blood  Dia:  epum  Levels 
For  the  comparison  between  blood  and  vitreous  humor  for  desmethyldiazepam,  r2  =  0.143 
indicating  that  no  correlation  exists  between  the  two  media.  In  comparing  SFE  with  SPE 
for  desmethyldiazepam,  a  coefficient  of  correlation  of  0.711,  was  found  with  the  gradient 
of  the  best  fit  line  at  1.40,  again  indicating  that  higher  drug  levels  are  being  found  by  SFE 
than  by  SPE. 
For  diazepam,  the  correlation  between  blood  and  vitreous  was  reasonably  good  (r`  =  0.714, 
gradient  =  0.70)  and  in  comparing  the  results  obtained  by  SFE  with  SPE  results  a 
coefficient  of  correlation  of  0.739  (gradient  =  1.51)  was  obtained. 
In  the  case  of  all  three  drugs  in  blood  by  SFE,  reasonable  correlation  with  results  obtained 
by  SPE  was  achieved.  It  should  be  noted  that  the  SPE  was  carried  out  only  once  as  1  ml  of 
blood  is  required  and  the  sample  volumes  obtained  from  the  pathologists  were  low. 
For  the  comparison  between  blood  and  vitreous  humor,  temazepam  and  diazepam 
correlated  well,  with  levels  in  blood  being  generally  higher  than  the  equivalent  vitreous 
values.  For  desmethyldiazepam,  no  correlation  was  seen  between  blood  and  vitreous 
humor.  It  is  not  known  whether  or  not  any  metabolic  reaction  of  the  benzodiazepines Chapter  Six:  Case  Results  Page224 
occurs  in  the  vitreous  humor,  however  in  the  cases  where  a  large  drop  was  observed 
between  the  diazepam  level  in  blood  and  vitreous  humor,  a  corresponding  increase  in 
desmethyldiazepam  was  also  observed  (cases:  K96  07,  K96  11,  K96  15,  K96  21). 
6.4.1.2  MORPHINE  AND  6MAM  IN  BLOOD  AND  VITREOUS  HUMOR 
As  with  the  benzodiazepines,  the  EIA  (opiate)  /  RIA  (morphine)  results  were  investigated 
before  commencing  analysis  of  the  samples  by  SFE.  Cases  which  were  found  to  be 
positive  were  analysed  for  the  presence  of  morphine.  The  results  for  the  analysis  of  the 
case  blood  and  vitreous  humor  samples  for  morphine  are  shown  in  Table  6.5.  Blood  and 
vitreous  humor  were  analysed  where  applicable  and  some  of  the  cases  were  also  analysed 
by  SPE  for  comparison. 
It  should  be  noted  that  6MAM  analysis  was  not  initially  carried  out  and  thus,  some  of  the 
blood  and  vitreous  samples  were  not  analysed  for  6MAM.  Where  this  was  the  case  n/c  has 
been  inserted. 
Table  6.5:  Morphine  Blood  SFE  and  SPE  and  Vitreous  Humor  Results 
Case  Blood  SFE 
(mg/L) 
SFE  Vitreous 
(mg/L) 
Blood  SPE 
(mg/L) 
SFE  6MAM 
Blood  (mg/L) 
SFE  6MAM 
Vitreous 
(m  ) 
EIA/RIA 
(ng/mg) 
Blood 
EIA/RIA 
(ng/mg) 
Vitreous 
K96  02  0.79  0.45  0.68  n/c  n/c  728  na 
K96  04  0.13  -ve  0.18  n/c  n/c  257  na 
K96  07  1.05  na  1.06  n/c  na  646  - 
K96  08  0.13  0.04  na  n/c  n/c  -  162 
K9610  0.23  -ve  0.3  n/c  n/c  237  291 
K9611  0.15  0.18  0.08  n/c  n/c  467  924 
K9612  0.25  0.08  0.14  n/c  n/c  399  359 
K96  14  0.10  0.086  0.06  n/c  n/c  +  411 
K96  16  0.62  0.46  0.6  0.13  0.032  +  1470 
K96  17  1.35  1.03  na  n/c  n/c  +  383 
K9618  0.91  1.94  0.7  -ve  -ve  +  na 
19  1-0.42  0.69  na  n/c  0.73  +  375 
K96  20  0.85  0.67  na  n/c  0.057  +  6989 
K96  21  1.97  1.48  1.7  -ve  0.96  +  10762 
K96  22  2.21  1.67  1.94  -ve  0.011  +  7355 
K96  25  0.48  0.067  0.45  0.005  -ve  +  630 
K96  27  0.19  0.12  0.26  -ve  0.048  268  1264 
K96  28  0.39  na  0.34  n/c  na  321  na Chapter  Six:  Case  Results 
Table  6.5:  Continued 
Paggc?  71 
Case  Blood  SFE 
(mg/L) 
SFE  Vitreous 
(mg/L) 
Blood  SPE 
(mg/L) 
SFE  6MAM 
Blood  (mg/L) 
SFE  6MAM 
Vitreous 
(mg/L) 
EIA/RIA 
(ng/mg) 
Blood 
EIA/RIA 
(ng/mg) 
Vitreous 
K96  29  0.79  0.62  0.51  n/c  n/c  +  6794 
K97  04  0.13  *  0.23  0.012  *  +  * 
K97  07  0.45  0.16  0.36  0.084  0.016  +  6293 
K97  09  0.19  0.31  0.42  0.088  -ve  +  6467 
K9710  0.17  0.18  na  0.38  -ve  +  5978 
K9711  0.054  -ve  0.11  -ve  -ve  +  4646 
K9714  0.74  0.71  na  -ve  0.02  +  7110 
K9715  0.20  0.25  na  0.23  0.20  +  5897 
K97  16  0.20  0.23  0.15  0.051  0.006  +  6018 
K9717  0.14  0.27  na  0.011  0.084  +  4494 
K9718  0.26  0.55  0.53  0.16  0.11  +  5132 
A  correlation  graph  of  blood  versus  vitreous  morphine  by  SFE  was  produced  from  these 
results  and  is  shown  in  Figure  6.8. 
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A  graph  of  the  results  obtained  by  comparing  SFE  to  SPE  was  also  plotted  as  shown  in 
Figure  6.9. 
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Figure  6.9:  Correlation  Between  S1,7;  and  SPE  Blood  Morphine  Levels 
The  correlation  between  blood  and  vitreous  humor  morphine  levels  was  good,  r2  =  0.712. 
As  with  the  benzodiazepines,  in  general  the  levels  found  in  vitreous  are  lower  than  the 
corresponding  levels  in  blood  (gradient  of  best  fit  line  =  0.79). 
For  the  comparison  between  SFE  and  SPE  for  morphine  in  blood,  again  a  good  correlation 
was  seen  between  the  two  methods  (r2  =  0.977)  and  the  gradient  of  the  best  tit  line  was 
1.13  thus,  taking  into  account  experimental  error,  the  two  techniques  yield  the  same  drug 
concentrations. 
6.4.1.3  MI1,7'HADON1;  IN  BLOO/)  ANI)  VI"1'REO  JS  HIIMQJ? 
The  final  drug  to  be  analysed  from  blood  and  vitreous  humor  samples  was  methadone.  As 
with  the  other  two  sets  of  drugs,  EIA  and  RIA  results  were  obtained.  In  addition  to  the 
methadone  it  was  noted  during  the  final  stages  of  this  study  that  EDDP  was  also  being Chapter  Six:  Case  Results  Page227 
extracted  from  blood  and  vitreous  humor  samples.  As  no  method  development  was  carried 
out  for  this  metabolite  it  could  not  be  quantitated.  Where  EDDP  was  detected  in  blood  or 
vitreous  humor  it  has  been  noted  with  the  corresponding  methadone  level. 
The  results  obtained  for  the  SFE  of  methadone  from  blood  and  vitreous  humor  samples  are 
given  in  Table  6.6.  The  levels  obtained  by  LLE  for  some  of  the  cases  are  also  noted. 
Table  6.6:  Methadone  Blood  SFE  and  LLE  and  Vitreous  Humor  Results 
Case  Blood  SFE 
(mg/L) 
Vitreous 
(mg/L) 
Blood  LLE 
(mg/L) 
Blood  EIA 
(ng/mg) 
Vitreous 
EIA/RIA 
nm) 
K96  08  0.44  0.35  0.36  263  315 
K96  23  0.25(EDDP)  -ve  0.23  96  -ve 
K96  21  0.56  0.20  0.32  +  47 
K96  22  0.28  0.12  0.12  +  68 
K96  24  0.55  0.14  (EDDP)  0.36  +  78 
K97  03  0.94  EDDP  0.21  (EDDP)  0.98  +  na 
K96  13  2.18(EDDP)  0.46  1.76  +  38 
K96  15  0.72  0.16  (EDDP)  0.68  +  295 
K97  10  0.10  0.08  -ve  +  17 
K97  13  0.41  0.34  -ve  +  355 
K97  18  0.48(EDDP)  0.10  (EDDP)  0.30  +  143 
A  graph  was  plotted  of  the  correlation  between  blood  and  vitreous  humor  methadone  levels 
obtained  using  SFE  (Figure  6.10). Chapter  Six:  Case  Results 
2.5 
2 
aý ö  1.5 
cý 
aý 
2 
0 
0.5 
0" 
0 
I'ýiýýcý''ti  ý` 
Figure  6.10:  Correlation  Between  Blood  and  Vitreous  Humor  Methadone  Levels  by  . S1.7; 
The  correlation  between  the  SFE  and  LLE  results  of  methadone  in  blood  is  shown  in 
Figure  6.11. 
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From  Figure  6.11,  the  coefficient  of  correlation  for  blood  and  vitreous  humor  methadone 
by  SFE  was  calculated  to  be  0.478.  Thus,  the  correlation  between  blood  and  vitreous 
humor  is  lower  than  has  been  seen  for  some  of  the  other  drugs,  however  there  is  still  a 
slight  correlation  between  the  results.  In  addition  to  this,  the  gradient  of  the  best  fit  line 
through  the  points  is  only  0.17  indicating  that  the  levels  in  vitreous  are  much  lower  than 
the  corresponding  blood  levels. 
The  coefficient  of  correlation  for  methadone  levels  obtained  using  SFE  and  SPE  was 
calculated  as  0.934.  The  gradient  of  the  best  fit  line  was  1.06. 
6.4.2  HAIR  ANALYSIS 
As  can  be  seen  from  Chapter  5,  the  analysis  of  benzodiazepines,  morphine  (6MAM)  and 
methadone  from  hair  samples  can  be  carried  out  using  the  same  SFE  method.  Prior  to 
being  extracted,  the  hair  samples  were  washed  in  MeOH,  dH2O  and  MeOH.  Once  dried, 
some  of  the  samples  were  then  sectioned.  In  most  cases  the  hair  samples  were  less  than  6 
cm  long  and  the  sectioning  consisted  of  separating  the  roots  from  the  bulk  hair.  In  cases 
where  the  hair  samples  were  longer  than  6  cm,  they  were  sectioned  in  6  cm  or  3  cm 
lengths.  The  sections  are  highlighted  after  the  case  numbers  in  the  results  tables  below. 
Once  the  sectioning  was  completed,  the  hair  was  finely  ground  under  liquid  nitrogen  using 
a  mortar  and  pestle  before  being  weighed  and  extracted  using  the  conditions  defined  in 
Chapter  5. 
The,  following  three  tables  show  the  results  obtained  for  the  hair  analysis.  Only  the  cases 
which  were  deemed  positive  have  been  reported.  The  method  used  for  the  calculation  of 
the  drug  concentrations  in  hair  is  given  in  Appendix  II. Chapter  Six:  Case  Results  Page230 
Table  6.7:  Benzodiazepine  Positive  Hair  Cases 
Case  Weight 
(mg) 
Temazepam 
(ng/mg) 
DMD 
(ng/mg) 
Diazepam 
(ng/mg) 
K96  01/uncut  50.46,25.80  3.53  (2)  7.36  7.31 
K96  02  uncut  29.85  8.44  15.99  14.16 
K96  04/uncut  28.33  0.78  -ve  -ve 
K96  05/R  16.27  -ve  -ve  -ve 
K96  05/lst3  34.77,39.14  1.04  (2)  1.36  0.95 
K96  05/B  31.19,49.26  2.06  (2)  2.45  2.36 
K96  07/uncut  37.49  9.15  -ve  -ve 
K96  08  uncut  27.94,15.61  5.00  (2)  3.98  3.23 
K96  09  uncut  26.83  23.55  -ve  -ve 
K96  11  uncut  86.27  111  -ve  -ve 
K96  16/lst6  32.35  2.33  -ve  -ve 
K96  16/2nd6  19.67  10.23  12.13  16.09 
K96  16/B  36.92  61.83  52.05  49.46 
K96  16/R  12.68  -ve  -ve  -ve 
K96  16  uncut  112.31  2.18  -ve  1.36 
K96  21/R  20.03  -ve  -ve  -ve 
K96  21/lst6  33.43  5.70  8.60  7.83 
K96  21/2nd6  28.85  5.29  9.88  8.19 
K96  211B  28.85  56.79  34.58  38.24 
K96  2318  14.68  -ve  -ve  -ve 
K96  23/B  22.15,14.39  45.43  (2)  25.28  80.14 
K96  24/R  16.44,24.49  2.52  (2)  3.03  4.62 
K96  24/6  45.37  23.89  18.78  20.08 
K96  24/5  53.35  6.06  3.83  13.53 
K96  24/B  54.81  37.05  57.38  16.04 
K96  24/B  54.81  4.22  2.69  12.11 
K96  29/R  25.14  -ve  -ve  -ve 
K96  29/3  10.38,26.94  13.50  (2)  12.84  10.81 
K96  30/R  9.64  -ve  -ve  -ve 
K96  30/5  49.11  0.93  1.17  0.85 
K96  30/B  16.80  9.13  3.67  24.25 
1(97  OUR  46.04  13.34  13.24  17.18 
K97  01B  72.25,21.35  -ve  7.91  (2)  4.96 
1(97  06/R  7.37  4.30  -ve  5.00 
K97  06/B  14.80  10.32  10.00  7.30 
K97  10/R  -ve  -ve  -ve  K97  10B  38.09  1.98  2.29  1.67 
K:  KOOLS 
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Table  6.8:  Morphine  and  6MAM  Positive  Hair  Cases 
Case  Weight 
(mg) 
Morphine 
(m  /L) 
6MAM 
(m  /L) 
Morphine/ 
6MAM 
K96  13/uncut  51.75  10.18  0.78  13.05 
K96  15/R  14.72  -ve  -ve  - 
K96  15/B  14.72  13.4  63.6  0.21 
K96  17/uncut  10.27  14.04  9.23  1.52 
K96  18/uncut  12.14  55.24  42.75  1.29 
K96  20/R  15.31  -ve  -ve  - 
K96  20/B  43.10  -ve  -ve  - 
K96  21/R  20.03  77.6  203.8  0.38 
K96  21/lst6  33.43  18.2  22.6  0.81 
K96  21/2nd6  28.85  40.5  64.0  0.63 
K96  22/R  14.16  41.5  41.5  1.00 
K96  22/3  34.68  15.8  -ve  - 
K96  22/B  29.64  4.24  1.41  3.01 
K96  24/R  30.90  0.65  2.07  0.31 
K96  24/6  91.26  1.15  1.28  0.9 
K96  24/5  53.53  1.57  2.62  0.60 
K96  24/B  87.59  1.06  0.75  1.41 
K96  25/B  22.67  10.37  5.56  1.87 
K96  26/R  12.85  -ve  -ve  - 
K96  26/B  83.26  99.1  16.61  5.97 
K96  29/R  7.41  40.77  5.36  7.61 
K96  29/3  8.71  46.82  -ve  - 
K96  29B  15.47  12.25  n/c 
K96  30/R  10.19  57.42  9.70  5.92 
K96  30/5  84.05  18.7  1.43  13.08 
K96  30/B  47.58  36.14  7.25  4.98 
K97  03/R  17.58  10.53  5.80  1.82 
K97  03/B  45.84  2.07  0.20  10.35 
K97  05/R  20.93  9.14  8.49  1.08 
K97  05/B  71.44  1.10  4.39  0.25 
K97  07/R  15.95  -ve  -ve  - 
K97  07/3  84.54  13.51  4.31  3.13 
K97  07/B  61.11  5.44  7.69  0.71 
K97  08/R  14.63  70.93  72.31  0.98 
K97  08/B  30.00  2.97  8.08  0.37 
K97  12/R  8.83  -ve  -ve  -  K97  12/B  56.72  -ve  -ve  -  K97  13/R  34.81  3.65  0.97  3.76 
K97  13/B  112.84  1.43  1.48  0.97 Chapter  Six:  Case  Results  Page232 
Table  6.8:  Methadone  Positive  Hair  Cases 
Case  Weight  (mg)  Methadone  (m  /L)  EDDP 
K96  13/uncut  51.75  24.02  ￿ 
K96  15/R  16.98  -ve  x 
K96  15/B  14.72  20.20  ￿ 
K96  17/uncut  10.27  1.26  x 
K96  18/uncut  12.14  0.70  ￿ 
K96  20/R  15.31  0.91  ￿ 
K96  20/B  43.10  2.12  ￿ 
K96  21/R  14.16  16.7  ￿ 
K96  21/lst6  33.43  4.16  ￿ 
K96  21/2nd6  28.85  -ve  x 
K96  22/R  14.16  7.81  ￿ 
K96  22/3  34.68  1.78  x 
K96  22/B  29.64  2.42  x 
K96  24/R  30.90  5.53  ￿ 
K96  24/6  91.26  8.09  ￿ 
K96  24/5  53.53  1.78  x 
K96  24B  87.59  -ve  x 
K96  25B  16.50  0.40  ￿ 
K96  25/R  26.28  0.53  ￿ 
K96  25/B  22.67  1.68  ￿ 
K96  29/R  7.41  9.07  ￿ 
K96  29/3  8.71  10.53  ￿ 
K96  29/B  15.47  5.93  ￿ 
K96  30/R  10.19  1.22  x 
K96  30/5  84.05  -ve  x 
K96  30/B  47.58 
-ve  x 
K97  0318  17.58  63.93  ￿ 
K97  03/B  45.84  11.92  ￿ 
K97  05/R  20.93  -ve  x 
K97  05/B  71.44  -ve  x 
K97  07/R  15.95  1.90  x 
K97  07/3  84.54  8.37  x 
K97  07B  61.11  -ve  x 
K97  08/R  14.63 
-ve  x 
K97  08/B  30.00  -ve  x 
K97  13/R  34.81  -ve  x 
K97  13B  112.84 
-ve  x 
As  with  the  t  ooa  ana  vitreous  humor  samples,  EDDP  was  detected  but  not  quantitated. 
￿:  Detected;  x:  not  detected. Chapter  Six:  Case  Results  Page233 
In  addition  to  analysing  the  SFE  hair  extracts  for  the  presence  of  drugs,  the  final  MeOH 
hair  wash  was  also  analysed.  All  washes  were  found  to  be  negative  for  the  drugs  being 
investigated. 
6.5  COMPARISON  OF  SFE  RESULTS  WITH  CASE  HISTORIES 
For  this  final  part  of  this  study,  the  cases  histories  were  individually  compared  firstly  with 
the  results  from  blood  and  vitreous  humor  and  secondly  with  the  hair  results.  The  first 
comparison  relates  to  the  circumstances  surrounding  the  death  of  the  deceased  and  the 
second  related  to  their  drug  history  over  the  past  year.  In  each  case,  an  example  of  how  the 
comparisons  were  made  will  be  given.  This  will  be  followed  by  a  summary  table  for  the 
remainder  of  the  cases. 
6.5.1  COMPARISON  OF  CASE  HISTORY  WITH  BLOOD  AND  VITREOUS  HUMOR  RESULTS 
The  case  which  will  be  discussed  here  is  K96  22  which  was  found  to  be  positive  for 
temazepam  (1.30  mg/L  blood;  0.76  mg/L  vitreous  humor),  desmethyldiazepam  (0.68  mg/L 
blood;  0.27  mg/L  vitreous  humor),  diazepam  (none  detected  in  blood;  0.62  mg/L  vitreous 
humor),  morphine  (2.21  mg/L  blood;  1.67  mg/L  vitreous  humor),  6MAM  (none  detected  in 
blood;  0.011  mg/L  vitreous  humor)  and  methadone  (0.28  mg/L  blood;  0.12  mg/L  vitreous 
humor).  The  case  was  that  of  a  27  year  old  female  and  from  the  post-mortem  report  it  was 
ascertained  that  the  cause  of  death  was  due  to  heroin  and  temazepam  intoxication.  The 
time  between  the  death  of  the  deceased  and  post-mortem  was  7  days,  indicating  that  a 
degree  of  decomposition  will  have  occurred. 
From  the  police  report  which  accompanied  the  case,  the  information  available  implied  that 
the  cause  of  death  was  heroin  related  as  a  syringe  was  found  in-situ.  The  deceased  was 
also  on  a  methadone  maintenance  programme  although  she  failed  to  pick  up  her  last 
prescription.  No  mention  was  made  in  the  report  of  the  use  of  benzodiazepines. 
If  no  police  report  had  been  available,  with  only  the  blood  results,  it  would  not  have  been 
possible  to  say  for  definite  that  the  case  of  death  was  due  to  heroin  intoxication  as  no 
6MAM  was  present  in  the  blood.  However,  the  analysis  of  vitreous  humor  shows  that Chapter  Six:  Case  Results  Pa  e234 
death  was  in  fact  heroin  related  as  a  small  amount  of  6MAM  was  detected  indicating  that 
heroin  had  been  used  shortly  before  death. 
Table  6.10  gives  a  brief  summary  of  the  cases  which  were  positive,  drugs  which  were 
detected,  and  expected  and  whether  the  results  obtained  agree  or  disagree  with  the  drug 
history. 
Table  6.10:  Comparison  of  Case  Results  with  PM  and  Police  Reports 
Case  Drugs  Detected  Drugs  Expected  Agree  /  Heroin 
Differ  Abuse 
M  6M  Meth  Benzo  Heroin  Meth  Benzo  Confirmed 
K96  02  ￿  n/c  x  ￿  ￿  x  ￿  A  -ve*  K96  03  x  x  x  ￿  ￿  x  x  D  -ve  K96  04  ￿  n/c  x  ￿  x  x  ￿  D  +ve* 
K96  07  ￿  n/c  x  ￿  ￿  ￿  ￿  D  -ve*  K96  08  ￿  n/c  ￿  ￿  ￿  ￿  ￿  A  -ve*  K96  10  ￿  n/c  x  x  ￿  x  x  A  -ve*  K96  11  ￿  n/c  x  ￿  ￿  x  x  D  -ve*  K96  12  ￿  n/c  x  x  x  x  x  D  -*  K96  13 
K96  14 
x 
￿ 
x 
n/c 
￿ 
x 
￿ 
￿ 
￿ 
x 
x 
x 
￿ 
x 
D 
D 
-ve 
-*  K96  15 
K96  17 
K9618 
K9619 
K96  20 
K96  21 
K96  22 
K96  23 
x 
￿ 
￿ 
￿ 
￿ 
￿ 
￿ 
x 
x 
n/c 
x 
￿ 
￿ 
￿ 
￿ 
x 
￿ 
x 
x 
x 
x 
￿ 
￿ 
￿ 
￿ 
x 
￿ 
x 
￿ 
￿ 
￿ 
￿ 
￿ 
￿ 
￿ 
￿ 
￿ 
￿ 
￿ 
x 
￿ 
x 
￿ 
x 
x 
￿ 
￿ 
x 
x 
x 
￿ 
x 
x 
￿ 
x 
￿ 
D 
A 
D 
A 
D 
A 
A 
D 
+ve 
-ve* 
-ve 
+ 
+ 
+ 
+ 
-  K96  24 
K96  25 
X 
￿ 
X 
￿ 
￿ 
x 
￿ 
￿ 
￿ 
￿ 
￿ 
x 
￿ 
￿ 
D 
A 
-ve 
+ 
K96  26 
K96  27 
K96  28 
x 
￿ 
￿ 
x 
￿ 
n/c 
x 
x 
x 
￿ 
￿ 
￿ 
￿ 
￿ 
X. 
x 
￿ 
x 
x 
￿ 
￿ 
D 
D 
D 
-ve 
+ 
-*  K96  29  ￿  n/c  x  ￿  ￿  x  ￿  A  -ve*  K96  30  x  x  x  ￿  ￿  x  ￿  D  -ve  K97  02  x  x  x  ￿  x  ￿  ￿  D  -  K97  03 
K97  04 
K97  07 
K97  09 
10 
x 
￿ 
￿ 
￿ 
￿ 
x 
￿ 
￿ 
￿ 
￿ 
￿ 
x 
x 
X. 
￿ 
x 
￿ 
x 
x 
X. 
￿ 
￿ 
￿ 
￿ 
x 
x 
x 
￿ 
￿ 
x 
x 
D 
A 
A 
A 
+ 
+ 
+  K97 
9711  ￿ 
x  x  x  ￿  D  +ve  K  x  X  X  ￿  X  ￿  D  -ve* Chapter  Six:  Case  Results  Page235 
Table  6.10:  Continued 
Case  Drugs  Detected  Drugs  Expected  Agree  / 
Differ 
Heroin 
Abuse 
M  6M  Meth  Benzo  Heroin  Meth  Benzo  Confirmed 
K97  13  x  x  ￿  x  ￿  ￿  x  D  -ve* 
K9714  ￿  ￿  x  x  ￿  x  x  A  + 
K97  15  ￿  ￿  x  x  x  x  x  D  +ve 
K9716  ￿  ￿  x  x  ￿  x  x  A  + 
K9717  ￿  ￿  x  x  ￿  x  x  A  + 
K9718  ￿  ￿  ￿  x  ￿  x  x  D  + 
M:  Morphine;  6M:  6MAM;  Meth:  Methadone;  Benzo:  Benzodiazepine. 
+:  heroin  confirmed  by  presence  of  6MAM  in  blood  and/or  vitreous 
-,  heroin  not  expected  and  not  determined 
-*:  heroin  not  expected,  morphine  not  detected  but  6MAM  not  analysed  for 
+ve:  heroin  determined  but  not  expected 
-ve:  heroin  expected  but  not  determined 
-ve*:  heroin  expected  but  not  determined  however,  morphine  positive  and  6MAM  not 
analysed  for 
:  expected  or  detected 
x::  not  expected  or  not  detected 
6.5.2  COMPARISON  OF  CASE  HISTORIES  WITH  HAIR  RESULTS 
As  mentioned  previously,  the  second  comparison  which  was  carried  out  was  to  use  the 
results  obtained  by  hair  analysis  to  confirm  past  drug  abuse.  Case  K96  24  was  chosen  as 
an  example. 
Case  K96  24  was  found  to  be  positive  for  all  three  types  of  drug.  As  the  hair  sample  was 
reasonably  long,  it  was  sectioned  into  three  parts  (roots  (R),  next  6  cm,  final  5  cm)  in 
addition  to  this  some  of  the  hair  was  left  unsectioned  as  a  bulk  (B)  sample.  As  can  be  seen 
from  Tables  6.7-6.9,  the  sample  contained  the  amounts  of  drugs  shown  in  Table  6.11. Chapter  Six:  Case  Results  Page236 
Table  6.11:  Summary  of  HairAnalvsis  Results  for  Case  K96  24 
Section  Benzod  iaze  ines  (n  /m)  Opiate  (n  /m)  Methadone 
Temaz  DMD  Diaz  Morphine  6MAM  (n  /m  ) 
Root  2.52  3.03  4.62  0.65  2.07  5.53 
6  cm  23.89  18.78  20.08  1.15  1.28  8.09 
5  cm  6.06  3.83  13.53  1.57  2.62  1.78 
Bulk  4.22  2.69  12.11  1.06  0.75  -ve 
The  deceased  in  this  case  was  a  20  year  old  female.  From  the  past  history  it  was  seen  that 
she  was  a  known  drug  abuser  whose  drug  problem  was  defined  as  "slight".  She  was  said  to 
have  taken  temazepam  when  depressed  and  had  taken  Valium®  the  week  before  her  death. 
In  addition,  she  was  known  to  have  smoked  heroin.  She  was  not  known  to  be  on  a 
methadone  maintenance  programme,  however  an  empty  bottle  of  methadone  mixture  was 
seized  from  the  locus. 
From  the  information  obtained  from  the  hair  analysis,  it  appears  that  the  deceased  had  been 
using  temazepam,  diazepam,  methadone  and  heroin  in  the  year  and  month  prior  to  death. 
The  blood  analysis  showed  the  presence  of  methadone,  temazepam,  diazepam  and 
desmethyldiazepam  which  were  confirmed  as  being  used  over  the  past  year  by  the  hair 
analysis.  No  heroin  was  detected  in  blood  or  vitreous  humor,  thus  without  the  use  of  hair 
analysis,  this  would  have  gone  undetermined. 
Although  the  detection  of  heroin  in  the  hair  of  the  deceased  is  not  relevant  in  terms  of  the 
cause  of  death,  in  cases  where  the  subject  is  still  alive  and  drug  abuse  is  suspected,  hair 
analysis  is  more  informative  than  blood  analysis.  In  particular,  the  roots  of  the  hair  were 
found  to  contain  all  three  types  of  drugs  indicating  use  of  these  drugs  within  one  month 
prior  to  death. 
Table  6.12  contains  summary  information  of  all  hair  samples  analysed  and  relates  then  to 
the  information  available  from  the  PM  and  police  reports. 
The  results  obtained  for  benzodiazepines,  morphine  and  methadone  were  compared  to  the 
deceased's  drug  history.  In  this  respect  the  hair  analysis  is  particularly  interesting  as 
findings  may  be  compared  to  the  drug  history  of  the  deceased  several  months  prior  to Chapter  Six:  Case  Results  Page237 
death.  In  some  cases,  the  results  obtained  supported  the  police  report,  however  there  were 
cases  where  drug  use  was  not  confirmed  and  indeed  some  cases  where  drugs  were  detected 
which  were  not  mentioned  in  the  deceased's  drug  history  (e.  g.  methadone  detected  in  the 
hair  of  a  subject  not  known  to  be  on  a  methadone  maintenance  programme). 
Table  6.12:  Comparison  of  Case  Hair  Results  with  PM  and  Police  Reports 
Case  Drugs  Detected  Drugs  Expected  Agree/ 
Differ 
Heroin 
Abuse 
M  6M  Meth  Benzo  Heroin  Meth  Benzo  Confirmed 
K96  01  x  n/c  x  ￿  x  x  ￿  A  -* 
K96  02  x  n/c  x  ￿  ￿  x  ￿  D  -ve* 
K96  04  x  n/c  x  ￿  x  x  ￿  A 
K96  05  x  n/c  x  ￿  ￿  ￿  ￿  D  -ve* 
K96  07  x  n/c  x  ￿  ￿  ￿  ￿  D  -ve* 
K96  08  x  n/c  x  ￿  X  ￿  ￿  D  -* 
K97  09  x  n/c  x  ￿  ￿  X  X  D  -ve* 
K96  11  x  n/c  x  ￿  ￿  x  x  D  -ve* 
K9613  ￿  ￿  ￿  x  ￿  x  ￿  D  + 
K9615  ￿  ￿  ￿  x  ￿  ￿  x  A  + 
K96  16  x  x  x  ￿  ￿  x  x  D  -ve 
K9617  ￿  ￿  ￿  x  ￿  x  x  D  + 
K9618  ￿  ￿  ￿  x  ￿  ￿  ￿  D  + 
K96  20  x  ￿  x  ￿  x  x  D  -ve 
K96  21  ￿  ￿  ￿  ￿  ￿  ￿  ￿  A  + 
K96  22  ￿  ￿  ￿  x  ￿  ￿  x  A  + 
K96  23  x  x  x  ￿  x  x  ￿  A  - 
K96  24  ￿  ￿  ￿  ￿  ￿  ￿  ￿  A  + 
K96  25  ￿  ￿  ￿  x  ￿  x  ￿  D  + 
K96  26  ￿  ￿  x  x  ￿  x  x  A  + 
K96  29  ￿  x  ￿  ￿  ￿  x  ￿  D  +* 
K96  30  ￿  ￿  ￿  ￿  ￿  x  ￿  D  + 
K97  01  X  X  X  ￿  ￿  X  X  D  -ve 
K97  03  ￿  ￿  ￿  x  x  ￿  ￿  D  +ve 
K97  05  ￿  ￿  x  x  x  x  x  D  +ve 
K97  06  x  x  x  ￿  x  ￿  ￿  D  - 
K97  07  ￿  ￿  ￿  x  ￿  x  x  D  + 
K97  08  ￿  ￿  ￿  x  ￿  ￿  x  A  + 
K9710  x  x  x  ￿  x  x  ￿  A  - 
K9712  ￿  ￿  x  x  ￿  ￿  ￿  D  + 
K97  13  ￿  ￿  ￿  x  ￿  ￿  x  A  + 
For  key  see  't'able  6.1U. Chapter  Six:  Case  Results  Page238 
From  Table  6.12,  it  can  be  seen  that  less  than  half  of  the  cases  correlate  to  the  results 
expected  from  the  PM  and  police  reports.  8  of  the  23  "known"  heroin  users  had  no 
morphine  or  6MAM  detected  in  their  hair  sample,  however  only  two  cases  were  detected 
where  heroin  abuse  was  not  suspected. 
For  methadone,  7  cases  (47%  of  total  positives)  were  found  to  be  positive  where  no 
mention  of  methadone  maintenance  was  given  in  the  police  report.  There  were  5  cases 
where  the  deceased  was  previously  on  a  maintenance  programme  where  no  methadone  was 
detected. 
The  best  correlation  between  the  reports  and  the  hair  analysis  results  was  for  the 
benzodiazepines.  Only  5  cases  were  found  not  to  be  positive  where  expected  and  only  4 
false  positives  were  determined  (no  record  of  previous  use  and  positive  hair  result). 
In  terms  of  agreement  of  the  comparison  between  the  results  by  blood  /  vitreous  humor  and 
hair  with  the  PM  and  police  reports,  there  is  little  difference  (39.5  %  agreement  for  blood  / 
vitreous  humor  and  35.5%  agreement  for  hair).  However,  in  terms  of  the  determination  of 
heroin  abuse,  hair  analysis  is  more  likely  to  detect  the  use  of  heroin  (%  agreement  =  61%) 
than  analysis  of  blood  or  vitreous  humor  (%  agreement  =  50%).  (It  should  be  noted  that 
the  cases  where  6MAM  was  not  analysed  for  have  been  omitted  from  the  %  agreement). 
6.6  CONCLUSIONS 
Post-mortem  blood,  vitreous  humor  samples  were  analysed  for  the  presence  of 
benzodiazepines  (temazepam,  desmethyldiazepam,  diazepam),  morphine  and  methadone 
using  the  SFE  methods  developed  in  Chapters  2,3  and  4  respectively.  Metabolites  of 
morphine  (6MAM)  and  methadone  (EDDP)  were  also  detected.  All  three  SFE  methods 
were  found  to  successfully  extract  the  drugs  from  the  matrices  and  yielded  results 
comparable  to  those  determines  using  SPE  and  LLE  techniques. 
The  usefulness  of  vitreous  humor  analysis  as  an  alternative  to  blood  was  highlighted. 
Good  correlations  between  blood  and  vitreous  humor  were  seen  for  most  of  the  drugs 
investigated  indicating  that  vitreous  humor  can  be  used  as  an  alternative  sample  when Chapter  Six:  Case  Results  Page239 
blood  is  not  available  for  analysis.  Due  to  its  relatively  simple  matrix,  vitreous  humor  also 
produced  cleaner  extracts  then  blood. 
As  with  the  blood  and  vitreous  humor  analysis,  the  hair  extraction  method  was  found  to 
successfully  recover  benzodiazepines,  morphine,  6MAM  and  methadone.  Although  the 
correlations  between  the  analytical  results  and  the  PM  and  police  reports  were  relatively 
poor,  it  was  possible  to  use  6MAM  as  a  marker  of  past  heroin  abuse  and  in  some  cases 
confirm  past  drug  use  up  to  one  year  prior  to  death.  The  use  of  hair  in  post-mortem  cases 
is  of  limited  use,  other  than  in  the  confirmation  of  drug  histories,  however  the  developed 
method  would  be  useful  in  determining  past  drug  use  in  other  areas  e.  g.  employee  and 
parolee  testing. Chapter  Seven:  Conclusions  Page240 
7.  CONCLUSIONS  FROM  THESIS 
The  aim  of  this  study  was  to  develop  extraction  methodology  using  supercritical  fluid 
technology  for  the  determination  of  drugs  of  forensic  interest  in  a  range  of  biological 
matrices.  Three  types  of  drug  were  investigated: 
1)  Benzodiazepines 
2)  Morphine 
3)  Methadone 
The  first  sample  matrix  to  be  investigated  was  blood.  Successful  method  development  was 
carried  out  and  methodology  was  established  for  all  three  drug  types.  The  benzodiazepines 
were  extracted  using  SF-CO2  with  ethyl  acetate  as  a  modifier  at  65  °C  and  3000  psi.  The 
extraction  yielded  >80%  recoveries  of  temazepam,  desmethyldiazepam  and  diazpam  within 
10  minutes. 
For  the  extraction  of  morphine  and  methadone,  it  was  found  that  both  drugs  extracted  with 
>80%  recoveries  using  the  same  conditions.  SF-CO2  was  still  used  as  the  main  extraction 
fluid  and  a  mixture  of  methanol  and  triethylamine  was  added  as  a  modifier.  The 
extractions  were  run  at  100  °C  and  3500  psi.  In  addition  to  efficiently  extracting  morphine 
and  methadone,  an  additional  benefit  of  this  extraction  was  that  it  also  allowed  for  the 
extraction  of  6-monoacetyl  morphine,  the  primary  metabolite  of  heroin.  Recoveries  and 
reproducibility  for  the  extraction  of  6MAM  were  good. 
The  second  sample  matrix  to  be  investigated  was  vitreous  humor.  It  was  found  that  the 
methods  which  had  been  developed  for  the  extraction  of  the  drugs  from  blood  were  also 
ideal  for  the  extractions  from  vitreous  humor.  This  allowed  direct  comparison  of  the  two 
sets  of  results  obtained  from  blood  and  vitreous  humor. 
The  final  matrix  to  be  investigated  was  hair.  Hair  analysis  is  becoming  of  increasing 
importance  in  the  forensic  field  as  it  provides  a  readily  available  marker  of  past  drug  use. Chapter  Seven:  Conclusions  Page241 
Methodology  was  developed  from  existing  procedures  and  all  three  types  of  drugs  were 
successfully  extracted  using  the  same  technique. 
Extractions  of  post-mortem  blood,  vitreous  humor  and  hair  samples  were  carried  out  using 
the  developed  methods  and  were  found  to  compare  well  to  conventional  extraction 
techniques. 
A  total  of  48  cases  were  investigated  and  the  following  comparisons  were  made. 
1)  Vitreous  humor  samples  were  analysed  and  the  results  compared  to  those  obtained  for 
blood  in  order  to  determine  the  usefulness  of  this  sample  matrix.  With  the  exception  of 
desmethyldiazepam,  all  drugs  investigated  gave  good  correlations  between  blood  and 
vitreous  humor  results,  although  the  levels  in  vitreous  humor  were  generally  lower  than 
the  corresponding  levels  in  blood. 
2)  In  order  to  confirm  that  the  developed  SFE  methods  were  efficient  for  the  extraction  of 
the  drugs  of  interest  from  authentic  samples  (all  method  development  was  carried  out 
using  spiked  samples)  some  of  the  cases  were  analysed  by  the  conventional  technique 
used  in  the  routine  laboratory  (SPE  for  benzodiazepines  and  morphine,  LLE  for 
methadone).  In  all  cases  the  two  methods  correlated  well. 
3)  The  results  obtained  for  benzodiazepines,  morphine  and  methadone  were  compared  to 
the  deceased's  drug  history  to  determine  if  correlations  existed.  Heroin  abuse  was 
confirmed  by  the  presence  of  6MAM  in  all  three  matrices.  Hair  analysis  was  found  to 
be  particularly  useful  as  it  provided  a  better  match  with  the  drug  history  than  blood  or 
vitreous  humor. 
It  has  been  shown,  that  supercritical  fluid  extraction  is  a  valuable  tool  for  the  analysis  of 
drugs  and  their  metabolites  in  a  variety  of  matrices.  The  developed  SFE  methods  are  more 
efficient  and  less  costly  in  consumables  than  conventional  extraction  techniques.  For  the 
analysis  of  hair,  SFE  has  the  additional  advantage  of  a  substantial  reduction  in  extraction 
time,  as  the  preparative  steps  can  be  included  in  the  methodology. Chapter  Eight:  References  Page242 
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CALCULATION  OF  CONCENTRATION  IN  BLOOD  /  VITREOUS  HUMOR  SAMPLES 
Sample  Ratio  = 
Response  of  Drug  in  Sample 
Response  of  Internal  Standard  in  Sample 
Standard  Ratio  = 
Response  of  Drug  in  Standard 
Response  of  internal  Standard  in  Standard 
Drug  Concentration  (mg  /  L)  = 
Sample  Ratio 
x 
Concentration  of  Drug  in  Standard 
Standard  Ratio  Dilution  Factor 
The  Dilution  Factor  is  used  when  the  volume  of  the  sample  and  standard  are  not  the  same 
e.  g.  1  ml  of  standard  and  100  µ1  of  sample  gives  a  dilution  factor  of  10. 
CALCULATION  OF  CONCENTRATION  IN  HAIR  SAMPLES 
Drug  Concentration(ng  /  mg)  = 
Sample  Ratio 
x 
Concentration  of  Drug  in  Standard  (ng) 
Standard  Ratio  Weight  of  Hair  Sample  (mg) 
RECOVERY  STUDIES 
For  recovery  studies,  the  calculations  were  carried  out  as  follows: 
%  Recovery  = 
Extracted  Standard  Ratio 
x  100 
Unextracted  Standard  Ratio Appendix  Two:  Calculation  of  Standard  Deviation  Page262 
STANDARD  DEVIATION: 
In  order  to  assess  variability  of  data  obtained,  the  relative  standard  deviation  (RSD)  was 
calculated  according  to  the  equation  below; 
RSD  = 
(x-x)2 
ý(n-1) Appendix  Three:  Distribution  of  Age/Sex  of  Cases  Nagc263 
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The  distribution  of  age  and  sex  of  the  cases  investigated  is  shown  in  the  above  figure.  lt 
can  be  seen  that  the  cases  were  predominantly  male  (72%)  and  that  the  most  common  age 
was  29  (mean  27). Appendix  Four:  Papers  in  Support  of  this  Thesis  Page264 
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This  article  details  the  supercritical  fluid  extraction  of  benzodiazepines,  morphine  and  methadone  from  post- 
mortem  blood,  vitreous  humor  and  hair  from  suspected  drug  abusers. 
A  comparison  between  post-mortem  blood  and  vitreous  humor  levels  was  made  in  order  to  investigate  the  use  of 
vitreous  humor  as  an  alternative  toxicological  medium  to  blood. 
Hair  analysis  was  carried  out  in  order  to  evaluate  the  use  of  hair  in  the  determination  of  chronic  drug  abuse. 
Keywords:  Supercritical  fluid  extraction,  hair,  vitreous  humor,  blood,  benzodiazepines,  morphine,  methadone. 
Introduction 
Most  present  methodology  for  the  extraction 
of  drugs  of  abuse  from  biological  liquids 
involve  solid  phase  or  liquid-liquid 
extractions[  1,2].  These  methods  can  be  time 
consuming,  costly  and  wasteful  of  sample.  With 
the  increase  in  demand  for  efficient 
toxicological  analyses  the  development  of  new 
extraction  technology  is  of  the  utmost 
importance.  Supercritical  fluid  technology  has 
grown  dramatically  over  the  past  decade, 
however  despite  this,  its  acceptance  in  routine 
forensic  analysis  has  been  limited[3,4,51. 
In  addition  to  speed  and  convenience  of  use, 
the  main  advantages  of  supercritical  fluids 
include  improved  efficiency,  non-toxicity  and 
cost-effectiveness[6].  The  possibility  for  direct 
extraction  from  complex  matrices,  in  parallel 
with  a  reduced  risk  of  sample  contamination 
highlights  the  power  of  supercritical  fluids  as  a 
tool  for  analysis. 
As  well  as  time  of  death  related  drug  analysis, 
it  can  be  important  to  obtain  information 
relating  to  long  term  drug  abuse.  Although  the 
analysis  of  hair  has  been  used  for  this 
purpose[7.8.9],  work  is  still  required  in  this  area 
in  order  to  provide  a  validated,  universally 
accepted  method. 
The  supercritical  fluid  analysis  of  drugs  of 
abuse  in  hair  has  also  been  reviewed[1o].  The 
results  obtained  tend  to  be  similar  to  those 
obtained  by  conventional  digestion  or 
methanolic  extraction  techniques  which  are  time 
consuming  and  destructive.  Here  again  the 
advantage  of  short  extraction  times  with 
supercritical  fluids  is  emphasised. 
Experimental 
Temazepam  and  prazepam  were  purchased 
from  Wyeth  Laboratory.  Morphine,  d3- 
morphine,  methadone  and  d3-methadone  were 
purchased  from  Sigma.  Methanol,  ethyl  acetate 
and  dichloromethane  are  HPLC  grade  (Lab  Scan 
Analytical  Sciences).  Triethylamine  is  HPLC 
grade  and  Na2HPO4  GPR  grade  (BDH). 
BSTFA  with  1%  TMCS  (Pierce)  was  used  for 
the  derivitisation  of  morphine  and  d3-morphine. 
The  CO2  is  supplied  by  Air  Products  and  comes 
in  25  kg  cylinders  fitted  with  a  dip-tube. 
Extrelut®  (Merck)  is  prewashed  in 
dichloromethane.  Collection  vials  for  SFE  are  6 
mL  HypoVialTM  (Pierce)  with  butyl  rubber  septa 
(Pierce  and  Warriner).  Columns  for  SFE  were 
made  using  3  cm  x  4.6  mm  i.  d.  stainless  steel 
tubing.  Water  was  deionised  using  a  Milli-Q® 
water  purification  system  (Millipore(D) 
The  SFE  system  consists  of  two  Gilson  306 
pumps,  two  rheodyne  valves  and  a  Pye  series 
104  GC  oven  with  pressure  restrictor.  All 
components  were  modified  to  suit  the 
supercritical  extractant.  The  CO2  pumphead 
was  refridgerated  to  maintain  the  flow  of  liquid 
CO2  using  a  Gilson  model  SFC3  refridgeration 
unit.  The  extraction  columns  were  placed  over 
positions  1  and  4  in  the  second  rheodyne  and  the 
extract  collected  by  expansion  into  McOH  in  a 
HypoVialVM  at  the  flow  outlet. 
For  the  extraction  of  temazepam  from  blood 
and  vitreous  humor,  the  method  used  was  that 
reported  by  Scott  and  Oliver[1II.  This  method 
proved  ineffective  in  the  extraction  from  hair. 
Methadone  and  morphine  analysis  was  carried 
out  using  a  triethylamine  :  methanol  modifier 
which  again  was  efficient  in  the  extraction  of 
these  drugs  from  blood  and  vitreous  humor  but 
failed  in  the  analysis  of  hair.  Successful 
extraction  of  morphine  from  hair  was  reported 
by  Cirimele,  et  al[10]  and  this  method  proved effective  in  the  extraction  of  all  three  drug  types 
from  hair. 
Sample  preparation 
Blood  and  vitreous  humor 
Extrelut®  was  used  as  a  support  medium  for 
blood  and  vitreous  humor  samples. 
Approximately  0.2  g  of  extrelut  were  placed  in  a 
plastic  weighing  boat  and  100  p.  L  of  sample 
loaded,  mixed  and  left  to  dry  at  room 
temperature.  The  contents  of  the  boat  were  then 
transfered  to  an  extraction  cell. 
Extraction  conditions 
Condition  Benzodiazepines  Morphine/Methadone 
Temp:  65  °C  100  °C 
Pressure:  300  psi  3500  psi 
Modifier  :  Ethyl  Acetate  McOH:  Et3N(85:  15) 
Flow:  2  mL/min  2  mUmin 
Time:  20  min  30  min 
Analysis:  HPLC  CC-MS 
Hair 
Hair  samples  were  decontaminated  by  washing 
with  H2O  then  methanol,  then  again  with  H20. 
In  order  to  maximise  the  surface  area  for 
extraction,  the  hair  was  ground  using  either  a 
mortar  and  pestle  with  liquid  nitrogen  or  an 
analytical  mill  (IKA,  Labortechnik)  with  dry  ice. 
Approximately  50  mg  of  decontaminated  ground 
hair  was  then  placed  in  an  extraction  cell. 
Extraction  conditions 
Condition  All  drugs 
Temp:  100  °C 
Pressure:  3500  psi 
Modifier:  MeOH:  Et3N:  H20  (2:  2:  1) 
Flow  Rate:  2  mUmin 
Cleanup:  Static  10  min 
Continuous  15  min 
Extract:  Add  500  pL  modifier 
Static  15  min 
Continuous  30  min 
Results  and  Discussion 
Blood  and  vitreous  humor 
Post-mortem  blood,  vitreous  and  hair  samples 
were  obtained  for  nine  suspected  drug  abuse 
cases.  In  all  nine  cases,  quantities  of  drug  were 
found  which  could  have  contributed  to  death. 
For  the  hair  samples,  the  three  wash  steps 
were  sufficient  to  remove  any  environmental 
contamination  from  the  hair  and  results  reported 
are  from  consumed  drugs  only. 
Seven  of  the  cases  showed  levels  of  morphine 
in  blood  from  0.07-1.20  mg/L  (mean  0.57).  Of 
these,  five  had  positive  vitreous  humor,  0.24- 
0.44  mg/L  (mean  0.35).  In  the  case  with  a  level 
of  0.07  mg/L  blood,  no  morphine  was  detected 
in  vitreous  humor  by  GC-MS  and  for  one  of  the 
cases  no  vitreous  humor  was  available. 
Only  two  of  the  cases  showed  positive 
methadone  levels  in  blood  and  vitreous  humor. 
In  blood,  the  levels  were  0.20  and  0.09  mg/L 
and  in  vitreous  humor  0.19  and  0.32  mg/L 
respectively. 
Six  of  the  cases  showed  positive  temazepam 
blood  levels  ranging  from  0.13-1.22  mg/L 
(mean  0.54).  Of  these,  three  showed  positive 
vitreous  humor  (in  two,  vitreous  humor  was  not 
available  and  in  one  temazepam  was  not 
detected  by  HPLC).  The  positive  measurements 
ranged  from  0.18-0.54  mg/L  (mean  0.31).  Other 
benzodiazepines  were  found  in  three  cases.  For 
one  of  these  cases  vitreous  humor  was  not 
available.  One  case  showed  1.01  mg/L 
desmethyldiazepam  (DMD)  in  blood  and  0.93 
mg/L  in  vitreous  humor.  The  other  case 
showed  0.47  mg/L  DMD  plus  1.00  mg/L 
diazepam  in  blood  and  0.18  mg/L  DMD  in 
vitreous  humor. 
Hair 
Four  cases  were  positive  for  morphine  in  hair 
and  the  values  ranged  from  1.09-1.50  ng/mg 
(mean  1.31).  The  same  cases  were  also  positive 
for  methadone.  Methadone  concentrations 
ranged  from  1.29-2.91  ng/mg  (mean  2.00).  In 
hair  only  temazepam  has  been  analysed  for  at 
present.  Five  cases  showed  positive  temazepam 
ranging  from  0.92-111  ng/mg  (mean  28.35). 
In  order  to  determine  if  any  relationship  exists 
between  blood  and  vitreous  humor  results,  it 
will  be  necessary  to  review  more  cases. 
However,  primary  results  have  shown  that  in 
general,  positive  vitreous  humor  results  are 
lower  than  the  corresponding  blood  results. 
The  results  obtained  from  hair  analysis  verify 
information  available  on  previous  drug  histories 
e.  g.  four  of  the  cases  were  receiving  methadone 
treament  prior  to  death.  In  two  of  these  cases 
methadone  was  not  detected  in  blood  or  vitreous 
humor.  The  hair  analysis  was  positive. 
Conclusions 
This  study  has  demonstrated  the  use  of 
supercritical  fluids  in  the  extraction  of  drugs  of 
abuse  from  blood,  vitreous  humor  and  hair.  It 
provides  a  fast  and  efficient  alternative  to 
conventional  extraction  methods. 
As  only  100  µL  of  sample  is  required  for 
blood  and  vitreous  humor  extractions,  it  is  more 
economical  in  its  use  of  sample  than 
conventional  procedures. 
It  is  beneficial  to  find  that  the  hair  extraction 
method  works  for  all  three  drug  types 
investigated,  resulting  in  a  requirement  for  only one  extraction  per  case.  Ordinarily,  the 
digestion  conditions  for  hair  have  to  be  carefully 
selected  to  ensure  no  artefact  production.  In  the 
case  of  supercritical  fluid  extraction  this  is  not 
an  issue  as  the  conditions  used  are  relatively 
mild. 
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Abstract 
A  supercritical  fluid  extraction  (SFE)  procedure  for  the  analysis  of 
temazepam  from  whole  blood  was  developed.  Quantitative 
recoveries  were  obtained  by  high-performance  liquid 
chromatography  using  prazepam  as  an  internal  standard  and 
carefully  monitoring  the  extraction  temperature  and  pressure.  The 
results  were  found  to  compare  well  with  those  obtained  by  solid- 
phase  extraction  techniques,  but  they  also  had  the  advantages  of 
reduced  solvent  consumption  and  minimal  sample  handling.  The 
application  of  this  method  to  authentic  forensic  blood  specimens 
showed  the  SFE  method  to  be  useful  as  an  alternative  procedure  for 
the  extraction  of  temazepam  in  the  toxicology  laboratory. 
Introduction 
In  western  Scotland  in  1994,  some  141  deaths  in  which 
temazepam  was  a  contributory  factor  were  reported.  Between 
1993  and  1995,  an  80%  increase  in  the  number  of  drivers  found 
with  considerable  levels  of  temazepam  was  observed  (1).  These 
figures  reflect  the  increasing  trend  in  temazepam  abuse  in 
Scotland. 
At  present,  temazepam  analysis  from  biological  matrices 
involves  a  solid-phase  extraction  (SPE)  method.  The  procedure 
used  is  a  modification  of  that  reported  by  Zweipfenning  et  al.  (2). 
Disadvantages  of  this  procedure  include  the  need  for  high-purity 
organic  solvents  and  the  resultant  generation  of  substantial 
quantities  of  waste  solvent.  In  addition,  the  sample  preparation 
can  be  tedious  and  time  consuming  with  increased  potential  for 
contamination  (3).  As  an  alternative  method  of  sample  prepa- 
ration,  the  use  of  supercritical  CO2  has  been  investigated. 
In  addition  to  speed  and  convenience,  the  main  advantages  of 
supercritical  fluid  extraction  (SFE)  are  the  improved  efficiency, 
the  nontoxicity,  the  cost  effectiveness  of  the  extraction  fluid, 
and  the  possibility  for  direct  analysis  of  complex  matrices,  thus 
reducing  the  risk  of  sample  contamination  (4). 
In  order  to  develop  a  method  for  SFE,  the  analyst  must  have 
an  understanding  of  the  properties  of  the  analyte  and  the  com- 
"  Author  to  wean  correspondence  should  be  addrossed. 
position  of  the  matrix  (5).  As  the  benzodiazepines  were  rela- 
tively  polar,  it  was  necessary  to  modify  the  CO2  by  the  addition 
of  an  entrainer  (ethyl  acetate)  in  order  for  the  extraction  to  be 
feasible.  The  solvating  power  of  the  supercritical  fluid  was 
optimized  by  varying  the  pressure  and  temperature  to  obtain 
the  maximum  recovery  of  temazepam. 
Quantitation  by  the  SFE  method  was  achieved  by  the  addi- 
tion  of  prazepam  as  an  internal  standard.  The  optimum  condi- 
tions  for  temazepam  gave  peak-area  ratios  comparable  with 
those  of  unextracted  standards  as  long  as  the  temperature  and 
pressure  were  carefully  controlled. 
The  developed  method  was  first  used  to  assess  SFE  in  com- 
parison  with  SPE  for  the  extraction  of  temazepam  and 
prazepam  standards  from  methanol  and  blood.  It  was  then 
used  to  investigate  the  analysis  of  authentic  forensic  blood 
specimens,  again  by  comparison  with  SPE. 
Experimental 
Materials 
Temazepam  and  prazepzm  were  supplied  by  Wyeth  Labora- 
tory  (Hants,  U.  K.  ).  Methanol,  ethyl  acetate,  diethyl  ether,  and 
dichloromethane  were  high-performance  liquid  chromato- 
graphic  HPLC/grade  (Lab  Scan  Analytical  Sciences,  Dublin, 
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Figure  1.  Peak-height  ratio  versus  pressure. 
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Ireland),  and  ammonia  was  analytical  grade  (Merck,  Poole, 
U.  K.  ).  KHIPO4  was  HiPerSolv  grade,  and  Na2HPO4  was  CPR 
grade  (Merck).  The  CO2  was  supplied  by  Air  Products  (Walton- 
on-Thames,  U.  K.  )  in  25-kg  cylinders  fitted  with  a  dip  tube. 
Plastic  syringes  for  SPE  were  10-mL  sterile  Plastipak  syringes 
(Becton  Dickinson,  Oxford,  U.  K.  ).  Glass  wool  for  SPE  was 
silanized  (Jones  Chromatography,  Mid  Glamorgan,  U.  K.  ). 
Extrelut®  (Merck)  was  prewashed  using  dichloromethane.  The 
vials  used  for  SPE'  were  Anchor  and  Trident  (FBC,  London, 
U.  K.  )  with  screw  caps  (Merck).  The  vials  used  for  SFE  were  6 
mL  HypoVialT`4  (Pierce,  Oud-Beijerland,  The  Netherlands)  with 
butyl  rubber  septa  (Pierce  and  Warriner,  Chester,  U.  K.  ). 
Columns  for  the  SFE  were  made  using  3  cm  x  4.6-mm  internal 
diameter  stainless  steel  tubing.  Water  for  the  HPLC  mobile 
phase  was  deionized  using  a  Milli-Q®  water  purification  system 
(Millipore,  Watford,  U.  K.  ).  -_ 
Apparatus 
The  SFE  system  consisted  of  two  Gilson  (Middleton,  WI)  306 
pumps,  a  PYE  Unicam  (Cambridge,  U.  K.  )  series  104  GC  oven  with 
pressure  restrictor,  and  a  Spectroflow  (Kratos,  Manchester,  U.  K) 
757  UV  detector.  All  components  were  modified  to  suit  the  super- 
critical  extractant.  The  CO2  pumphead  was  refrigerated  with  a 
Gilson  model  SFC3  refrigeration  unit  to  maintain  the  flow  of 
liquid  CO:.  The  extraction  cell  was  placed  over  the  loop  position 
2.7  Extracted  standard  -"  Unextracted  Standard 
2.3 
1.9 
1.5 
54  59  64  69 
Temperaturt  (°C) 
Figure  2.  Peak-height  ratio  versus  temperature. 
2 
o  Unextncud  "  SPE  McOH  "  SFE  McOH 
0 
5  11. 
0.5 
10  12  14 
Concentration  of  temazepam  (mg/L) 
Figure  3.  Peak-area  ratio  versus  concentration  for  methanol-extracted 
standards. 
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of  a  Rheodyne  (Cotati,  CA)  7161.  The  extract  was  collected  by 
expansion  into  methanol  in  a  HypoVial  at  the  flow  outlet.  The 
extractant  was  C02-ethyl  acetate  (95:  5)  at  2  mUmin.  The  tem- 
perature  and  pressure  were  65°C  and  3000  psi,  respectively.  The 
extraction  was  monitored  at  a  wavelength  of  254  nm. 
The  HPLC  system  consisted  of  a  Gilson  305  pump  and  a  Gilson 
115  UV  detector.  The  column  (25  cm  x  4.6  mm)  and  guard 
column  (2  cm  x  4.6  mm)  used  were  prepacked  with  Hypersil  ODS 
(5  µm)  (Capital  HPLC  Specialists,  Bathgate,  U.  K).  The  injector 
valve  was  a  Rheodyne  7161  with  a  24-µI,  sample  loop.  The  mobile 
phase  used  was  Na2HP04-methanol  (30:  70,  W.  The  flow  rate  was 
1  mUmin,  and  the  eluent  was  monitored  at  254  nm. 
Preparation  of  standards  for  comparison 
A  series  of  standards  ranging  from  0  to  12.8  mg/L  temazepam 
with  11.24  mg/L  praaepam  were  prepared  in  both  methanol  and 
blood.  Both  sets  were  prepared  by  adding  the  appropriate  vol- 
umes  of  each  drug  stock  standard  (12.8  mg  temazepam  per 
liter  methanol,  56.2  mg  prazepam  per  liter  methanol)  to  a  vial, 
evaporating  at  65°C  under  N2,  and  reconstituting  in  5  mL  of 
either  methanol  or  blood. 
SPE  procedure 
The  extraction  columns  were  prepared  by  plugging  the  end 
of  a  10-mL  plastic  syringe  with  glass  wool,  filling  the  syringe 
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Figure  4.  Peak-area  ratio  versus  concentration  for  blood-extracted  standards. 
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with  approximately  10  g  of  Extrelut,  and  pipetting  0.25  mL  of 
a  5%  NH3  solution  onto  the  top.  Either  1  mL  of  standard 
blood,  0.9  mL  of  blank  blood,  and  100  uL  prazepam  standard 
(5  mg/100  mL  in  methanol)  or  0.9  mL  of  sample  blood  and 
100  pL  prazepam  (5  mg/100  mL)  were  pipetted  into  a  clean 
glass  vial.  To  this  mixture,  1  mL  of  phosphate  buffer  (A,  13.6 
g  KHIP04  in  500  mL  H20;  B,  4g  NaOH  in  500  mL  H20,450 
mL 
i  and  355  mL  B,  pH  adjusted  to  4  using  A  or  B)  and  0.25 
mL  of  a  5%  NH3  solution  were  added.  The  contents  of  the  vial 
were  mixed  thoroughly,  then  pipetted  onto  the  extraction 
column.  After  5  min,  the  temazepam  and  prazepam  were 
eluted  under  the  influence  of  gravity  using  diethyl  ether.  Once 
8  mL  was  collected,  the  eluent  was  evaporated  to  dryness  at 
65°C  under  nitrogen  and  reconstituted  in  180  pL  of  HPLC 
mobile  phase. 
SFE  procedure 
Approximately  0.2  g  of  Extrelut  was  placed  in  a  plastic  weigh- 
ing  boat.  To  this  solution,  0.5  mL  of  standard  blood-methanol. 
0.4  mL  blank  blood,  and  100  pL  prazeparn  (5  mg/100  mL)  or 
0.4  mL  sample  blood  and  100  pL  prazepam  (5  mg/100  mL)  were 
Table  1.  Comparison  of  SPE  and  SFE  Results  for  the 
Analysis  of  Forensic  Toxicological  Case  Samples 
SPE  SEE 
Case  (mg/L)  (mg/L)  %  Difference 
RTD94  266  8.04  757  5.8 
RTD9S  032  2.38  2.13  10.5 
RTD95  036  2.34  2.43  3.8 
RTD93  039  3.20  3.06  4.4 
RTD93  057  1.08  1.22  13.0 
T941297  2.43  2.51  3.3 
T941310  1.40  1.48  5.7 
1941329  2.92  3.12  6.8 
T95117  1.81  1.77  2.2 
793182  3.45  3.83  11.0 
T95  241  1.07  1.02 
_ 
4.7 
added.  After  mixing.  the  contents  of  the  boat  were  allowed  to  dry 
at  room  temperature,  until  a  friable  consistency  was  achieved 
(approximately  1-2  h),  before  being  transferred  to  an  extraction 
column.  It  was  not  necessary  to  completely  dry  the  samples 
but,  when  possible,  the  samples  were  left  overnight.  The  column 
was  sealed  and  placed  over  the  loop  position  of  the  Rheodyne  in 
the  equilibrated  SFE  system.  The  extraction  was  started  by 
switching  the  Rheodyne  from  load  to  inject  and  was  carried  out 
for  10  min.  The  collected  extract  was  dried  at  65°C  under  nitro- 
gen  and  reconstituted  in  50  uL  of  HPLC  mobile  phase. 
Results  and  Discussion 
Reproducibility  problems  were  encountered  when  the  extrac-' 
tion  conditions  were  not  carefully  controlled;  in  particular, 
care  was  required  in  the  control  of  pressure.  Figure  1  shows 
how  small  fluctuations  in  pressure  can  affect  the  peak-height 
ratios.  The  pressure  chosen  for  the  extractions  was  3000  psi. 
The  rate  of  change  in  peak-height  ratio  with  pressure  for  the 
extracted  standards  compared  with  unextracted  standards  was 
less  pronounced. 
Extractions  were  tried  at  various  temperatures  between  50 
and  100°C.  The  temperature  for  the  optimum  recovery  of 
temazepam  was  found  to  be  around  60°C.  Figure  2  shows  the 
variation  in  peak-height  ratio  around  this  value.  and,  from  this, 
an  extraction  temperature  of  65°C  was  chosen. 
In  the  absence  of  matrix  interferences,  the  peak-area  ratios 
obtained  by  SFE  were  found  to  be  linear  over  the  range  0-12.8 
mg/L  temazepam  (r2  =  0.999).  Figure  3  shows  that  the  peak- 
area  ratios  for  both  SFE  and  SPE  compare  well  with  those 
obtained  for  unextracted  standards  (m,,,,  =  0.15,  m5  =  0.134, 
mSPE  =  0.158). 
As  SFE  exhibits  its  best  advantages  when  extracting  analytes 
from  solids  or  semi-solids  (6),  all  blood  samples  were  dried 
before  analysis.  This  also  avoids  problems  that  may  occur 
because  of  Joule-Thomson  cooling  as  the  supercriti:.  al  fluid 
expands  at  the  outlet.  No  matrix  interferences 
from  the  blood  were  noted  other  than  a  slight 
decrease  in  the  recovery  of  both  drugs 
(80-100%  compared  with  90-100%  from 
methanol).  Again,  the  SFE  was  found  to  be 
linear  over  the  range  0-12.8  mg/L  temazepam 
as  shown  in  Figure  4  (r2  =  0.995).  Compar- 
ison  with  unextracted  standards  and  SPE  was 
favorable  (m,,,, 
vd  =  0.11,  msFE  =  0.111.  msPE  = 
0.131).  A  comparative  chromatogram  of  SPE 
and  SFE  extracted  blood  standards  is  given  in 
Figure  S. 
Investigation  of  the  SFE  and  SPE  methods 
st  on  authentic  forensic  specimens  showed  that 
sPE  the  methods  correlate  well.  Table  I  and  Figure 
15.00  6  show  the  results  obtained.  The  SFE  method 
was  also  found  to  extract  other  benzodi- 
'E.  (SFE  temazepam-  azepines  and  their  metabolites  of  forensic  in- 
terest,  including  diazepam,  nordiazepam,  ox- 
azepam,  and  chlordiazepoxide. 
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Conclusion 
With  careful  control  of  temperature  and  pressure,  both 
temazeparn  and  prazepam  can  be  extracted  to  the  same  extent 
from  blood  with  recoveries  of  80-100%.  Reproducible  results 
can  also  be  achieved  as  long  as  the  pressure  fluctuations  are 
kept  to  a  minimum  (=150  psi). 
The  results  obtained  show  that  the  SFE  method  can  be  used 
as  an  alternative  procedure  for  the  extraction  of  temazepam 
from  forensic  blood  samples,  with  the  potential  for  use  as  an 
extraction  procedure  for  other  benzodiazepines  of  forensic  sig- 
nificance.  The  method  offers  a  rapid,  environmentally  friendly 
approach  that  requires  minimal  sample  handling. 
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Abstract 
The  use  of  supercritical  fluid  extraction  (SFE)  was  investigated  for  the  detection  of 
heroin  abuse  by  quantifying  levels  of  morphine  and  6-monoacetyl-morphine  (6- 
MAM)  in  post-mortem  blood  and  vitreous  humor  samples.  The  levels  achieved  in 
each  of  the  two  toxicological  specimens  were  compared  on  a  case  to  case  basis  to 
determine  if  a  correlation  exists. 
Blood/vitreous  humor  samples  containing  deuterated  morphine  as  the  internal 
standard,  were  loaded  on  Extrelut®,  dried  at  room  temperature  and  then  extracted 
using  supercritical  carbon  dioxide:  methanol:  triethylamine  (90:  8.5:  1.5)  at  100°C  and 
3500  psi  for  20  minutes.  The  collected  extracts  were  analysed  by  GC/MS. 
Results  show  that,  in  general,  the  levels  of  morphine  obtained  from  blood  are  higher 
than  the  corresponding  levels  in  vitreous  humor  and  that  correlation  between  the  two 
sample  types  is  good.  Preliminary  studies  for  6-MAM  again  show  lower  levels  in 
vitreous  humor  than  in  blood,  with  the  levels  being  lower  than  the  corresponding 
morphine  levels  in  both  cases.  However  for  6-MAM,  no  correlation  between  blood 
and  vitreous  humor  was  found. Introduction 
Heroin  (diamorphine)  abuse  in  the  West  of  Scotland  has  been  on  the  increase  for 
several  years  now  and  has  only  just  started  to  decrease  with  the  introduction  of 
methadone  maintenance  programmes(1).  At  present  confirmation  of  heroin  abuse  as  a 
contributory  factor  to  death,  is  achieved  by  the  detection  of  morphine  in  the  blood  or 
urine  and  circumstantial  evidence  obtained  from  the  examination  of  postmortem 
reports,  police  reports  and  statements  from  friends  and  relatives  of  the  deceased. 
However,  in  some  cases  the  information  gathered  may  be  insufficient  to  confirm  the 
use  of  heroin  prior  to  death.  Therefore,  by  detecting  the  presence  of  the  primary 
metabolite  of  diamorphine  (6-monoacetylmorphine)  in  body  fluids,  namely  blood  and 
vitreous  humor,  the  abuse  of  heroin  could  be  verified. 
Over  the  past  few  decades,  supercritical  fluid  extraction  (SFE)  has  been  widely 
investigated  in  many  fields  of  study  including  forensic  toxicology(2,3).  Although  its 
use  has  not  escalated  in  the  routine  laboratory,  it  has  many  advantages  which  may  be 
exploited  by  the  toxicologist.  Due  to  difficulties  in  automating  instrumentation  for 
SFE,  its  advantages  must  be  taken  on  a  case  to  case  basis.  Extractions  can  be  carried 
out  quickly  and  efficiently  with  minimal  sample  handling.  Unlike  other  types  of 
extraction  where  selectivity  is  achieved  using  separate  solvents,  the  same  solvent  can 
be  used  to  selectively  extract  a  wide  range  of  sample  types  by  simply  varying  the 
pressure,  temperature  or  percentage  of  solvent  in  the  supercritical  fluid.  Commonly 
used  supercritical  fluids  include  carbon  dioxide  and  Xenon  thus  reducing  and  in  some 
cases  omitting  the  risks  incurred  on  the  environment  by  conventional  liquid  solvents. 
Experimental 
Sample  preparation  (21 
Approximately  0.2  g  of  Extrelut0  were  placed  in  a  plastic  weighing  boat.  To  this, 
200  tL  of  sample  blood  /  vitreous  humor  and  100  µL  of  D3-morphine  were  added. 
After  mixing,  the  contents  of  the  boat  were  allowed  to  dry  at  room  temperature,  until  a friable  consistency  was  achieved  (-1-2  hours),  before  being  transferred  to  an 
extraction  column.  It  is  not  necessary  to  completely  dry  the  samples,  but  where 
possible,  the  samples  were  left  overnight.  The  column  was  sealed  and  placed  over  the 
sample  loop  position  of  the  Rheodyne  in  the  equilibrated  SFE  system.  The  extraction 
was  started  by  switching  the  Rheodyne  from  load  to  inject.  The  collected  extract  was 
dried  at  65  °C  under  nitrogen  then  derivatised  with  50  tL  of  BSTFA  (1%TMCS)  at  90 
°C  for  10  minutes  before  injecting  onto  the  GC-MS. 
SFE 
The  SFE  system  consisted  of  two  Gilson  306  pumps  and  a  PYE  series  104  GC  oven 
with  pressure  restrictor.  All  components  were  modified  to  suit  the  supercritical 
extractant.  The  CO2  pumphead  was  refrigerated  to  maintain  the  flow  of  liquid  CO2 
using  a  Gilson  model  SFC3  refrigeration  unit.  The  extraction  cell  was  placed  over  the 
loop  position  of  a  Rheodyne  7161.  The  extract  was  collected  for  20  minutes  by 
expansion  into  methanol  in  a  HypoVialT""  at  the  flow  outlet.  The  extractant  was  C02  : 
methanol  :  triethylamine  (90  :  8.5  :  1.5)  at  2  mlJmin.  The  temperature  and  pressure 
were  100  °C  and  3500  psi  respectively. 
GC-MS  conditions 
Model:  Fisons  GC8000  series  with  MD800  EI  mode  (70eV) 
Column:  HP-1  fused  silica  widebore  capillary  (30  m,  0.53  mm 
i.  d.,  0.88  µm  film  thickness) 
Temperature  programme:  150°C-300°C  @  10°C/min,  hold  for  5  minutes 
Injector  temperature:  225°C 
Interface  temperature:  250°C 
SIM:  Morphine  m/z:  414,429 
6-MAM  m/z:  340,399 
D3-morphine  m/z:  432 Cases 
The  information  available  on  the  20  cases  studied  is  summarised  below: 
"  13  males:  Age  20-39  (mean  30);  7  females:  Age  27-40  (mean  31) 
"  Cause  of  death:  11  respiratory  failure,  4  aspiration  of  gastric  contents.  All  drug 
related 
"  12  known  intravenous  drug  abusers 
"  17  sudden  deaths 
"  17  with  fresh  needle  puncture  marks  (not  due  to  hospital  treatment) 
"  15  with  drug  paraphernalia  at  the  place  of  death  (e.  g.  syringe  in  close 
proximity/still  injected,  powders/tablets  in  the  vacinity  of  the  body,  ligature  still 
tied  round  arm) 
"  18  poly  drug  deaths  (8x2  drugs,  5x3  drugs,  3x4  drugs,  1x5  drugs,  lx9  drugs). 
Drugs  found:  benzodiazepines  (n=15),  methadone  (n=4),  paracetamol  (n=2), 
norpropoxyphene  (n=1),  amphetamines  (n=1),  cocaine  (n=1) 
"9  cases  positive  for  alcohol 
The  morphine  and  6-monoacetylmorphine  levels  found  in  each  of  the  20  cases  are 
listed  in  Table  1.  A  plot  of  the  concentration  found  in  blood  versus  the  concentration 
found  in  vitreous  humor  is  shown  in  Figure  1.  It  can  be  seen  that  a  correlation  exists 
between  the  matrices  for  morphine  (r2  =  0.697).  In  addition  the  levels  found  in 
vitreous  humor  are  in  general  less  than  the  corresponding  blood  levels  (gradient  = 
0.701).  In  contrast  from  Figure  2  it  is  apparent  that  no  correlation  exists  between 
blood  and  vitreous  humor  for  6-monoacetylmorphine  (r2  =  0.006). Case  B10od 
Morphine  (mg/L)  6-MAM  (mg/L) 
Vitreous  Humor 
Morphine  (mg/L)  6-MAM  (mg/L) 
1  1.18  0.51  1.22  0.42 
2  1.30  0.14  0.13  0.51 
3  0.05  0.10  0.09  1.72 
4  0.73  0.14  0.46  0.03 
5  0.81  -ve  0.42  0.73 
6  0.81  -ve  0.67  0.06 
7  1.68  0.07  1.48  0.96 
8  2.14  0.04  1.69  0.01 
9  0.48  -ve  0.07  -ve 
10  0.24  -ve  0.18  0.05 
11  0.34  -ve  0.44  -ve 
12  0.79  -ve  0.62  -ve 
13  0.45  0.08  0.16  0.02 
14  0.25  -ve  0.31  0.09 
15  0.16  0.38  0.18  -ve 
16  0.74  -ve  0.71  0.02 
17  0.25  0.23  0.23  -ve 
18  0.28  0.05  0.23  0.006 
19  0.28  0.01  0.27  0.08 
20  0.29  0.16  0.55  0.11 
Table  1  Case  Results 
All  20  of  the  cases  studied  were  positive  for  morphine,  however  from  Table  I  it  can 
be  seen  that  three  of  the  cases  were  not  positive  for  6-MAM  in  either  blood  or  vitreous 
humor.  In  these  instances,  if  corroborative  information  were  not  available,  it  would 
not  be  possible  to  state  that  the  death  was  heroin  related. Cl  3 
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Figure  1:  Morphine  Blood  v  Vitreous  Humor 
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Figure  2:  6-MAM  Blood  v  Vitreous  Humor 
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In  conclusion  we  have  found  SFE  to  be  a  useful  tool  in  the  analysis  of  morphine  and 
6-monoacetylmorphine  from  both  blood  and  vitreous  humor  samples.  This  in  addition 
to  the  information  available  on  the  deceased  can  be  used  to  prove  that  death  was 
contributed  to  by  the  use  of  heroin.  The  method  has  been  found  to  compare  well  to 
conventional  solid-phase  extraction  methods  for  morphine  (r2=0.99)t33  and  therefore 
can  be  used  in  the  toxicology  laboratory.  In  addition  we  have  shown  that  it  is  possible 
to  use  vitreous  humor  as  a  toxicological  sample.  This  may  be  of  use  in  cases  where 
blood  is  not  avalable  for  analysis. 
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Abstract 
The  use  of  vitreous  humor  as  an  alternative  sample  to  blood  was  investigated  for  the 
detection  of  heroin  abuse  by  quantifying  levels  of  morphine  and  6-monoacetyl- 
morphine  (6-MAM)  in  post-mortem  samples.  The  levels  achieved  in  each  of  the  two 
toxicological  specimens  were  compared  on  a  case  to  case  basis  to  determine  if  a 
correlation  existed.  A  total  of  20  positive  morphine  cases  were  examined.  In  general 
the  levels  of  morphine  in  blood  were  higher  than  in  the  corresponding  vitreous  humor 
samples,  with  some  correlation  existing.  6-MAM  was  found  in  15  blood  samples  and 
17  vitreous  humor  samples.  Although  no  correlation  was  found  between  the  levels  of 
6-MAM  in  blood  and  vitreous  humor,  the  latter  may  still  be  used  for  verification  of 
heroin  abuse. 
Introduction 
The  use  of  vitreous  humor  as  an  alternative  sample  matrix  for  the  determination  of 
drugs  has  been  recently  reviewed  by  several  workers.  (Bermejo  et  al,  1992,  McKinney 
et  al,  1994,  Samuel  et  al,  1994)  However,  without  further  understanding  of  the 
relationship  between  the  levels  obtained  in  conventional  sample  types  (i.  e.  blood, 
urine)  the  interpretation  of  analytical  results  for  vitreous  humor  is difficult. 
For  several  years  deaths  due  to  the  abuse  of  heroin  (diamorphine)  in  the  West  of 
Scotland  have  been  on  the  increase.  However,  at  present  the  confirmation  of  heroin abuse  as  a  contributory  factor  to  death,  depends  heavily  on  the  circumstantial  evidence 
obtained  from  the  examination  of  postmortem  reports,  police  reports  and  witness 
statements.  This  information  is  verified  by  quantitation  of  morphine  in  the  case  blood 
or,  urine.  In  order  to  provide  a  better  toxicological  support  for  the  circumstantial 
evidence  it  is  necessary  to  look  for  a  more  specific  diamorphine  marker.  The 
metabolic  pathway  of  diamorphine  is  shown  in  Figure  1.  From  the  half  lives  it  is 
apparent  that  the  routine  detection  of  diamorphine  is  not  practical.  However,  due  to 
its  longer  half  life,  6-MAM  should  provide  a  more  practical  diamorphine  marker  and 
thus  it  was  chosen  for  this  study. 
A  recent  study  on  the  comparison  of  supercritical  fluid  extraction  and  solid-phase 
extraction  for  the  detection  of  morphine  in  postmortem  blood  samples  showed 
excellent  correlation  between  the  two  methods.  (Allen  et  al,  1997)  Although  the  use 
of  SFE  in  forensic  toxicology  is  not  widespread,  it  has  many  advantages  which  may  be 
exploited  by  the  toxicologist.  In  addition  to  speed  and  efficiency  of  extraction  one  of 
the  main  advantages  of  SFE  is  the  potential  for  using  a  single  solvent  to  selectively 
extract  a  wide  range  of  sample  types  simply  by  varying  the  pressure  or  temperature  of 
the  supercritical  fluid.  Due  to  its  practical  critical  temperature  and  pressure  and  low 
cost,  carbon  dioxide  is  the  most  commonly  used  supercritical  fluid,  thus  the  need  for 
organic  solvents  is  reduced. 
Experimental 
Materials 
Morphine,  6-monoacetlymorphine  and  D3-morphine  were  supplied  by  Sigma  (Poole, 
U.  K.  ).  Methanol,  dichloromethane  were  high  performance  liquid  chromatographic 
(HPLC)  grade,  (Lab  Scan  Analytical  Sciences,  Dublin,  Ireland).  BSTFA  (1%  TMCS) 
used  as  the  GC-MS  derivatising  agent  was  supplied  by  Pierce  (Rockford,  IL,  USA). 
Triethylamine  general  purpose  reagent  (GPR)  grade  was  supplied  by  Merck  (Poole, 
U.  K.  ).  Extrelut®  (Merck)  was  prewashed  using  dichloromethane.  The  collection vials  for  SFE,  were  6mL  HypoVialTM  (Pierce,  Oud-Biejerland,  The  Netherlands)  with 
butyl  rubber  septa  (Pierce  and  Warriner,  Chester,  U.  K.  ) 
Apparatus 
The  SFE  system  is  described  elsewhere  (Scott  et  al,  1997).  The  extraction  was  carried 
out  for  20-30  minutes  using  C02-methanol-triethylamine  (90:  8.5:  1.5)  at  2.0  mL/min 
with  a  temperature  of  100  °C  and  a  pressure  of  3500  psi.  The  analytes  were  collected 
by  expansion  into  methanol  at  the  flow  outlet. 
The  GC/MS  system  consisted  of  a  Fisons  GC8000  series  with  MD800  EI  mode  (70 
eV)  fitted  with  a  HP-1  fused  silica  widebore  capillary  column  (30  m,  0.53  mm  i.  d., 
0.88  µm  film  thickness).  The  temperature  was  programmed  from  150  °C  to  300  °C  at 
10  °C/minute  and  held  for  5  minutes.  The  injector  temperature  was  225  °C  and  the 
interface  temperature  250  °C.  Selected  ion  monitoring  was  used  with  the  following 
ions:  morphine  m/z  414  and  429,6-MAM  m/z  340  and  399,  D3-morphine  m/z  432. 
Sample  preparation 
Approximately  0.2  g  of  Extrelut0  was  placed  in  a  plastic  weighing  boat.  To  this,  200 
µL  of  sample  blood  /  vitreous  humor  and  100  µL  of  D3-morphine  were  added.  After 
mixing,  the  contents  of  the  boat  were  allowed  to  dry  at  room  temperature,  until  a 
friable  consistency  was  achieved  (-1-2  hours),  before  being  transferred  to  an 
extraction  column.  The  column  was  sealed  and  placed  over  the  loop  position  of  the 
Rheodyne  in  the  equilibrated  SFE  system.  The  extraction  was  started  by  switching  the 
Rheodyne  from  load  to  inject.  The  collected  extract  was  dried  at  65  °C  under  nitrogen 
then  derivatised  with  50  µL  of  BSTFA  (1%TMCS)  at  90  °C  for  10  minutes  before 
injecting  onto  the  GC-MS. Cases 
The  information  available  on  the  20  cases  studied  is  summarised  in  Table  I.  Using 
only  this  information  it  should  be  possible  to  predict  whether  6-MAM  will  be  present 
in  the  blood  and  vitreous  humor.  For  example  in  case  1,  the  deceased  was  a  known 
intravenous  heroin  abuser  who  died  suddenly.  Fresh  needle  puncture  marks  were 
found  on  the  body  and  a  syringe  was  found  in  close  proximity  to  the  body.  Therefore, 
in  this  case,  we  would  expect  to  find  traces  of  6-MAM.  In  contrast  with  case  15,  there 
was  no  evidence  of  heroin  abuse  and  thus  we  would  not  expect  to  find  morphine  or  6- 
MAM. 
Results  and  discussion 
The  levels  of  morphine  and  6-monoacetylmorphine  found  in  each  of  the  20  cases  are 
listed  in  Table  II.  A  plot  of  the  morphine  concentration  found  in  blood  versus  the 
concentration  found  in  vitreous  humor  is  shown  in  Figure  2.  It  can  be  seen  that  a 
correlation  exists  between  the  matrices  for  morphine  (r2  =  0.697).  For  the  17  sudden 
death  cases  only,  the  correlation  coefficient  is  0.885,  indicating  a  dependance  on  the 
rate  of  death.  The  levels  found  in  vitreous  humor  are  in  general  less  than  the 
corresponding  blood  levels  (gradient  =  0.701  (0.811  for  sudden  deaths)).  In  contrast 
from  Figure  3  it  is  apparent  that  no  correlation  exists  between  the  levels  found  in 
blood  and  vitreous  humor  for  6-monoacetylmorphine  (r2  =  0.006)  even  when  the 
sudden  deaths  are  taken  separately  (r2  =  0.03). 
All  20  of  the  cases  studied  were  positive  for  morphine,  however  from  Table  I  it  can  be 
seen  that  three  of  the  cases  were  not  positive  for  6-MAM  in  either  blood  or  vitreous 
humor  (9,11,12)  Therefore,  in  the  absence  of  corroborative  information,  it  would  not 
be  possible  to  state  that  the  death  was  heroin  related  in  these  cases.  On  the  other  hand, 
the  circumstantial  evidence  does  not  imply  death  related  to  heroin  overdose  in  cases  2, 
4,15  and  19,  yet  the  results  show  that  these  cases  were  in  fact  heroin  related  due  to  the 
presence  of  6-MAM  in  the  blood  /  vitreous  humor. Conclusions 
SFE  can  be  successfully  used  for  the  quantitation  of  6-MAM  in  both  blood  and 
vitreous  humor  samples.  The  detection  of  this  compound  is  useful  in  the  confirmation 
of  death  due  to  heroin  overdose.  However,  due  to  the  short  half  life  of  6-MAM  it  is 
necessary  to  review  the  case  notes  relating  to  a  particular  toxicology  file  before 
making  a  judgement  as  to  the  contribution  of  drugs  to  the  death.  The  good  correlation 
between  blood  and  vitreous  humor  levels  for  morphine,  indicates  that  this  is  an  ideal 
matrix  for  use  when  blood  is  not  available  or  is  badly  denatured.  For  the 
determination  of  6-MAM,  it  has  been  shown  that  in  general  higher  levels  are 
measured  in  this  matrix,  however  no  correlation  between  the  two  matrices  exists  and 
thus  further  work  will  need  to  be  carried  out  in  order  to  determine  the  value  of 
vitreous  humor  as  an  alternative  for  the  quantitation  of  6-MAM. 
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